US20230102879A1 - Trna synthetase inhibitors - Google Patents
Trna synthetase inhibitors Download PDFInfo
- Publication number
- US20230102879A1 US20230102879A1 US17/573,405 US202217573405A US2023102879A1 US 20230102879 A1 US20230102879 A1 US 20230102879A1 US 202217573405 A US202217573405 A US 202217573405A US 2023102879 A1 US2023102879 A1 US 2023102879A1
- Authority
- US
- United States
- Prior art keywords
- optionally substituted
- alkyl
- cycloalkyl
- aryl
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 title abstract description 14
- 108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 title abstract description 14
- 239000003112 inhibitor Substances 0.000 title description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 129
- -1 secondary amine compounds Chemical class 0.000 claims abstract description 93
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 284
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 98
- 125000001072 heteroaryl group Chemical group 0.000 claims description 78
- 125000003107 substituted aryl group Chemical group 0.000 claims description 75
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 69
- 125000003118 aryl group Chemical group 0.000 claims description 68
- 125000003545 alkoxy group Chemical group 0.000 claims description 62
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 60
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 55
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims description 45
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 45
- 125000002947 alkylene group Chemical group 0.000 claims description 43
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 36
- 125000004104 aryloxy group Chemical group 0.000 claims description 36
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 28
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 27
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 23
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims description 23
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 21
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 21
- 125000005114 heteroarylalkoxy group Chemical group 0.000 claims description 21
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 21
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 21
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 17
- 125000006717 (C3-C10) cycloalkenyl group Chemical group 0.000 claims description 17
- 150000004820 halides Chemical class 0.000 claims description 17
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims description 17
- 229910003844 NSO2 Inorganic materials 0.000 claims description 15
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 13
- 208000035143 Bacterial infection Diseases 0.000 claims description 12
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 12
- 125000005309 thioalkoxy group Chemical group 0.000 claims description 11
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 9
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 8
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 7
- 125000006564 (C4-C8) cycloalkyl group Chemical group 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 abstract description 8
- 201000008827 tuberculosis Diseases 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 230000002147 killing effect Effects 0.000 abstract description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 538
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 537
- 238000005160 1H NMR spectroscopy Methods 0.000 description 431
- 239000000203 mixture Substances 0.000 description 276
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 240
- 238000004128 high performance liquid chromatography Methods 0.000 description 132
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 103
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 92
- 239000012071 phase Substances 0.000 description 90
- 239000012279 sodium borohydride Substances 0.000 description 85
- 229910000033 sodium borohydride Inorganic materials 0.000 description 85
- 239000000243 solution Substances 0.000 description 68
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 65
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 46
- 239000002904 solvent Substances 0.000 description 46
- 239000011541 reaction mixture Substances 0.000 description 44
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 42
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 40
- 238000006243 chemical reaction Methods 0.000 description 40
- UHBZEAPZATVYKV-UHFFFAOYSA-N cyclohexylacetone Chemical compound CC(=O)CC1CCCCC1 UHBZEAPZATVYKV-UHFFFAOYSA-N 0.000 description 37
- 239000000047 product Substances 0.000 description 37
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 35
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 35
- 239000012267 brine Substances 0.000 description 33
- 229910052938 sodium sulfate Inorganic materials 0.000 description 33
- 239000007832 Na2SO4 Substances 0.000 description 31
- 238000002360 preparation method Methods 0.000 description 31
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 25
- 230000002829 reductive effect Effects 0.000 description 25
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 24
- 235000019439 ethyl acetate Nutrition 0.000 description 24
- 239000012044 organic layer Substances 0.000 description 23
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 22
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 22
- 125000000623 heterocyclic group Chemical group 0.000 description 22
- 125000004429 atom Chemical group 0.000 description 19
- 238000004440 column chromatography Methods 0.000 description 19
- 239000007787 solid Substances 0.000 description 19
- 239000003921 oil Substances 0.000 description 17
- 235000019198 oils Nutrition 0.000 description 17
- 239000012074 organic phase Substances 0.000 description 17
- 238000003786 synthesis reaction Methods 0.000 description 16
- 239000000725 suspension Substances 0.000 description 15
- 238000001704 evaporation Methods 0.000 description 14
- 230000008020 evaporation Effects 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- 125000006413 ring segment Chemical group 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- 150000001412 amines Chemical class 0.000 description 13
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 13
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- MKQGUCPIBZQIRP-UHFFFAOYSA-N methyl 2-[2-(chloromethyl)phenyl]acetate Chemical compound COC(=O)CC1=CC=CC=C1CCl MKQGUCPIBZQIRP-UHFFFAOYSA-N 0.000 description 11
- GIXSTBOIKJPUKD-UHFFFAOYSA-N norpropylhexedrine Chemical compound CC(N)CC1CCCCC1 GIXSTBOIKJPUKD-UHFFFAOYSA-N 0.000 description 11
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 10
- 239000003242 anti bacterial agent Substances 0.000 description 10
- 125000002619 bicyclic group Chemical group 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Substances [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 8
- SMQUZDBALVYZAC-UHFFFAOYSA-N salicylaldehyde Chemical compound OC1=CC=CC=C1C=O SMQUZDBALVYZAC-UHFFFAOYSA-N 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- JJMDTERTPNYIGZ-UHFFFAOYSA-N 2-cyclohexylacetaldehyde Chemical compound O=CCC1CCCCC1 JJMDTERTPNYIGZ-UHFFFAOYSA-N 0.000 description 7
- RKFNAZGRJVNWEW-UHFFFAOYSA-N 3-cyclohexylpropionaldehyde Natural products O=CCCC1CCCCC1 RKFNAZGRJVNWEW-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- IUDMXOOVKMKODN-UHFFFAOYSA-N 2-(cyclohexen-1-yl)ethanamine Chemical compound NCCC1=CCCCC1 IUDMXOOVKMKODN-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 6
- 238000004821 distillation Methods 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- BNEIFWJSGRGFJC-UHFFFAOYSA-N 2-[(2-fluorophenyl)methoxy]benzaldehyde Chemical compound FC1=CC=CC=C1COC1=CC=CC=C1C=O BNEIFWJSGRGFJC-UHFFFAOYSA-N 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 229940125782 compound 2 Drugs 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 5
- 125000003367 polycyclic group Chemical group 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 238000000547 structure data Methods 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 4
- XARVANDLQOZMMJ-CHHVJCJISA-N 2-[(z)-[1-(2-amino-1,3-thiazol-4-yl)-2-oxo-2-(2-oxoethylamino)ethylidene]amino]oxy-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)O\N=C(/C(=O)NCC=O)C1=CSC(N)=N1 XARVANDLQOZMMJ-CHHVJCJISA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- CZIBOTXHUUNSHR-UHFFFAOYSA-N N-benzyl-2-cyclohexyl-1-cyclopropylethanamine Chemical compound C(C1=CC=CC=C1)NC(CC1CCCCC1)C1CC1 CZIBOTXHUUNSHR-UHFFFAOYSA-N 0.000 description 4
- 229910020889 NaBH3 Inorganic materials 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- TXWOGHSRPAYOML-UHFFFAOYSA-N cyclobutanecarboxylic acid Chemical compound OC(=O)C1CCC1 TXWOGHSRPAYOML-UHFFFAOYSA-N 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 3
- 239000001431 2-methylbenzaldehyde Substances 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 244000034356 Aframomum angustifolium Species 0.000 description 3
- SCJZMRYGLZRTBX-UHFFFAOYSA-N C(C1=CC=CC=C1)NC(CC1CCCCC1)CC Chemical compound C(C1=CC=CC=C1)NC(CC1CCCCC1)CC SCJZMRYGLZRTBX-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 3
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 125000004452 carbocyclyl group Chemical group 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000010408 film Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- SJFNDMHZXCUXSA-UHFFFAOYSA-M methoxymethyl(triphenyl)phosphanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(COC)C1=CC=CC=C1 SJFNDMHZXCUXSA-UHFFFAOYSA-M 0.000 description 3
- 125000001620 monocyclic carbocycle group Chemical group 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 229960003128 mupirocin Drugs 0.000 description 3
- 229930187697 mupirocin Natural products 0.000 description 3
- QYBIZZCHZXZBFQ-UHFFFAOYSA-N n-benzyl-2,3-dihydro-1h-inden-2-amine;hydrochloride Chemical compound Cl.C1C2=CC=CC=C2CC1NCC1=CC=CC=C1 QYBIZZCHZXZBFQ-UHFFFAOYSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- IOBJYPSGKNVNFQ-UHFFFAOYSA-N tert-butyl N-(1-cyclohexylpropan-2-yl)-N-(1H-indol-7-ylmethyl)carbamate Chemical compound N1C=CC2=CC=CC(=C12)CN(C(OC(C)(C)C)=O)C(CC1CCCCC1)C IOBJYPSGKNVNFQ-UHFFFAOYSA-N 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- HFACYWDPMNWMIW-UHFFFAOYSA-N 2-cyclohexylethanamine Chemical compound NCCC1CCCCC1 HFACYWDPMNWMIW-UHFFFAOYSA-N 0.000 description 2
- WMPDAIZRQDCGFH-UHFFFAOYSA-N 3-methoxybenzaldehyde Chemical compound COC1=CC=CC(C=O)=C1 WMPDAIZRQDCGFH-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 241000982938 Enterobacter cancerogenus Species 0.000 description 2
- 241000604777 Flavobacterium columnare Species 0.000 description 2
- 241000382842 Flavobacterium psychrophilum Species 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000589014 Kingella kingae Species 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 239000006142 Luria-Bertani Agar Substances 0.000 description 2
- 241001478294 Moraxella osloensis Species 0.000 description 2
- 241001138504 Mycoplasma bovis Species 0.000 description 2
- 241000202952 Mycoplasma fermentans Species 0.000 description 2
- 241001148639 Mycoplasma haemofelis Species 0.000 description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 241000520871 Pseudomonas asplenii Species 0.000 description 2
- 241000589540 Pseudomonas fluorescens Species 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 241000607323 Vibrio campbellii Species 0.000 description 2
- IHDICKBHPLOLJL-UHFFFAOYSA-N [2-(methylsulfonylmethyl)phenyl]methanamine Chemical compound CS(=O)(=O)CC1=CC=CC=C1CN IHDICKBHPLOLJL-UHFFFAOYSA-N 0.000 description 2
- WVOBZSPWTXATGB-UHFFFAOYSA-N [2-[(2-cyclohexylethylamino)methyl]phenyl]boronic acid Chemical compound C1(CCCCC1)CCNCC1=C(C=CC=C1)B(O)O WVOBZSPWTXATGB-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- VNMDBLNACZCMDE-UHFFFAOYSA-N diethyl 2-acetamido-2-[[2-(aminomethyl)phenyl]methyl]propanedioate Chemical compound C(C)(=O)NC(C(=O)OCC)(C(=O)OCC)CC1=C(C=CC=C1)CN VNMDBLNACZCMDE-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 238000007422 luminescence assay Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 2
- YKPHDCVTZKWWRK-UHFFFAOYSA-N methyl 2-[2-(aminomethyl)phenyl]acetate Chemical compound COC(=O)CC1=CC=CC=C1CN YKPHDCVTZKWWRK-UHFFFAOYSA-N 0.000 description 2
- NHEAYNQPEMDTEQ-UHFFFAOYSA-N methyl 2-[7-[[1-cyclohexylpropan-2-yl-[(2-methylpropan-2-yl)oxycarbonyl]amino]methyl]indol-1-yl]acetate Chemical compound C(C)(C)(C)OC(=O)N(C(CC1CCCCC1)C)CC=1C=CC=C2C=CN(C=12)CC(=O)OC NHEAYNQPEMDTEQ-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 229920001206 natural gum Polymers 0.000 description 2
- BTFQKIATRPGRBS-UHFFFAOYSA-N o-tolualdehyde Chemical compound CC1=CC=CC=C1C=O BTFQKIATRPGRBS-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000012788 optical film Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- FXLOVSHXALFLKQ-UHFFFAOYSA-N p-tolualdehyde Chemical compound CC1=CC=C(C=O)C=C1 FXLOVSHXALFLKQ-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- LFQDNHWZDQTITF-UHFFFAOYSA-N tavaborole Chemical compound FC1=CC=C2B(O)OCC2=C1 LFQDNHWZDQTITF-UHFFFAOYSA-N 0.000 description 2
- 229960002636 tavaborole Drugs 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- LBDAWOOJHHQJNO-UHFFFAOYSA-N tert-butyl N-(1-cyclohexylpropan-2-yl)-N-[[1-(2-hydroxyethyl)indol-7-yl]methyl]carbamate Chemical compound C1(CCCCC1)CC(C)N(C(OC(C)(C)C)=O)CC=1C=CC=C2C=CN(C=12)CCO LBDAWOOJHHQJNO-UHFFFAOYSA-N 0.000 description 2
- CSOWZRUUDXLCHZ-UHFFFAOYSA-N tert-butyl N-[(2-aminophenyl)methyl]-N-(1-cyclohexylpropan-2-yl)carbamate Chemical compound NC1=C(CN(C(OC(C)(C)C)=O)C(CC2CCCCC2)C)C=CC=C1 CSOWZRUUDXLCHZ-UHFFFAOYSA-N 0.000 description 2
- WZLCRKYCULAGBY-UHFFFAOYSA-N tert-butyl n-[3-(aminomethyl)phenyl]-n-methylcarbamate Chemical compound CC(C)(C)OC(=O)N(C)C1=CC=CC(CN)=C1 WZLCRKYCULAGBY-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- WTSHAOZLVNGDNR-CACIRBSMSA-N (1S,2R)-N-benzyl-2-(3,4-difluorophenyl)cyclopropan-1-amine hydrochloride Chemical compound Cl.C(C1=CC=CC=C1)N[C@@H]1[C@H](C1)C1=CC(=C(C=C1)F)F WTSHAOZLVNGDNR-CACIRBSMSA-N 0.000 description 1
- JUHKDIJPAIQKKO-UHFFFAOYSA-N (2-cyclobutyloxyphenyl)methanamine Chemical compound NCC1=CC=CC=C1OC1CCC1 JUHKDIJPAIQKKO-UHFFFAOYSA-N 0.000 description 1
- AQJQZWYCESCJNC-UHFFFAOYSA-N (2-cyclohexyloxyphenyl)methanamine Chemical compound NCC1=CC=CC=C1OC1CCCCC1 AQJQZWYCESCJNC-UHFFFAOYSA-N 0.000 description 1
- YLEJNHKGVADOTF-MRVPVSSYSA-N (2R)-1-(cyclohexen-1-yl)propan-2-amine Chemical compound [C@H](C)(N)CC1=CCCCC1 YLEJNHKGVADOTF-MRVPVSSYSA-N 0.000 description 1
- YLEJNHKGVADOTF-QMMMGPOBSA-N (2S)-1-(cyclohexen-1-yl)propan-2-amine Chemical compound C[C@H](N)CC1=CCCCC1 YLEJNHKGVADOTF-QMMMGPOBSA-N 0.000 description 1
- QCROEUHUOJOKOA-MBABXSBOSA-N (2S)-2-acetamido-3-[2-[(2-cyclohexylpropylamino)methyl]phenyl]propanoic acid Chemical compound C(C)(=O)N[C@H](C(=O)O)CC1=C(C=CC=C1)CNCC(C)C1CCCCC1 QCROEUHUOJOKOA-MBABXSBOSA-N 0.000 description 1
- AUCGCBZOEJUHIL-IBYPIGCZSA-N (2S)-2-amino-3-[2-[(2-cyclohexylpropylamino)methyl]phenyl]propanoic acid Chemical compound N[C@H](C(=O)O)CC1=C(C=CC=C1)CNCC(C)C1CCCCC1 AUCGCBZOEJUHIL-IBYPIGCZSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 description 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- SECMYYVPSMBAIC-OUKQBFOZSA-N (E)-N-benzyl-4-cyclohexylbut-3-en-2-amine Chemical compound C(C1=CC=CC=C1)NC(C)\C=C\C1CCCCC1 SECMYYVPSMBAIC-OUKQBFOZSA-N 0.000 description 1
- UZHVXJZEHGSWQV-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrole Chemical compound C1NCC2CCCC21 UZHVXJZEHGSWQV-UHFFFAOYSA-N 0.000 description 1
- SRQMOHGEWMZUOI-UHFFFAOYSA-N 1,2,4,5-tetrahydro-2-benzazepin-3-one Chemical compound C1NC(=O)CCC2=CC=CC=C21 SRQMOHGEWMZUOI-UHFFFAOYSA-N 0.000 description 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- UDGKZGLPXCRRAM-UHFFFAOYSA-N 1,2,5-thiadiazole Chemical compound C=1C=NSN=1 UDGKZGLPXCRRAM-UHFFFAOYSA-N 0.000 description 1
- YOTIBQOCCYWJMZ-UHFFFAOYSA-N 1,2,5-thiadiazole 1,1-dioxide Chemical compound O=S1(=O)N=CC=N1 YOTIBQOCCYWJMZ-UHFFFAOYSA-N 0.000 description 1
- ZZGPYPVNEPAJHG-UHFFFAOYSA-N 1,2,5-thiadiazole 1-oxide Chemical compound O=S1N=CC=N1 ZZGPYPVNEPAJHG-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 description 1
- XGYCWCIGCYGQFU-UHFFFAOYSA-N 1,2-thiazolidine 1,1-dioxide Chemical compound O=S1(=O)CCCN1 XGYCWCIGCYGQFU-UHFFFAOYSA-N 0.000 description 1
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 description 1
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 description 1
- JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical compound C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 description 1
- DKYBVKMIZODYKL-UHFFFAOYSA-N 1,3-diazinane Chemical compound C1CNCNC1 DKYBVKMIZODYKL-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- SAQHGEILSGZDQP-UHFFFAOYSA-N 1-(2-adamantyl)ethanone Chemical compound C1C(C2)CC3CC1C(C(=O)C)C2C3 SAQHGEILSGZDQP-UHFFFAOYSA-N 0.000 description 1
- ARCZZRLYYJWGRK-UHFFFAOYSA-N 1-(4,4-difluorocyclohexyl)-N-[[2-[(2-fluorophenyl)methoxy]phenyl]methyl]propan-2-amine Chemical compound C(C1=C(F)C=CC=C1)OC1=C(C=CC=C1)CNC(C)CC1CCC(F)(F)CC1 ARCZZRLYYJWGRK-UHFFFAOYSA-N 0.000 description 1
- VZNYLZUHNQSEET-UHFFFAOYSA-N 1-(4-cyclopropylcyclohexyl)-N-[[2-[(2-fluorophenyl)methoxy]phenyl]methyl]propan-2-amine Chemical compound CC(CC1CCC(CC1)C1CC1)NCC1=C(OCC2=C(F)C=CC=C2)C=CC=C1 VZNYLZUHNQSEET-UHFFFAOYSA-N 0.000 description 1
- AOVGZMBKVGDCMG-UHFFFAOYSA-N 1-(4-cyclopropylcyclohexyl)propan-2-amine Chemical compound CC(N)CC1CCC(CC1)C1CC1 AOVGZMBKVGDCMG-UHFFFAOYSA-N 0.000 description 1
- NIKFVRJNCDTQMW-UHFFFAOYSA-N 1-(4-ethylcyclohexyl)propan-2-amine Chemical compound CCC1CCC(CC(C)N)CC1 NIKFVRJNCDTQMW-UHFFFAOYSA-N 0.000 description 1
- RZEJLTGNNNLYTL-UHFFFAOYSA-N 1-(4-methoxynaphthalen-1-yl)propan-2-one Chemical compound C1=CC=C2C(OC)=CC=C(CC(C)=O)C2=C1 RZEJLTGNNNLYTL-UHFFFAOYSA-N 0.000 description 1
- MXYIFSDFEJOQMN-UHFFFAOYSA-N 1-(4-methylcyclohexyl)propan-2-amine Chemical compound CC(N)CC1CCC(C)CC1 MXYIFSDFEJOQMN-UHFFFAOYSA-N 0.000 description 1
- WRDWFBGOAZBWOK-UHFFFAOYSA-N 1-(4-propan-2-ylcyclohexyl)propan-2-amine Chemical compound CC(N)CC1CCC(C(C)C)CC1 WRDWFBGOAZBWOK-UHFFFAOYSA-N 0.000 description 1
- ZTJUTHDEPYHGKS-UHFFFAOYSA-N 1-[2-(aminomethyl)phenyl]-N,N-dimethylmethanesulfonamide Chemical compound CN(C)S(=O)(=O)CC1=CC=CC=C1CN ZTJUTHDEPYHGKS-UHFFFAOYSA-N 0.000 description 1
- SPEGLSZMUMYDJL-UHFFFAOYSA-N 1-[2-(aminomethyl)phenyl]-N-(1-methylpiperidin-4-yl)methanesulfonamide Chemical compound C1CN(C)CCC1NS(=O)(=O)CC1=CC=CC=C1CN SPEGLSZMUMYDJL-UHFFFAOYSA-N 0.000 description 1
- KUKQEKANABWPMO-UHFFFAOYSA-N 1-[2-(aminomethyl)phenyl]-N-(2-methoxyethyl)methanesulfonamide Chemical compound COCCNS(=O)(=O)CC1=CC=CC=C1CN KUKQEKANABWPMO-UHFFFAOYSA-N 0.000 description 1
- UBUVKHFCWVYHDY-LBPRGKRZSA-N 1-[2-(aminomethyl)phenyl]-N-[(2S)-2,3-dihydroxypropyl]-N-methylmethanesulfonamide Chemical compound NCC1=C(C=CC=C1)CS(=O)(=O)N(C)C[C@@H](CO)O UBUVKHFCWVYHDY-LBPRGKRZSA-N 0.000 description 1
- ZGBJWBNELFMVJG-UHFFFAOYSA-N 1-[2-(aminomethyl)phenyl]-N-ethylmethanesulfonamide Chemical compound CCNS(=O)(=O)CC1=CC=CC=C1CN ZGBJWBNELFMVJG-UHFFFAOYSA-N 0.000 description 1
- KVZHOBPWLRRVHQ-UHFFFAOYSA-N 1-[2-(aminomethyl)phenyl]-n-(oxolan-2-ylmethyl)methanesulfonamide Chemical compound NCC1=CC=CC=C1CS(=O)(=O)NCC1OCCC1 KVZHOBPWLRRVHQ-UHFFFAOYSA-N 0.000 description 1
- DWCPYDOKYHSAOI-UHFFFAOYSA-N 1-[2-(aminomethyl)phenyl]-n-methylmethanesulfonamide Chemical compound CNS(=O)(=O)CC1=CC=CC=C1CN DWCPYDOKYHSAOI-UHFFFAOYSA-N 0.000 description 1
- OOUTWJGCFMHQFV-UHFFFAOYSA-N 1-[2-[(1-cyclohexylpropan-2-ylamino)methyl]phenyl]-N,N-dimethylmethanesulfonamide Chemical compound CC(CC1CCCCC1)NCC1=C(CS(=O)(=O)N(C)C)C=CC=C1 OOUTWJGCFMHQFV-UHFFFAOYSA-N 0.000 description 1
- QCBJIDHJDOHYCI-UHFFFAOYSA-N 1-[2-[(1-cyclohexylpropan-2-ylamino)methyl]phenyl]-N-(1-methylpiperidin-4-yl)methanesulfonamide Chemical compound CC(CC1CCCCC1)NCC1=C(CS(=O)(=O)NC2CCN(C)CC2)C=CC=C1 QCBJIDHJDOHYCI-UHFFFAOYSA-N 0.000 description 1
- NTIIPOHLXSNPNT-LFABVHOISA-N 1-[2-[(1-cyclohexylpropan-2-ylamino)methyl]phenyl]-N-[(2S)-2,3-dihydroxypropyl]-N-methylmethanesulfonamide Chemical compound CC(CC1CCCCC1)NCC1=C(CS(=O)(=O)N(C)C[C@H](O)CO)C=CC=C1 NTIIPOHLXSNPNT-LFABVHOISA-N 0.000 description 1
- NWHYOSHMTBRVFD-UHFFFAOYSA-N 1-[2-[(1-cyclohexylpropan-2-ylamino)methyl]phenyl]-N-ethylmethanesulfonamide Chemical compound CCNS(=O)(=O)CC1=C(CNC(C)CC2CCCCC2)C=CC=C1 NWHYOSHMTBRVFD-UHFFFAOYSA-N 0.000 description 1
- ZBVJZKYAZZATIW-UHFFFAOYSA-N 1-[2-[(1-cyclohexylpropan-2-ylamino)methyl]phenyl]-N-methylmethanesulfonamide Chemical compound CNS(=O)(=O)CC1=C(CNC(C)CC2CCCCC2)C=CC=C1 ZBVJZKYAZZATIW-UHFFFAOYSA-N 0.000 description 1
- STHHLVCQSLRQNI-UHFFFAOYSA-N 1-azabicyclo[3.2.1]octane Chemical compound C1C2CCN1CCC2 STHHLVCQSLRQNI-UHFFFAOYSA-N 0.000 description 1
- FMEHIMDNLRASDU-UHFFFAOYSA-N 1-azabicyclo[3.3.1]nonane Chemical compound C1CCN2CCCC1C2 FMEHIMDNLRASDU-UHFFFAOYSA-N 0.000 description 1
- FJGFHPNQSDXCFC-UHFFFAOYSA-N 1-azaspiro[4.4]nonane Chemical compound C1CCCC21NCCC2 FJGFHPNQSDXCFC-UHFFFAOYSA-N 0.000 description 1
- JLWHAFKUTFPEJL-UHFFFAOYSA-N 1-benzylindole-7-carbaldehyde Chemical compound O=Cc1cccc2ccn(Cc3ccccc3)c12 JLWHAFKUTFPEJL-UHFFFAOYSA-N 0.000 description 1
- SDTJLSYGACMWOC-UHFFFAOYSA-N 1-cyclohexyl-N-[[2-(2-ethylcyclohexyl)oxyphenyl]methyl]propan-2-amine Chemical compound CCC1CCCCC1OC1=C(CNC(C)CC2CCCCC2)C=CC=C1 SDTJLSYGACMWOC-UHFFFAOYSA-N 0.000 description 1
- IRGRWTUSIHGYBG-UHFFFAOYSA-N 1-cyclohexyl-N-[[2-(2-fluorophenoxy)phenyl]methyl]propan-2-amine Chemical compound CC(CC1CCCCC1)NCC1=C(OC2=C(F)C=CC=C2)C=CC=C1 IRGRWTUSIHGYBG-UHFFFAOYSA-N 0.000 description 1
- FFSJNZZZFACTGK-UHFFFAOYSA-N 1-cyclohexyl-N-[[2-(2-methylcyclohexyl)oxyphenyl]methyl]propan-2-amine Chemical compound CC(CC1CCCCC1)NCC1=C(OC2CCCCC2C)C=CC=C1 FFSJNZZZFACTGK-UHFFFAOYSA-N 0.000 description 1
- QFTZOJGIDOBWIP-UHFFFAOYSA-N 1-cyclohexyl-N-[[2-(4,4-difluorocyclohexyl)oxyphenyl]methyl]propan-2-amine Chemical compound CC(CC1CCCCC1)NCC1=C(OC2CCC(F)(F)CC2)C=CC=C1 QFTZOJGIDOBWIP-UHFFFAOYSA-N 0.000 description 1
- PJBYIQVFXPVDKC-UHFFFAOYSA-N 1-cyclohexyl-N-[[2-(4-methylcyclohexyl)oxyphenyl]methyl]propan-2-amine Chemical compound CC(CC1CCCCC1)NCC1=C(OC2CCC(C)CC2)C=CC=C1 PJBYIQVFXPVDKC-UHFFFAOYSA-N 0.000 description 1
- SHFRGCPFFCDOSA-UHFFFAOYSA-N 1-cyclohexyl-N-[[2-[(2-iodophenyl)methoxy]phenyl]methyl]propan-2-amine Chemical compound CC(CC1CCCCC1)NCC1=C(OCC2=C(I)C=CC=C2)C=CC=C1 SHFRGCPFFCDOSA-UHFFFAOYSA-N 0.000 description 1
- XKWPTSRVZYYGOT-UHFFFAOYSA-N 1-cyclohexyl-N-[[2-[(2-phenoxyphenyl)methoxy]phenyl]methyl]propan-2-amine Chemical compound CC(CC1CCCCC1)NCC1=C(OCC2=C(OC3=CC=CC=C3)C=CC=C2)C=CC=C1 XKWPTSRVZYYGOT-UHFFFAOYSA-N 0.000 description 1
- OUOFYWJXKJJXSW-UHFFFAOYSA-N 1-cyclohexyl-N-[[2-[(3-methylphenyl)methoxy]phenyl]methyl]propan-2-amine Chemical compound CC(CC1CCCCC1)NCC1=C(OCC2=CC(C)=CC=C2)C=CC=C1 OUOFYWJXKJJXSW-UHFFFAOYSA-N 0.000 description 1
- BXBIZHTVRSLJHS-UHFFFAOYSA-N 1-cyclohexyl-n-[(2-phenylmethoxyphenyl)methyl]propan-2-amine Chemical compound C=1C=CC=C(OCC=2C=CC=CC=2)C=1CNC(C)CC1CCCCC1 BXBIZHTVRSLJHS-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- WOHLSTOWRAOMSG-UHFFFAOYSA-N 2,3-dihydro-1,3-benzothiazole Chemical compound C1=CC=C2SCNC2=C1 WOHLSTOWRAOMSG-UHFFFAOYSA-N 0.000 description 1
- HRCMXYXVAWHBTH-UHFFFAOYSA-N 2,3-dihydro-1,3-benzoxazole Chemical compound C1=CC=C2OCNC2=C1 HRCMXYXVAWHBTH-UHFFFAOYSA-N 0.000 description 1
- XBARKDQKGSJDLG-UHFFFAOYSA-N 2-(1h-indol-4-yl)ethanamine Chemical compound NCCC1=CC=CC2=C1C=CN2 XBARKDQKGSJDLG-UHFFFAOYSA-N 0.000 description 1
- JRWUXZQPAULKLR-UHFFFAOYSA-N 2-(1h-indol-7-yl)ethanamine Chemical compound NCCC1=CC=CC2=C1NC=C2 JRWUXZQPAULKLR-UHFFFAOYSA-N 0.000 description 1
- USJLTGISJLKIGC-UHFFFAOYSA-N 2-(2-cyclohexylethyl)-4,5-dihydro-1H-2-benzazepin-3-one Chemical compound O=C1CCC2=C(CN1CCC1CCCCC1)C=CC=C2 USJLTGISJLKIGC-UHFFFAOYSA-N 0.000 description 1
- SOJNHZHNBWHIIR-UHFFFAOYSA-N 2-(2-cyclohexylpropyl)-1,4-dihydroisoquinolin-3-one Chemical compound C1(CCCCC1)C(CN1CC2=CC=CC=C2CC1=O)C SOJNHZHNBWHIIR-UHFFFAOYSA-N 0.000 description 1
- JFILVJGARSPOGL-UHFFFAOYSA-N 2-(2-cyclopentylethyl)-1,4-dihydroisoquinolin-3-one Chemical compound O=C1CC2=C(CN1CCC1CCCC1)C=CC=C2 JFILVJGARSPOGL-UHFFFAOYSA-N 0.000 description 1
- IBGVDLDIASPYHY-UHFFFAOYSA-N 2-(2-methoxynaphthalen-1-yl)ethanamine Chemical compound C1=CC=CC2=C(CCN)C(OC)=CC=C21 IBGVDLDIASPYHY-UHFFFAOYSA-N 0.000 description 1
- BXKLFCREVJPUJY-UHFFFAOYSA-N 2-(2-methylcyclohexyl)ethanamine Chemical compound CC1CCCCC1CCN BXKLFCREVJPUJY-UHFFFAOYSA-N 0.000 description 1
- HPRXQDUDLVKATH-UHFFFAOYSA-N 2-(3-bicyclo[2.2.1]heptanylmethoxy)benzaldehyde Chemical compound O=CC1=CC=CC=C1OCC1C(C2)CCC2C1 HPRXQDUDLVKATH-UHFFFAOYSA-N 0.000 description 1
- BFZWLRTYKGGBFP-UHFFFAOYSA-N 2-(3-methylcyclohexyl)ethanamine Chemical compound CC1CCCC(CCN)C1 BFZWLRTYKGGBFP-UHFFFAOYSA-N 0.000 description 1
- NDRZWXBIKCFBSU-UHFFFAOYSA-N 2-(aminomethyl)benzenesulfonamide Chemical compound NCC1=CC=CC=C1S(N)(=O)=O NDRZWXBIKCFBSU-UHFFFAOYSA-N 0.000 description 1
- XBFNWKMKUGXPCR-UHFFFAOYSA-N 2-(benzylamino)-3-cyclohexylpropan-1-ol Chemical compound C=1C=CC=CC=1CNC(CO)CC1CCCCC1 XBFNWKMKUGXPCR-UHFFFAOYSA-N 0.000 description 1
- WTDFUDAYEVDUCA-UHFFFAOYSA-N 2-(benzylamino)-3-cyclohexylpropanoic acid Chemical compound C=1C=CC=CC=1CNC(C(=O)O)CC1CCCCC1 WTDFUDAYEVDUCA-UHFFFAOYSA-N 0.000 description 1
- OSVQHCJYCVPPKY-UHFFFAOYSA-N 2-(cyclohexen-1-yl)-n-[(2-methylphenyl)methyl]ethanamine Chemical compound CC1=CC=CC=C1CNCCC1=CCCCC1 OSVQHCJYCVPPKY-UHFFFAOYSA-N 0.000 description 1
- MGZXTXVHBHMHOD-UHFFFAOYSA-N 2-(cyclohexen-1-yl)-n-[(3-methylphenyl)methyl]ethanamine Chemical compound CC1=CC=CC(CNCCC=2CCCCC=2)=C1 MGZXTXVHBHMHOD-UHFFFAOYSA-N 0.000 description 1
- YKKABOKSWPNSMV-UHFFFAOYSA-N 2-(cyclohexen-1-yl)-n-[(4-methylphenyl)methyl]ethanamine Chemical compound C1=CC(C)=CC=C1CNCCC1=CCCCC1 YKKABOKSWPNSMV-UHFFFAOYSA-N 0.000 description 1
- HFUYJXBCIYKCDA-UHFFFAOYSA-N 2-(cyclohexen-1-ylmethyl)piperidine Chemical compound C(C1CCCCN1)C1=CCCCC1 HFUYJXBCIYKCDA-UHFFFAOYSA-N 0.000 description 1
- VWNQLHAXTPHOSF-UHFFFAOYSA-N 2-(cyclohexen-1-ylmethyl)pyrrolidine Chemical compound C(C1CCCN1)C1=CCCCC1 VWNQLHAXTPHOSF-UHFFFAOYSA-N 0.000 description 1
- BZMADPOGYCRPAI-UHFFFAOYSA-N 2-(oxan-4-yl)ethanamine Chemical compound NCCC1CCOCC1 BZMADPOGYCRPAI-UHFFFAOYSA-N 0.000 description 1
- UCNCEWRKAYFRPO-UHFFFAOYSA-N 2-(thian-4-yl)ethanamine Chemical compound NCCC1CCSCC1 UCNCEWRKAYFRPO-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- IRWBEPDMVHOCPD-UHFFFAOYSA-N 2-[(1-cyclohexylpropan-2-ylamino)methyl]phenol Chemical compound C=1C=CC=C(O)C=1CNC(C)CC1CCCCC1 IRWBEPDMVHOCPD-UHFFFAOYSA-N 0.000 description 1
- FPXHAUDZSCBEPP-UHFFFAOYSA-N 2-[(2-cyclohexylethylamino)methyl]phenol Chemical compound OC1=CC=CC=C1CNCCC1CCCCC1 FPXHAUDZSCBEPP-UHFFFAOYSA-N 0.000 description 1
- UMXYAWQAPONXOJ-UHFFFAOYSA-N 2-[(2-iodophenyl)methoxy]benzaldehyde Chemical compound IC1=CC=CC=C1COC1=CC=CC=C1C=O UMXYAWQAPONXOJ-UHFFFAOYSA-N 0.000 description 1
- LJCQKUDIZCSKDV-UHFFFAOYSA-N 2-[(3-methyl-2-oxo-1,3-oxazolidin-5-yl)methylsulfanyl]benzaldehyde Chemical compound CN1C(OC(C1)CSC1=C(C=O)C=CC=C1)=O LJCQKUDIZCSKDV-UHFFFAOYSA-N 0.000 description 1
- OFOOGVHIOYRRGF-UHFFFAOYSA-N 2-[(4-fluorophenyl)methoxy]benzaldehyde Chemical compound C1=CC(F)=CC=C1COC1=CC=CC=C1C=O OFOOGVHIOYRRGF-UHFFFAOYSA-N 0.000 description 1
- JKTRDDJNOCRXJU-UHFFFAOYSA-N 2-[2-(2-fluorophenyl)ethoxy]benzaldehyde Chemical compound Fc1ccccc1CCOc1ccccc1C=O JKTRDDJNOCRXJU-UHFFFAOYSA-N 0.000 description 1
- MJAFTTLRDCMYOJ-UHFFFAOYSA-N 2-[2-(2-methylcyclohexyl)ethyl]-1,4-dihydroisoquinolin-3-one Chemical compound CC1CCCCC1CCN1CC2=C(CC1=O)C=CC=C2 MJAFTTLRDCMYOJ-UHFFFAOYSA-N 0.000 description 1
- DEXCCSARFSJKKW-UHFFFAOYSA-N 2-[2-(cyclohexen-1-yl)ethyl]-1,4-dihydroisoquinolin-3-one Chemical compound C1(=CCCCC1)CCN1CC2=CC=CC=C2CC1=O DEXCCSARFSJKKW-UHFFFAOYSA-N 0.000 description 1
- REZXLWXJXKDMSJ-UHFFFAOYSA-N 2-[2-[(1-cyclohexylpropan-2-ylamino)methyl]phenyl]ethanesulfonamide Chemical compound C1(CCCCC1)CC(C)NCC1=C(C=CC=C1)CCS(=O)(=O)N REZXLWXJXKDMSJ-UHFFFAOYSA-N 0.000 description 1
- NINJAJLCZUYDGV-UHFFFAOYSA-N 2-azaspiro[4.4]nonane Chemical compound C1CCCC21CNCC2 NINJAJLCZUYDGV-UHFFFAOYSA-N 0.000 description 1
- SZIFAVKTNFCBPC-UHFFFAOYSA-N 2-chloroethanol Chemical compound OCCCl SZIFAVKTNFCBPC-UHFFFAOYSA-N 0.000 description 1
- TYRMEBINDCQOHD-UHFFFAOYSA-N 2-chloroethylcyclohexane Chemical compound ClCCC1CCCCC1 TYRMEBINDCQOHD-UHFFFAOYSA-N 0.000 description 1
- KGUSYCRGABWRNU-UHFFFAOYSA-N 2-cycloheptylacetaldehyde Chemical compound O=CCC1CCCCCC1 KGUSYCRGABWRNU-UHFFFAOYSA-N 0.000 description 1
- XOQWQVXVVDEVTB-UHFFFAOYSA-N 2-cyclohexyl-1,4-dihydroisoquinolin-3-one Chemical compound O=C1CC2=CC=CC=C2CN1C1CCCCC1 XOQWQVXVVDEVTB-UHFFFAOYSA-N 0.000 description 1
- DVYIRGDXJAMJLL-UHFFFAOYSA-N 2-cyclohexyl-N-[(2-trimethylsilylphenyl)methyl]ethanamine hydrochloride Chemical compound Cl.C1(CCCCC1)CCNCC1=C(C=CC=C1)[Si](C)(C)C DVYIRGDXJAMJLL-UHFFFAOYSA-N 0.000 description 1
- DKTQKJANKANIOO-UHFFFAOYSA-N 2-cyclohexyl-N-[[2-(oxan-4-ylmethoxy)phenyl]methyl]ethanamine Chemical compound C1(CCCCC1)CCNCC1=C(C=CC=C1)OCC1CCOCC1 DKTQKJANKANIOO-UHFFFAOYSA-N 0.000 description 1
- DJMQLAJAEKFINM-UHFFFAOYSA-N 2-cyclohexyl-N-[[2-(oxolan-2-ylmethoxy)phenyl]methyl]ethanamine Chemical compound C1(CCCCC1)CCNCC1=C(C=CC=C1)OCC1OCCC1 DJMQLAJAEKFINM-UHFFFAOYSA-N 0.000 description 1
- XNIPODHURRYQTR-UHFFFAOYSA-N 2-cyclohexyl-N-[[2-(oxolan-3-ylmethoxy)phenyl]methyl]ethanamine Chemical compound C1(CCCCC1)CCNCC1=C(C=CC=C1)OCC1COCC1 XNIPODHURRYQTR-UHFFFAOYSA-N 0.000 description 1
- GISFOOKREJCWNP-UHFFFAOYSA-N 2-cyclohexyl-N-[[3-(methylaminomethyl)phenyl]methyl]ethanamine Chemical compound C1(CCCCC1)CCNCC1=CC(=CC=C1)CNC GISFOOKREJCWNP-UHFFFAOYSA-N 0.000 description 1
- CDIYOXVOAKRWQT-UHFFFAOYSA-N 2-cyclohexylpropan-1-amine Chemical compound NCC(C)C1CCCCC1 CDIYOXVOAKRWQT-UHFFFAOYSA-N 0.000 description 1
- UQURIQWAEZGLAC-UHFFFAOYSA-N 2-cyclohexylpropanal Chemical compound O=CC(C)C1CCCCC1 UQURIQWAEZGLAC-UHFFFAOYSA-N 0.000 description 1
- UKPLRVAKKXWITN-UHFFFAOYSA-N 2-cyclopentylethanamine Chemical compound NCCC1CCCC1 UKPLRVAKKXWITN-UHFFFAOYSA-N 0.000 description 1
- ZWDVQMVZZYIAHO-UHFFFAOYSA-N 2-fluorobenzaldehyde Chemical compound FC1=CC=CC=C1C=O ZWDVQMVZZYIAHO-UHFFFAOYSA-N 0.000 description 1
- NSTREUWFTAOOKS-UHFFFAOYSA-N 2-fluorobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1F NSTREUWFTAOOKS-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- PBEJTRAJWCNHRS-UHFFFAOYSA-N 2-phenylmethoxybenzaldehyde Chemical compound O=CC1=CC=CC=C1OCC1=CC=CC=C1 PBEJTRAJWCNHRS-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- YNKVCLQNSSTHTD-UHFFFAOYSA-N 3,9-diazaspiro[5.5]undecane Chemical compound C1CNCCC21CCNCC2 YNKVCLQNSSTHTD-UHFFFAOYSA-N 0.000 description 1
- BPTJTDAUVUOVHH-UHFFFAOYSA-N 3-[(2-cyclohexylethylamino)methyl]-N-methylaniline Chemical compound CNc1cccc(CNCCC2CCCCC2)c1 BPTJTDAUVUOVHH-UHFFFAOYSA-N 0.000 description 1
- KPUSZZFAYGWAHZ-UHFFFAOYSA-N 3-azabicyclo[2.2.2]octane Chemical compound C1CC2CCC1NC2 KPUSZZFAYGWAHZ-UHFFFAOYSA-N 0.000 description 1
- HGWUUOXXAIISDB-UHFFFAOYSA-N 3-azabicyclo[3.1.0]hexane Chemical compound C1NCC2CC21 HGWUUOXXAIISDB-UHFFFAOYSA-N 0.000 description 1
- NEOIOGUWEUTYIH-UHFFFAOYSA-N 3-azabicyclo[3.2.0]heptane Chemical compound C1NCC2CCC21 NEOIOGUWEUTYIH-UHFFFAOYSA-N 0.000 description 1
- CJQNJRRDTPULTL-UHFFFAOYSA-N 3-azabicyclo[3.2.1]octane Chemical compound C1C2CCC1CNC2 CJQNJRRDTPULTL-UHFFFAOYSA-N 0.000 description 1
- XAIUACHCJPWUEF-UHFFFAOYSA-N 3-azabicyclo[3.3.1]nonane Chemical compound C1NCC2CCCC1C2 XAIUACHCJPWUEF-UHFFFAOYSA-N 0.000 description 1
- LIZKZVQBLDHKCY-UHFFFAOYSA-N 3-azaspiro[5.5]undecane Chemical compound C1CCCCC21CCNCC2 LIZKZVQBLDHKCY-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- IYTJRMRETHPZAC-UHFFFAOYSA-N 4,4-dibenzylpiperidine Chemical compound C1CNCCC1(CC=1C=CC=CC=1)CC1=CC=CC=C1 IYTJRMRETHPZAC-UHFFFAOYSA-N 0.000 description 1
- USWBQWMBXCEERJ-UHFFFAOYSA-N 4-[2-(benzylamino)ethyl]cyclohexan-1-one Chemical compound C(C1=CC=CC=C1)NCCC1CCC(CC1)=O USWBQWMBXCEERJ-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- VJPPDEZWWKCSIV-UHFFFAOYSA-N 6-azabicyclo[3.2.1]octane Chemical compound C1C2CNC1CCC2 VJPPDEZWWKCSIV-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000604451 Acidaminococcus Species 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 241000588624 Acinetobacter calcoaceticus Species 0.000 description 1
- 241000930995 Acinetobacter gyllenbergii Species 0.000 description 1
- 241001148231 Acinetobacter haemolyticus Species 0.000 description 1
- 241000122230 Acinetobacter junii Species 0.000 description 1
- 241001135518 Acinetobacter lwoffii Species 0.000 description 1
- 241001528221 Acinetobacter nosocomialis Species 0.000 description 1
- 241000930987 Acinetobacter parvus Species 0.000 description 1
- 241000229113 Acinetobacter pittii Species 0.000 description 1
- 241001556023 Acinetobacter schindleri Species 0.000 description 1
- 241001116605 Acinetobacter seifertii Species 0.000 description 1
- 241000271152 Acinetobacter soli Species 0.000 description 1
- 241001556024 Acinetobacter ursingii Species 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 241000511654 Actinomyces gerencseriae Species 0.000 description 1
- 241000186041 Actinomyces israelii Species 0.000 description 1
- 241000511582 Actinomyces meyeri Species 0.000 description 1
- 241000186045 Actinomyces naeslundii Species 0.000 description 1
- 241001464988 Actinomyces neuii Species 0.000 description 1
- 241000186066 Actinomyces odontolyticus Species 0.000 description 1
- 241000900280 Actinomyces radingae Species 0.000 description 1
- 241000900275 Actinomyces turicensis Species 0.000 description 1
- 241000186044 Actinomyces viscosus Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241001024600 Aggregatibacter Species 0.000 description 1
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 description 1
- 241000606828 Aggregatibacter aphrophilus Species 0.000 description 1
- 241000606806 Aggregatibacter segnis Species 0.000 description 1
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000100578 Amorphophallus variabilis Species 0.000 description 1
- 241000722955 Anaerobiospirillum Species 0.000 description 1
- 241000786447 Anaerobiospirillum thomasii Species 0.000 description 1
- 108010085443 Anserine Proteins 0.000 description 1
- 241001135163 Arcobacter Species 0.000 description 1
- 241001135164 Arcobacter butzleri Species 0.000 description 1
- 241001135165 Arcobacter cryaerophilus Species 0.000 description 1
- 241001135723 Arcobacter skirrowii Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000588732 Atlantibacter hermannii Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 241000606660 Bartonella Species 0.000 description 1
- 241000511683 Bartonella alsatica Species 0.000 description 1
- 241001077761 Bartonella ancashensis Species 0.000 description 1
- 241000606685 Bartonella bacilliformis Species 0.000 description 1
- 241000011631 Bartonella capreoli Species 0.000 description 1
- 241000567117 Bartonella clarridgeiae Species 0.000 description 1
- 241001464950 Bartonella doshiae Species 0.000 description 1
- 241000606070 Bartonella elizabethae Species 0.000 description 1
- 241001464952 Bartonella grahamii Species 0.000 description 1
- 241001518086 Bartonella henselae Species 0.000 description 1
- 241001104727 Bartonella japonica Species 0.000 description 1
- 241000332162 Bartonella koehlerae Species 0.000 description 1
- 241001603744 Bartonella peromysci Species 0.000 description 1
- 241000606108 Bartonella quintana Species 0.000 description 1
- 241000895318 Bartonella rochalimae Species 0.000 description 1
- 241000383843 Bartonella schoenbuchensis Species 0.000 description 1
- 241000280718 Bartonella talpae Species 0.000 description 1
- 241000142360 Bartonella tamiae Species 0.000 description 1
- 241001464954 Bartonella taylorii Species 0.000 description 1
- 241001673680 Bartonella tribocorum Species 0.000 description 1
- 241001464955 Bartonella vinsonii Species 0.000 description 1
- 241001112440 Bartonella washoensis Species 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000853395 Bordetella ansorpii Species 0.000 description 1
- 241000588851 Bordetella avium Species 0.000 description 1
- 241000588779 Bordetella bronchiseptica Species 0.000 description 1
- 241001477981 Bordetella hinzii Species 0.000 description 1
- 241001495147 Bordetella holmesii Species 0.000 description 1
- 241000588780 Bordetella parapertussis Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000543043 Bordetella trematum Species 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 241000589978 Borrelia hermsii Species 0.000 description 1
- 241000216520 Borrelia miyamotoi Species 0.000 description 1
- 241000589976 Borrelia parkeri Species 0.000 description 1
- 241000180135 Borrelia recurrentis Species 0.000 description 1
- 241000589977 Borrelia turicatae Species 0.000 description 1
- 241001148604 Borreliella afzelii Species 0.000 description 1
- 241000142472 Borreliella andersonii Species 0.000 description 1
- 241000908527 Borreliella bissettii Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 241001584047 Borreliella carolinensis Species 0.000 description 1
- 241001148605 Borreliella garinii Species 0.000 description 1
- 241001226990 Borreliella kurtenbachii Species 0.000 description 1
- 241001446608 Borreliella lusitaniae Species 0.000 description 1
- 241000004488 Borreliella sinica Species 0.000 description 1
- 241000019016 Borreliella spielmanii Species 0.000 description 1
- 241001148534 Brachyspira Species 0.000 description 1
- 241001148535 Brachyspira aalborgi Species 0.000 description 1
- 241000589893 Brachyspira hyodysenteriae Species 0.000 description 1
- 241000510930 Brachyspira pilosicoli Species 0.000 description 1
- 241000589173 Bradyrhizobium Species 0.000 description 1
- 241000589174 Bradyrhizobium japonicum Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 241001453380 Burkholderia Species 0.000 description 1
- 241000589513 Burkholderia cepacia Species 0.000 description 1
- 241001646389 Burkholderia dolosa Species 0.000 description 1
- 241000722910 Burkholderia mallei Species 0.000 description 1
- 241001136175 Burkholderia pseudomallei Species 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- OZTUWOGBBJGKGC-UHFFFAOYSA-N C(C1=CC=CC=C1)N1C(C2CCCCC2CC1)=O Chemical compound C(C1=CC=CC=C1)N1C(C2CCCCC2CC1)=O OZTUWOGBBJGKGC-UHFFFAOYSA-N 0.000 description 1
- UILCHLNDDALGKU-UHFFFAOYSA-N C(C1=CC=CC=C1)N1C=CC2=CC=CC(=C12)CNC(CC1CCCCC1)C Chemical compound C(C1=CC=CC=C1)N1C=CC2=CC=CC(=C12)CNC(CC1CCCCC1)C UILCHLNDDALGKU-UHFFFAOYSA-N 0.000 description 1
- DRBTYCKXVWHPAF-UHFFFAOYSA-N C(C1=CC=CC=C1)NC(CC1CCCCC1)CCC Chemical compound C(C1=CC=CC=C1)NC(CC1CCCCC1)CCC DRBTYCKXVWHPAF-UHFFFAOYSA-N 0.000 description 1
- KLIILNPBQHJPLQ-UHFFFAOYSA-N C(C1=CC=CC=C1)NCCC1C(CCCC1)C(=O)O Chemical compound C(C1=CC=CC=C1)NCCC1C(CCCC1)C(=O)O KLIILNPBQHJPLQ-UHFFFAOYSA-N 0.000 description 1
- IUGVAVXEMIEBJF-UHFFFAOYSA-N C(CN1CCC2=C(C1)C=CC=C2)C1CCCCC1 Chemical compound C(CN1CCC2=C(C1)C=CC=C2)C1CCCCC1 IUGVAVXEMIEBJF-UHFFFAOYSA-N 0.000 description 1
- XDHYYWZOMABUOS-UHFFFAOYSA-N C(COC1=C(C=CC=C1)CNC(C)CC1CCCCC1)C1=CC=CC=C1F Chemical compound C(COC1=C(C=CC=C1)CNC(C)CC1CCCCC1)C1=CC=CC=C1F XDHYYWZOMABUOS-UHFFFAOYSA-N 0.000 description 1
- AWTRVPJZEJFKJP-UHFFFAOYSA-N C(F)(F)(F)C1CCC(CC(=O)C)CC1 Chemical compound C(F)(F)(F)C1CCC(CC(=O)C)CC1 AWTRVPJZEJFKJP-UHFFFAOYSA-N 0.000 description 1
- RNEPHULIBNHXBJ-UHFFFAOYSA-N C1(=CC=CC=C1)CCC1NC(CC2=CC=CC=C12)=O Chemical compound C1(=CC=CC=C1)CCC1NC(CC2=CC=CC=C12)=O RNEPHULIBNHXBJ-UHFFFAOYSA-N 0.000 description 1
- QAVSIQCJIBTGOC-UHFFFAOYSA-N C1(CCCCC1)CC(C)NCC1=C(C=CC=C1)CCCO Chemical compound C1(CCCCC1)CC(C)NCC1=C(C=CC=C1)CCCO QAVSIQCJIBTGOC-UHFFFAOYSA-N 0.000 description 1
- GHQDVUZMJVZQQC-UHFFFAOYSA-N C1(CCCCC1)CC(C)NCC1=C(C=CC=C1)OC1CCCCC1 Chemical compound C1(CCCCC1)CC(C)NCC1=C(C=CC=C1)OC1CCCCC1 GHQDVUZMJVZQQC-UHFFFAOYSA-N 0.000 description 1
- FONGHCQZWJBYPL-UHFFFAOYSA-N C1(CCCCC1)CC(C)NCC1=C(C=CC=C1)SCC1CN(C(O1)=O)C Chemical compound C1(CCCCC1)CC(C)NCC1=C(C=CC=C1)SCC1CN(C(O1)=O)C FONGHCQZWJBYPL-UHFFFAOYSA-N 0.000 description 1
- LLHRNISHLJZQMT-UHFFFAOYSA-N C1(CCCCC1)CC(C)NCC=1C=CC=C2C=CN(C=12)CC(=O)OC Chemical compound C1(CCCCC1)CC(C)NCC=1C=CC=C2C=CN(C=12)CC(=O)OC LLHRNISHLJZQMT-UHFFFAOYSA-N 0.000 description 1
- HAXLSAQRSVKTLO-UHFFFAOYSA-N C1(CCCCC1)CCCN1CC2=CC=CC=C2CC1=O Chemical compound C1(CCCCC1)CCCN1CC2=CC=CC=C2CC1=O HAXLSAQRSVKTLO-UHFFFAOYSA-N 0.000 description 1
- JBHQPKSTBDZWBD-UHFFFAOYSA-N C1(CCCCC1)CCN1C(C2=CC=CC=C2C1)=O Chemical compound C1(CCCCC1)CCN1C(C2=CC=CC=C2C1)=O JBHQPKSTBDZWBD-UHFFFAOYSA-N 0.000 description 1
- WJHSGGKSCSMZAV-UHFFFAOYSA-N C1(CCCCC1)CCNCC1=C(CB(O)O)C=CC=C1 Chemical compound C1(CCCCC1)CCNCC1=C(CB(O)O)C=CC=C1 WJHSGGKSCSMZAV-UHFFFAOYSA-N 0.000 description 1
- QTOVEJOVYNNAQU-UHFFFAOYSA-N C1(CCCCC1)CCNCC=1C=C(C=CC=1)CC(=O)OC Chemical compound C1(CCCCC1)CCNCC=1C=C(C=CC=1)CC(=O)OC QTOVEJOVYNNAQU-UHFFFAOYSA-N 0.000 description 1
- FRRPBDUAROXYKR-UHFFFAOYSA-N C1(CCCCC1)CCNCC=1C=C(C=CC=1)N(C(OC(C)(C)C)=O)C Chemical compound C1(CCCCC1)CCNCC=1C=C(C=CC=1)N(C(OC(C)(C)C)=O)C FRRPBDUAROXYKR-UHFFFAOYSA-N 0.000 description 1
- ACXUVRIASULLOQ-UHFFFAOYSA-N C12(CCCCC2C1)CCNC(C1=CC=CC=C1)=O Chemical compound C12(CCCCC2C1)CCNC(C1=CC=CC=C1)=O ACXUVRIASULLOQ-UHFFFAOYSA-N 0.000 description 1
- MOCQPXCUZTVFNQ-UHFFFAOYSA-N C12C(CC(CC1)C2)OC1=C(CNC(CC2CCCCC2)C)C=CC=C1 Chemical compound C12C(CC(CC1)C2)OC1=C(CNC(CC2CCCCC2)C)C=CC=C1 MOCQPXCUZTVFNQ-UHFFFAOYSA-N 0.000 description 1
- DNUDOYNJTPCSBO-UHFFFAOYSA-N C1=CC=2CN(C(=O)OC=2C=C1)C(C)CC1CCCCC1 Chemical compound C1=CC=2CN(C(=O)OC=2C=C1)C(C)CC1CCCCC1 DNUDOYNJTPCSBO-UHFFFAOYSA-N 0.000 description 1
- GYMBMJKWZUTKIS-UHFFFAOYSA-N CC(CC1CCCCC1)N1CC2=C(CC1=O)C=CC=C2 Chemical compound CC(CC1CCCCC1)N1CC2=C(CC1=O)C=CC=C2 GYMBMJKWZUTKIS-UHFFFAOYSA-N 0.000 description 1
- GPJAVHPHBGYFNG-UHFFFAOYSA-N CC(CC1CCCCC1)NCC1=C(CCC2=C(F)C=CC=C2)C=CC=C1 Chemical compound CC(CC1CCCCC1)NCC1=C(CCC2=C(F)C=CC=C2)C=CC=C1 GPJAVHPHBGYFNG-UHFFFAOYSA-N 0.000 description 1
- UXQFQDMBXAYZIW-UHFFFAOYSA-N CC(CC1CCCCC1)NCC1=C(CS(=O)(=O)N2CCN(C)CC2)C=CC=C1 Chemical compound CC(CC1CCCCC1)NCC1=C(CS(=O)(=O)N2CCN(C)CC2)C=CC=C1 UXQFQDMBXAYZIW-UHFFFAOYSA-N 0.000 description 1
- RESODYLYVVSWJR-UHFFFAOYSA-N CC(CC1CCCCC1)NCC1=C(CS(=O)(=O)NC(=O)NC2CCC(C)CC2)C=CC=C1 Chemical compound CC(CC1CCCCC1)NCC1=C(CS(=O)(=O)NC(=O)NC2CCC(C)CC2)C=CC=C1 RESODYLYVVSWJR-UHFFFAOYSA-N 0.000 description 1
- JMPVWBRBANFCSJ-UHFFFAOYSA-N CC(CC1CCCCC1)NCC1=C(CS(=O)(=O)NCC2CCCO2)C=CC=C1 Chemical compound CC(CC1CCCCC1)NCC1=C(CS(=O)(=O)NCC2CCCO2)C=CC=C1 JMPVWBRBANFCSJ-UHFFFAOYSA-N 0.000 description 1
- FDPJCUQSSYPCIJ-UHFFFAOYSA-N CC(CC1CCCCC1)NCC1=C(CS(C)(=O)=O)C=CC=C1 Chemical compound CC(CC1CCCCC1)NCC1=C(CS(C)(=O)=O)C=CC=C1 FDPJCUQSSYPCIJ-UHFFFAOYSA-N 0.000 description 1
- WINSZPJPEUTWGD-UHFFFAOYSA-N CC(CC1CCCCC1)NCC1=C(OC2CC3CC2C2CCCC32)C=CC=C1 Chemical compound CC(CC1CCCCC1)NCC1=C(OC2CC3CC2C2CCCC32)C=CC=C1 WINSZPJPEUTWGD-UHFFFAOYSA-N 0.000 description 1
- ZWLDLPQAIRPTHJ-UHFFFAOYSA-N CC(CC1CCCCC1)NCC1=C(OC2CCCC(C)C2)C=CC=C1 Chemical compound CC(CC1CCCCC1)NCC1=C(OC2CCCC(C)C2)C=CC=C1 ZWLDLPQAIRPTHJ-UHFFFAOYSA-N 0.000 description 1
- XNWUWNLKMOXZNM-UHFFFAOYSA-N CC(CC1CCCCC1)NCC1=C(OCC2=C(C=CC=C2)C2CC2)C=CC=C1 Chemical compound CC(CC1CCCCC1)NCC1=C(OCC2=C(C=CC=C2)C2CC2)C=CC=C1 XNWUWNLKMOXZNM-UHFFFAOYSA-N 0.000 description 1
- VAWBEAAFEGCPPX-UHFFFAOYSA-N CC(CC1CCCCC1)NCC1=C(OCC2=CC=C(C)C=C2)C=CC=C1 Chemical compound CC(CC1CCCCC1)NCC1=C(OCC2=CC=C(C)C=C2)C=CC=C1 VAWBEAAFEGCPPX-UHFFFAOYSA-N 0.000 description 1
- VBWZWKHAONPDPC-UHFFFAOYSA-N CC(CC1CCCCC1)NCC1=C(OCC2=CC=C(F)C=C2)C=CC=C1 Chemical compound CC(CC1CCCCC1)NCC1=C(OCC2=CC=C(F)C=C2)C=CC=C1 VBWZWKHAONPDPC-UHFFFAOYSA-N 0.000 description 1
- NRPOHXOUAGVCHA-UHFFFAOYSA-N CC(N)CC1CCC(F)(F)CC1 Chemical compound CC(N)CC1CCC(F)(F)CC1 NRPOHXOUAGVCHA-UHFFFAOYSA-N 0.000 description 1
- CGBJRLWWWPTDTJ-UHFFFAOYSA-N CC1CCC(CC1)NC(=O)NS(=O)(=O)CC1=C(CN)C=CC=C1 Chemical compound CC1CCC(CC1)NC(=O)NS(=O)(=O)CC1=C(CN)C=CC=C1 CGBJRLWWWPTDTJ-UHFFFAOYSA-N 0.000 description 1
- VVOGULJAUSJIJJ-UHFFFAOYSA-N CC1CCCC(CCN2CC3=C(CC2=O)C=CC=C3)C1 Chemical compound CC1CCCC(CCN2CC3=C(CC2=O)C=CC=C3)C1 VVOGULJAUSJIJJ-UHFFFAOYSA-N 0.000 description 1
- XYMNJLDPWCKMPZ-UHFFFAOYSA-N CCC1CCC(CC(C)NCC2=C(OCC3=C(F)C=CC=C3)C=CC=C2)CC1 Chemical compound CCC1CCC(CC(C)NCC2=C(OCC3=C(F)C=CC=C3)C=CC=C2)CC1 XYMNJLDPWCKMPZ-UHFFFAOYSA-N 0.000 description 1
- GOMPHAYYQUNOHQ-UHFFFAOYSA-N COC1=CC=CC(COC2=C(CNC(C)CC3CCCCC3)C=CC=C2)=C1 Chemical compound COC1=CC=CC(COC2=C(CNC(C)CC3CCCCC3)C=CC=C2)=C1 GOMPHAYYQUNOHQ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000589877 Campylobacter coli Species 0.000 description 1
- 241000589874 Campylobacter fetus Species 0.000 description 1
- 241001290832 Campylobacter hominis Species 0.000 description 1
- 241000589872 Campylobacter hyointestinalis Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000589986 Campylobacter lari Species 0.000 description 1
- 241001135528 Campylobacter upsaliensis Species 0.000 description 1
- 241000606177 Campylobacter ureolyticus Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000207206 Cardiobacterium Species 0.000 description 1
- 241001466752 Cardiobacterium valvarum Species 0.000 description 1
- 240000008031 Chamaedorea elegans Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000755920 Christensenella Species 0.000 description 1
- 241000914543 Christensenella massiliensis Species 0.000 description 1
- 241000801624 Christensenella minuta Species 0.000 description 1
- 241001254467 Christensenella timonensis Species 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 241001494522 Citrobacter amalonaticus Species 0.000 description 1
- 241000580513 Citrobacter braakii Species 0.000 description 1
- 241000588917 Citrobacter koseri Species 0.000 description 1
- 241000949032 Citrobacter sedlakii Species 0.000 description 1
- IOWNLZAZYFWQCM-UHFFFAOYSA-N Cl.C(C1=CC=CC=C1)NC(C(=O)N)CC1CCCCC1 Chemical compound Cl.C(C1=CC=CC=C1)NC(C(=O)N)CC1CCCCC1 IOWNLZAZYFWQCM-UHFFFAOYSA-N 0.000 description 1
- PUBNYAHXQFLSOU-UHFFFAOYSA-N Cl.C(C1=CC=CC=C1)NC(C(=O)OC)CC1CCCCC1 Chemical compound Cl.C(C1=CC=CC=C1)NC(C(=O)OC)CC1CCCCC1 PUBNYAHXQFLSOU-UHFFFAOYSA-N 0.000 description 1
- XGMIVWYNELPYEK-UHFFFAOYSA-N Cl.C(C1=CC=CC=C1)NC(CC1CCCCC1)C1=CC=CC=C1 Chemical compound Cl.C(C1=CC=CC=C1)NC(CC1CCCCC1)C1=CC=CC=C1 XGMIVWYNELPYEK-UHFFFAOYSA-N 0.000 description 1
- IPXWKKPNHCQKLA-UHFFFAOYSA-N Cl.C(C1=CC=CC=C1)NC(CC1CCCCC1)COC Chemical compound Cl.C(C1=CC=CC=C1)NC(CC1CCCCC1)COC IPXWKKPNHCQKLA-UHFFFAOYSA-N 0.000 description 1
- LFXBCQYFGALEOP-UHFFFAOYSA-N Cl.C(C1=CC=CC=C1)NCC1C2=C(B(O1)O)C(=CC=C2)OC Chemical compound Cl.C(C1=CC=CC=C1)NCC1C2=C(B(O1)O)C(=CC=C2)OC LFXBCQYFGALEOP-UHFFFAOYSA-N 0.000 description 1
- GETJETOJQOCWTO-UHFFFAOYSA-N Cl.C(C1=CC=CC=C1)NCC1CCC2=CC=CC=C12 Chemical compound Cl.C(C1=CC=CC=C1)NCC1CCC2=CC=CC=C12 GETJETOJQOCWTO-UHFFFAOYSA-N 0.000 description 1
- AXFIWXLDOYHMFN-UHFFFAOYSA-N Cl.C(C1=CC=CC=C1)NCC1CCCC2=CC=CC=C12 Chemical compound Cl.C(C1=CC=CC=C1)NCC1CCCC2=CC=CC=C12 AXFIWXLDOYHMFN-UHFFFAOYSA-N 0.000 description 1
- DDIOHGVUZZSZIL-UHFFFAOYSA-N Cl.C(C1=CC=CC=C1)NCCC1CC=CCC1 Chemical compound Cl.C(C1=CC=CC=C1)NCCC1CC=CCC1 DDIOHGVUZZSZIL-UHFFFAOYSA-N 0.000 description 1
- DTTKNMGUJAPUDG-UHFFFAOYSA-N Cl.C(C1=CC=CC=C1)NCCC1CCC(CC1)(F)F Chemical compound Cl.C(C1=CC=CC=C1)NCCC1CCC(CC1)(F)F DTTKNMGUJAPUDG-UHFFFAOYSA-N 0.000 description 1
- AXDSFKKRYRVHII-UHFFFAOYSA-N Cl.C(C1=CC=CC=C1)NCCC1CCNCC1 Chemical compound Cl.C(C1=CC=CC=C1)NCCC1CCNCC1 AXDSFKKRYRVHII-UHFFFAOYSA-N 0.000 description 1
- XGMIVWYNELPYEK-ZMBIFBSDSA-N Cl.C(C1=CC=CC=C1)N[C@H](CC1CCCCC1)C1=CC=CC=C1 Chemical compound Cl.C(C1=CC=CC=C1)N[C@H](CC1CCCCC1)C1=CC=CC=C1 XGMIVWYNELPYEK-ZMBIFBSDSA-N 0.000 description 1
- URBKFMRCFSLOEO-NTISSMGPSA-N Cl.C(C1=CC=CC=C1)N[C@H]1CCC2=CC=C(C=C12)F Chemical compound Cl.C(C1=CC=CC=C1)N[C@H]1CCC2=CC=C(C=C12)F URBKFMRCFSLOEO-NTISSMGPSA-N 0.000 description 1
- FSEFQOBZBHWZKN-LMOVPXPDSA-N Cl.C(C1=CC=CC=C1)N[C@H]1CCC2=CC=C(C=C12)OC Chemical compound Cl.C(C1=CC=CC=C1)N[C@H]1CCC2=CC=C(C=C12)OC FSEFQOBZBHWZKN-LMOVPXPDSA-N 0.000 description 1
- DREUSLSOXDXOTG-UHFFFAOYSA-N Cl.C1(=C(C=CC=C1)CNCCC1CCCCC1)C1=CC=CC=C1 Chemical compound Cl.C1(=C(C=CC=C1)CNCCC1CCCCC1)C1=CC=CC=C1 DREUSLSOXDXOTG-UHFFFAOYSA-N 0.000 description 1
- VXXPBEXKOXAJGC-UHFFFAOYSA-N Cl.C1(CCCCC1)CC(C)NCC1=C(C=CC=C1)CCC(=O)OC Chemical compound Cl.C1(CCCCC1)CC(C)NCC1=C(C=CC=C1)CCC(=O)OC VXXPBEXKOXAJGC-UHFFFAOYSA-N 0.000 description 1
- JLWYTEUAEXRCQS-UHFFFAOYSA-N Cl.C1(CCCCC1)CC(C)NCC1=C(C=CC=C1)NC(C1=C(C=CC=C1)F)=O Chemical compound Cl.C1(CCCCC1)CC(C)NCC1=C(C=CC=C1)NC(C1=C(C=CC=C1)F)=O JLWYTEUAEXRCQS-UHFFFAOYSA-N 0.000 description 1
- MJDBKEDISPXJHM-UHFFFAOYSA-N Cl.C1(CCCCC1)CC(C)NCC=1C=CC=C2C=CN(C12)C Chemical compound Cl.C1(CCCCC1)CC(C)NCC=1C=CC=C2C=CN(C12)C MJDBKEDISPXJHM-UHFFFAOYSA-N 0.000 description 1
- QYGSTPJVGFWHLB-UHFFFAOYSA-N Cl.C1(CCCCC1)CC(C)NCC=1C=CC=C2C=CN(C12)CC(=O)OC Chemical compound Cl.C1(CCCCC1)CC(C)NCC=1C=CC=C2C=CN(C12)CC(=O)OC QYGSTPJVGFWHLB-UHFFFAOYSA-N 0.000 description 1
- NINWRJWBYVCIBM-UHFFFAOYSA-N Cl.C1(CCCCC1)CC(C)NCC=1C=CC=C2C=CN(C12)CCO Chemical compound Cl.C1(CCCCC1)CC(C)NCC=1C=CC=C2C=CN(C12)CCO NINWRJWBYVCIBM-UHFFFAOYSA-N 0.000 description 1
- UISIOOPTOMFNDT-UHFFFAOYSA-N Cl.C1(CCCCC1)CC(C)NCC=1C=CC=C2C=CN(C=12)CC(=O)O Chemical compound Cl.C1(CCCCC1)CC(C)NCC=1C=CC=C2C=CN(C=12)CC(=O)O UISIOOPTOMFNDT-UHFFFAOYSA-N 0.000 description 1
- YDKMLBRXHCNAPW-UHFFFAOYSA-N Cl.C1(CCCCC1)CC(CC)NCC1=C(C=CC=C1)F Chemical compound Cl.C1(CCCCC1)CC(CC)NCC1=C(C=CC=C1)F YDKMLBRXHCNAPW-UHFFFAOYSA-N 0.000 description 1
- DMPJFZAHFHHFCW-UHFFFAOYSA-N Cl.C1(CCCCC1)CCNCC1=C(C(=O)O)C=CC=C1 Chemical compound Cl.C1(CCCCC1)CCNCC1=C(C(=O)O)C=CC=C1 DMPJFZAHFHHFCW-UHFFFAOYSA-N 0.000 description 1
- RAGHMKGSDMVGEY-UHFFFAOYSA-N Cl.C1(CCCCC1)CCNCC1=C(C(=O)OC)C=CC=C1 Chemical compound Cl.C1(CCCCC1)CCNCC1=C(C(=O)OC)C=CC=C1 RAGHMKGSDMVGEY-UHFFFAOYSA-N 0.000 description 1
- KWGNEEIHVXYXBC-UHFFFAOYSA-N Cl.C1(CCCCC1)CCNCC1=C(C=CC=C1)C(C)C Chemical compound Cl.C1(CCCCC1)CCNCC1=C(C=CC=C1)C(C)C KWGNEEIHVXYXBC-UHFFFAOYSA-N 0.000 description 1
- QJRPAICDAWHRLT-UHFFFAOYSA-N Cl.C1(CCCCC1)CCNCC1=C(C=CC=C1)C(F)(F)F Chemical compound Cl.C1(CCCCC1)CCNCC1=C(C=CC=C1)C(F)(F)F QJRPAICDAWHRLT-UHFFFAOYSA-N 0.000 description 1
- DKRMQDJCTZDFQL-UHFFFAOYSA-N Cl.C1(CCCCC1)CCNCC1=C(C=CC=C1)C1=CC2=CC=CC=C2C=C1 Chemical compound Cl.C1(CCCCC1)CCNCC1=C(C=CC=C1)C1=CC2=CC=CC=C2C=C1 DKRMQDJCTZDFQL-UHFFFAOYSA-N 0.000 description 1
- ATMJIULGJISRLM-UHFFFAOYSA-N Cl.C1(CCCCC1)CCNCC1=C(C=CC=C1)C1=CC=CC2=CC=CC=C12 Chemical compound Cl.C1(CCCCC1)CCNCC1=C(C=CC=C1)C1=CC=CC2=CC=CC=C12 ATMJIULGJISRLM-UHFFFAOYSA-N 0.000 description 1
- OTSVIEGMEZRDMS-UHFFFAOYSA-N Cl.C1(CCCCC1)CCNCC1=C(C=CC=C1)C1CC1 Chemical compound Cl.C1(CCCCC1)CCNCC1=C(C=CC=C1)C1CC1 OTSVIEGMEZRDMS-UHFFFAOYSA-N 0.000 description 1
- HMYIPTZOSXHAMI-UHFFFAOYSA-N Cl.C1(CCCCC1)CCNCC1=C(C=CC=C1)C=1OC=CC1 Chemical compound Cl.C1(CCCCC1)CCNCC1=C(C=CC=C1)C=1OC=CC1 HMYIPTZOSXHAMI-UHFFFAOYSA-N 0.000 description 1
- OOSAFLZMFBTCRH-UHFFFAOYSA-N Cl.C1(CCCCC1)CCNCC1=C(C=CC=C1)C=1SC=CC1 Chemical compound Cl.C1(CCCCC1)CCNCC1=C(C=CC=C1)C=1SC=CC1 OOSAFLZMFBTCRH-UHFFFAOYSA-N 0.000 description 1
- PDHGLBXGTMWEIW-UHFFFAOYSA-N Cl.C1(CCCCC1)CCNCC1=C(C=CC=C1)CC Chemical compound Cl.C1(CCCCC1)CCNCC1=C(C=CC=C1)CC PDHGLBXGTMWEIW-UHFFFAOYSA-N 0.000 description 1
- ATLBZOVATJNMGG-UHFFFAOYSA-N Cl.C1(CCCCC1)CCNCC1=C(C=CC=C1)CO Chemical compound Cl.C1(CCCCC1)CCNCC1=C(C=CC=C1)CO ATLBZOVATJNMGG-UHFFFAOYSA-N 0.000 description 1
- ANLOTRAKTCZGQW-UHFFFAOYSA-N Cl.C1(CCCCC1)CCNCC1=C(C=CC=C1)OC Chemical compound Cl.C1(CCCCC1)CCNCC1=C(C=CC=C1)OC ANLOTRAKTCZGQW-UHFFFAOYSA-N 0.000 description 1
- HHCPTZUOLWKTSI-UHFFFAOYSA-N Cl.C1(CCCCC1)CCNCC1=C(C=CC=C1)OC1=CC=CC=C1 Chemical compound Cl.C1(CCCCC1)CCNCC1=C(C=CC=C1)OC1=CC=CC=C1 HHCPTZUOLWKTSI-UHFFFAOYSA-N 0.000 description 1
- XTWAFRULNXDHQT-UHFFFAOYSA-N Cl.C1(CCCCC1)CCNCC1=C(C=CC=C1)OCC1OCCCC1 Chemical compound Cl.C1(CCCCC1)CCNCC1=C(C=CC=C1)OCC1OCCCC1 XTWAFRULNXDHQT-UHFFFAOYSA-N 0.000 description 1
- BSCDZFLRTBMJRX-UHFFFAOYSA-N Cl.C1(CCCCC1)CCNCC1=C(N)C=CC=C1 Chemical compound Cl.C1(CCCCC1)CCNCC1=C(N)C=CC=C1 BSCDZFLRTBMJRX-UHFFFAOYSA-N 0.000 description 1
- ZXLKOCZMNFMHJV-UHFFFAOYSA-N Cl.Cl.C1(CCCCC1)CC(C)NCC1=C(NCC2=C(C=CC=C2)F)C=CC=C1 Chemical compound Cl.Cl.C1(CCCCC1)CC(C)NCC1=C(NCC2=C(C=CC=C2)F)C=CC=C1 ZXLKOCZMNFMHJV-UHFFFAOYSA-N 0.000 description 1
- PMNXUOFQVKEYKX-AFPGXMFESA-N Cl.Cl.N[C@H](C(=O)NS(=O)(=O)CC1=C(C=CC=C1)CNC(CC1CCCCC1)C)CC(C)C Chemical compound Cl.Cl.N[C@H](C(=O)NS(=O)(=O)CC1=C(C=CC=C1)CNC(CC1CCCCC1)C)CC(C)C PMNXUOFQVKEYKX-AFPGXMFESA-N 0.000 description 1
- SENVIHGBRCSPPJ-UHFFFAOYSA-N Cl.NCC1=C(CNCCC2CCCCC2)C=CC=C1 Chemical compound Cl.NCC1=C(CNCCC2CCCCC2)C=CC=C1 SENVIHGBRCSPPJ-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241001087672 Cosenzaea myxofaciens Species 0.000 description 1
- 241000606678 Coxiella burnetii Species 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 244000251786 Cymbopogon rectus Species 0.000 description 1
- 241000605056 Cytophaga Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241001535083 Dialister Species 0.000 description 1
- 241001535058 Dialister pneumosintes Species 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588878 Eikenella corrodens Species 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241001240954 Escherichia albertii Species 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 241000588720 Escherichia fergusonii Species 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- 241000131484 Ewingella americana Species 0.000 description 1
- JCBNWFXZSFKPME-UHFFFAOYSA-N FC(C(=O)O)(F)F.C1(CCCCC1)CC(C)NCC1=C(C=CC=C1)CCC(=O)N Chemical compound FC(C(=O)O)(F)F.C1(CCCCC1)CC(C)NCC1=C(C=CC=C1)CCC(=O)N JCBNWFXZSFKPME-UHFFFAOYSA-N 0.000 description 1
- AVYXNUDRYMIIOA-UHFFFAOYSA-N FC(C(=O)O)(F)F.C1(CCCCC1)CC(C)NCC1=C(C=CC=C1)CCC(=O)O Chemical compound FC(C(=O)O)(F)F.C1(CCCCC1)CC(C)NCC1=C(C=CC=C1)CCC(=O)O AVYXNUDRYMIIOA-UHFFFAOYSA-N 0.000 description 1
- VZEOSSGRAFSLSS-UHFFFAOYSA-N FC(C(=O)O)(F)F.C1(CCCCC1)CCNCC1=C(C(=O)N)C=CC=C1 Chemical compound FC(C(=O)O)(F)F.C1(CCCCC1)CCNCC1=C(C(=O)N)C=CC=C1 VZEOSSGRAFSLSS-UHFFFAOYSA-N 0.000 description 1
- CSUOEPFTCHLCQB-UHFFFAOYSA-N FC1(C2CCCCC12CCNC(C1=CC=CC=C1)=O)F Chemical compound FC1(C2CCCCC12CCNC(C1=CC=CC=C1)=O)F CSUOEPFTCHLCQB-UHFFFAOYSA-N 0.000 description 1
- 241000589565 Flavobacterium Species 0.000 description 1
- 241000555689 Flavobacterium branchiophilum Species 0.000 description 1
- 241000605108 Flavobacterium johnsoniae Species 0.000 description 1
- 241000589601 Francisella Species 0.000 description 1
- 241000245629 Francisella noatunensis Species 0.000 description 1
- 241001135321 Francisella philomiragia Species 0.000 description 1
- 241000589602 Francisella tularensis Species 0.000 description 1
- 241000589599 Francisella tularensis subsp. novicida Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 241000605952 Fusobacterium necrophorum Species 0.000 description 1
- 241000605986 Fusobacterium nucleatum Species 0.000 description 1
- 241001291922 Fusobacterium nucleatum subsp. polymorphum Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010008488 Glycylglycine Proteins 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000606788 Haemophilus haemolyticus Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000606766 Haemophilus parainfluenzae Species 0.000 description 1
- 241001059853 Haemophilus pittmaniae Species 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 241001503513 Helicobacter bilis Species 0.000 description 1
- 241000590014 Helicobacter cinaedi Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000029793 Isoleucine-tRNA ligase Human genes 0.000 description 1
- 101710176147 Isoleucine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
- 241001454354 Kingella Species 0.000 description 1
- 241000589015 Kingella denitrificans Species 0.000 description 1
- 241000589012 Kingella oralis Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- 241001534216 Klebsiella granulomatis Species 0.000 description 1
- 241000697618 Klebsiella michiganensis Species 0.000 description 1
- 241000588749 Klebsiella oxytoca Species 0.000 description 1
- 241000906776 Klebsiella quasipneumoniae Species 0.000 description 1
- 241001014264 Klebsiella variicola Species 0.000 description 1
- 241000588752 Kluyvera Species 0.000 description 1
- 241000588773 Kluyvera cryocrescens Species 0.000 description 1
- 241001245548 Kluyvera georgiana Species 0.000 description 1
- 244000100096 Knema intermedia Species 0.000 description 1
- 241001245439 Kosakonia cowanii Species 0.000 description 1
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 241001135524 Legionella anisa Species 0.000 description 1
- 241001135525 Legionella birminghamensis Species 0.000 description 1
- 241001135526 Legionella cherrii Species 0.000 description 1
- 241001135527 Legionella cincinnatiensis Species 0.000 description 1
- 241001441459 Legionella clemsonensis Species 0.000 description 1
- 241000589259 Legionella feeleii Species 0.000 description 1
- 241000589240 Legionella hackeliae Species 0.000 description 1
- 241000589276 Legionella jordanis Species 0.000 description 1
- 241000189478 Legionella lansingensis Species 0.000 description 1
- 241000589264 Legionella longbeachae Species 0.000 description 1
- 241001148224 Legionella oakridgensis Species 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 241000589272 Legionella rubrilucens Species 0.000 description 1
- 241001135522 Legionella sainthelensi Species 0.000 description 1
- 241000678048 Legionella steelei Species 0.000 description 1
- 241000122902 Legionella tucsonensis Species 0.000 description 1
- 241001135523 Legionella wadsworthii Species 0.000 description 1
- 241000937844 Legionella waltersii Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 240000007890 Leonurus cardiaca Species 0.000 description 1
- 241000589947 Leptonema illini Species 0.000 description 1
- 241001453171 Leptotrichia Species 0.000 description 1
- 241000123728 Leptotrichia buccalis Species 0.000 description 1
- 241000029613 Leptotrichia goodfellowii Species 0.000 description 1
- 241000080854 Lomatium gormanii Species 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 241000589323 Methylobacterium Species 0.000 description 1
- 241000135180 Methylobacterium aminovorans Species 0.000 description 1
- 241001542929 Methylobacterium fujisawaense Species 0.000 description 1
- 241001249758 Methylobacterium lusitanum Species 0.000 description 1
- 241001535042 Methylobacterium mesophilicum Species 0.000 description 1
- 241001430258 Methylobacterium radiotolerans Species 0.000 description 1
- 241000219277 Methylobacterium thiocyanatum Species 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 241001478301 Moraxella atlantae Species 0.000 description 1
- 241000738045 Moraxella boevrei Species 0.000 description 1
- 241000293008 Moraxella caprae Species 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 241001478293 Moraxella cuniculi Species 0.000 description 1
- 241000866062 Moraxella equi Species 0.000 description 1
- 241000588629 Moraxella lacunata Species 0.000 description 1
- 241000293012 Moraxella lincolnii Species 0.000 description 1
- 241000588630 Moraxella nonliquefaciens Species 0.000 description 1
- 241001144643 Moraxella oblonga Species 0.000 description 1
- 241001482853 Moraxella pluranimalium Species 0.000 description 1
- 241000622911 Moraxella porci Species 0.000 description 1
- 241001645837 Moraxella saccharolytica Species 0.000 description 1
- 241000588772 Morganella morganii Species 0.000 description 1
- 241001508003 Mycobacterium abscessus Species 0.000 description 1
- 241001502334 Mycobacterium avium complex bacterium Species 0.000 description 1
- 241000187478 Mycobacterium chelonae Species 0.000 description 1
- 241001455333 Mycobacterium fortuitum complex Species 0.000 description 1
- 241001509451 Mycobacterium genavense Species 0.000 description 1
- 241000187484 Mycobacterium gordonae Species 0.000 description 1
- 241001147828 Mycobacterium haemophilum Species 0.000 description 1
- 241000186363 Mycobacterium kansasii Species 0.000 description 1
- 241000187493 Mycobacterium malmoense Species 0.000 description 1
- 241000187492 Mycobacterium marinum Species 0.000 description 1
- 241000168058 Mycobacterium peregrinum Species 0.000 description 1
- 241000187490 Mycobacterium scrofulaceum Species 0.000 description 1
- 241000187489 Mycobacterium simiae Species 0.000 description 1
- 241000187496 Mycobacterium szulgai Species 0.000 description 1
- 241000775110 Mycobacterium terrae complex Species 0.000 description 1
- 241000187917 Mycobacterium ulcerans Species 0.000 description 1
- 241000187494 Mycobacterium xenopi Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000499356 Mycoplasma adleri Species 0.000 description 1
- 241001468276 Mycoplasma agassizii Species 0.000 description 1
- 241000217740 Mycoplasma alligatoris Species 0.000 description 1
- 241000435276 Mycoplasma amphoriforme Species 0.000 description 1
- 241000191277 Mycoplasma bovoculi Species 0.000 description 1
- 241000544264 Mycoplasma buccale Species 0.000 description 1
- 241001148552 Mycoplasma canis Species 0.000 description 1
- 241000204025 Mycoplasma capricolum Species 0.000 description 1
- 241000544259 Mycoplasma caviae Species 0.000 description 1
- 241000565677 Mycoplasma faucium Species 0.000 description 1
- 241000204022 Mycoplasma gallisepticum Species 0.000 description 1
- 241000204051 Mycoplasma genitalium Species 0.000 description 1
- 241000963347 Mycoplasma haemocanis Species 0.000 description 1
- 241000546176 Mycoplasma haemomuris Species 0.000 description 1
- 241000204048 Mycoplasma hominis Species 0.000 description 1
- 241000204045 Mycoplasma hyopneumoniae Species 0.000 description 1
- 241000202938 Mycoplasma hyorhinis Species 0.000 description 1
- 241000202966 Mycoplasma lipophilum Species 0.000 description 1
- 241000202964 Mycoplasma mobile Species 0.000 description 1
- 241000202936 Mycoplasma mycoides Species 0.000 description 1
- 241000202894 Mycoplasma orale Species 0.000 description 1
- 241001148556 Mycoplasma ovipneumoniae Species 0.000 description 1
- 241001135743 Mycoplasma penetrans Species 0.000 description 1
- 241000202892 Mycoplasma pirum Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 241000202889 Mycoplasma salivarium Species 0.000 description 1
- 241000894426 Mycoplasma spermatophilum Species 0.000 description 1
- 241000317904 Mycoplasma spumans Species 0.000 description 1
- 241000202942 Mycoplasma synoviae Species 0.000 description 1
- MDXGYYOJGPFFJL-QMMMGPOBSA-N N(alpha)-t-butoxycarbonyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)OC(C)(C)C MDXGYYOJGPFFJL-QMMMGPOBSA-N 0.000 description 1
- PVDVSINTNSTYGA-UHFFFAOYSA-N N-[(1-hydroxy-3H-2,1-benzoxaborol-6-yl)methyl]-1-phenylmethanamine Chemical compound OB1OCC2=C1C=C(CNCC1=CC=CC=C1)C=C2 PVDVSINTNSTYGA-UHFFFAOYSA-N 0.000 description 1
- VQLQOZWSSBLAOI-UHFFFAOYSA-N N-[(2-cyclobutyloxyphenyl)methyl]-1-cyclohexylpropan-2-amine Chemical compound C1(CCC1)OC1=C(CNC(CC2CCCCC2)C)C=CC=C1 VQLQOZWSSBLAOI-UHFFFAOYSA-N 0.000 description 1
- QFOSNGQISICIAL-UHFFFAOYSA-N N-[[2-(2-bicyclo[2.2.1]heptanylmethoxy)phenyl]methyl]-1-cyclohexylpropan-2-amine Chemical compound C12C(CC(CC1)C2)COC1=C(CNC(CC2CCCCC2)C)C=CC=C1 QFOSNGQISICIAL-UHFFFAOYSA-N 0.000 description 1
- LAIRRWQKQLXWIR-UHFFFAOYSA-N N-[[2-(2-bicyclo[2.2.2]octanyloxy)phenyl]methyl]-1-cyclohexylpropan-2-amine Chemical compound C12C(CC(CC1)CC2)OC1=C(CNC(CC2CCCCC2)C)C=CC=C1 LAIRRWQKQLXWIR-UHFFFAOYSA-N 0.000 description 1
- DKOFAKYRLAULNC-UHFFFAOYSA-N N-[[2-[(2-fluorophenyl)methoxy]phenyl]methyl]-1-(4-methylcyclohexyl)propan-2-amine Chemical compound FC1=C(COC2=C(CNC(CC3CCC(CC3)C)C)C=CC=C2)C=CC=C1 DKOFAKYRLAULNC-UHFFFAOYSA-N 0.000 description 1
- SMYKSBXTZJTKHO-UHFFFAOYSA-N N-[[2-[(2-fluorophenyl)methoxy]phenyl]methyl]-1-(4-propan-2-ylcyclohexyl)propan-2-amine Chemical compound FC1=C(COC2=C(CNC(CC3CCC(CC3)C(C)C)C)C=CC=C2)C=CC=C1 SMYKSBXTZJTKHO-UHFFFAOYSA-N 0.000 description 1
- JLMYXYGRTLCXKZ-UHFFFAOYSA-N N-[[2-[(2-fluorophenyl)methoxy]phenyl]methyl]-1-[4-(trifluoromethyl)cyclohexyl]propan-2-amine Chemical compound FC1=C(COC2=C(CNC(CC3CCC(CC3)C(F)(F)F)C)C=CC=C2)C=CC=C1 JLMYXYGRTLCXKZ-UHFFFAOYSA-N 0.000 description 1
- CVIMQOMWZLYOAH-UHFFFAOYSA-N N-benzyl-1-(3,4-dimethylcyclohex-3-en-1-yl)propan-2-amine Chemical compound C(C1=CC=CC=C1)NC(CC1CC(=C(CC1)C)C)C CVIMQOMWZLYOAH-UHFFFAOYSA-N 0.000 description 1
- KIFPTIVJOGMWBB-UHFFFAOYSA-N N-benzyl-1-cyclohex-3-en-1-ylpropan-2-amine Chemical compound C(C1=CC=CC=C1)NC(CC1CC=CCC1)C KIFPTIVJOGMWBB-UHFFFAOYSA-N 0.000 description 1
- DPDLWXADXOOGMO-UHFFFAOYSA-N N-benzyl-2-(1-hydroxycyclohexyl)acetamide Chemical compound OC1(CC(=O)NCc2ccccc2)CCCCC1 DPDLWXADXOOGMO-UHFFFAOYSA-N 0.000 description 1
- LSUTWDNUDGTLKV-UHFFFAOYSA-N N-benzyl-2-(4-methylcyclohexyl)acetamide Chemical compound C(C1=CC=CC=C1)NC(CC1CCC(CC1)C)=O LSUTWDNUDGTLKV-UHFFFAOYSA-N 0.000 description 1
- UIOPDHWZSXEJEG-UHFFFAOYSA-N N-benzyl-2-(7-methoxynaphthalen-1-yl)acetamide Chemical compound C(C1=CC=CC=C1)NC(CC1=CC=CC2=CC=C(C=C12)OC)=O UIOPDHWZSXEJEG-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- OOFKPZRYVBLAPT-UHFFFAOYSA-N N-tert-butyl-2-(2-formylphenyl)ethanesulfonamide Chemical compound C(C)(C)(C)NS(=O)(=O)CCC1=C(C=CC=C1)C=O OOFKPZRYVBLAPT-UHFFFAOYSA-N 0.000 description 1
- PXTDDWXMLMUTTJ-UHFFFAOYSA-N N-tert-butyl-2-[2-[(1-cyclohexylpropan-2-ylamino)methyl]phenyl]ethanesulfonamide Chemical compound C(C)(C)(C)NS(=O)(=O)CCC1=C(C=CC=C1)CNC(CC1CCCCC1)C PXTDDWXMLMUTTJ-UHFFFAOYSA-N 0.000 description 1
- OKCJPWDZYOQWQZ-UHFFFAOYSA-N NC(C(=O)O)CC1=C(C=CC=C1)CNC(CC1CCCCC1)C Chemical compound NC(C(=O)O)CC1=C(C=CC=C1)CNC(CC1CCCCC1)C OKCJPWDZYOQWQZ-UHFFFAOYSA-N 0.000 description 1
- WTFXOZNRGHXLCF-UHFFFAOYSA-N NCC1=C(CS(=O)(=O)NC(=O)NC2CCCCC2)C=CC=C1 Chemical compound NCC1=C(CS(=O)(=O)NC(=O)NC2CCCCC2)C=CC=C1 WTFXOZNRGHXLCF-UHFFFAOYSA-N 0.000 description 1
- IEXMRPICTWLMBL-UHFFFAOYSA-N NCC1=C(CS(=O)(=O)NCC(O)CO)C=CC=C1 Chemical compound NCC1=C(CS(=O)(=O)NCC(O)CO)C=CC=C1 IEXMRPICTWLMBL-UHFFFAOYSA-N 0.000 description 1
- AWJXWDOCXRXZPR-UHFFFAOYSA-N NCCC1CCCCC1O Chemical compound NCCC1CCCCC1O AWJXWDOCXRXZPR-UHFFFAOYSA-N 0.000 description 1
- YMVBGDXCHWAGDN-UHFFFAOYSA-N NCc1ccccc1OC1CC2CCC1C2 Chemical compound NCc1ccccc1OC1CC2CCC1C2 YMVBGDXCHWAGDN-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588654 Neisseria cinerea Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000588660 Neisseria polysaccharea Species 0.000 description 1
- 241000588645 Neisseria sicca Species 0.000 description 1
- 244000038458 Nepenthes mirabilis Species 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 241001405565 Nocardia concava Species 0.000 description 1
- 241000948822 Nocardia cyriacigeorgica Species 0.000 description 1
- 241001238128 Nocardia donostiensis Species 0.000 description 1
- 241001110407 Nocardia exalbida Species 0.000 description 1
- 241001503673 Nocardia farcinica Species 0.000 description 1
- 241001118701 Nocardia harenae Species 0.000 description 1
- 241000331056 Nocardia higoensis Species 0.000 description 1
- 241001302004 Nocardia ignorata Species 0.000 description 1
- 241001248497 Nocardia inohanensis Species 0.000 description 1
- 241000492189 Nocardia jinanensis Species 0.000 description 1
- 241000686171 Nocardia kroppenstedtii Species 0.000 description 1
- 241000038096 Nocardia kruczakiae Species 0.000 description 1
- 241000496361 Nocardia mexicana Species 0.000 description 1
- 241000390559 Nocardia mikamii Species 0.000 description 1
- 241000660524 Nocardia neocaledoniensis Species 0.000 description 1
- 241001248502 Nocardia niigatensis Species 0.000 description 1
- 241001093235 Nocardia ninae Species 0.000 description 1
- 241000793348 Nocardia niwae Species 0.000 description 1
- 241001503638 Nocardia nova Species 0.000 description 1
- 241000187679 Nocardia otitidiscaviarum Species 0.000 description 1
- 241000189134 Nocardia paucivorans Species 0.000 description 1
- 241000331201 Nocardia pneumoniae Species 0.000 description 1
- 241000193826 Nocardia pseudobrasiliensis Species 0.000 description 1
- 241001243261 Nocardia puris Species 0.000 description 1
- 241000087804 Nocardia shinanonensis Species 0.000 description 1
- 241001045831 Nocardia sienata Species 0.000 description 1
- 241001421890 Nocardia takedensis Species 0.000 description 1
- 241000801334 Nocardia terpenica Species 0.000 description 1
- 241001405616 Nocardia thailandica Species 0.000 description 1
- 241001503640 Nocardia transvalensis Species 0.000 description 1
- 241001405591 Nocardia vermiculata Species 0.000 description 1
- 241000905501 Nocardia veterana Species 0.000 description 1
- 241000999446 Nocardia vulneris Species 0.000 description 1
- 241000180571 Nocardia wallacei Species 0.000 description 1
- 241001248499 Nocardia yamanashiensis Species 0.000 description 1
- HVNMNNOXFJBSDF-UHFFFAOYSA-N O=C1CC(CN1)COC1=C(C=O)C=CC=C1 Chemical compound O=C1CC(CN1)COC1=C(C=O)C=CC=C1 HVNMNNOXFJBSDF-UHFFFAOYSA-N 0.000 description 1
- XFQVZRRAEBUHBB-UHFFFAOYSA-N O=C1CC2=C(CN1CCC1CCCCCC1)C=CC=C2 Chemical compound O=C1CC2=C(CN1CCC1CCCCCC1)C=CC=C2 XFQVZRRAEBUHBB-UHFFFAOYSA-N 0.000 description 1
- QLTOTIPDWDJOFT-UHFFFAOYSA-N O=C1CC2=C(CN1CCC1CCOCC1)C=CC=C2 Chemical compound O=C1CC2=C(CN1CCC1CCOCC1)C=CC=C2 QLTOTIPDWDJOFT-UHFFFAOYSA-N 0.000 description 1
- OPOOOSGTAMEWGV-UHFFFAOYSA-N O=C1CC2=C(CN1CCC1CCSCC1)C=CC=C2 Chemical compound O=C1CC2=C(CN1CCC1CCSCC1)C=CC=C2 OPOOOSGTAMEWGV-UHFFFAOYSA-N 0.000 description 1
- JMGPMSYDDVTWMM-UHFFFAOYSA-N OB1OCC2=C1C=C(CCNCC1=CC=CC=C1)C=C2 Chemical compound OB1OCC2=C1C=C(CCNCC1=CC=CC=C1)C=C2 JMGPMSYDDVTWMM-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001499143 Pantoea septica Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L PdCl2(PPh3)2 Substances [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- 240000004299 Pinalia flavescens Species 0.000 description 1
- 240000000697 Pinguicula vulgaris Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000210053 Potentilla elegans Species 0.000 description 1
- 241001135223 Prevotella melaninogenica Species 0.000 description 1
- 101710149031 Probable isoleucine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241001076189 Proteus hauseri Species 0.000 description 1
- 241001472782 Proteus penneri Species 0.000 description 1
- 240000005519 Prunus mexicana Species 0.000 description 1
- 241000588733 Pseudescherichia vulneris Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000218934 Pseudomonas amygdali Species 0.000 description 1
- 241000520869 Pseudomonas anguilliseptica Species 0.000 description 1
- 241000857755 Pseudomonas argentinensis Species 0.000 description 1
- 241000202216 Pseudomonas avellanae Species 0.000 description 1
- 241000218935 Pseudomonas azotoformans Species 0.000 description 1
- 241001365263 Pseudomonas blatchfordae Species 0.000 description 1
- 241000226031 Pseudomonas brassicacearum Species 0.000 description 1
- 241000007104 Pseudomonas cannabina Species 0.000 description 1
- 241000204712 Pseudomonas caricapapayae Species 0.000 description 1
- 241001508466 Pseudomonas cichorii Species 0.000 description 1
- 241000647960 Pseudomonas coronafaciens pv. coronafaciens Species 0.000 description 1
- 241000425890 Pseudomonas costantinii Species 0.000 description 1
- 241000039931 Pseudomonas cremoricolorata Species 0.000 description 1
- 241001253546 Pseudomonas entomophila Species 0.000 description 1
- 241000520898 Pseudomonas ficuserectae Species 0.000 description 1
- 241000780651 Pseudomonas floridensis Species 0.000 description 1
- 241000589538 Pseudomonas fragi Species 0.000 description 1
- 241000490004 Pseudomonas fuscovaginae Species 0.000 description 1
- 241001670039 Pseudomonas lundensis Species 0.000 description 1
- 241000218905 Pseudomonas luteola Species 0.000 description 1
- 241000394642 Pseudomonas marginalis pv. marginalis Species 0.000 description 1
- 241001074440 Pseudomonas mediterranea Species 0.000 description 1
- 241000589755 Pseudomonas mendocina Species 0.000 description 1
- 241001291501 Pseudomonas monteilii Species 0.000 description 1
- 241000204709 Pseudomonas mucidolens Species 0.000 description 1
- 241000218904 Pseudomonas oryzihabitans Species 0.000 description 1
- 241001343452 Pseudomonas otitidis Species 0.000 description 1
- 241001425590 Pseudomonas palleroniana Species 0.000 description 1
- 241000954716 Pseudomonas panacis Species 0.000 description 1
- 241001223182 Pseudomonas plecoglossicida Species 0.000 description 1
- 241001598040 Pseudomonas reptilivorous Species 0.000 description 1
- 241001425588 Pseudomonas salomonii Species 0.000 description 1
- 241001148183 Pseudomonas savastanoi Species 0.000 description 1
- 241001615702 Pseudomonas simiae Species 0.000 description 1
- 241000589614 Pseudomonas stutzeri Species 0.000 description 1
- 241000589615 Pseudomonas syringae Species 0.000 description 1
- 241000589626 Pseudomonas syringae pv. tomato Species 0.000 description 1
- 241000218903 Pseudomonas taetrolens Species 0.000 description 1
- 241001148199 Pseudomonas tolaasii Species 0.000 description 1
- 241001144903 Pseudomonas tremae Species 0.000 description 1
- 241001464820 Pseudomonas viridiflava Species 0.000 description 1
- 241000475377 Pseudoscardovia suis Species 0.000 description 1
- 241001647875 Pseudoxanthomonas Species 0.000 description 1
- 241001647876 Pseudoxanthomonas broegbernensis Species 0.000 description 1
- 241000982689 Pseudoxanthomonas japonensis Species 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241001495403 Rickettsia africae Species 0.000 description 1
- 241000606723 Rickettsia akari Species 0.000 description 1
- 241000688833 Rickettsia asiatica Species 0.000 description 1
- 241000606720 Rickettsia australis Species 0.000 description 1
- 241000606699 Rickettsia conorii Species 0.000 description 1
- 241000147135 Rickettsia felis Species 0.000 description 1
- 241000303241 Rickettsia heilongjiangensis Species 0.000 description 1
- 241001495405 Rickettsia helvetica Species 0.000 description 1
- 241001523686 Rickettsia honei Species 0.000 description 1
- 241001495395 Rickettsia massiliae Species 0.000 description 1
- 241001559658 Rickettsia monacensis Species 0.000 description 1
- 241001495398 Rickettsia parkeri Species 0.000 description 1
- 241000217142 Rickettsia peacockii Species 0.000 description 1
- 241000606697 Rickettsia prowazekii Species 0.000 description 1
- 241000606695 Rickettsia rickettsii Species 0.000 description 1
- 241000606726 Rickettsia typhi Species 0.000 description 1
- 244000181616 Rosa pimpinellifolia Species 0.000 description 1
- 241000429264 Rouxiella chamberiensis Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000533331 Salmonella bongori Species 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000218654 Serratia fonticola Species 0.000 description 1
- 241000607717 Serratia liquefaciens Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 241001622809 Serratia plymuthica Species 0.000 description 1
- 241000881771 Serratia rubidaea Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 240000003377 Shepherdia canadensis Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000607766 Shigella boydii Species 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 241000607760 Shigella sonnei Species 0.000 description 1
- 240000005831 Sicana odorifera Species 0.000 description 1
- 241001115883 Sneathia amnii Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241001464874 Solobacterium moorei Species 0.000 description 1
- 241000736131 Sphingomonas Species 0.000 description 1
- 241000628340 Sphingomonas gei Species 0.000 description 1
- 241000344853 Sphingomonas koreensis Species 0.000 description 1
- 241000736110 Sphingomonas paucimobilis Species 0.000 description 1
- 241000589973 Spirochaeta Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000122971 Stenotrophomonas Species 0.000 description 1
- 241000122973 Stenotrophomonas maltophilia Species 0.000 description 1
- 241001647881 Stenotrophomonas nitritireducens Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000722072 Suttonella indologenes Species 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 241000589262 Tatlockia micdadei Species 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 241000589892 Treponema denticola Species 0.000 description 1
- 241000520888 Treponema lecithinolyticum Species 0.000 description 1
- 241000498553 Treponema maltophilum Species 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 241000520890 Treponema socranskii Species 0.000 description 1
- 241000984746 Treponema vincentii Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 101150110932 US19 gene Proteins 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607281 Vibrio adaptatus Species 0.000 description 1
- 241000607594 Vibrio alginolyticus Species 0.000 description 1
- 241000544286 Vibrio anguillarum Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000607291 Vibrio fluvialis Species 0.000 description 1
- 241001148070 Vibrio furnissii Species 0.000 description 1
- 241000607618 Vibrio harveyi Species 0.000 description 1
- 241000965623 Vibrio lentus Species 0.000 description 1
- 241000607253 Vibrio mimicus Species 0.000 description 1
- 241001135139 Vibrio ordalii Species 0.000 description 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
- 241000896074 Vibrio pectenicida Species 0.000 description 1
- 241000510690 Vibrio tapetis Species 0.000 description 1
- 241001148039 Vibrio tubiashii Species 0.000 description 1
- 241000607265 Vibrio vulnificus Species 0.000 description 1
- 241000604961 Wolbachia Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 241001148126 Yersinia aldovae Species 0.000 description 1
- 241000607475 Yersinia bercovieri Species 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- 241001148127 Yersinia frederiksenii Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 241000607477 Yersinia pseudotuberculosis Species 0.000 description 1
- 241001148129 Yersinia ruckeri Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- JVVXZOOGOGPDRZ-SLFFLAALSA-N [(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methanamine Chemical compound NC[C@]1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 JVVXZOOGOGPDRZ-SLFFLAALSA-N 0.000 description 1
- XXDIHNKOCHOMLH-UHFFFAOYSA-N [2-(2-fluorophenoxy)phenyl]methanamine Chemical compound NCC1=CC=CC=C1OC1=CC=CC=C1F XXDIHNKOCHOMLH-UHFFFAOYSA-N 0.000 description 1
- BFVANMKDEBYSJR-UHFFFAOYSA-N [2-(2-methylcyclohexyl)oxyphenyl]methanamine Chemical compound CC1CCCCC1OC1=CC=CC=C1CN BFVANMKDEBYSJR-UHFFFAOYSA-N 0.000 description 1
- NZZXDMYIRNNZTR-UHFFFAOYSA-N [2-(3-methylcyclohexyl)oxyphenyl]methanamine Chemical compound C1C(C)CCCC1OC1=CC=CC=C1CN NZZXDMYIRNNZTR-UHFFFAOYSA-N 0.000 description 1
- CKZYQTIKLRQGND-UHFFFAOYSA-N [2-(8-tricyclo[5.2.1.02,6]decanyloxy)phenyl]methanamine Chemical compound C1CCC2C3C(CC(C12)C3)OC1=C(C=CC=C1)CN CKZYQTIKLRQGND-UHFFFAOYSA-N 0.000 description 1
- XNTVKFUZEPLUTB-UHFFFAOYSA-N [2-(aminomethyl)phenyl]methanesulfonamide Chemical compound NCC1=CC=CC=C1CS(N)(=O)=O XNTVKFUZEPLUTB-UHFFFAOYSA-N 0.000 description 1
- BUPNMXABHBDXSH-UHFFFAOYSA-N [2-[(1-cyclohexylpropan-2-ylamino)methyl]phenyl]methanesulfonamide Chemical compound C1(CCCCC1)CC(C)NCC1=C(C=CC=C1)CS(=O)(=O)N BUPNMXABHBDXSH-UHFFFAOYSA-N 0.000 description 1
- WAFPVALMOPQNQS-UHFFFAOYSA-N [2-[(2-cyclohexylethylamino)methyl]phenyl] acetate Chemical compound C(C)(=O)OC1=C(C=CC=C1)CNCCC1CCCCC1 WAFPVALMOPQNQS-UHFFFAOYSA-N 0.000 description 1
- OQEOOMPYAVZOAO-UHFFFAOYSA-N [2-[(2-cyclopropylphenyl)methoxy]phenyl]methanamine Chemical compound C1(CC1)C1=C(COC2=C(C=CC=C2)CN)C=CC=C1 OQEOOMPYAVZOAO-UHFFFAOYSA-N 0.000 description 1
- LPYKACVQTOAUQJ-UHFFFAOYSA-N [2-[(2-fluorophenyl)methoxy]phenyl]methanamine Chemical compound NCC1=CC=CC=C1OCC1=CC=CC=C1F LPYKACVQTOAUQJ-UHFFFAOYSA-N 0.000 description 1
- GJAZLGZSKFZHNC-UHFFFAOYSA-N [2-[(2-phenoxyphenyl)methoxy]phenyl]methanamine Chemical compound O(C1=CC=CC=C1)C1=C(COC2=C(C=CC=C2)CN)C=CC=C1 GJAZLGZSKFZHNC-UHFFFAOYSA-N 0.000 description 1
- QFRDYNWATUOZII-UHFFFAOYSA-N [2-[(2-propan-2-ylphenyl)methoxy]phenyl]methanamine Chemical compound C(C)(C)C1=C(COC2=C(C=CC=C2)CN)C=CC=C1 QFRDYNWATUOZII-UHFFFAOYSA-N 0.000 description 1
- JWYDQSLEQXXWAU-UHFFFAOYSA-N [2-[(3-methoxyphenyl)methoxy]phenyl]methanamine Chemical compound COC1=CC=CC(COC=2C(=CC=CC=2)CN)=C1 JWYDQSLEQXXWAU-UHFFFAOYSA-N 0.000 description 1
- BVNIAXYZXFKRDN-UHFFFAOYSA-N [2-[(3-methylphenyl)methoxy]phenyl]methanamine Chemical compound CC1=CC=CC(COC=2C(=CC=CC=2)CN)=C1 BVNIAXYZXFKRDN-UHFFFAOYSA-N 0.000 description 1
- ZBDSIFYVLWXOPJ-UHFFFAOYSA-N [2-[(4-methylphenyl)methoxy]phenyl]methanamine Chemical compound C1=CC(C)=CC=C1COC1=CC=CC=C1CN ZBDSIFYVLWXOPJ-UHFFFAOYSA-N 0.000 description 1
- HSFKPFROHRBMGO-UHFFFAOYSA-N [2-[(4-methylpiperazin-1-yl)sulfonylmethyl]phenyl]methanamine Chemical compound C1CN(C)CCN1S(=O)(=O)CC1=CC=CC=C1CN HSFKPFROHRBMGO-UHFFFAOYSA-N 0.000 description 1
- LGXTWOHLSHAPRI-UHFFFAOYSA-N [2-[2-(2-fluorophenyl)ethyl]phenyl]methanamine Chemical compound NCC1=CC=CC=C1CCC1=CC=CC=C1F LGXTWOHLSHAPRI-UHFFFAOYSA-N 0.000 description 1
- KEVVSIIOOJIAIQ-UHFFFAOYSA-N [3-[[2-[(1-cyclohexylpropan-2-ylamino)methyl]phenyl]methylsulfonylamino]phenyl]boronic acid Chemical compound C1(CCCCC1)CC(C)NCC1=C(C=CC=C1)CS(=O)(=O)NC=1C=C(C=CC=1)B(O)O KEVVSIIOOJIAIQ-UHFFFAOYSA-N 0.000 description 1
- ABJMVLHELXKIJA-UHFFFAOYSA-N [4-[[2-(aminomethyl)phenyl]methylsulfonylamino]phenyl]boronic acid Chemical compound NCC1=C(C=CC=C1)CS(=O)(=O)NC1=CC=C(C=C1)B(O)O ABJMVLHELXKIJA-UHFFFAOYSA-N 0.000 description 1
- 241000606834 [Haemophilus] ducreyi Species 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- MPPQYFREIJCHTB-UHFFFAOYSA-N acetic acid;phenylmethanamine Chemical compound CC([O-])=O.[NH3+]CC1=CC=CC=C1 MPPQYFREIJCHTB-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- 150000005405 azaspiro[5.5]undecanes Chemical class 0.000 description 1
- AXMNGEUJXLXFRY-UHFFFAOYSA-N azaspirodecane Chemical compound C1CCCC21CCNCC2 AXMNGEUJXLXFRY-UHFFFAOYSA-N 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 229940028420 bactroban Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 150000001925 cycloalkenes Chemical class 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- JBWDOSMVKONPSD-UHFFFAOYSA-N diethyl 2-acetamido-2-[[2-[(1-cyclohexylpropan-2-ylamino)methyl]phenyl]methyl]propanedioate Chemical compound C(C)(=O)NC(C(=O)OCC)(C(=O)OCC)CC1=C(C=CC=C1)CNC(CC1CCCCC1)C JBWDOSMVKONPSD-UHFFFAOYSA-N 0.000 description 1
- CXFDRFQUWMKGTG-UHFFFAOYSA-N diethyl 2-acetamido-2-[[2-[(2-cyclohexylpropylamino)methyl]phenyl]methyl]propanedioate Chemical compound C(C)(=O)NC(C(=O)OCC)(C(=O)OCC)CC1=C(C=CC=C1)CNCC(C)C1CCCCC1 CXFDRFQUWMKGTG-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- WOAZEKPXTXCPFZ-UHFFFAOYSA-N dimethyl(phenyl)azanium;chloride Chemical compound Cl.CN(C)C1=CC=CC=C1 WOAZEKPXTXCPFZ-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000012054 flavored emulsion Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229940043257 glycylglycine Drugs 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical class COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- OVWYEQOVUDKZNU-UHFFFAOYSA-N m-tolualdehyde Chemical compound CC1=CC=CC(C=O)=C1 OVWYEQOVUDKZNU-UHFFFAOYSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- FATVDDYIMWBSTB-SECBINFHSA-N methyl (2R)-2-[[2-(aminomethyl)phenyl]methylsulfonylamino]propanoate Chemical compound NCC1=C(CS(=O)(=O)N[C@H](C)C(=O)OC)C=CC=C1 FATVDDYIMWBSTB-SECBINFHSA-N 0.000 description 1
- MOZHFDPWXQAUJO-ZYMOGRSISA-N methyl (2R)-2-[[2-[(1-cyclohexylpropan-2-ylamino)methyl]phenyl]methylsulfonylamino]propanoate Chemical compound C1(CCCCC1)CC(C)NCC1=C(CS(=O)(=O)N[C@H](C)C(=O)OC)C=CC=C1 MOZHFDPWXQAUJO-ZYMOGRSISA-N 0.000 description 1
- SODIELMLQMRCBL-UHFFFAOYSA-N methyl 2-[3-(aminomethyl)phenyl]acetate Chemical compound COC(=O)CC1=CC=CC(CN)=C1 SODIELMLQMRCBL-UHFFFAOYSA-N 0.000 description 1
- XIYXFMOPHFCWPL-UHFFFAOYSA-N methyl 2-[[2-[[2-(aminomethyl)phenyl]methylsulfonylamino]acetyl]amino]acetate Chemical compound NCC1=C(CS(=O)(=O)NCC(=O)NCC(=O)OC)C=CC=C1 XIYXFMOPHFCWPL-UHFFFAOYSA-N 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- YRMODRRGEUGHTF-UHFFFAOYSA-N methyl 2-formylbenzoate Chemical compound COC(=O)C1=CC=CC=C1C=O YRMODRRGEUGHTF-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229940076266 morganella morganii Drugs 0.000 description 1
- RTJNHLXWVAXRBH-UHFFFAOYSA-N n-benzyl-2-(cyclohexen-1-yl)ethanamine Chemical compound C=1C=CC=CC=1CNCCC1=CCCCC1 RTJNHLXWVAXRBH-UHFFFAOYSA-N 0.000 description 1
- VCICLUQIFXIOEJ-UHFFFAOYSA-N n-benzyl-2-cyclohex-2-en-1-ylacetamide Chemical compound C=1C=CC=CC=1CNC(=O)CC1CCCC=C1 VCICLUQIFXIOEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- OHENQANLQNOMAO-UHFFFAOYSA-N oxaborole Chemical class O1B=CC=C1 OHENQANLQNOMAO-UHFFFAOYSA-N 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- CDQXHVDVGLVACE-UHFFFAOYSA-N propan-2-amine Chemical compound [CH2]C(C)N CDQXHVDVGLVACE-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- STZCRXQWRGQSJD-UHFFFAOYSA-M sodium;4-[[4-(dimethylamino)phenyl]diazenyl]benzenesulfonate Chemical compound [Na+].C1=CC(N(C)C)=CC=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-UHFFFAOYSA-M 0.000 description 1
- RNVYQYLELCKWAN-UHFFFAOYSA-N solketal Chemical compound CC1(C)OCC(CO)O1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229950002757 teoclate Drugs 0.000 description 1
- OGZIEVHPPVVVDV-UHFFFAOYSA-N tert-butyl 4-[2-(benzylamino)ethyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CCNCC1=CC=CC=C1 OGZIEVHPPVVVDV-UHFFFAOYSA-N 0.000 description 1
- SSKHBDMIQBDFAF-UHFFFAOYSA-N tert-butyl N-(1-cyclohexylpropan-2-yl)-N-[(1-methylindol-7-yl)methyl]carbamate Chemical compound C1(CCCCC1)CC(C)N(C(OC(C)(C)C)=O)CC=1C=CC=C2C=CN(C=12)C SSKHBDMIQBDFAF-UHFFFAOYSA-N 0.000 description 1
- LRCHHZHLWFUJJM-UHFFFAOYSA-N tert-butyl N-(1-cyclohexylpropan-2-yl)-N-[[2-(sulfamoylmethyl)phenyl]methyl]carbamate Chemical compound C1(CCCCC1)CC(C)N(C(OC(C)(C)C)=O)CC1=C(C=CC=C1)CS(N)(=O)=O LRCHHZHLWFUJJM-UHFFFAOYSA-N 0.000 description 1
- VTXBGNXZTXDBJL-UHFFFAOYSA-N tert-butyl N-(1-cyclohexylpropan-2-yl)-N-[[2-[(2-fluorobenzoyl)amino]phenyl]methyl]carbamate Chemical compound C1(CCCCC1)CC(C)N(C(OC(C)(C)C)=O)CC1=C(C=CC=C1)NC(C1=C(C=CC=C1)F)=O VTXBGNXZTXDBJL-UHFFFAOYSA-N 0.000 description 1
- FXORKQOZKNHPAA-UHFFFAOYSA-N tert-butyl N-(1-cyclohexylpropan-2-yl)-N-[[2-[(2-fluorophenyl)methylamino]phenyl]methyl]carbamate Chemical compound C1(CCCCC1)CC(C)N(C(OC(C)(C)C)=O)CC1=C(C=CC=C1)NCC1=C(C=CC=C1)F FXORKQOZKNHPAA-UHFFFAOYSA-N 0.000 description 1
- MDNCRQUTSFFWDW-UHFFFAOYSA-N tert-butyl N-[[2-(carbamoylamino)phenyl]methyl]-N-(2-cyclohexylethyl)carbamate Chemical compound C1(CCCCC1)CCN(C(OC(C)(C)C)=O)CC1=C(C=CC=C1)NC(=O)N MDNCRQUTSFFWDW-UHFFFAOYSA-N 0.000 description 1
- ZKVJKHOVABAYTE-UHFFFAOYSA-N tert-butyl N-benzyl-N-(1-cyclohexyl-3-oxopropan-2-yl)carbamate Chemical compound C1CCCCC1CC(C=O)N(C(=O)OC(C)(C)C)CC1=CC=CC=C1 ZKVJKHOVABAYTE-UHFFFAOYSA-N 0.000 description 1
- CFCNZHUVRGQJBU-UHFFFAOYSA-N tert-butyl N-benzyl-N-[2-(2-chloro-1-hydroxycyclohexyl)ethyl]carbamate Chemical compound C(C1=CC=CC=C1)N(C(OC(C)(C)C)=O)CCC1(C(CCCC1)Cl)O CFCNZHUVRGQJBU-UHFFFAOYSA-N 0.000 description 1
- GOCKUYPIQJLPOA-UHFFFAOYSA-N tert-butyl N-benzyl-N-[2-(2-methoxycyclohexyl)ethyl]carbamate Chemical compound C(C1=CC=CC=C1)N(C(OC(C)(C)C)=O)CCC1C(CCCC1)OC GOCKUYPIQJLPOA-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- AJZGFFKDLABHDD-UHFFFAOYSA-N thiazinane Chemical compound C1CCSNC1 AJZGFFKDLABHDD-UHFFFAOYSA-N 0.000 description 1
- DNGMYXZLJGHHOM-UHFFFAOYSA-N thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCCCN1 DNGMYXZLJGHHOM-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
- C07C211/35—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
- C07C211/38—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/40—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing only non-condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
- C07C211/49—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring having at least two amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/18—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with hydroxy groups and at least two amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/20—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated the carbon skeleton being saturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
- C07C215/50—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/76—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and etherified hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C219/28—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
- C07C225/04—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
- C07C225/08—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
- C07C225/12—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings with doubly-bound oxygen atoms bound to carbon atoms being part of rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/36—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/14—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
- C07C275/48—Y being a hydrogen or a carbon atom
- C07C275/50—Y being a hydrogen or an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/31—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
- C07C311/35—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
- C07C311/55—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C07D213/643—2-Phenoxypyridines; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
- C07D327/06—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/20—All rings being cycloaliphatic the ring system containing seven carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/38—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing five carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/44—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing eight carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
- C07C2603/28—Phenalenes; Hydrogenated phenalenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Definitions
- Gram-negative bacteria are intrinsically resistant to many small molecules owing to the presence of an outer membrane, which acts as a permeability barrier.
- tRNA synthetases are involved in protein biosynthesis so that inhibition thereof may be expected to lead to a cessation of cell growth.
- the compound mupirocin produced by the organism Pseudomonas fluorescens , is an antibacterial agent and is used as the active ingredient in the product Bactroban, marketed by GlaxoSmithKline.
- mupirocin is only effective against Gram-positive, but not Gram-negative bacteria. Mupirocin has been shown to be an inhibitor of the isoleucyl tRNA synthetase.
- tRNA synthetase inhibitors which are selective for bacterial cells over mammalian cells are of considerable therapeutic interest as they have the potential to be used as antibacterial agents. Thus, there remains a need to develop compounds having inhibitory activity toward tRNA synthetase in Gram-negative bacteria.
- the invention provides a compound of formula (I):
- the invention provides a compound of formula (II′):
- the invention provides a compound of formula (III′):
- the invention further provides compounds, or pharmaceutically acceptable salts thereof, of the compounds listed in Table 1.
- the invention provides pharmaceutical compositions comprising a compound of any one of claims 1 - 38 , in combination with a pharmaceutically acceptable carrier.
- the invention provides methods of treating a bacterial infection in a subject, comprising administering to the subject a therapeutically effective amount of a compound of the invention, i.e., a compound of formula (I), formula (II), formula (II′), formula (III), formula (III′), or a compound pictured in Table 1, or a pharmaceutical composition comprising the compound.
- a compound of the invention i.e., a compound of formula (I), formula (II), formula (II′), formula (III), formula (III′), or a compound pictured in Table 1, or a pharmaceutical composition comprising the compound.
- the invention further provides methods of treating a bacterial infection in a subject, comprising administering to the subject a therapeutically effective amount of a compound of formula (IV′):
- R 21 and R 25 are not OH, —OC(O)((C 1 -C 8 )alkyl), optionally substituted (C 1 -C 8 )alkoxy, optionally substituted (C 1 -C 8 )haloalkoxy, optionally substituted aryloxy, optionally substituted arylalkoxy, optionally substituted heteroaryloxy, optionally substituted heteroarylalkoxy, optionally substituted (C 3 -C 10 )cycloalkoxy, optionally substituted (C 2 -C 9 )heterocycloalkoxy, —O—CH 2 —R 28 , or —O—CH 2 CH 2 —O—R 29 .
- the invention provides methods of treating tuberculosis, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the invention, i.e., a compound of formula (I), formula (II), formula (II′), formula (III), formula (III′), or a compound pictured in Table 1, or a pharmaceutical composition comprising the compound.
- a compound of the invention i.e., a compound of formula (I), formula (II), formula (II′), formula (III), formula (III′), or a compound pictured in Table 1, or a pharmaceutical composition comprising the compound.
- the invention further provides methods of treating tuberculosis, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (V′):
- FIG. 1 shows that the compounds of the invention, such as B1, can be used in combination with other tRNA synthetase inhibitors in order to overcome antibiotic resistance.
- the present invention is based on the discovery of a class of compounds with surprising antibacterial activity. A description of example embodiments of the invention follows.
- Alkyl means an optionally substituted saturated aliphatic branched or straight-chain monovalent hydrocarbon radical having the specified number of carbon atoms.
- (C 1 -C 6 ) alkyl means a radical having from 1-6 carbon atoms in a linear or branched arrangement.
- (C 1 -C 6 )alkyl includes methyl, ethyl, propyl, butyl, pentyl and hexyl.
- Alkylene means an optionally substituted saturated aliphatic branched or straight-chain divalent hydrocarbon radical having the specified number of carbon atoms.
- (C 1 -C 6 )alkylene includes a divalent saturated aliphatic radical having from 1-6 carbon atoms in a linear arrangement, e.g., —[(CH 2 ) n ]—, where n is an integer from 1 to 6, “(C 1 -C 6 )alkylene” includes methylene, ethylene, propylene, butylene, pentylene and hexylene.
- (C 1 -C 6 )alkylene also includes a divalent saturated radical having from 1-6 carbon atoms in a branched arrangement, for example: —[(CH 2 CH 2 CH 2 CH 2 CH(CH 3 )]—, —[(CH 2 CH 2 CH 2 CH 2 C(CH 3 ) 2 ]—, —[(CH 2 C(CH 3 ) 2 CH(CH 3 ))]—, and the like.
- alkylene is optionally and independently substituted with one or more substituents independently selected from halo, (C 1 -C 6 )alkyl, —OH, ⁇ O, (C 1 -C 6 )alkoxy, and (C 1 -C 6 )haloalkyl.
- Aryl or “aromatic” means an aromatic monocyclic or polycyclic (e.g. bicyclic or tricyclic) carbocyclic ring system.
- aryl is a 6-12 membered monocylic or bicyclic system.
- Aryl systems include, but not limited to, phenyl, naphthyl, fluorenyl, indenyl, azulenyl, and anthracenyl. In certain preferred embodiments, “aryl” is phenyl.
- Carbocyclyl means a cyclic group with only ring carbon atoms. “Carbocyclyl” includes 3-12 membered saturated or unsaturated aliphatic cyclic hydrocarbon rings or 6-12 membered aryl rings. A carbocyclyl moiety can be monocyclic, fused bicyclic, bridged bicyclic, spiro bicyclic, or polycyclic.
- Monocyclic carbocyclyls are saturated or unsaturated aliphatic cyclic hydrocarbon rings or aromatic hydrocarbon rings having the specified number of carbon atoms.
- Monocyclic carbocyclyls include cycloalkyl, cycloalkenyl, cycloalkynyl and phenyl.
- a fused bicyclic carbocyclyl has two rings which have two adjacent ring atoms in common.
- the first ring is a monocyclic carbocyclyl and the second ring is a monocyclic carbocyclyl or a monocyclic heterocyclyl.
- a bridged bicyclic carbocyclyl has two rings which have three or more adjacent ring atoms in common.
- the first ring is a monocyclic carbocyclyl and the second ring is a monocyclic carbocyclyl or a monocyclic heterocyclyl.
- a bridged bicyclic carbocylyl is adamantyl.
- a spiro bicyclic carbocyclyl has two rings which have only one ring atom in common.
- the first ring is a monocyclic carbocyclyl and the second ring is a monocyclic carbocyclyl or a monocyclic heterocyclyl.
- Polycyclic carbocyclyls have more than two rings (e.g., three rings resulting in a tricyclic ring system) and adjacent rings have at least one ring atom in common.
- the first ring is a monocyclic carbocyclyl and the remainder of the ring structures are monocyclic carbocyclyls or monocyclic heterocyclyls.
- Polycyclic ring systems include fused, bridged and spiro ring systems.
- a fused polycyclic ring system has at least two rings that have two adjacent ring atoms in common.
- a spiro polycyclic ring system has at least two rings that have only one ring atom in common.
- a bridged polycyclic ring system has at least two rings that have three or more adjacent ring atoms in common.
- Cycloalkyl means a saturated aliphatic cyclic hydrocarbon ring.
- (C 3 -C 7 )cycloalkyl means a hydrocarbon radical of a (3-7 membered) saturated aliphatic cyclic hydrocarbon ring.
- a C 3 -C 7 cycloalkyl includes, but is not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
- “Cycloalkene” means an aliphatic cyclic hydrocarbon ring having one or more double bonds in the ring.
- Cycloalkyne means an aliphatic cyclic hydrocarbon ring having one or more triple bonds in the ring.
- Hetero refers to the replacement of at least one carbon atom member in a ring system with at least one heteroatom selected from N, S, and O. “Hetero” also refers to the replacement of at least one carbon atom member in a acyclic system.
- a hetero ring system or a hetero acyclic system may have 1, 2, 3 or 4 carbon atom members replaced by a heteroatom.
- Heterocyclyl means a cyclic 4-12 membered saturated or unsaturated aliphatic or aromatic ring containing 1, 2, 3, 4 or 5 heteroatoms independently selected from N, O or S. When one heteroatom is S, it can be optionally mono- or di-oxygenated (i.e. —S(O)— or —S(O) 2 —).
- the heterocyclyl can be monocyclic, fused bicyclic, bridged bicyclic, spiro bicyclic or polycyclic.
- “Saturated heterocyclyl” means an aliphatic heterocyclyl group without any degree of unsaturation (i.e. no double bond or triple bond). It can be monocyclic, fused bicyclic, bridged bicyclic, spiro bicyclic or polycyclic.
- Examples of monocyclic saturated heterocyclyls include, but are not limited to, azetidine, pyrrolidine, piperidine, piperazine, azepane, hexahydropyrimidine, tetrahydrofuran, tetrahydropyran, morpholine, thiomorpholine, thiomorpholine 1,1-dioxide, tetrahydro-2H-1,2-thiazine, tetrahydro-2H-1,2-thiazine 1,1-dioxide, isothiazolidine, isothiazolidine 1,1-dioxide.
- a fused bicyclic heterocyclyl has two rings which have two adjacent ring atoms in common.
- the first ring is a monocyclic heterocyclyl and the second ring is a monocyclic carbocycle (such as a cycloalkyl or phenyl) or a monocyclic heterocyclyl.
- the second ring is a (C 3 -C 6 )cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
- the second ring is phenyl.
- fused bicyclic heterocyclyls include, but are not limited to, octahydrocyclopenta[c]pyrrolyl, indoline, isoindoline, 2,3-dihydro-H-benzo[d]imidazole, 2,3-dihydrobenzo[d]oxazole, 2,3-dihydrobenzo[d]thiazole, octahydrobenzo[d]oxazole, octahydro-1H-benzo[d]imidazole, octahydrobenzo[d]thiazole, octahydrocyclopenta[c]pyrrole, 3-azabicyclo[3.1.0]hexane, and 3-azabicyclo[3.2.0]heptane.
- a spiro bicyclic heterocyclyl has two rings which have only one ring atom in common.
- the first ring is a monocyclic heterocyclyl and the second ring is a monocyclic carbocycle (such as a cycloalkyl or phenyl) or a monocyclic heterocyclyl.
- the second ring is a (C 3 -C 6 )cycloalkyl.
- the second ring is phenyl.
- Example of spiro bicyclic heterocyclyl includes, but are not limited to, azaspiro[4.4]nonane, 7-azaspiro[4.4]nonane, azaspiro[4.5]decane, 8-azaspiro[4.5]decane, azaspiro[5.5]undecane, 3-azaspiro[5.5]undecane and 3,9-diazaspiro[5.5]undecane.
- a bridged bicyclic heterocyclyl has two rings which have three or more adjacent ring atoms in common.
- the first ring is a monocyclic heterocyclyl and the other ring is a monocyclic carbocycle (such as a cycloalkyl or phenyl) or a monocyclic heterocyclyl.
- bridged bicyclic heterocyclyls include, but are not limited to, azabicyclo[3.3.1]nonane, 3-azabicyclo[3.3.1]nonane, azabicyclo[3.2.1]octane, 3-azabicyclo[3.2.1]octane, 6-azabicyclo[3.2.1]octane and azabicyclo[2.2.2]octane, 2-azabicyclo[2.2.2]octane.
- Polycyclic heterocyclyls have more than two rings, one of which is a heterocyclyl (e.g., three rings resulting in a tricyclic ring system) and adjacent rings having at least one ring atom in common.
- Polycyclic ring systems include fused, bridged and spiro ring systems.
- a fused poly cyclic ring system has at least two rings that have two adjacent ring atoms in common.
- a spiro polycyclic ring system has at least two rings that have only one ring atom in common.
- a bridged polycyclic ring system has at least two rings that have three or more adjacent ring atoms in common.
- Heteroaryl or “heteroaromatic ring” means a 5-12 membered monovalent heteroaromatic monocyclic or bicyclic ring radical.
- a heteroaryl contains 1, 2, 3 or 4 heteroatoms independently selected from N, O, and S.
- Heteroaryls include, but are not limited to furan, oxazole, thiophene, 1,2,3-triazole, 1,2,4-triazine, 1,2,4-triazole, 1,2,5-thiadiazole 1,1-dioxide, 1,2,5-thiadiazole 1-oxide, 1,2,5-thiadiazole, 1,3,4-oxadiazole, 1,3,4-thiadiazole, 1,3,5-triazine, imidazole, isothiazole, isoxazole, pyrazole, pyridazine, pyridine, pyridine-N-oxide, pyrazine, pyrimidine, pyrrole, tetrazole, and thiazole.
- Bicyclic heteroaryl rings include, but are not limited to, bicyclo[4.4.0] and bicyclo[4.3.0]fused ring systems such as indolizine, indole, isoindole, indazole, benzimidazole, benzthiazole, purine, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, quinoxaline, 1,8-naphthyridine, and pteridine.
- bicyclo[4.4.0] and bicyclo[4.3.0]fused ring systems such as indolizine, indole, isoindole, indazole, benzimidazole, benzthiazole, purine, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, quinoxaline, 1,8-naphthyridine, and pteridine.
- a group such as alkylene, adamantyl, naphthyl, or aryl may be optionally substituted.
- substituents include halo, (C 1 -C 6 )alkyl, —OH, ⁇ O, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkylene, (C 1 -C 6 )haloalkyl, (C 1 -C 6 )haloalkoxy, and —C(O)—(C 1 -C 6 )alkyl.
- a phenyl group may have two adjacent substituents that, taken together with the intervening atoms, form an optionally substituted heteroaryl, aryl, cycloalkyl, or heterocycloalkyl ring.
- a phenyl group having two adjacent substituents that, taken together with the intervening atoms, form a pyridinyl group can have the structure
- a phenyl group having two adjacent substituents that, taken together with the intervening atoms, form a tetrahydropyranyl group can have the structure
- Halogen and “halo” are interchangeably used herein and each refers to fluorine, chlorine, bromine, or iodine.
- Alkoxy means an alkyl radical attached through an oxygen linking atom.
- (C 1 -C 6 )-alkoxy includes methoxy, ethoxy, propoxy, butoxy, pentoxy and hexoxy.
- Haloalkyl includes mono, poly, and perhaloalkyl groups where each halogen is independently selected from fluorine, chlorine, and bromine.
- “Pharmaceutically acceptable carrier” means non-therapeutic components that are of sufficient purity and quality for use in the formulation of a composition of the invention that, when appropriately administered to an animal or human, typically do not produce an adverse reaction, and that are used as a vehicle for a drug substance (i.e. a compound of the present invention).
- compositions of the present invention are also included.
- an acid salt of a compound of the present invention containing an amine or other basic group can be obtained by reacting the compound with a suitable organic or inorganic acid, resulting in pharmaceutically acceptable anionic salt forms.
- anionic salts include the acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, bromide, calcium edetate, camsylate, carbonate, chloride, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, glyceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, methylsulfate, mucate, napsylate, nitrate, pamoate, pantothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, sulfate, tannate,
- Salts of the compounds of the present invention containing a carboxylic acid or other acidic functional group can be prepared by reacting with a suitable base.
- a suitable base which affords a pharmaceutically acceptable cation, which includes alkali metal salts (especially sodium and potassium), alkaline earth metal salts (especially calcium and magnesium), aluminum salts and ammonium salts, as well as salts made from physiologically acceptable organic bases such as trimethylamine, triethylamine, morpholine, pyridine, piperidine, picoline, dicyclohexylamine, N,N′-dibenzylethylenediamine, 2-hydroxyethylamine, bis-(2-hydroxyethyl)amine, tri-(2-hydroxyethyl)amine, procaine, dibenzylpiperidine, dehydroabietylamine, N,N′-bisdehydroabietylamine, glucamine, N-methylglucamine, collidine, quinine, quinoline,
- the invention provides a compound of formula (I):
- R 6 is (C 1 -C 6 )alkyl, for example, methyl.
- R 6 may be H.
- R 7 is optionally substituted cyclohexyl or cyclohexenyl. In some preferred embodiments, R 7 is optionally substituted cyclohexyl.
- R 1 , R 2 , R 3 , R 4 , and R 5 are H.
- R 2 , R 3 , R 4 , and R 5 may each be H.
- R 1 is selected from the group consisting of (C 3 -C 8 )alkyl, (C 2 -C 8 )hydroxyalkyl, (C 1 -C 8 )aminoalkyl, (C 4 -C 8 )cycloalkyl, aryl, heteroaryl, (CH 3 SO 2 )(C 1 -C 8 )alkyl, and di((C 1 -C 8 )alkyl)amino.
- R 1 is selected from the group consisting of aryl and heteroaryl.
- R 1 represents optionally substituted (R b 2 NSO 2 )(C 1 -C 8 )alkylene.
- R 1 may be selected from the group consisting of straight chain (C 2 -C 8 )alkoxy, (C 1 -C 8 )haloalkoxy, aryloxy, —OC(O)((C 1 -C 8 )alkyl), —O—CH 2 —R 8 , and —O—CH 2 CH 2 —O—R 9 .
- R 1 may be selected from the group consisting of straight chain (C 2 -C 8 )alkoxy, (C 1 -C 8 )haloalkoxy, and aryloxy.
- R 1 is selected from the group consisting of —O—CH 2 —R 8 and —O—CH 2 CH 2 —O—R 9 .
- R 1 is —O—CH 2 —R 8 and R 8 is optionally substituted heteroaryl wherein the heteroaryl is not 4-pyridinyl, benzimidazole or thiazole.
- the invention provides a compound of formula (II′):
- the invention provides a compound of formula (II):
- R 10 , R 11 , R 12 , and R 13 are H.
- R 10 , R 11 , R 12 , and R 13 may each be H.
- R 14 is H.
- R 14 may be (C 1 -C 6 )alkyl, e.g., methyl.
- R 15 is optionally substituted cyclohexyl or cyclohexenyl. In some preferred embodiments, R 15 is optionally substituted cyclohexyl.
- R a may represent (C 3 -C 10 )cycloalkyl or (C 1 -C 8 )alkyl.
- the invention provides a compound of formula (III′):
- the invention provides a compound of formula (III):
- R 40 , R 41 , R 42 , and R 43 are H.
- R 40 , R 41 , R 42 , and R 43 may each be H.
- R 44 is H.
- R 44 may be (C 1 -C 6 )alkyl, e.g., methyl.
- R 45 is optionally substituted cyclohexyl or cyclohexenyl. In some preferred embodiments, R 45 is optionally substituted cyclohexyl.
- R c is H
- R d independently for each occurrence, is selected from H and (C 1 -C 8 )alkyl, preferably H. In other embodiments, each R d is methyl. In certain embodiments, one R d is methyl or ethyl and the other R d is H.
- one R d is optionally substituted —C(O)alkyl, such as —C(O)CH(NH 2 )CH 2 CHMe 2 .
- one R d is —C(O)NH—(C 3 -C 10 )cycloalkyl, such as —C(O)NH-cyclohexyl, optionally substituted with methyl.
- one R d is optionally substituted (C 1 -C 8 )alkyl, such as —CH 2 CH(OH)CH 2 OH. In other embodiments, one R d is —CH 2 CH(OH)CH 2 OH and the other R d is methyl. In certain embodiments, one R d is —CH 2 C(O)NHCH 2 COOH. In some embodiments, one R d is —CH 2 CH 2 OMe. In certain embodiments, one R d is —CH 2 COOH. In other embodiments, one R d is —CH(Me)COOH. In other embodiments, one R d is —CH 2 -heterocyclyl, such as —CH 2 -furanyl.
- one R d is optionally substituted cycloalkyl, such as 3-COOHcyclobutyl. In other embodiments, one R d is optionally substituted aryl, such as 3-(B(OH 3 ))-phenyl. In certain embodiments, one R d is optionally substituted heterocyclyl, such as N-methylpiperidinyl.
- both R d are taken together with the nitrogen atom to which they are attached to form an optionally substituted 5-6-membered heterocyclyl, such as an N-methylpiperizinyl.
- the invention provides a compound, or a pharmaceutically acceptable salt thereof, selected from Table 1:
- the invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of the invention (e.g., a compound of formula (I)), in combination with a pharmaceutically acceptable carrier.
- the invention further includes the process for making the composition comprising mixing one or more of the present compounds and an optional pharmaceutically acceptable carrier; and includes those compositions resulting from such a process, which process includes conventional pharmaceutical techniques.
- compositions of the invention include ocular, oral, nasal, transdermal, topical with or without occlusion, intravenous (both bolus and infusion), inhalable, and injection (intraperitoneally, subcutaneously, intramuscularly, intralesionally, or parenterally) formulations.
- the composition may be in a dosage unit such as a tablet, pill, capsule, powder, granule, liposome, ion exchange resin, sterile ocular solution, or ocular delivery device (such as a contact lens and the like facilitating immediate release, timed release, or sustained release), parenteral solution or suspension, metered aerosol or liquid spray, drop, ampoule, auto-injector device, or suppository; for administration ocularly, orally, intranasally, sublingually, parenterally, or rectally, or by inhalation or insufflation.
- a dosage unit such as a tablet, pill, capsule, powder, granule, liposome, ion exchange resin, sterile ocular solution, or ocular delivery device (such as a contact lens and the like facilitating immediate release, timed release, or sustained release), parenteral solution or suspension, metered aerosol or liquid spray, drop, ampoule, auto-injector device, or suppository; for administration
- compositions of the invention suitable for oral administration include solid forms such as pills, tablets, caplets, capsules (each including immediate release, timed release, and sustained release formulations), granules and powders; and, liquid forms such as solutions, syrups, elixirs, emulsions, and suspensions.
- forms useful for ocular administration include sterile solutions or ocular delivery devices.
- forms useful for parenteral administration include sterile solutions, emulsions, and suspensions.
- compositions of the invention may be administered in a form suitable for once-weekly or once-monthly administration.
- an insoluble salt of the active compound may be adapted to provide a depot preparation for intramuscular injection (e.g., a decanoate salt) or to provide a solution for ophthalmic administration.
- the dosage form containing the composition of the invention contains an effective amount of the active ingredient necessary to provide a therapeutic effect.
- the composition may contain from about 5,000 mg to about 0.5 mg (preferably, from about 1,000 mg to about 0.5 mg) of a compound of the invention or salt form thereof and may be constituted into any form suitable for the selected mode of administration.
- the composition may be administered about 1 to about 5 times per day. Daily administration or post-periodic dosing may be employed.
- the composition is preferably in the form of a tablet or capsule containing, e.g., 500 to 0.5 milligrams of the active compound. Dosages will vary depending on factors associated with the particular patient being treated (e.g., age, weight, diet, and time of administration), the severity of the condition being treated, the compound being employed, the mode of administration, and the strength of the preparation.
- the oral composition is preferably formulated as a homogeneous composition, wherein the active ingredient is dispersed evenly throughout the mixture, which may be readily subdivided into dosage units containing equal amounts of a compound of the invention.
- the compositions are prepared by mixing a compound of the invention (or pharmaceutically acceptable salt thereof) with one or more optionally present pharmaceutical carriers (such as a starch, sugar, diluent, granulating agent, lubricant, glidant, binding agent, and disintegrating agent), one or more optionally present inert pharmaceutical excipients (such as water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and syrup), one or more optionally present conventional tableting ingredients (such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate, and any of a variety of gums), and an optional diluent (such as water).
- pharmaceutical carriers such as a
- Binder agents include starch, gelatin, natural sugars (e.g., glucose and beta-lactose), corn sweeteners and natural and synthetic gums (e.g., acacia and tragacanth).
- Disintegrating agents include starch, methyl cellulose, agar, and bentonite.
- Tablets and capsules represent an advantageous oral dosage unit form. Tablets may be sugarcoated or film-coated using standard techniques. Tablets may also be coated or otherwise compounded to provide a prolonged, control-release therapeutic effect.
- the dosage form may comprise an inner dosage and an outer dosage component, wherein the outer component is in the form of an envelope over the inner component.
- the two components may further be separated by a layer which resists disintegration in the stomach (such as an enteric layer) and permits the inner component to pass intact into the duodenum or a layer which delays or sustains release.
- enteric and non-enteric layer or coating materials such as polymeric acids, shellacs, acetyl alcohol, and cellulose acetate or combinations thereof may be used.
- Compounds of the invention may also be administered via a slow release composition; wherein the composition includes a compound of the invention and a biodegradable slow release carrier (e.g., a polymeric carrier) or a pharmaceutically acceptable non-biodegradable slow release carrier (e.g., an ion exchange carrier).
- a biodegradable slow release carrier e.g., a polymeric carrier
- a pharmaceutically acceptable non-biodegradable slow release carrier e.g., an ion exchange carrier
- Biodegradable and non-biodegradable slow release carriers are well known in the art.
- Biodegradable carriers are used to form particles or matrices which retain an active agent(s) and which slowly degrade/dissolve in a suitable environment (e.g., aqueous, acidic, basic and the like) to release the agent.
- a suitable environment e.g., aqueous, acidic, basic and the like
- Such particles degrade/dissolve in body fluids to release the active compound(s) therein.
- the particles are preferably nanoparticles or nanoemulsions (e.g., in the range of about 1 to 500 nm in diameter, preferably about 50-200 nm in diameter, and most preferably about 100 nm in diameter).
- a slow release carrier and a compound of the invention are first dissolved or dispersed in an organic solvent.
- the resulting mixture is added into an aqueous solution containing an optional surface-active agent(s) to produce an emulsion.
- the organic solvent is then evaporated from the emulsion to provide a colloidal suspension of particles containing the slow release carrier and the compound of the invention.
- the compounds disclosed herein may be incorporated for administration orally or by injection in a liquid form such as aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil and the like, or in elixirs or similar pharmaceutical vehicles.
- Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone, and gelatin.
- the liquid forms in suitably flavored suspending or dispersing agents may also include synthetic and natural gums.
- sterile suspensions and solutions are desired. Isotonic preparations, which generally contain suitable preservatives, are employed when intravenous administration is desired.
- a parenteral formulation may consist of the active ingredient dissolved in or mixed with an appropriate inert liquid carrier.
- Acceptable liquid carriers usually comprise aqueous solvents and other optional ingredients for aiding solubility or preservation.
- aqueous solvents include sterile water, Ringer's solution, or an isotonic aqueous saline solution.
- Other optional ingredients include vegetable oils (such as peanut oil, cottonseed oil, and sesame oil), and organic solvents (such as solketal, glycerol, and formyl).
- a sterile, non-volatile oil may be employed as a solvent or suspending agent.
- the parenteral formulation is prepared by dissolving or suspending the active ingredient in the liquid carrier whereby the final dosage unit contains from 0.005 to 10% by weight of the active ingredient.
- Other additives include preservatives, isotonizers, solubilizers, stabilizers, and pain-soothing agents.
- injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed.
- Compounds of the invention may be administered intranasally using a suitable intranasal vehicle.
- the compounds of this invention may be administered directly to the lungs by inhalation.
- Compounds of the invention may also be administered topically or enhanced by using a suitable topical transdermal vehicle or a transdermal patch.
- the composition is preferably in the form of an ophthalmic composition.
- the ophthalmic compositions are preferably formulated as eye-drop formulations and filled in appropriate containers to facilitate administration to the eye, for example a dropper fitted with a suitable pipette.
- the compositions are sterile and aqueous based, using purified water.
- an ophthalmic composition may contain one or more of: a) a surfactant such as a polyoxyethylene fatty acid ester; b) a thickening agents such as cellulose, cellulose derivatives, carboxyvinyl polymers, polyvinyl polymers, and polyvinylpyrrolidones, typically at a concentration n the range of about 0.05 to about 5.0% (wt/vol); c) (as an alternative to or in addition to storing the composition in a container containing nitrogen and optionally including a free oxygen absorber such as Fe), an anti-oxidant such as butylated hydroxyanisol, ascorbic acid, sodium thiosulfate, or butylated hydroxytoluene at a concentration of about 0.00005 to about 0.1% (wt/vol); d) ethanol at a concentration of about 0.01 to 0.5% (wt/vol); and e) other excipients such as an isotonic agent, buffer, preservitol, typically at a
- the pharmaceutical composition of the invention further comprises one or more additional agents, such as a second antibacterial agent.
- the other agent may be ay agent that is capable of treating, suppressing, or preventing a bacterial infection.
- the other therapeutic agent may be an antibacterial compound.
- the other therapeutic agent may be any agent of benefit to a patient when administered in combination with the tRNA synthetase inhibitor compound in this invention.
- the second antibacterial agent in the pharmaceutical composition of the invention is a tRNA synthetase inhibitor.
- tRNA synthetase inhibitors include oxaborole compounds such as AN3365.
- the invention provides methods of treating a bacterial infection in a subject, comprising administering to the subject a therapeutically effective amount of a compound of the invention, i.e., a compound of formula (I), formula (II), formula (II′), formula (III), formula (III′), or a compound pictured in Table 1, or a pharmaceutical composition comprising the compound.
- a compound of the invention i.e., a compound of formula (I), formula (II), formula (II′), formula (III), formula (III′), or a compound pictured in Table 1, or a pharmaceutical composition comprising the compound.
- the invention further provides methods of treating a bacterial infection in a subject, comprising administering to the subject a therapeutically effective amount of a compound of formula (IV′):
- R 21 and R 25 are not OH, —OC(O)((C 1 -C 8 )alkyl), optionally substituted (C 1 -C 8 )alkoxy, optionally substituted (C 1 -C 8 )haloalkoxy, optionally substituted aryloxy, optionally substituted arylalkoxy, optionally substituted heteroaryloxy, optionally substituted heteroarylalkoxy, optionally substituted (C 3 -C 10 )cycloalkoxy, optionally substituted (C 2 -C 9 )heterocycloalkoxy, —O—CH 2 —R 28 , or —O—CH 2 CH 2 —O—R 29 .
- the invention further provides methods of treating a bacterial infection in a subject, comprising administering to the subject a therapeutically effective amount of a compound of formula (IV):
- R 21 and R 25 are not OH, —OC(O)((C 1 -C 8 )alkyl), optionally substituted (C 1 -C 8 )alkoxy, optionally substituted (C 1 -C 8 )haloalkoxy, optionally substituted aryloxy, optionally substituted arylalkoxy, optionally substituted heteroaryloxy, optionally substituted heteroarylalkoxy, optionally substituted (C 3 -C 10 )cycloalkoxy, optionally substituted (C 2 -C 9 )heterocycloalkoxy, —O—CH 2 —R 28 , or —O—CH 2 CH 2 —O—R 29 .
- the bacterial infection is caused by Gram-negative bacteria.
- Exemplary Gram-negative bacteria used with the methods of the invention include Acidaminococcus spp (e.g. A. fermentans, A. intestin ), Acinetobacter spp (e.g. A. baumannii, A. calcoaceticus, A. gyllenbergii, A. haemolyticus, A. junii, A. lwoffii, A. nosocomialis, A. parvus, A. pittii, A. schindleri, A. seifertii, A. soli, A. ursingii, A. variabilis ), Aggregatibacter spp ( A. actinomycetemcomitans, A. aphrophilus, A.
- Acinetobacter spp e.g. A. baumannii, A. calcoaceticus, A. gyllenbergii, A. haemolyticus, A. junii, A. lwoffi
- Agrobacterium tumefaciens e.g. A. skirrowii, A. butzleri, A. cryaerophilus
- Arcobacter spp e.g. A. skirrowii, A. butzleri, A. cryaerophilus
- Bacteroides spp ( B. fragilis, B. ureolyticus, B. melaninogenicus ), Bartonella spp (e.g. B. japonica, B. koehlerae, B. taylorii, B. alsatica, B. ancashensis, B. bacilliformis, B. capreoli, B. clarridgeiae, B.
- B. burgdorferi e.g. B. burgdorferi, B. afzelii, B. garinii, B. andersonii, B. anserine, B. bissettii, B. carolinensis, B. hermsii, B. kurtenbachii, B. lusitaniae, B. miyamotoi, B. parkeri, B. recurrentis, B. sinica, B. spielmanii, B. turicatae ), Brachyspira spp (e.g. B. aalborgi, B. pilosicoli, B. hyodysenteriae ), Bradyrhizobium spp (e.g. B. japonicum, B.
- B. burgdorferi e.g. burgdorferi, B. afzelii, B. garinii, B. andersonii, B. anserine, B. bissettii, B. car
- Burkholderia spp e.g. B. mallei, B. pseudomallei, B. cepacia, B. dolosa
- Campylobacter spp. e.g. C. jejuni, C. coli, C. upsaliensis, C. fetus, C. lari, C. hyointestinalis, C. rectus
- Cardiobacterium spp. e.g. C. hominis, C. valvarum
- Christensenella spp e.g. C. minuta, C. massiliensis, C. timonensis
- Citrobacter spp. e.g. C. amalonaticus, C.
- Cytophaga spp. e.g. C. columnaris, C. johnsonae, C. psychrophila ), Dialister spp (e.g. D. pneumosintes ), Eikenella corrodens, Enterobacter spp (e.g. E. cloacae, E. aerogenes, E. cancerogenus aka E. taylorae, E. cowanii ), Escherichia spp (e.g. E. coli, E. fergusonii, E. hermannii, E. albertii, E.
- Flavobacterium spp e.g. F. psychrophilum, F. columnare, F. branchiophilum
- Francisella spp. e.g. F. novicida, F. tularensis, F. piscicida, F. philomiragia
- Fusobacterium spp e.g F. necrophorum, F. nucleatum, F. polymorphum
- Haemophilus spp e.g H. felis, H. haemolyticus, H. influenzae, H. parainfluenzae, H. pittmaniae, H.
- H. pylori H. bilis, H. canadensis, H. canis, H. cinaedi
- Kingella spp e.g. Kingella kingae aka Moraxella kingae, K. indologenes, K. denitrificans, K. oralis
- Klebsiella spp e.g. K. pneumoniae, K. granulomatis, K. oxytoca, K. michiganensis, K. quasipneumoniae, K. variicola
- Kluyvera spp e.g. K. intermedia, K. ascorbate, K.
- cryocrescens K. intestine, K. georgiana
- Legionella spp e.g Legionella clemsonensis, Legionella pneumophila, L. wadsworthii, L. waltersii, L. anisa, L. birminghamensis, L. bozemanae, L. cardiaca, L. cherrii, L. multiplinnatiensis, L. dumoffli, L. feeleii, L. gormanii, L. hackeliae, L. jordanis, L. lansingensis, L. longbeachae, L. oakridgensis, L. micdadei, L. rubrilucens, L.
- Legionella spp e.g Legionella clemsonensis, Legionella pneumophila, L. wadsworthii, L. waltersii, L. anisa, L. birminghamensis, L. bozemanae
- osloensis M. atlantae, M. boevrei, M. bovoculi, M. canis, M. caprae, M. catarrhalis, M. caviae, M. cuniculi, M. equi, M. lincolnii, M. nonliquefaciens, M. oblonga, M. osloensis, M. pluranimalium, M. porci, M. saccharolytica ), Morganella morganii, Mycoplasma spp. (e.g M. spumans, M. adleri, M agalactiae, M. agassizii, M. alligatoris, M.
- M. bovis amphoriforme
- M. buccale M. capricolum
- M. faucium M. fermentans
- M. gallisepticum M. genitalium
- M. haemofelis M. haemomuris
- M. hominis M. hyopneumoniae
- M. hyorhinis M. lipophilum
- M. mobile M. mycoides
- M. orale, M. ovipneumoniae M. penetrans, M. pirum, M. pneumoniae, M, primatum, M. salivarium, M. spermatophilum, M. synoviae ), Neisseria spp. (e.g. N.
- Proteus spp. e.g. P. mirabilis, P. penneri, P. hauseri, P. myxofaciens, P. vulgaris
- Pseudomonas spp. e.g. P. aeruginosa, P. oryzihabitans, P. luteola, P. floridensis, P. syringae, P. anguilliseptica, P. argentinensis, P. flavescens, P. mendocina, P. asplenii, P. corrugate, P.
- Rickettsia spp. e.g. R. rickettsii, R. asiatica, R. australis, R. conorii, R. felis, R. heilongjiangensis, R. helvetica, R. honei, R. japonica, R. massiliae, R. monacensis, R. parkeri, R. peacockii, R. prowazekii, R. akari, R. africae, R. sibirica, R. typhi ), Rouxiella chamberiensis, Salmonella spp (e.g. S. bongori, S. enterica ), Serratia spp. (e.g.
- S. marcescens S. plymuthica, S. liquefaciens, S. rubidaea, S. odorifera, S. fonticola ), Shigella spp. (e.g. S. dysenteriae, S. flexneri, S. boydii, S. sonnei ), Solobacterium moorei, Sphingomonas spp ( S. gei, S. paucimobilis, S. koreensis ), Spirochaeta spp, Stenotrophomonas spp (e.g. S. nitritireducens, S. maltophilia ), Treponema spp. (e.g. T.
- Vibrio spp e.g. V. adaptatus, V. azasii, V. campbellii, V. cholera, V. alginolyticus, V. anguillarum, V. campbellii, V. fluvialis, V. furnissii, V. harveyi, V. lentus, V. mimicus, V. ordalii, V. parahaemolyticus, V. pectenicida, V. tapetis, V. tubiashii, V.
- Y. aldovae e.g. Y. aldovae, Y. bercovieri, Y. enterocolitica, Y. frederiksenii, Y. pestis, Y. pseudotuberculosis, Y. ruckeri ).
- the bacterial infection treated by the methods of the invention is caused by Mycobacterium kansasii, Mycobacterium marinum, Mycobacterium simiae, Mycobacterium scrofulaceum, Mycobacterium szulgai, Mycobacterium gordonae; Mycobacterium avium complex, Mycobacterium ulcerans, Mycobacterium xenopi, Mycobacterium malmoense, Mycobacterium terrae complex, Mycobacterium haemophilum, Mycobacterium genavense, Mycobacterium abscessus complex, Mycobacterium chelonae, Mycobacterium fortuitum complex, or Mycobacterium peregrinum.
- the bacterial infection treated by the methods of the invention is caused by a Nocardia species selected from N. concava, N. cyriacigeorgica, N. donostiensis, N. elegans, N. exalbida, N. farcinica, N. harenae, N. higoensis, N. ignorata, N. inohanensis, N. jinanensis, N. kroppenstedtii, N. kruczakiae, N. mexicana, N. mikamii, N. neocaledoniensis, N. niigatensis, N. ninae, N. niwae, N.
- a Nocardia species selected from N. concava, N. cyriacigeorgica, N. donostiensis, N. elegans, N. exalbida, N. farcinica, N. harenae, N. higo
- the bacterial infection treated by the methods of the invention is caused by a Actinomyces species selected from A. israelii, A. viscosus, A. meyeri, A. naeslundii, A. odontolyticus, A. gerencseriae, A. neuii, A. turicensis , and A. radingae.
- a Actinomyces species selected from A. israelii, A. viscosus, A. meyeri, A. naeslundii, A. odontolyticus, A. gerencseriae, A. neuii, A. turicensis , and A. radingae.
- the compounds of the invention When administered in combination with a second antibacterial agent, the compounds of the invention may be effective to overcome bacterial resistance to the second antibacterial agent.
- the method of treating a bacterial infection provided by the invention further comprises administering to the subject a second antibacterial agent.
- the second antibacterial agent is a tRNA synthtase inhibitor such as AN3365.
- the invention provides methods of treating tuberculosis, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the invention, i.e., a compound of formula (I), formula (II), formula (II′), formula (III), formula (III′), or a compound pictured in Table 1, or a pharmaceutical composition comprising the compound.
- a compound of the invention i.e., a compound of formula (I), formula (II), formula (II′), formula (III), formula (III′), or a compound pictured in Table 1, or a pharmaceutical composition comprising the compound.
- the invention further provides methods of treating tuberculosis, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (V′):
- the invention further provides methods of treating tuberculosis, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (V):
- R 31 , R 32 , R 33 , R 34 , and R 35 are H.
- R 32 , R 33 , R 34 , and R 35 may each be H.
- R 31 and R 32 taken together with the intervening atoms, form an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group, preferably a heteroaryl group.
- R 31 is selected from the group consisting of —OH, —OC(O)((C 1 -C 8 )alkyl), optionally substituted (C 1 -C 8 )alkoxy, optionally substituted (C 1 -C 8 )haloalkoxy, optionally substituted aryloxy, optionally substituted arylalkoxy, optionally substituted heteroaryloxy, optionally substituted heteroarylalkoxy, optionally substituted (C 3 -C 10 )cycloalkoxy, optionally substituted (C 2 -C 9 )heterocycloalkoxy, —O—CH 2 —R 38 , and —O—CH 2 CH 2 —O—R 39 .
- R 36 is (C 1 -C 6 )alkyl, e.g., methyl.
- R 36 may be H.
- R 37 is optionally substituted cyclohexyl or cyclohexenyl, preferably optionally substituted cyclohexyl.
- the subject is a mammal, e.g., a human.
- N-benzyl-1-cyclohexylbutan-2-amine (B164) was synthesized as follows:
- N-benzyl-2-cyclohexyl-1-cyclopropylethanamine (B167) was synthesized as follows: N-benzyl-2-cyclohexyl-1-cyclopropylethanamine
- Step 1 See Scheme 1, step 1
- N-benzyl-2,3-dihydro-1H-inden-2-amine hydrochloride (B206) was synthesized according to Synthetic Scheme 3.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Disclosed herein are secondary amine compounds that inhibit tRNA synthetase. The compounds of the invention are useful in inhibiting tRNA synthetase in Gram-negative bacteria and are useful in killing Gram-negative bacteria. The secondary amine compounds of the invention are also useful in the treatment of tuberculosis.
Description
- This application is a continuation of U.S. application Ser. No. 16/961,516, filed on Jul. 10, 2020, which is the U.S. National Stage of International Application No. PCT/US19/13305, filed on Jan. 11, 2019, published in English, which claims the benefit of U.S. Provisional Application No. 62/616,979, filed on Jan. 12, 2018. The entire teachings of the above application(s) are incorporated herein by reference.
- This invention was made with government support under U19 AI109764 from the National Institute of Allergy and Infectious Disease. The government has certain rights in the invention.
- Gram-negative bacteria are intrinsically resistant to many small molecules owing to the presence of an outer membrane, which acts as a permeability barrier. tRNA synthetases are involved in protein biosynthesis so that inhibition thereof may be expected to lead to a cessation of cell growth. Thus, for instance, the compound mupirocin, produced by the organism Pseudomonas fluorescens, is an antibacterial agent and is used as the active ingredient in the product Bactroban, marketed by GlaxoSmithKline. However, mupirocin is only effective against Gram-positive, but not Gram-negative bacteria. Mupirocin has been shown to be an inhibitor of the isoleucyl tRNA synthetase. Each tRNA synthetase represents a separate target for drug discovery. tRNA synthetase inhibitors which are selective for bacterial cells over mammalian cells are of considerable therapeutic interest as they have the potential to be used as antibacterial agents. Thus, there remains a need to develop compounds having inhibitory activity toward tRNA synthetase in Gram-negative bacteria.
- In certain aspects, the invention provides a compound of formula (I):
-
- or a pharmaceutically acceptable salt thereof,
- wherein:
- each of R1, R2, R3, R4, and R5 is independently selected from H, OH, —NH2, halide, sulfonamido, (C1-C6)alkylsulfonyl, —OC(O)((C1-C8)alkyl), —C(O)O((C1-C8)alkyl), —C(O)OH, optionally substituted —NHC(O)(aryl), —C(O)NH2, —B(OH)2, tri((C1-C8)alkyl)silyl, optionally substituted (C1-C8)alkyl, optionally substituted (C1-C8)alkoxy, optionally substituted (C1-C8)aminoalkyl, optionally substituted (C1-C8)hydroxyalkyl, optionally substituted (C1-C8)haloalkyl, optionally substituted (C1-C8)haloalkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryloxy, optionally substituted arylalkoxy, optionally substituted heteroaryloxy, optionally substituted heteroarylalkoxy, optionally substituted (C3-C10)cycloalkyl, optionally substituted (C3-C10)cycloalkoxy, optionally substituted (C2-C9)heterocycloalkyl, optionally substituted (C2-C9)heterocycloalkoxy, (H3CSO2)(C1-C8)alkylene, optionally substituted (Rb 2NSO2)(C1-C8)alkylene, optionally substituted di((C1-C8)alkyl)amino, —NH—CH2—R8, —O—CH2—R8, and —O—CH2CH2—O—R9;
- or R1 and R2, R2 and R3, R3 and R4, or R4 and R5, taken together with the intervening atoms, form an optionally substituted aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group;
- R6 is H or (C1-C6)alkyl;
- R7 is optionally substituted (C3-C10)cycloalkyl or (C3-C10)cycloalkenyl;
- R8 is selected from —C(O)((C2-C9)heterocycloalkyl), —C(O)NH((C1-C8)alkyl), —C(O)NH(aryl(C1-C8)alkyl), —C(O)NH((C3-C8)cycloalkyl), —C(O)NH((C3-C8)cycloalkyl(C1-C8)alkyl), —C(O)N(CH3)((C3-C8)cycloalkyl), —C(O)N(CH3)(aryl(C1-C8)alkyl), —C(O)NHC(O)NH((C3-C8)cycloalkyl), —C(O)NHC(O)NH((C1-C8)alkyl), —C(O)NHC(O)NH2, optionally substituted heteroaryl wherein the heteroaryl is not 4-pyridinyl, benzimidazole or thiazole, optionally substituted aryloxy(C1-C8)alkyl, (C3-C8)cycloalkyl, (C2-C9)heterocycloalkyl, (C2-C9)heterocycloalkyl(C2-C8)alkyl, heteroaryl(C1-C8)alkyl, (C2-C8)alkoxy, (C3-C8)hydroxyalkyl, (C1-C8)alkoxy(C1-C8)alkyl, (C1-C8)haloalkoxy(C1-C8)alkyl, (C1-C8)thioalkoxy(C1-C8)alkyl, (CH3SO2)(C1-C8)alkyl, and ((C1-C8)alkylC(O))(C1-C8)alkyl;
- R9 is selected from (C3-C10)cycloalkyl, (C3-C10)cycloalkyl(C1-C8)alkyl, (C1-C8)haloalkyl, (C1-C8)hydroxyalkyl, (C1-C8)alkyl, (C1-C8)alkoxy(C1-C8)alkyl, and optionally substituted aryl; and
- Rb, independently for each occurrence, is selected from H, optionally substituted (C1-C8)alkyl, optionally substituted (C1-C8)haloalkyl, optionally substituted (C1-C8)hydroxyalkyl, optionally substituted (C3-C10)cycloalkyl, optionally substituted (C3-C10)cycloalkyl(C1-C8)alkyl, optionally substituted aryl, and optionally substituted aryl(C1-C8) alkyl;
- further wherein:
- at least one of R1, R2, R3, R4, and R5 is selected from (C3-C8)alkyl, (C2-C8)hydroxyalkyl, (C1-C8)aminoalkyl, straight chain (C2-C8)alkoxy, (C1-C8)haloalkoxy, (C4-C8)cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryloxy, (C6-C10)cycloalkoxy, —OC(O)((C1-C8)alkyl), —NHC(O)(aryl), (H3CSO2)(C1-C8)alkylene, optionally substituted (Rb 2NSO2)(C1-C8)alkylene, di((C1-C8)alkyl)amino, —NH—CH2—R8, —O—CH2—R8, and —O—CH2CH2—O—R9.
- In other aspects, the invention provides a compound of formula (II′):
-
- or a pharmaceutically acceptable salt thereof;
- wherein:
- X is O or S;
- each of R10, R11, R12, and R13 is independently selected from H, OH, —NH2, halide, sulfonamido, (C1-C6)alkylsulfonyl, —OC(O)((C1-C8)alkyl), —C(O)O((C1-C8)alkyl), —C(O)OH, optionally substituted —NHC(O)(aryl), —C(O)NH2, —B(OH)2, tri((C1-C8)alkyl)silyl, optionally substituted (C1-C8)alkyl, optionally substituted (C1-C8)alkoxy, optionally substituted (C1-C8)aminoalkyl, optionally substituted (C1-C8)hydroxyalkyl, optionally substituted (C1-C8)haloalkyl, optionally substituted (C1-C8)haloalkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryloxy, optionally substituted arylalkoxy, optionally substituted heteroaryloxy, optionally substituted heteroarylalkoxy, optionally substituted (C3-C10)cycloalkyl, optionally substituted (C3-C10)cycloalkoxy, optionally substituted (C2-C9)heterocycloalkyl, optionally substituted (C2-C9)heterocycloalkoxy, (H3CSO2)(C1-C8)alkylene, (H2NSO2)(C1-C8)alkylene, optionally substituted di((C1-C8)alkyl)amino;
- or R10 and R11, R11 and R12, or R12 and R13, taken together with the intervening atoms, form an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group;
- R14 is H or (C1-C6)alkyl;
- R15 is optionally substituted (C3-C10)cycloalkyl or (C3-C10)cycloalkenyl;
- represents a heterocyclic group substituted by oxo (═O) and optionally substituted by one or more additional substituents; and
-
- n is an integer from 1-3.
- In further aspects, the invention provides a compound of formula (III′):
-
- or a pharmaceutically acceptable salt thereof,
- wherein:
- each of R40, R41, R42, and R43 is independently selected from H, OH, —NH2, halide, sulfonamido, (C1-C6)alkylsulfonyl, —OC(O)((C1-C8)alkyl), —C(O)O((C1-C8)alkyl), —C(O)OH, optionally substituted —NHC(O)(aryl), —C(O)NH2, —B(OH)2, tri((C1-C8)alkyl)silyl, optionally substituted (C1-C8)alkyl, optionally substituted (C1-C8)alkoxy, optionally substituted (C1-C8)aminoalkyl, optionally substituted (C1-C8)hydroxyalkyl, optionally substituted (C1-C8)haloalkyl, optionally substituted (C1-C8)haloalkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryloxy, optionally substituted arylalkoxy, optionally substituted heteroaryloxy, optionally substituted heteroarylalkoxy, optionally substituted (C3-C10)cycloalkyl, optionally substituted (C3-C10)cycloalkoxy, optionally substituted (C2-C9)heterocycloalkyl, optionally substituted (C2-C9)heterocycloalkoxy, (H3CSO2)(C1-C8)alkylene, (H2NSO2)(C1-C8)alkylene, optionally substituted di((C1-C8)alkyl)amino;
- or R40 and R41, R41 and R42, or R42 and R43, taken together with the intervening atoms, form an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group;
- R44 is H or (C1-C6)alkyl;
- R45 is optionally substituted (C3-C10)cycloalkyl or (C3-C10)cycloalkenyl;
- Rc, independently for each occurrence, is selected from H, (C1-C8)alkyl, (C1-C8)haloalkyl, (C1-C8)alkoxyl, (C1-C8)hydroxyalkyl, (C3-C10)cycloalkyl, (C3-C10)cycloalkyl(C1-C8)alkyl, aryl, and aryl(C1-C8) alkyl;
- Rd, independently for each occurrence, is selected from H, optionally substituted —C(O)(C1-C8)alkyl, optionally substituted —C(O)NH—(C3-C10)cycloalkyl, optionally substituted (C1-C8)alkyl, optionally substituted (C1-C8)haloalkyl, optionally substituted (C1-C8)hydroxyalkyl, optionally substituted (C3-C10)cycloalkyl, optionally substituted heterocyclyl, optionally substituted (C3-C10)cycloalkyl(C1-C8)alkyl, optionally substituted aryl, and optionally substituted aryl(C1-C8) alkyl, or
- two Rd are taken together with the nitrogen atom to which they are attached to form an optionally substituted 5-6-membered heterocyclyl; and
- m is an integer from 1-3.
- The invention further provides compounds, or pharmaceutically acceptable salts thereof, of the compounds listed in Table 1.
- In other aspects, the invention provides pharmaceutical compositions comprising a compound of any one of claims 1-38, in combination with a pharmaceutically acceptable carrier.
- In certain aspects, the invention provides methods of treating a bacterial infection in a subject, comprising administering to the subject a therapeutically effective amount of a compound of the invention, i.e., a compound of formula (I), formula (II), formula (II′), formula (III), formula (III′), or a compound pictured in Table 1, or a pharmaceutical composition comprising the compound.
- The invention further provides methods of treating a bacterial infection in a subject, comprising administering to the subject a therapeutically effective amount of a compound of formula (IV′):
-
- or a pharmaceutically acceptable salt thereof,
- wherein:
- each of R21, R22, R23, R24, and R25 is independently selected from H, OH, —NH2, halide, sulfonamido, (C1-C6)alkylsulfonyl, —OC(O)((C1-C8)alkyl), —C(O)O((C1-C8)alkyl), —C(O)OH, optionally substituted —NHC(O)(aryl), —C(O)NH2, —B(OH)2, optionally substituted —S—(C1-C6)alkyl; tri((C1-C8)alkyl)silyl, optionally substituted (C1-C8)alkyl, optionally substituted (C1-C8)alkoxy, optionally substituted (C1-C8)aminoalkyl, optionally substituted (C1-C8)hydroxyalkyl, optionally substituted (C1-C8)haloalkyl, optionally substituted (C1-C8)haloalkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryloxy, optionally substituted arylalkoxy, optionally substituted heteroaryloxy, optionally substituted heteroarylalkoxy, optionally substituted (C3-C10)cycloalkyl, optionally substituted (C3-C10)cycloalkoxy, optionally substituted (C2-C9)heterocycloalkyl, optionally substituted (C2-C9)heterocycloalkoxy, (H3CSO2)(C1-C8)alkylene, optionally substituted (Re 2NSO2)(C1-C8)alkylene, optionally substituted di((C1-C8)alkyl)amino, —NH—CH2—R28, —O—CH2—R28, and —O—CH2CH2—O—R29;
- or R21 and R22, R22 and R23, R23 and R24, or R24 and R25, taken together with the intervening atoms, form an optionally substituted aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group;
- R26 is H or (C1-C6)alkyl;
- R27 is optionally substituted (C3-C10)cycloalkyl or (C3-C10)cycloalkenyl;
- R28 is selected from H, —C(O)((C2-C9)heterocycloalkyl), —C(O)NH((C1-C8)alkyl), —C(O)NH(aryl(C1-C8)alkyl), —C(O)NH((C3-C8)cycloalkyl), —C(O)NH((C3-C8)cycloalkyl(C1-C8)alkyl), —C(O)N(CH3)((C3-C8)cycloalkyl), —C(O)N(CH3)(aryl(C1-C8)alkyl), —C(O)NHC(O)NH((C3-C8)cycloalkyl), —C(O)NHC(O)NH((C1-C8)alkyl), —C(O)NHC(O)NH2, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted aryloxy(C1-C8)alkyl, (C3-C8)cycloalkyl, (C2-C9)heterocycloalkyl, (C2-C9)heterocycloalkyl(C2-C8)alkyl, heteroaryl(C1-C8)alkyl, (C1-C8)alkoxy, (C2-C8)hydroxyalkyl, (C1-C8)alkoxy(C1-C8)alkyl, (C1-C8)haloalkoxy(C1-C8)alkyl, (C1-C8)thioalkoxy(C1-C8)alkyl, (CH3SO2)(C1-C8)alkyl, and ((C1-C8)alkylC(O))(C1-C8)alkyl;
- R29 is selected from (C3-C10)cycloalkyl, (C3-C10)cycloalkyl(C1-C8)alkyl, (C1-C8)haloalkyl, (C1-C8)hydroxyalkyl, (C1-C8)alkyl, (C1-C8)alkoxy(C1-C8)alkyl, and optionally substituted aryl; and
- Re, independently for each occurrence, is selected from H, optionally substituted —C(O)(C1-C8)alkyl, optionally substituted —C(O)NH—(C3-C10)cycloalkyl, optionally substituted (C1-C8)alkyl, optionally substituted (C1-C8)haloalkyl, optionally substituted (C1-C8)hydroxyalkyl, optionally substituted (C3-C10)cycloalkyl, optionally substituted heterocyclyl, optionally substituted (C3-C10)cycloalkyl(C1-C8)alkyl, optionally substituted aryl, and optionally substituted aryl(C1-C8) alkyl, or
- two Re are taken together with the nitrogen atom to which they are attached to form an optionally substituted 5-6-membered heterocyclyl;
- further wherein:
- if R26 is (C1-C6)alkyl and R27 is (C6)cycloalkyl, then R21 and R25 are not OH, —OC(O)((C1-C8)alkyl), optionally substituted (C1-C8)alkoxy, optionally substituted (C1-C8)haloalkoxy, optionally substituted aryloxy, optionally substituted arylalkoxy, optionally substituted heteroaryloxy, optionally substituted heteroarylalkoxy, optionally substituted (C3-C10)cycloalkoxy, optionally substituted (C2-C9)heterocycloalkoxy, —O—CH2—R28, or —O—CH2CH2—O—R29.
- In certain aspects, the invention provides methods of treating tuberculosis, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the invention, i.e., a compound of formula (I), formula (II), formula (II′), formula (III), formula (III′), or a compound pictured in Table 1, or a pharmaceutical composition comprising the compound.
- The invention further provides methods of treating tuberculosis, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (V′):
-
- or a pharmaceutically acceptable salt thereof,
- wherein:
- each of R31, R32, R33, R34, and R35 is independently selected from H, OH, —NH2, halide, sulfonamido, (C1-C6)alkylsulfonyl, —OC(O)((C1-C8)alkyl), —C(O)O((C1-C8)alkyl), —C(O)OH, optionally substituted —NHC(O)(aryl), —C(O)NH2, —B(OH)2, optionally substituted —S—(C1-C6)alkyl; tri((C1-C8)alkyl)silyl, optionally substituted (C1-C8)alkyl, optionally substituted (C1-C8)alkoxy, optionally substituted (C1-C8)aminoalkyl, optionally substituted (C1-C8)hydroxyalkyl, optionally substituted (C1-C8)haloalkyl, optionally substituted (C1-C8)haloalkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryloxy, optionally substituted arylalkoxy, optionally substituted heteroaryloxy, optionally substituted heteroarylalkoxy, optionally substituted (C3-C10)cycloalkyl, optionally substituted (C3-C10)cycloalkoxy, optionally substituted (C2-C9)heterocycloalkyl, optionally substituted (C2-C9)heterocycloalkoxy, (H3CSO2)(C1-C8)alkylene, optionally substituted (Rf 2NSO2)(C1-C8)alkylene, optionally substituted di((C1-C8)alkyl)amino, —NH—CH2—R38, —O—CH2—R38, and —O—CH2CH2—O—R39;
- or R31 and R32, R32 and R33, R33 and R34, or R34 and R35, taken together with the intervening atoms, form an optionally substituted aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group;
- R36 is H or (C1-C6)alkyl;
- R37 is optionally substituted (C3-C10)cycloalkyl or (C3-C10)cycloalkenyl;
- R38 is selected from H, —C(O)((C2-C9)heterocycloalkyl), —C(O)NH((C1-C8)alkyl), —C(O)NH(aryl(C1-C8)alkyl), —C(O)NH((C3-C8)cycloalkyl), —C(O)NH((C3-C8)cycloalkyl(C1-C8)alkyl), —C(O)N(CH3)((C3-C8)cycloalkyl), —C(O)N(CH3)(aryl(C1-C8)alkyl), —C(O)NHC(O)NH((C3-C8)cycloalkyl), —C(O)NHC(O)NH((C1-C8)alkyl), —C(O)NHC(O)NH2, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted aryloxy(C1-C8)alkyl, (C3-C8)cycloalkyl, (C2-C9)heterocycloalkyl, (C2-C9)heterocycloalkyl(C2-C8)alkyl, heteroaryl(C1-C8)alkyl, (C1-C8)alkoxy, (C2-C8)hydroxyalkyl, (C1-C8)alkoxy(C1-C8)alkyl, (C1-C8)haloalkoxy(C1-C8)alkyl, (C1-C8)thioalkoxy(C1-C8)alkyl, (CH3SO2)(C1-C8)alkyl, and ((C1-C8)alkylC(O))(C1-C8)alkyl;
- R39 is selected from (C3-C10)cycloalkyl, (C3-C10)cycloalkyl(C1-C8)alkyl, (C1-C8)haloalkyl, (C1-C8)hydroxyalkyl, (C1-C8)alkyl, (C1-C8)alkoxy(C1-C8)alkyl, and optionally substituted aryl; and
- Rf, independently for each occurrence, is selected from H, optionally substituted —C(O)(C1-C8)alkyl, optionally substituted —C(O)NH—(C3-C10)cycloalkyl, optionally substituted (C1-C8)alkyl, optionally substituted (C1-C8)haloalkyl, optionally substituted (C1-C8)hydroxyalkyl, optionally substituted (C3-C10)cycloalkyl, optionally substituted heterocyclyl, optionally substituted (C3-C10)cycloalkyl(C1-C8)alkyl, optionally substituted aryl, and optionally substituted aryl(C1-C8) alkyl, or
- two Rf are taken together with the nitrogen atom to which they are attached to form an optionally substituted 5-6-membered heterocyclyl.
- The foregoing will be apparent from the following more particular description of example embodiments of the invention, as illustrated in the accompanying drawings in which like reference characters refer to the same parts throughout the different views. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating embodiments of the present invention.
-
FIG. 1 shows that the compounds of the invention, such as B1, can be used in combination with other tRNA synthetase inhibitors in order to overcome antibiotic resistance. - The present invention is based on the discovery of a class of compounds with surprising antibacterial activity. A description of example embodiments of the invention follows.
- “Alkyl” means an optionally substituted saturated aliphatic branched or straight-chain monovalent hydrocarbon radical having the specified number of carbon atoms. Thus, “(C1-C6) alkyl” means a radical having from 1-6 carbon atoms in a linear or branched arrangement. “(C1-C6)alkyl” includes methyl, ethyl, propyl, butyl, pentyl and hexyl.
- “Alkylene” means an optionally substituted saturated aliphatic branched or straight-chain divalent hydrocarbon radical having the specified number of carbon atoms. Thus, “(C1-C6)alkylene” includes a divalent saturated aliphatic radical having from 1-6 carbon atoms in a linear arrangement, e.g., —[(CH2)n]—, where n is an integer from 1 to 6, “(C1-C6)alkylene” includes methylene, ethylene, propylene, butylene, pentylene and hexylene. “(C1-C6)alkylene” also includes a divalent saturated radical having from 1-6 carbon atoms in a branched arrangement, for example: —[(CH2CH2CH2CH2CH(CH3)]—, —[(CH2CH2CH2CH2C(CH3)2]—, —[(CH2C(CH3)2CH(CH3))]—, and the like. Where indicated, alkylene is optionally and independently substituted with one or more substituents independently selected from halo, (C1-C6)alkyl, —OH, ═O, (C1-C6)alkoxy, and (C1-C6)haloalkyl.
- “Aryl” or “aromatic” means an aromatic monocyclic or polycyclic (e.g. bicyclic or tricyclic) carbocyclic ring system. In one embodiment, “aryl” is a 6-12 membered monocylic or bicyclic system. Aryl systems include, but not limited to, phenyl, naphthyl, fluorenyl, indenyl, azulenyl, and anthracenyl. In certain preferred embodiments, “aryl” is phenyl.
- “Carbocyclyl” means a cyclic group with only ring carbon atoms. “Carbocyclyl” includes 3-12 membered saturated or unsaturated aliphatic cyclic hydrocarbon rings or 6-12 membered aryl rings. A carbocyclyl moiety can be monocyclic, fused bicyclic, bridged bicyclic, spiro bicyclic, or polycyclic.
- Monocyclic carbocyclyls are saturated or unsaturated aliphatic cyclic hydrocarbon rings or aromatic hydrocarbon rings having the specified number of carbon atoms. Monocyclic carbocyclyls include cycloalkyl, cycloalkenyl, cycloalkynyl and phenyl.
- A fused bicyclic carbocyclyl has two rings which have two adjacent ring atoms in common. The first ring is a monocyclic carbocyclyl and the second ring is a monocyclic carbocyclyl or a monocyclic heterocyclyl.
- A bridged bicyclic carbocyclyl has two rings which have three or more adjacent ring atoms in common. The first ring is a monocyclic carbocyclyl and the second ring is a monocyclic carbocyclyl or a monocyclic heterocyclyl. In some preferred embodiments, a bridged bicyclic carbocylyl is adamantyl.
- A spiro bicyclic carbocyclyl has two rings which have only one ring atom in common. The first ring is a monocyclic carbocyclyl and the second ring is a monocyclic carbocyclyl or a monocyclic heterocyclyl.
- Polycyclic carbocyclyls have more than two rings (e.g., three rings resulting in a tricyclic ring system) and adjacent rings have at least one ring atom in common. The first ring is a monocyclic carbocyclyl and the remainder of the ring structures are monocyclic carbocyclyls or monocyclic heterocyclyls. Polycyclic ring systems include fused, bridged and spiro ring systems. A fused polycyclic ring system has at least two rings that have two adjacent ring atoms in common. A spiro polycyclic ring system has at least two rings that have only one ring atom in common. A bridged polycyclic ring system has at least two rings that have three or more adjacent ring atoms in common.
- “Cycloalkyl” means a saturated aliphatic cyclic hydrocarbon ring. Thus, “(C3-C7)cycloalkyl” means a hydrocarbon radical of a (3-7 membered) saturated aliphatic cyclic hydrocarbon ring. A C3-C7cycloalkyl includes, but is not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
- “Cycloalkene” means an aliphatic cyclic hydrocarbon ring having one or more double bonds in the ring.
- “Cycloalkyne” means an aliphatic cyclic hydrocarbon ring having one or more triple bonds in the ring.
- “Hetero” refers to the replacement of at least one carbon atom member in a ring system with at least one heteroatom selected from N, S, and O. “Hetero” also refers to the replacement of at least one carbon atom member in a acyclic system. A hetero ring system or a hetero acyclic system may have 1, 2, 3 or 4 carbon atom members replaced by a heteroatom.
- “Heterocyclyl” means a cyclic 4-12 membered saturated or unsaturated aliphatic or aromatic ring containing 1, 2, 3, 4 or 5 heteroatoms independently selected from N, O or S. When one heteroatom is S, it can be optionally mono- or di-oxygenated (i.e. —S(O)— or —S(O)2—). The heterocyclyl can be monocyclic, fused bicyclic, bridged bicyclic, spiro bicyclic or polycyclic.
- “Saturated heterocyclyl” means an aliphatic heterocyclyl group without any degree of unsaturation (i.e. no double bond or triple bond). It can be monocyclic, fused bicyclic, bridged bicyclic, spiro bicyclic or polycyclic.
- Examples of monocyclic saturated heterocyclyls include, but are not limited to, azetidine, pyrrolidine, piperidine, piperazine, azepane, hexahydropyrimidine, tetrahydrofuran, tetrahydropyran, morpholine, thiomorpholine, thiomorpholine 1,1-dioxide, tetrahydro-2H-1,2-thiazine, tetrahydro-2H-1,2-thiazine 1,1-dioxide, isothiazolidine, isothiazolidine 1,1-dioxide.
- A fused bicyclic heterocyclyl has two rings which have two adjacent ring atoms in common. The first ring is a monocyclic heterocyclyl and the second ring is a monocyclic carbocycle (such as a cycloalkyl or phenyl) or a monocyclic heterocyclyl. For example, the second ring is a (C3-C6)cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Alternatively, the second ring is phenyl. Examples of fused bicyclic heterocyclyls include, but are not limited to, octahydrocyclopenta[c]pyrrolyl, indoline, isoindoline, 2,3-dihydro-H-benzo[d]imidazole, 2,3-dihydrobenzo[d]oxazole, 2,3-dihydrobenzo[d]thiazole, octahydrobenzo[d]oxazole, octahydro-1H-benzo[d]imidazole, octahydrobenzo[d]thiazole, octahydrocyclopenta[c]pyrrole, 3-azabicyclo[3.1.0]hexane, and 3-azabicyclo[3.2.0]heptane.
- A spiro bicyclic heterocyclyl has two rings which have only one ring atom in common. The first ring is a monocyclic heterocyclyl and the second ring is a monocyclic carbocycle (such as a cycloalkyl or phenyl) or a monocyclic heterocyclyl. For example, the second ring is a (C3-C6)cycloalkyl. Alternatively, the second ring is phenyl. Example of spiro bicyclic heterocyclyl includes, but are not limited to, azaspiro[4.4]nonane, 7-azaspiro[4.4]nonane, azaspiro[4.5]decane, 8-azaspiro[4.5]decane, azaspiro[5.5]undecane, 3-azaspiro[5.5]undecane and 3,9-diazaspiro[5.5]undecane.
- A bridged bicyclic heterocyclyl has two rings which have three or more adjacent ring atoms in common. The first ring is a monocyclic heterocyclyl and the other ring is a monocyclic carbocycle (such as a cycloalkyl or phenyl) or a monocyclic heterocyclyl. Examples of bridged bicyclic heterocyclyls include, but are not limited to, azabicyclo[3.3.1]nonane, 3-azabicyclo[3.3.1]nonane, azabicyclo[3.2.1]octane, 3-azabicyclo[3.2.1]octane, 6-azabicyclo[3.2.1]octane and azabicyclo[2.2.2]octane, 2-azabicyclo[2.2.2]octane.
- Polycyclic heterocyclyls have more than two rings, one of which is a heterocyclyl (e.g., three rings resulting in a tricyclic ring system) and adjacent rings having at least one ring atom in common. Polycyclic ring systems include fused, bridged and spiro ring systems. A fused poly cyclic ring system has at least two rings that have two adjacent ring atoms in common. A spiro polycyclic ring system has at least two rings that have only one ring atom in common. A bridged polycyclic ring system has at least two rings that have three or more adjacent ring atoms in common.
- “Heteroaryl” or “heteroaromatic ring” means a 5-12 membered monovalent heteroaromatic monocyclic or bicyclic ring radical. A heteroaryl contains 1, 2, 3 or 4 heteroatoms independently selected from N, O, and S. Heteroaryls include, but are not limited to furan, oxazole, thiophene, 1,2,3-triazole, 1,2,4-triazine, 1,2,4-triazole, 1,2,5-thiadiazole 1,1-dioxide, 1,2,5-thiadiazole 1-oxide, 1,2,5-thiadiazole, 1,3,4-oxadiazole, 1,3,4-thiadiazole, 1,3,5-triazine, imidazole, isothiazole, isoxazole, pyrazole, pyridazine, pyridine, pyridine-N-oxide, pyrazine, pyrimidine, pyrrole, tetrazole, and thiazole. Bicyclic heteroaryl rings include, but are not limited to, bicyclo[4.4.0] and bicyclo[4.3.0]fused ring systems such as indolizine, indole, isoindole, indazole, benzimidazole, benzthiazole, purine, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, quinoxaline, 1,8-naphthyridine, and pteridine.
- In certain embodiments, where indicated, a group such as alkylene, adamantyl, naphthyl, or aryl may be optionally substituted. Exemplary substituents include halo, (C1-C6)alkyl, —OH, ═O, (C1-C6)alkoxy, (C1-C6)alkoxy-(C1-C6)alkylene, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, and —C(O)—(C1-C6)alkyl.
- In certain embodiments, where indicated, a phenyl group may have two adjacent substituents that, taken together with the intervening atoms, form an optionally substituted heteroaryl, aryl, cycloalkyl, or heterocycloalkyl ring. By way of example, a phenyl group having two adjacent substituents that, taken together with the intervening atoms, form a pyridinyl group can have the structure
- or any positional isomer thereof. In another example, a phenyl group having two adjacent substituents that, taken together with the intervening atoms, form a tetrahydropyranyl group can have the structure
- or any positional isomer thereof.
- “Halogen” and “halo” are interchangeably used herein and each refers to fluorine, chlorine, bromine, or iodine.
- “Alkoxy” means an alkyl radical attached through an oxygen linking atom. “(C1-C6)-alkoxy” includes methoxy, ethoxy, propoxy, butoxy, pentoxy and hexoxy.
- Haloalkyl includes mono, poly, and perhaloalkyl groups where each halogen is independently selected from fluorine, chlorine, and bromine.
- “Pharmaceutically acceptable carrier” means non-therapeutic components that are of sufficient purity and quality for use in the formulation of a composition of the invention that, when appropriately administered to an animal or human, typically do not produce an adverse reaction, and that are used as a vehicle for a drug substance (i.e. a compound of the present invention).
- Pharmaceutically acceptable salts of the compounds of the present invention are also included. For example, an acid salt of a compound of the present invention containing an amine or other basic group can be obtained by reacting the compound with a suitable organic or inorganic acid, resulting in pharmaceutically acceptable anionic salt forms. Examples of anionic salts include the acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, bromide, calcium edetate, camsylate, carbonate, chloride, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, glyceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, methylsulfate, mucate, napsylate, nitrate, pamoate, pantothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, sulfate, tannate, tartrate, teoclate, tosylate, triethiodide, and trifluoroacetate salts.
- Salts of the compounds of the present invention containing a carboxylic acid or other acidic functional group can be prepared by reacting with a suitable base. Such a pharmaceutically acceptable salt may be made with a base which affords a pharmaceutically acceptable cation, which includes alkali metal salts (especially sodium and potassium), alkaline earth metal salts (especially calcium and magnesium), aluminum salts and ammonium salts, as well as salts made from physiologically acceptable organic bases such as trimethylamine, triethylamine, morpholine, pyridine, piperidine, picoline, dicyclohexylamine, N,N′-dibenzylethylenediamine, 2-hydroxyethylamine, bis-(2-hydroxyethyl)amine, tri-(2-hydroxyethyl)amine, procaine, dibenzylpiperidine, dehydroabietylamine, N,N′-bisdehydroabietylamine, glucamine, N-methylglucamine, collidine, quinine, quinoline, and basic amino acids such as lysine and arginine.
- tRNA Synthetase Inhibitor Compounds
- In certain aspects, the invention provides a compound of formula (I):
-
- or a pharmaceutically acceptable salt thereof;
- wherein:
- each of R1, R2, R3, R4, and R5 is independently selected from H, OH, —NH2, halide, sulfonamido, (C1-C6)alkylsulfonyl, —OC(O)((C1-C8)alkyl), —C(O)O((C1-C8)alkyl), —C(O)OH, optionally substituted —NHC(O)(aryl), —C(O)NH2, —B(OH)2, tri((C1-C8)alkyl)silyl, optionally substituted (C1-C8)alkyl, optionally substituted (C1-C8)alkoxy, optionally substituted (C1-C8)aminoalkyl, optionally substituted (C1-C8)hydroxyalkyl, optionally substituted (C1-C8)haloalkyl, optionally substituted (C1-C8)haloalkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryloxy, optionally substituted arylalkoxy, optionally substituted heteroaryloxy, optionally substituted heteroarylalkoxy, optionally substituted (C3-C10)cycloalkyl, optionally substituted (C3-C10)cycloalkoxy, optionally substituted (C2-C9)heterocycloalkyl, optionally substituted (C2-C9)heterocycloalkoxy, (H3CSO2)(C1-C8)alkylene, optionally substituted (Rb 2NSO2)(C1-C8)alkylene, optionally substituted di((C1-C8)alkyl)amino, —NH—CH2—R8, —O—CH2—R8, and —O—CH2CH2—O—R9;
- or R1 and R2, R2 and R3, R3 and R4, or R4 and R5, taken together with the intervening atoms, form an optionally substituted aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group;
- R6 is H or (C1-C6)alkyl;
- R7 is optionally substituted (C3-C10)cycloalkyl or (C3-C10)cycloalkenyl;
- R8 is selected from —C(O)((C2-C9)heterocycloalkyl), —C(O)NH((C1-C8)alkyl), —C(O)NH(aryl(C1-C8)alkyl), —C(O)NH((C3-C8)cycloalkyl), —C(O)NH((C3-C8)cycloalkyl(C1-C8)alkyl), —C(O)N(CH3)((C3-C8)cycloalkyl), —C(O)N(CH3)(aryl(C1-C8)alkyl), —C(O)NHC(O)NH((C3-C8)cycloalkyl), —C(O)NHC(O)NH((C1-C8)alkyl), —C(O)NHC(O)NH2, optionally substituted heteroaryl wherein the heteroaryl is not 4-pyridinyl, benzimidazole or thiazole, optionally substituted aryloxy(C1-C8)alkyl, (C3-C8)cycloalkyl, (C2-C9)heterocycloalkyl, (C2-C9)heterocycloalkyl(C2-C8)alkyl, heteroaryl(C1-C8)alkyl, (C2-C8)alkoxy, (C3-C8)hydroxyalkyl, (C1-C8)alkoxy(C1-C8)alkyl, (C1-C8)haloalkoxy(C1-C8)alkyl, (C1-C8)thioalkoxy(C1-C8)alkyl, (CH3SO2)(C1-C8)alkyl, and ((C1-C8)alkylC(O))(C1-C8)alkyl;
- R9 is selected from (C3-C10)cycloalkyl, (C3-C10)cycloalkyl(C1-C8)alkyl, (C1-C8)haloalkyl, (C1-C8)hydroxyalkyl, (C1-C8)alkyl, (C1-C8)alkoxy(C1-C8)alkyl, and optionally substituted aryl; and
- Rb, independently for each occurrence, is selected from H, optionally substituted (C1-C8)alkyl, optionally substituted (C1-C8)haloalkyl, optionally substituted (C1-C8)hydroxyalkyl, optionally substituted (C3-C10)cycloalkyl, optionally substituted (C3-C10)cycloalkyl(C1-C8)alkyl, optionally substituted aryl, and optionally substituted aryl(C1-C8) alkyl;
- further wherein:
- at least one of R1, R2, R3, R4, and R5 is selected from (C3-C8)alkyl, (C2-C8)hydroxyalkyl, (C1-C8)aminoalkyl, straight chain (C2-C8)alkoxy, (C1-C8)haloalkoxy, (C4-C8)cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryloxy, (C6-C10)cycloalkoxy, —OC(O)((C1-C8)alkyl), —NHC(O)(aryl), (H3CSO2)(C1-C8)alkylene, optionally substituted (Rb 2NSO2)(C1-C8)alkylene, di((C1-C8)alkyl)amino, —NH—CH2—R8, —O—CH2—R8, and —O—CH2CH2—O—R9.
- In certain embodiments, R6 is (C1-C6)alkyl, for example, methyl.
- Alternatively, R6 may be H.
- In certain embodiments, R7 is optionally substituted cyclohexyl or cyclohexenyl. In some preferred embodiments, R7 is optionally substituted cyclohexyl.
- In certain embodiments, four of R1, R2, R3, R4, and R5 are H. For example, R2, R3, R4, and R5 may each be H.
- In certain embodiments, R1 is selected from the group consisting of (C3-C8)alkyl, (C2-C8)hydroxyalkyl, (C1-C8)aminoalkyl, (C4-C8)cycloalkyl, aryl, heteroaryl, (CH3SO2)(C1-C8)alkyl, and di((C1-C8)alkyl)amino. In some preferred embodiments, R1 is selected from the group consisting of aryl and heteroaryl.
- In some embodiments, R1 represents optionally substituted (Rb 2NSO2)(C1-C8)alkylene.
- Alternatively, R1 may be selected from the group consisting of straight chain (C2-C8)alkoxy, (C1-C8)haloalkoxy, aryloxy, —OC(O)((C1-C8)alkyl), —O—CH2—R8, and —O—CH2CH2—O—R9. For example, R1 may be selected from the group consisting of straight chain (C2-C8)alkoxy, (C1-C8)haloalkoxy, and aryloxy. In other embodiments, R1 is selected from the group consisting of —O—CH2—R8 and —O—CH2CH2—O—R9. In some preferred embodiments, R1 is —O—CH2—R8 and R8 is optionally substituted heteroaryl wherein the heteroaryl is not 4-pyridinyl, benzimidazole or thiazole.
- In further aspects, the invention provides a compound of formula (II′):
-
- or a pharmaceutically acceptable salt thereof;
- wherein:
- X is O or S;
- each of R10, R11, R12, and R13 is independently selected from H, OH, —NH2, halide, sulfonamido, (C1-C6)alkylsulfonyl, —OC(O)((C1-C8)alkyl), —C(O)O((C1-C8)alkyl), —C(O)OH, optionally substituted —NHC(O)(aryl), —C(O)NH2, —B(OH)2, tri((C1-C8)alkyl)silyl, optionally substituted (C1-C8)alkyl, optionally substituted (C1-C8)alkoxy, optionally substituted (C1-C8)aminoalkyl, optionally substituted (C1-C8)hydroxyalkyl, optionally substituted (C1-C8)haloalkyl, optionally substituted (C1-C8)haloalkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryloxy, optionally substituted arylalkoxy, optionally substituted heteroaryloxy, optionally substituted heteroarylalkoxy, optionally substituted (C3-C10)cycloalkyl, optionally substituted (C3-C10)cycloalkoxy, optionally substituted (C2-C9)heterocycloalkyl, optionally substituted (C2-C9)heterocycloalkoxy, (H3CSO2)(C1-C8)alkylene, (H2NSO2)(C1-C8)alkylene, optionally substituted di((C1-C8)alkyl)amino;
- or R10 and R11, R11 and R12, or R12 and R13, taken together with the intervening atoms, form an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group;
- R14 is H or (C1-C6)alkyl;
- R15 is optionally substituted (C3-C10)cycloalkyl or (C3-C10)cycloalkenyl;
- represents a heterocyclic group substituted by oxo (═O) and optionally substituted by one or more additional substituents; and
-
- n is an integer from 1-3.
- In further aspects, the invention provides a compound of formula (II):
-
- or a pharmaceutically acceptable salt thereof,
- wherein:
- each of R10, R11, R12, and R13 is independently selected from H, OH, —NH2, halide, sulfonamido, (C1-C6)alkylsulfonyl, —OC(O)((C1-C8)alkyl), —C(O)O((C1-C8)alkyl), —C(O)OH, optionally substituted —NHC(O)(aryl), —C(O)NH2, —B(OH)2, tri((C1-C8)alkyl)silyl, optionally substituted (C1-C8)alkyl, optionally substituted (C1-C8)alkoxy, optionally substituted (C1-C8)aminoalkyl, optionally substituted (C1-C8)hydroxyalkyl, optionally substituted (C1-C8)haloalkyl, optionally substituted (C1-C8)haloalkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryloxy, optionally substituted arylalkoxy, optionally substituted heteroaryloxy, optionally substituted heteroarylalkoxy, optionally substituted (C3-C10)cycloalkyl, optionally substituted (C3-C10)cycloalkoxy, optionally substituted (C2-C9)heterocycloalkyl, optionally substituted (C2-C9)heterocycloalkoxy, (H3CSO2)(C1-C8)alkylene, (H2NSO2)(C1-C8)alkylene, optionally substituted di((C1-C8)alkyl)amino;
- or R10 and R11, R11 and R12, or R12 and R13, taken together with the intervening atoms, form an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group;
- R14 is H or (C1-C6)alkyl;
- R15 is optionally substituted (C3-C10)cycloalkyl or (C3-C10)cycloalkenyl;
- represents a heterocyclic group substituted by oxo (═O) and optionally substituted by one or more additional substituents; and
-
- n is an integer from 1-3.
- In certain embodiments of the compounds of formula (II) and (II′), at least three of R10, R11, R12, and R13 are H. For example, R10, R11, R12, and R13 may each be H.
- In certain embodiments, R14 is H. Alternatively, R14 may be (C1-C6)alkyl, e.g., methyl.
- In certain embodiments, R15 is optionally substituted cyclohexyl or cyclohexenyl. In some preferred embodiments, R15 is optionally substituted cyclohexyl.
- In certain embodiments,
- represents optionally substituted oxazolidinone.
- For example
- may represent
- Alternatively,
- may represent
- and Ra may represent (C3-C10)cycloalkyl or (C1-C8)alkyl.
- In further aspects, the invention provides a compound of formula (III′):
-
- or a pharmaceutically acceptable salt thereof,
- wherein:
- each of R40, R41, R42, and R43 is independently selected from H, OH, —NH2, halide, sulfonamido, (C1-C6)alkylsulfonyl, —OC(O)((C1-C8)alkyl), —C(O)O((C1-C8)alkyl), —C(O)OH, optionally substituted —NHC(O)(aryl), —C(O)NH2, —B(OH)2, tri((C1-C8)alkyl)silyl, optionally substituted (C1-C8)alkyl, optionally substituted (C1-C8)alkoxy, optionally substituted (C1-C8)aminoalkyl, optionally substituted (C1-C8)hydroxyalkyl, optionally substituted (C1-C8)haloalkyl, optionally substituted (C1-C8)haloalkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryloxy, optionally substituted arylalkoxy, optionally substituted heteroaryloxy, optionally substituted heteroarylalkoxy, optionally substituted (C3-C10)cycloalkyl, optionally substituted (C3-C10)cycloalkoxy, optionally substituted (C2-C9)heterocycloalkyl, optionally substituted (C2-C9)heterocycloalkoxy, (H3CSO2)(C1-C8)alkylene, (H2NSO2)(C1-C8)alkylene, optionally substituted di((C1-C8)alkyl)amino;
- or R40 and R41, R41 and R42, or R42 and R43, taken together with the intervening atoms, form an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group;
- R44 is H or (C1-C6)alkyl;
- R45 is optionally substituted (C3-C10)cycloalkyl or (C3-C10)cycloalkenyl;
- Rc, independently for each occurrence, is selected from H, (C1-C8)alkyl, (C1-C8)haloalkyl, (C1-C8)alkoxyl, (C1-C8)hydroxyalkyl, (C3-C10)cycloalkyl, (C3-C10)cycloalkyl(C1-C8)alkyl, aryl, and aryl(C1-C8) alkyl;
- Rd, independently for each occurrence, is selected from H, optionally substituted —C(O)alkyl, optionally substituted —C(O)NH—(C3-C10)cycloalkyl, optionally substituted (C1-C8)alkyl, optionally substituted (C1-C8)haloalkyl, optionally substituted (C1-C8)hydroxyalkyl, optionally substituted (C3-C10)cycloalkyl, optionally substituted heterocyclyl, optionally substituted (C3-C10)cycloalkyl(C1-C8)alkyl, optionally substituted aryl, and optionally substituted aryl(C1-C8) alkyl, or
- two Rd are taken together with the nitrogen atom to which they are attached to form an optionally substituted 5-6-membered heterocyclyl; and
- m is an integer from 1-3.
- In other aspects, the invention provides a compound of formula (III):
-
- or a pharmaceutically acceptable salt thereof;
- wherein:
- each of R40, R41, R42, and R43 is independently selected from H, OH, —NH2, halide, sulfonamido, (C1-C6)alkylsulfonyl, —OC(O)((C1-C8)alkyl), —C(O)O((C1-C8)alkyl), —C(O)OH, optionally substituted —NHC(O)(aryl), —C(O)NH2, —B(OH)2, tri((C1-C8)alkyl)silyl, optionally substituted (C1-C8)alkyl, optionally substituted (C1-C8)alkoxy, optionally substituted (C1-C8)aminoalkyl, optionally substituted (C1-C8)hydroxyalkyl, optionally substituted (C1-C8)haloalkyl, optionally substituted (C1-C8)haloalkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryloxy, optionally substituted arylalkoxy, optionally substituted heteroaryloxy, optionally substituted heteroarylalkoxy, optionally substituted (C3-C10)cycloalkyl, optionally substituted (C3-C10)cycloalkoxy, optionally substituted (C2-C9)heterocycloalkyl, optionally substituted (C2-C9)heterocycloalkoxy, (H3CSO2)(C1-C8)alkylene, (H2NSO2)(C1-C8)alkylene, optionally substituted di((C1-C8)alkyl)amino;
- or R40 and R41, R41 and R42, or R42 and R43, taken together with the intervening atoms, form an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group;
- R44 is H or (C1-C6)alkyl;
- R45 is optionally substituted (C3-C10)cycloalkyl or (C3-C10)cycloalkenyl;
- Rc, independently for each occurrence, is selected from H, (C1-C8)alkyl, (C1-C8)haloalkyl, (C1-C8)alkoxyl, (C1-C8)hydroxyalkyl, (C3-C10)cycloalkyl, (C3-C10)cycloalkyl(C1-C8)alkyl, aryl, and aryl(C1-C8) alkyl;
- Rd, independently for each occurrence, is selected from H, optionally substituted (C1-C8)alkyl, optionally substituted (C1-C8)haloalkyl, optionally substituted (C1-C8)hydroxyalkyl, optionally substituted (C3-C10)cycloalkyl, optionally substituted (C3-C10)cycloalkyl(C1-C8)alkyl, optionally substituted aryl, and optionally substituted aryl(C1-C8) alkyl; and
- m is an integer from 1-3.
- In certain embodiments of the compounds of formula (III), at least three of R40, R41, R42, and R43 are H. For example, R40, R41, R42, and R43 may each be H.
- In certain embodiments, R44 is H. Alternatively, R44 may be (C1-C6)alkyl, e.g., methyl.
- In certain embodiments, R45 is optionally substituted cyclohexyl or cyclohexenyl. In some preferred embodiments, R45 is optionally substituted cyclohexyl.
- In certain embodiments, Rc is H.
- In certain embodiments, Rd, independently for each occurrence, is selected from H and (C1-C8)alkyl, preferably H. In other embodiments, each Rd is methyl. In certain embodiments, one Rd is methyl or ethyl and the other Rd is H.
- In certain embodiments, one Rd is optionally substituted —C(O)alkyl, such as —C(O)CH(NH2)CH2CHMe2. In other embodiments, one Rd is —C(O)NH—(C3-C10)cycloalkyl, such as —C(O)NH-cyclohexyl, optionally substituted with methyl.
- In certain embodiments, one Rd is optionally substituted (C1-C8)alkyl, such as —CH2CH(OH)CH2OH. In other embodiments, one Rd is —CH2CH(OH)CH2OH and the other Rd is methyl. In certain embodiments, one Rd is —CH2C(O)NHCH2COOH. In some embodiments, one Rd is —CH2CH2OMe. In certain embodiments, one Rd is —CH2COOH. In other embodiments, one Rd is —CH(Me)COOH. In other embodiments, one Rd is —CH2-heterocyclyl, such as —CH2-furanyl.
- In certain embodiments, one Rd is optionally substituted cycloalkyl, such as 3-COOHcyclobutyl. In other embodiments, one Rd is optionally substituted aryl, such as 3-(B(OH3))-phenyl. In certain embodiments, one Rd is optionally substituted heterocyclyl, such as N-methylpiperidinyl.
- In certain embodiments, both Rd are taken together with the nitrogen atom to which they are attached to form an optionally substituted 5-6-membered heterocyclyl, such as an N-methylpiperizinyl.
- In some aspects, the invention provides a compound, or a pharmaceutically acceptable salt thereof, selected from Table 1:
- Further compounds of the invention include, but are not limited to the following compounds in Table 2.
- In certain aspects, the invention also provides a pharmaceutical composition comprising a compound of the invention (e.g., a compound of formula (I)), in combination with a pharmaceutically acceptable carrier.
- The invention further includes the process for making the composition comprising mixing one or more of the present compounds and an optional pharmaceutically acceptable carrier; and includes those compositions resulting from such a process, which process includes conventional pharmaceutical techniques.
- The compositions of the invention include ocular, oral, nasal, transdermal, topical with or without occlusion, intravenous (both bolus and infusion), inhalable, and injection (intraperitoneally, subcutaneously, intramuscularly, intralesionally, or parenterally) formulations. The composition may be in a dosage unit such as a tablet, pill, capsule, powder, granule, liposome, ion exchange resin, sterile ocular solution, or ocular delivery device (such as a contact lens and the like facilitating immediate release, timed release, or sustained release), parenteral solution or suspension, metered aerosol or liquid spray, drop, ampoule, auto-injector device, or suppository; for administration ocularly, orally, intranasally, sublingually, parenterally, or rectally, or by inhalation or insufflation.
- Compositions of the invention suitable for oral administration include solid forms such as pills, tablets, caplets, capsules (each including immediate release, timed release, and sustained release formulations), granules and powders; and, liquid forms such as solutions, syrups, elixirs, emulsions, and suspensions. Forms useful for ocular administration include sterile solutions or ocular delivery devices. Forms useful for parenteral administration include sterile solutions, emulsions, and suspensions.
- The compositions of the invention may be administered in a form suitable for once-weekly or once-monthly administration. For example, an insoluble salt of the active compound may be adapted to provide a depot preparation for intramuscular injection (e.g., a decanoate salt) or to provide a solution for ophthalmic administration.
- The dosage form containing the composition of the invention contains an effective amount of the active ingredient necessary to provide a therapeutic effect. The composition may contain from about 5,000 mg to about 0.5 mg (preferably, from about 1,000 mg to about 0.5 mg) of a compound of the invention or salt form thereof and may be constituted into any form suitable for the selected mode of administration. The composition may be administered about 1 to about 5 times per day. Daily administration or post-periodic dosing may be employed.
- For oral administration, the composition is preferably in the form of a tablet or capsule containing, e.g., 500 to 0.5 milligrams of the active compound. Dosages will vary depending on factors associated with the particular patient being treated (e.g., age, weight, diet, and time of administration), the severity of the condition being treated, the compound being employed, the mode of administration, and the strength of the preparation.
- The oral composition is preferably formulated as a homogeneous composition, wherein the active ingredient is dispersed evenly throughout the mixture, which may be readily subdivided into dosage units containing equal amounts of a compound of the invention. Preferably, the compositions are prepared by mixing a compound of the invention (or pharmaceutically acceptable salt thereof) with one or more optionally present pharmaceutical carriers (such as a starch, sugar, diluent, granulating agent, lubricant, glidant, binding agent, and disintegrating agent), one or more optionally present inert pharmaceutical excipients (such as water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and syrup), one or more optionally present conventional tableting ingredients (such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate, and any of a variety of gums), and an optional diluent (such as water).
- Binder agents include starch, gelatin, natural sugars (e.g., glucose and beta-lactose), corn sweeteners and natural and synthetic gums (e.g., acacia and tragacanth). Disintegrating agents include starch, methyl cellulose, agar, and bentonite.
- Tablets and capsules represent an advantageous oral dosage unit form. Tablets may be sugarcoated or film-coated using standard techniques. Tablets may also be coated or otherwise compounded to provide a prolonged, control-release therapeutic effect. The dosage form may comprise an inner dosage and an outer dosage component, wherein the outer component is in the form of an envelope over the inner component. The two components may further be separated by a layer which resists disintegration in the stomach (such as an enteric layer) and permits the inner component to pass intact into the duodenum or a layer which delays or sustains release. A variety of enteric and non-enteric layer or coating materials (such as polymeric acids, shellacs, acetyl alcohol, and cellulose acetate or combinations thereof) may be used.
- Compounds of the invention may also be administered via a slow release composition; wherein the composition includes a compound of the invention and a biodegradable slow release carrier (e.g., a polymeric carrier) or a pharmaceutically acceptable non-biodegradable slow release carrier (e.g., an ion exchange carrier).
- Biodegradable and non-biodegradable slow release carriers are well known in the art. Biodegradable carriers are used to form particles or matrices which retain an active agent(s) and which slowly degrade/dissolve in a suitable environment (e.g., aqueous, acidic, basic and the like) to release the agent. Such particles degrade/dissolve in body fluids to release the active compound(s) therein. The particles are preferably nanoparticles or nanoemulsions (e.g., in the range of about 1 to 500 nm in diameter, preferably about 50-200 nm in diameter, and most preferably about 100 nm in diameter). In a process for preparing a slow release composition, a slow release carrier and a compound of the invention are first dissolved or dispersed in an organic solvent. The resulting mixture is added into an aqueous solution containing an optional surface-active agent(s) to produce an emulsion. The organic solvent is then evaporated from the emulsion to provide a colloidal suspension of particles containing the slow release carrier and the compound of the invention.
- The compounds disclosed herein may be incorporated for administration orally or by injection in a liquid form such as aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil and the like, or in elixirs or similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions, include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone, and gelatin. The liquid forms in suitably flavored suspending or dispersing agents may also include synthetic and natural gums. For parenteral administration, sterile suspensions and solutions are desired. Isotonic preparations, which generally contain suitable preservatives, are employed when intravenous administration is desired.
- The compounds may be administered parenterally via injection. A parenteral formulation may consist of the active ingredient dissolved in or mixed with an appropriate inert liquid carrier. Acceptable liquid carriers usually comprise aqueous solvents and other optional ingredients for aiding solubility or preservation. Such aqueous solvents include sterile water, Ringer's solution, or an isotonic aqueous saline solution. Other optional ingredients include vegetable oils (such as peanut oil, cottonseed oil, and sesame oil), and organic solvents (such as solketal, glycerol, and formyl). A sterile, non-volatile oil may be employed as a solvent or suspending agent. The parenteral formulation is prepared by dissolving or suspending the active ingredient in the liquid carrier whereby the final dosage unit contains from 0.005 to 10% by weight of the active ingredient. Other additives include preservatives, isotonizers, solubilizers, stabilizers, and pain-soothing agents. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed.
- Compounds of the invention may be administered intranasally using a suitable intranasal vehicle.
- In other embodiments, the compounds of this invention may be administered directly to the lungs by inhalation.
- Compounds of the invention may also be administered topically or enhanced by using a suitable topical transdermal vehicle or a transdermal patch.
- For ocular administration, the composition is preferably in the form of an ophthalmic composition. The ophthalmic compositions are preferably formulated as eye-drop formulations and filled in appropriate containers to facilitate administration to the eye, for example a dropper fitted with a suitable pipette. Preferably, the compositions are sterile and aqueous based, using purified water. In addition to the compound of the invention, an ophthalmic composition may contain one or more of: a) a surfactant such as a polyoxyethylene fatty acid ester; b) a thickening agents such as cellulose, cellulose derivatives, carboxyvinyl polymers, polyvinyl polymers, and polyvinylpyrrolidones, typically at a concentration n the range of about 0.05 to about 5.0% (wt/vol); c) (as an alternative to or in addition to storing the composition in a container containing nitrogen and optionally including a free oxygen absorber such as Fe), an anti-oxidant such as butylated hydroxyanisol, ascorbic acid, sodium thiosulfate, or butylated hydroxytoluene at a concentration of about 0.00005 to about 0.1% (wt/vol); d) ethanol at a concentration of about 0.01 to 0.5% (wt/vol); and e) other excipients such as an isotonic agent, buffer, preservative, and/or pH-controlling agent. The pH of the ophthalmic composition is desirably within the range of 4 to 8.
- In certain embodiments, the pharmaceutical composition of the invention further comprises one or more additional agents, such as a second antibacterial agent. The other agent may be ay agent that is capable of treating, suppressing, or preventing a bacterial infection. For example, the other therapeutic agent may be an antibacterial compound. Alternatively, the other therapeutic agent may be any agent of benefit to a patient when administered in combination with the tRNA synthetase inhibitor compound in this invention.
- In certain embodiments, the second antibacterial agent in the pharmaceutical composition of the invention is a tRNA synthetase inhibitor. Exemplary tRNA synthetase inhibitors include oxaborole compounds such as AN3365.
- In certain aspects, the invention provides methods of treating a bacterial infection in a subject, comprising administering to the subject a therapeutically effective amount of a compound of the invention, i.e., a compound of formula (I), formula (II), formula (II′), formula (III), formula (III′), or a compound pictured in Table 1, or a pharmaceutical composition comprising the compound.
- The invention further provides methods of treating a bacterial infection in a subject, comprising administering to the subject a therapeutically effective amount of a compound of formula (IV′):
-
- or a pharmaceutically acceptable salt thereof;
- wherein:
- each of R21, R22, R23, R24, and R25 is independently selected from H, OH, —NH2, halide, sulfonamido, (C1-C6)alkylsulfonyl, —OC(O)((C1-C8)alkyl), —C(O)O((C1-C8)alkyl), —C(O)OH, optionally substituted —NHC(O)(aryl), —C(O)NH2, —B(OH)2, optionally substituted —S—(C1-C6)alkyl; tri((C1-C8)alkyl)silyl, optionally substituted (C1-C8)alkyl, optionally substituted (C1-C8)alkoxy, optionally substituted (C1-C8)aminoalkyl, optionally substituted (C1-C8)hydroxyalkyl, optionally substituted (C1-C8)haloalkyl, optionally substituted (C1-C8)haloalkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryloxy, optionally substituted arylalkoxy, optionally substituted heteroaryloxy, optionally substituted heteroarylalkoxy, optionally substituted (C3-C10)cycloalkyl, optionally substituted (C3-C10)cycloalkoxy, optionally substituted (C2-C9)heterocycloalkyl, optionally substituted (C2-C9)heterocycloalkoxy, (H3CSO2)(C1-C8)alkylene, optionally substituted (Re 2NSO2)(C1-C8)alkylene, optionally substituted di((C1-C8)alkyl)amino, —NH—CH2—R28, —O—CH2—R28, and —O—CH2CH2—O—R29;
- or R21 and R22, R22 and R23, R23 and R24, or R24 and R25, taken together with the intervening atoms, form an optionally substituted aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group;
- R26 is H or (C1-C6)alkyl;
- R27 is optionally substituted (C3-C10)cycloalkyl or (C3-C10)cycloalkenyl;
- R28 is selected from H, —C(O)((C2-C9)heterocycloalkyl), —C(O)NH((C1-C8)alkyl), —C(O)NH(aryl(C1-C8)alkyl), —C(O)NH((C3-C8)cycloalkyl), —C(O)NH((C3-C8)cycloalkyl(C1-C8)alkyl), —C(O)N(CH3)((C3-C8)cycloalkyl), —C(O)N(CH3)(aryl(C1-C8)alkyl), —C(O)NHC(O)NH((C3-C8)cycloalkyl), —C(O)NHC(O)NH((C1-C8)alkyl), —C(O)NHC(O)NH2, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted aryloxy(C1-C8)alkyl, (C3-C8)cycloalkyl, (C2-C9)heterocycloalkyl, (C2-C9)heterocycloalkyl(C2-C8)alkyl, heteroaryl(C1-C8)alkyl, (C1-C8)alkoxy, (C2-C8)hydroxyalkyl, (C1-C8)alkoxy(C1-C8)alkyl, (C1-C8)haloalkoxy(C1-C8)alkyl, (C1-C8)thioalkoxy(C1-C8)alkyl, (CH3SO2)(C1-C8)alkyl, and ((C1-C8)alkylC(O))(C1-C8)alkyl;
- R29 is selected from (C3-C10)cycloalkyl, (C3-C10)cycloalkyl(C1-C8)alkyl, (C1-C8)haloalkyl, (C1-C8)hydroxyalkyl, (C1-C8)alkyl, (C1-C8)alkoxy(C1-C8)alkyl, and optionally substituted aryl; and
- Re, independently for each occurrence, is selected from H, optionally substituted —C(O)(C1-C8)alkyl, optionally substituted —C(O)NH—(C3-C10)cycloalkyl, optionally substituted (C1-C8)alkyl, optionally substituted (C1-C8)haloalkyl, optionally substituted (C1-C8)hydroxyalkyl, optionally substituted (C3-C10)cycloalkyl, optionally substituted heterocyclyl, optionally substituted (C3-C10)cycloalkyl(C1-C8)alkyl, optionally substituted aryl, and optionally substituted aryl(C1-C8) alkyl, or
- two Re are taken together with the nitrogen atom to which they are attached to form a 5-6-membered heterocyclyl;
- further wherein:
- if R26 is (C1-C6)alkyl and R27 is (C6)cycloalkyl, then R21 and R25 are not OH, —OC(O)((C1-C8)alkyl), optionally substituted (C1-C8)alkoxy, optionally substituted (C1-C8)haloalkoxy, optionally substituted aryloxy, optionally substituted arylalkoxy, optionally substituted heteroaryloxy, optionally substituted heteroarylalkoxy, optionally substituted (C3-C10)cycloalkoxy, optionally substituted (C2-C9)heterocycloalkoxy, —O—CH2—R28, or —O—CH2CH2—O—R29.
- The invention further provides methods of treating a bacterial infection in a subject, comprising administering to the subject a therapeutically effective amount of a compound of formula (IV):
-
- or a pharmaceutically acceptable salt thereof;
- wherein:
- each of R21, R22, R23, R24, and R25 is independently selected from H, OH, —NH2, halide, sulfonamido, (C1-C6)alkylsulfonyl, —OC(O)((C1-C8)alkyl), —C(O)O((C1-C8)alkyl), —C(O)OH, optionally substituted —NHC(O)(aryl), —C(O)NH2, —B(OH)2, tri((C1-C8)alkyl)silyl, optionally substituted (C1-C8)alkyl, optionally substituted (C1-C8)alkoxy, optionally substituted (C1-C8)aminoalkyl, optionally substituted (C1-C8)hydroxyalkyl, optionally substituted (C1-C8)haloalkyl, optionally substituted (C1-C8)haloalkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryloxy, optionally substituted arylalkoxy, optionally substituted heteroaryloxy, optionally substituted heteroarylalkoxy, optionally substituted (C3-C10)cycloalkyl, optionally substituted (C3-C10)cycloalkoxy, optionally substituted (C2-C9)heterocycloalkyl, optionally substituted (C2-C9)heterocycloalkoxy, (H3CSO2)(C1-C8)alkylene, optionally substituted (Re 2NSO2)(C1-C8)alkylene, optionally substituted di((C1-C8)alkyl)amino, —NH—CH2—R28, —O—CH2—R28, and —O—CH2CH2—O—R29;
- or R21 and R22, R22 and R23, R23 and R24, or R24 and R25, taken together with the intervening atoms, form an optionally substituted aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group;
- R26 is H or (C1-C6)alkyl;
- R27 is optionally substituted (C3-C10)cycloalkyl or (C3-C10)cycloalkenyl;
- R28 is selected from —C(O)((C2-C9)heterocycloalkyl), —C(O)NH((C1-C8)alkyl), —C(O)NH(aryl(C1-C8)alkyl), —C(O)NH((C3-C8)cycloalkyl), —C(O)NH((C3-C8)cycloalkyl(C1-C8)alkyl), —C(O)N(CH3)((C3-C8)cycloalkyl), —C(O)N(CH3)(aryl(C1-C8)alkyl), —C(O)NHC(O)NH((C3-C8)cycloalkyl), —C(O)NHC(O)NH((C1-C8)alkyl), —C(O)NHC(O)NH2, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted aryloxy(C1-C8)alkyl, (C3-C8)cycloalkyl, (C2-C9)heterocycloalkyl, (C2-C9)heterocycloalkyl(C2-C8)alkyl, heteroaryl(C1-C8)alkyl, (C1-C8)alkoxy, (C2-C8)hydroxyalkyl, (C1-C8)alkoxy(C1-C8)alkyl, (C1-C8)haloalkoxy(C1-C8)alkyl, (C1-C8)thioalkoxy(C1-C8)alkyl, (CH3SO2)(C1-C8)alkyl, and ((C1-C8)alkylC(O))(C1-C8)alkyl;
- R29 is selected from (C3-C10)cycloalkyl, (C3-C10)cycloalkyl(C1-C8)alkyl, (C1-C8)haloalkyl, (C1-C8)hydroxyalkyl, (C1-C8)alkyl, (C1-C8)alkoxy(C1-C8)alkyl, and optionally substituted aryl; and
- Re, independently for each occurrence, is selected from H, optionally substituted (C1-C8)alkyl, optionally substituted (C1-C8)haloalkyl, optionally substituted (C1-C8)hydroxyalkyl, optionally substituted (C3-C10)cycloalkyl, optionally substituted (C3-C10)cycloalkyl(C1-C8)alkyl, optionally substituted aryl, and optionally substituted aryl(C1-C8) alkyl;
- further wherein:
- if R26 is (C1-C6)alkyl and R27 is (C6)cycloalkyl, then R21 and R25 are not OH, —OC(O)((C1-C8)alkyl), optionally substituted (C1-C8)alkoxy, optionally substituted (C1-C8)haloalkoxy, optionally substituted aryloxy, optionally substituted arylalkoxy, optionally substituted heteroaryloxy, optionally substituted heteroarylalkoxy, optionally substituted (C3-C10)cycloalkoxy, optionally substituted (C2-C9)heterocycloalkoxy, —O—CH2—R28, or —O—CH2CH2—O—R29.
- In certain embodiments of the methods of the invention, the bacterial infection is caused by Gram-negative bacteria.
- Exemplary Gram-negative bacteria used with the methods of the invention include Acidaminococcus spp (e.g. A. fermentans, A. intestin), Acinetobacter spp (e.g. A. baumannii, A. calcoaceticus, A. gyllenbergii, A. haemolyticus, A. junii, A. lwoffii, A. nosocomialis, A. parvus, A. pittii, A. schindleri, A. seifertii, A. soli, A. ursingii, A. variabilis), Aggregatibacter spp (A. actinomycetemcomitans, A. aphrophilus, A. segnis), Agrobacterium tumefaciens, Anaerobiospirillum aka Anaerobiospirillum thomasii, Arcobacter spp (e.g. A. skirrowii, A. butzleri, A. cryaerophilus), Bacteroides spp, (B. fragilis, B. ureolyticus, B. melaninogenicus), Bartonella spp (e.g. B. japonica, B. koehlerae, B. taylorii, B. alsatica, B. ancashensis, B. bacilliformis, B. capreoli, B. clarridgeiae, B. doshiae, B. elizabethae, B. grahamii, B. henselae, B. peromysci, B. quintana, B. rochalimae, B. schoenbuchensis, B. talpae, B. tamiae, B. tribocorum, B. vinsonii, B. washoensis), Bordetella spp (e.g. B. ansorpii, B. avium, B. bronchiseptica, B. hinzii, B. holmesii, B. parapertussis, B. pertussis, B. trematum), Borrelia spp. (e.g. B. burgdorferi, B. afzelii, B. garinii, B. andersonii, B. anserine, B. bissettii, B. carolinensis, B. hermsii, B. kurtenbachii, B. lusitaniae, B. miyamotoi, B. parkeri, B. recurrentis, B. sinica, B. spielmanii, B. turicatae), Brachyspira spp (e.g. B. aalborgi, B. pilosicoli, B. hyodysenteriae), Bradyrhizobium spp (e.g. B. japonicum, B. enterica), Burkholderia spp (e.g. B. mallei, B. pseudomallei, B. cepacia, B. dolosa), Campylobacter spp. (e.g. C. jejuni, C. coli, C. upsaliensis, C. fetus, C. lari, C. hyointestinalis, C. rectus), Cardiobacterium spp. (e.g. C. hominis, C. valvarum), Christensenella spp (e.g. C. minuta, C. massiliensis, C. timonensis), Citrobacter spp. (e.g. C. amalonaticus, C. braakii, C. koseri, C. sedlakii), Coxiella burnetii, Cytophaga spp. (e.g. C. columnaris, C. johnsonae, C. psychrophila), Dialister spp (e.g. D. pneumosintes), Eikenella corrodens, Enterobacter spp (e.g. E. cloacae, E. aerogenes, E. cancerogenus aka E. taylorae, E. cowanii), Escherichia spp (e.g. E. coli, E. fergusonii, E. hermannii, E. albertii, E. vulneris), Ewingella americana, Flavobacterium spp (e.g. F. psychrophilum, F. columnare, F. branchiophilum), Francisella spp. (e.g. F. novicida, F. tularensis, F. piscicida, F. philomiragia), Fusobacterium spp (e.g F. necrophorum, F. nucleatum, F. polymorphum), Haemophilus spp (e.g H. felis, H. haemolyticus, H. influenzae, H. parainfluenzae, H. pittmaniae, H. ducreyi), Helicobacter spp (e.g. H. pylori, H. bilis, H. canadensis, H. canis, H. cinaedi), Kingella spp (e.g. Kingella kingae aka Moraxella kingae, K. indologenes, K. denitrificans, K. oralis), Klebsiella spp (e.g. K. pneumoniae, K. granulomatis, K. oxytoca, K. michiganensis, K. quasipneumoniae, K. variicola), Kluyvera spp (e.g. K. intermedia, K. ascorbate, K. cryocrescens, K. intestine, K. georgiana), Legionella spp (e.g Legionella clemsonensis, Legionella pneumophila, L. wadsworthii, L. waltersii, L. anisa, L. birminghamensis, L. bozemanae, L. cardiaca, L. cherrii, L. cincinnatiensis, L. dumoffli, L. feeleii, L. gormanii, L. hackeliae, L. jordanis, L. lansingensis, L. longbeachae, L. oakridgensis, L. micdadei, L. rubrilucens, L. sainthelensi, L. steelei, L. tucsonensis), Leptonema illini, Leptotrichia spp (e.g. L. buccalis, L. amnionii, L. trevesanii, L. goodfellowii), Methylobacterium spp (e.g. M. fujisawaense, M. mesophilicum, M. thiocyanatum, M. aminovorans, M. lusitanum, M. radiotolerans), Moraxella spp. (e.g. M. lacunata aka Morax-Axenfeld diplobacilli, M. bovis, M. osloensis, M. atlantae, M. boevrei, M. bovoculi, M. canis, M. caprae, M. catarrhalis, M. caviae, M. cuniculi, M. equi, M. lincolnii, M. nonliquefaciens, M. oblonga, M. osloensis, M. pluranimalium, M. porci, M. saccharolytica), Morganella morganii, Mycoplasma spp. (e.g M. spumans, M. adleri, M agalactiae, M. agassizii, M. alligatoris, M. amphoriforme, M. bovis, M. buccale, M. capricolum, M. faucium, M. fermentans, M. gallisepticum, M. genitalium, M. haemofelis, M. haemomuris, M. hominis, M. hyopneumoniae, M. hyorhinis, M. lipophilum, M. mobile, M. mycoides, M. orale, M. ovipneumoniae, M. penetrans, M. pirum, M. pneumoniae, M, primatum, M. salivarium, M. spermatophilum, M. synoviae), Neisseria spp. (e.g. N. gonorrhoeae, N. meningitides, N. cinerea, N. polysaccharea, N. sicca), Proteus spp. (e.g. P. mirabilis, P. penneri, P. hauseri, P. myxofaciens, P. vulgaris), Pseudomonas spp. (e.g. P. aeruginosa, P. oryzihabitans, P. luteola, P. floridensis, P. syringae, P. anguilliseptica, P. argentinensis, P. flavescens, P. mendocina, P. asplenii, P. corrugate, P. fragi, P. lundensis, P. taetrolens, P. azotoformans, P. blatchfordae, P. brassicacearum, P. fluorescens, P. marginalis, P. mediterranea, P. mucidolens, P. panacis, P. tolaasii, P. cremoricolorata, P. entomophila, P. monteilii, P. plecoglossicida, P. stutzeri, P. amygdali, P. avellanae, P. caricapapayae, P. cichorii, P. coronafaciens, P. ficuserectae, P. helianthin, P. meiae, P. savastanoi, P. tomato, P. viridiflava, P. asplenii, P. cannabina, P. costantinii, P. fuscovaginae, P. otitidis, P. palleroniana, P. perolens, P. reptilivora, P. salomonii, P. septica, P. simiae, P. suis, P. tremae, P. turbinellae), Pseudoxanthomonas spp. (e.g. P. broegbernensis, P. japonensis, P. mexicana), Rickettsia spp. (e.g. R. rickettsii, R. asiatica, R. australis, R. conorii, R. felis, R. heilongjiangensis, R. helvetica, R. honei, R. japonica, R. massiliae, R. monacensis, R. parkeri, R. peacockii, R. prowazekii, R. akari, R. africae, R. sibirica, R. typhi), Rouxiella chamberiensis, Salmonella spp (e.g. S. bongori, S. enterica), Serratia spp. (e.g. S. marcescens, S. plymuthica, S. liquefaciens, S. rubidaea, S. odorifera, S. fonticola), Shigella spp. (e.g. S. dysenteriae, S. flexneri, S. boydii, S. sonnei), Solobacterium moorei, Sphingomonas spp (S. gei, S. paucimobilis, S. koreensis), Spirochaeta spp, Stenotrophomonas spp (e.g. S. nitritireducens, S. maltophilia), Treponema spp. (e.g. T. pallidum, T. carateum, T. denticola, T. lecithinolyticum, T. maltophilum, T. socranskii, T. vincentii), Vibrio spp (e.g. V. adaptatus, V. azasii, V. campbellii, V. cholera, V. alginolyticus, V. anguillarum, V. campbellii, V. fluvialis, V. furnissii, V. harveyi, V. lentus, V. mimicus, V. ordalii, V. parahaemolyticus, V. pectenicida, V. tapetis, V. tubiashii, V. vulnificus), Wolbachia spp., and Yersinia spp. (e.g. Y. aldovae, Y. bercovieri, Y. enterocolitica, Y. frederiksenii, Y. pestis, Y. pseudotuberculosis, Y. ruckeri).
- In other embodiments, the bacterial infection treated by the methods of the invention is caused by Mycobacterium kansasii, Mycobacterium marinum, Mycobacterium simiae, Mycobacterium scrofulaceum, Mycobacterium szulgai, Mycobacterium gordonae; Mycobacterium avium complex, Mycobacterium ulcerans, Mycobacterium xenopi, Mycobacterium malmoense, Mycobacterium terrae complex, Mycobacterium haemophilum, Mycobacterium genavense, Mycobacterium abscessus complex, Mycobacterium chelonae, Mycobacterium fortuitum complex, or Mycobacterium peregrinum.
- In further embodiments, the bacterial infection treated by the methods of the invention is caused by a Nocardia species selected from N. concava, N. cyriacigeorgica, N. donostiensis, N. elegans, N. exalbida, N. farcinica, N. harenae, N. higoensis, N. ignorata, N. inohanensis, N. jinanensis, N. kroppenstedtii, N. kruczakiae, N. mexicana, N. mikamii, N. neocaledoniensis, N. niigatensis, N. ninae, N. niwae, N. nova, N. otitidiscaviarum, N. paucivorans, N. pneumoniae, N. pseudobrasiliensis, N. puris, N. shinanonensis, N. sienata, N. takedensis, N. terpenica, N. testaceae, N. thailandica, N. transvalensis, N. vermiculata, N. veterana, N. vulneris, N. wallacei, and N. yamanashiensis.
- In further embodiments, the bacterial infection treated by the methods of the invention is caused by a Actinomyces species selected from A. israelii, A. viscosus, A. meyeri, A. naeslundii, A. odontolyticus, A. gerencseriae, A. neuii, A. turicensis, and A. radingae.
- When administered in combination with a second antibacterial agent, the compounds of the invention may be effective to overcome bacterial resistance to the second antibacterial agent. Thus, in certain embodiments, the method of treating a bacterial infection provided by the invention further comprises administering to the subject a second antibacterial agent. In some embodiments, the second antibacterial agent is a tRNA synthtase inhibitor such as AN3365.
- In certain embodiments, the invention provides methods of treating tuberculosis, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the invention, i.e., a compound of formula (I), formula (II), formula (II′), formula (III), formula (III′), or a compound pictured in Table 1, or a pharmaceutical composition comprising the compound.
- The invention further provides methods of treating tuberculosis, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (V′):
-
- or a pharmaceutically acceptable salt thereof;
- wherein:
- each of R31, R32, R33, R34, and R35 is independently selected from H, OH, —NH2, halide, sulfonamido, (C1-C6)alkylsulfonyl, —OC(O)((C1-C8)alkyl), —C(O)O((C1-C8)alkyl), —C(O)OH, optionally substituted —NHC(O)(aryl), —C(O)NH2, —B(OH)2, optionally substituted —S—(C1-C6)alkyl; tri((C1-C8)alkyl)silyl, optionally substituted (C1-C8)alkyl, optionally substituted (C1-C8)alkoxy, optionally substituted (C1-C8)aminoalkyl, optionally substituted (C1-C8)hydroxyalkyl, optionally substituted (C1-C8)haloalkyl, optionally substituted (C1-C8)haloalkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryloxy, optionally substituted arylalkoxy, optionally substituted heteroaryloxy, optionally substituted heteroarylalkoxy, optionally substituted (C3-C10)cycloalkyl, optionally substituted (C3-C10)cycloalkoxy, optionally substituted (C2-C9)heterocycloalkyl, optionally substituted (C2-C9)heterocycloalkoxy, (H3CSO2)(C1-C8)alkylene, optionally substituted (Rf 2NSO2)(C1-C8)alkylene, optionally substituted di((C1-C8)alkyl)amino, —NH—CH2—R38, —O—CH2—R38, and —O—CH2CH2—O—R39;
- or R31 and R32, R32 and R33, R33 and R34, or R34 and R35, taken together with the intervening atoms, form an optionally substituted aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group;
- R36 is H or (C1-C6)alkyl;
- R37 is optionally substituted (C3-C10)cycloalkyl or (C3-C10)cycloalkenyl;
- R38 is selected from H, —C(O)((C2-C9)heterocycloalkyl), —C(O)NH((C1-C8)alkyl), —C(O)NH(aryl(C1-C8)alkyl), —C(O)NH((C3-C8)cycloalkyl), —C(O)NH((C3-C8)cycloalkyl(C1-C8)alkyl), —C(O)N(CH3)((C3-C8)cycloalkyl), —C(O)N(CH3)(aryl(C1-C8)alkyl), —C(O)NHC(O)NH((C3-C8)cycloalkyl), —C(O)NHC(O)NH((C1-C8)alkyl), —C(O)NHC(O)NH2, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted aryloxy(C1-C8)alkyl, (C3-C8)cycloalkyl, (C2-C9)heterocycloalkyl, (C2-C9)heterocycloalkyl(C2-C8)alkyl, heteroaryl(C1-C8)alkyl, (C1-C8)alkoxy, (C2-C8)hydroxyalkyl, (C1-C8)alkoxy(C1-C8)alkyl, (C1-C8)haloalkoxy(C1-C8)alkyl, (C1-C8)thioalkoxy(C1-C8)alkyl, (CH3SO2)(C1-C8)alkyl, and ((C1-C8)alkylC(O))(C1-C8)alkyl;
- R39 is selected from (C3-C10)cycloalkyl, (C3-C10)cycloalkyl(C1-C8)alkyl, (C1-C8)haloalkyl, (C1-C8)hydroxyalkyl, (C1-C8)alkyl, (C1-C8)alkoxy(C1-C8)alkyl, and optionally substituted aryl; and
- Rf, independently for each occurrence, is selected from H, optionally substituted —C(O)(C1-C8)alkyl, optionally substituted —C(O)NH—(C3-C10)cycloalkyl, optionally substituted (C1-C8)alkyl, optionally substituted (C1-C8)haloalkyl, optionally substituted (C1-C8)hydroxyalkyl, optionally substituted (C3-C10)cycloalkyl, optionally substituted heterocyclyl, optionally substituted (C3-C10)cycloalkyl(C1-C8)alkyl, optionally substituted aryl, and optionally substituted aryl(C1-C8) alkyl, or
- two Rf are taken together with the nitrogen atom to which they are attached to form a 5-6-membered heterocyclyl.
- The invention further provides methods of treating tuberculosis, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (V):
-
- or a pharmaceutically acceptable salt thereof;
- wherein:
- each of R31, R32, R33, R34, and R35 is independently selected from H, OH, —NH2, halide, sulfonamido, (C1-C6)alkylsulfonyl, —OC(O)((C1-C8)alkyl), —C(O)O((C1-C8)alkyl), —C(O)OH, optionally substituted —NHC(O)(aryl), —C(O)NH2, —B(OH)2, tri((C1-C8)alkyl)silyl, optionally substituted (C1-C8)alkyl, optionally substituted (C1-C8)alkoxy, optionally substituted (C1-C8)aminoalkyl, optionally substituted (C1-C8)hydroxyalkyl, optionally substituted (C1-C8)haloalkyl, optionally substituted (C1-C8)haloalkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryloxy, optionally substituted arylalkoxy, optionally substituted heteroaryloxy, optionally substituted heteroarylalkoxy, optionally substituted (C3-C10)cycloalkyl, optionally substituted (C3-C10)cycloalkoxy, optionally substituted (C2-C9)heterocycloalkyl, optionally substituted (C2-C9)heterocycloalkoxy, (H3CSO2)(C1-C8)alkylene, optionally substituted (Rf 2NSO2)(C1-C8)alkylene, optionally substituted di((C1-C8)alkyl)amino, —NH—CH2—R38, —O—CH2—R38, and —O—CH2CH2—O—R39;
- or R31 and R32, R32 and R33, R33 and R34, or R34 and R35, taken together with the intervening atoms, form an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group;
- R36 is H or (C1-C6)alkyl;
- R37 is optionally substituted (C3-C10)cycloalkyl or (C3-C10)cycloalkenyl;
- R38 is selected from —C(O)((C2-C9)heterocycloalkyl), —C(O)NH((C1-C8)alkyl), —C(O)NH(aryl(C1-C8)alkyl), —C(O)NH((C3-C8)cycloalkyl), —C(O)NH((C3-C8)cycloalkyl(C1-C8)alkyl), —C(O)N(CH3)((C3-C8)cycloalkyl), —C(O)N(CH3)(aryl(C1-C8)alkyl), —C(O)NHC(O)NH((C3-C8)cycloalkyl), —C(O)NHC(O)NH((C1-C8)alkyl), —C(O)NHC(O)NH2, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted aryloxy(C1-C8)alkyl, (C3-C8)cycloalkyl, (C2-C9)heterocycloalkyl, (C2-C9)heterocycloalkyl(C2-C8)alkyl, heteroaryl(C1-C8)alkyl, (C1-C8)alkoxy, (C2-C8)hydroxyalkyl, (C1-C8)alkoxy(C1-C8)alkyl, (C1-C8)haloalkoxy(C1-C8)alkyl, (C1-C8)thioalkoxy(C1-C8)alkyl, (CH3SO2)(C1-C8)alkyl, and ((C1-C8)alkylC(O))(C1-C8)alkyl;
- R39 is selected from (C3-C10)cycloalkyl, (C3-C10)cycloalkyl(C1-C8)alkyl, (C1-C8)haloalkyl, (C1-C8)hydroxyalkyl, (C1-C8)alkyl, (C1-C8)alkoxy(C1-C8)alkyl, and optionally substituted aryl; and
- Rf, independently for each occurrence, is selected from H, optionally substituted (C1-C8)alkyl, optionally substituted (C1-C8)haloalkyl, optionally substituted (C1-C8)hydroxyalkyl, optionally substituted (C3-C10)cycloalkyl, optionally substituted (C3-C10)cycloalkyl(C1-C8)alkyl, optionally substituted aryl, and optionally substituted aryl(C1-C8) alkyl.
- In some embodiments, at least four of R31, R32, R33, R34, and R35 are H. For example, R32, R33, R34, and R35 may each be H.
- In certain embodiments, R31 and R32, taken together with the intervening atoms, form an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group, preferably a heteroaryl group.
- In certain embodiments, R31 is selected from the group consisting of —OH, —OC(O)((C1-C8)alkyl), optionally substituted (C1-C8)alkoxy, optionally substituted (C1-C8)haloalkoxy, optionally substituted aryloxy, optionally substituted arylalkoxy, optionally substituted heteroaryloxy, optionally substituted heteroarylalkoxy, optionally substituted (C3-C10)cycloalkoxy, optionally substituted (C2-C9)heterocycloalkoxy, —O—CH2—R38, and —O—CH2CH2—O—R39.
- In certain embodiments, R36 is (C1-C6)alkyl, e.g., methyl. Alternatively, R36 may be H.
- In certain embodiments, R37 is optionally substituted cyclohexyl or cyclohexenyl, preferably optionally substituted cyclohexyl.
- In certain embodiments, the subject is a mammal, e.g., a human.
- Certain compounds of the invention are synthesized according to Synthetic Scheme 1:
- Synthetic Scheme 1
- For example, N-benzyl-1-cyclohexylbutan-2-amine (B164) was synthesized as follows:
-
- To a solution of 1 (1.5 g, 11.895 mmol, 1.0 eq) in THF (24 mL, c=0.5) was added dropwise ethylmagnesium bromide (24 mL, 1M in THF, 23.79 mmol, 2.0 eq) at 0° C. under nitrogen. After 0.5 h at 0° C., the reaction mixture was added to aq. HCl (2N, 40 mL) at 0° C. The solution was extracted with EA (3×30 mL). The combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated in vacuum. The residue was purified by column chromatography to give the desired product 2 (1.313 g, yield=71%) as a yellow oil.
-
- To a solution of 2 (1.25 g, 8.005 mmol, 1 eq) and triethylamine (4.05 g, 40.026 mmol, 5.0 eq) in DCM (32 mL, c=0.25) was added dropwise MsCl (2.3 g, 20.013 mmol, 2.5 eq) at 0° C. After 20 min at 0° C., the reaction mixture was washed with aq.HCl (2N, 2×30 mL) and extracted with EA (3×30 mL). The combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated in vacuum. The residue was purified by column chromatography to give the desired product 3 (1.511 g, yield=81%) as a yellow oil.
-
- To a solution of 3 (100 mg, 0.427 mmol, 1 eq) in CH3CN (2 mL, c=0.2) was added BnNH2 (275 mg, 2.562 mmol, 6 eq) and KI (35 mg, 0.213 mmol, 0.5 eq) and the reaction mixture was refluxed at 80° C. for 1.5 h. After completion, the suspension was concentrated in vacuum and the residue was purified by column chromatography to give the desired product B164 (30.8 mg, yield=29%) as a yellow oil. 1H NMR (400 MHz, DMSO): δ 7.34-7.20 (m, 5H), 3.74-3.64 (m, 2H), 2.50-2.45 (m, 1H), 1.62-1.10 (m, 15H), 0.89-0.75 (m, 3H). Mass: m/z=246 [M+H]+
- The following compounds were synthesized via similar routes:
-
Compound Name, ID Structure 1H NMR (400 MHz), MS B165: N-benzyl-1- cyclohexylpentan-2- amine 1H NMR (DMSO): δ 7.35-7.28 (m, 4H), 7.23-7.21 (m, 1H), 3.73-3.71 (m, 2H), 2.52-2.50 (m, 1H), 1.64-0.81 (m, 20H); Mass: m/z = 260 [M + H]+ B166: 1-cyclohexyl-N- (2-fluorobenzyl)butan- 2-amine hydrochloride 1H NMR (DMSO): δ 8.86-8.84 (m, 2H), 7.72-7.65 (m, 1H), 7.49-7.48 (m, 1H), 7.34-7.28 (m, 2H), 4.25-4.10 (m, 2H), 3.15-3.05 (m, 1H), 1.73-0.84 (m, 18H); Mass: m/z = 264 [M − HCl + H]+ B213: N-benzyl-1-(2,3- dihydro-1H-inden-1- yl)methanamine hydrochloride 1H NMR (DMSO): δ 9.70-9.10 (m, 2H), 7.65-7.55 (m, 2H), 7.45-7.35 (m, 3H), 7.25-7.10 (m, 4H), 4.30-4.10 (m, 2H), 3.60-3.55 (m, 1H), 3.33-3.30 (m, 1H), 3.00-2.75 (m, 3H), 2.35-2.20 (m, 1H), 2.05-1.85 (m, 1H); Mass: m/z = 238 [M − HCl + H]+ B214: N-benzyl-1- (1,2,3,4- tetrahydronaphthalen-1- yl)methanamine hydrochloride 1H NMR (DMSO): δ 9.55-9.40 (m, 1H), 9.20-9.05 (m, 1H), 7.75-7.05 (m, 9H), 4.30-4.10 (m, 2H), 3.35-3.25 (m, 1H), 3.20-3.00 (m, 2H), 2.75-2.65 (m, 2H), 2.05-0.60 (m, 4H); Mass: m/z = 252 [M − HCl + H]+ B215: N-benzyl-2- (piperidin-4- yl)ethanamine hydrochloride 1H NMR (DMSO): δ 9.45-9.20 (m, 2H), 8.95-8.55 (m, 2H), 7.64-7.38 (m, 5H), 4.15-4.05 (m, 2H), 3.30-3.20 (m, 2H), 3.00-2.75 (m, 4H), 1.85-1.20 (m, 7H). B216: tert-butyl 4-(2- (benzylamino)ethyl) piperidine-1-carboxylate 1H NMR (DMSO): δ 7.60-7.40 (m, 5H), 4.18-4.10 (m, 2H), 3.95-3.80 (m, 2H), 2.95-2.85 (m, 2H), 2.75-2.60 (m, 2H), 1.70-0.90 (m, 16H). B218: 4-(2- (benzylamino)ethyl) cyclohexanone 1H NMR (DMSO): δ 7.50-7.10 (m, 5H), 4.15-4.10 (m, 2H), 3.75-3.65 (m, 2H), 2.20-1.10 (m, 11H); Mass: m/z = 232 [M + H]+ B219: (E)-N-benzyl-4- cyclohexylbut-3-en-2- amine 1H NMR (DMSO): δ 7.50-7.20 (m, 5H), 3.90-3.60 (m, 2H), 3.40-3.20 (m, 1H), 2.90-2.80 (m, 1H), 1.80-0.80 (m, 15H); Mass: m/z = 244 [M + H]+ -
Synthetic Scheme 2 - For example, N-benzyl-2-cyclohexyl-1-cyclopropylethanamine (B167) was synthesized as follows: N-benzyl-2-cyclohexyl-1-cyclopropylethanamine
-
- Step 1: See Scheme 1, step 1
-
- To a solution of 4 (565 mg, 8.005 mmol, 1 eq) in THF (14 mL, c=0.25) was added dropwise DPPA (1.11 g, 4.032 mmol, 1.2 eq) and DBU (614 mg, 4.032 mmol, 1.2 eq) at 0° C. and the reaction mixture was stirred at 50° C. overnight. After completion, the reaction mixture was washed with water (20 mL) and extracted with EA (2×20 mL). The combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated in vacuum. The residue was purified by column chromatography to give the desired product 5 (348.8 mg, yield=50%) as an oil.
-
- To a solution of 5 (267 mg, 1.382 mmol, 1 eq) in THF (7 mL, c=0.2) was added Pd/C (20% wt, 53 mg). H2 was bubbled through the reaction mixture to saturate the solution. The reaction mixture was stirred at room temperature for 0.5 h. After completion, the reaction solution was filtered and washed with EtOH (4×30 mL). The filtrate was concentrated in vacuum and the residue was purified on a silica gel column to give the product 6 (125 mg, yield=54%) as a yellow solid.
-
- To a solution of 6 (63 mg, 0.377 mmol, 1 eq) in MeOH (3.4 mL, c=0.2) was added benzaldehyde (147 mg, 1.382 mmol, 4 eq) and MgSO4 (62 mg). The reaction mixture was stirred at 40° C. for 1 h. After that, AcOH (0.1 mL) and NaBH3CN (91 mg, 1.4415 mmol, 3 eq) was added and the resulting mixture was stirred at 80° C. overnight. After completion, the suspension was concentrated in vacuum and the residue was purified by column chromatography to give the desired product (8.5 mg, yield=9%) as a yellow oil. After that, the product was dissolved in a solution of HCl/MeOH (4M, 0.5 mL) again and the resulting mixture was concentrated in vacuum to give the desired product B167 (9.5 mg, yield=95%) as a yellow oil. 1H NMR (400 MHz, DMSO): δ 9.00-8.70 (m, 2H), 7.60-7.35 (m, 5H), 4.23-4.10 (m, 2H), 3.30-3.25 (m, 1H), 1.90-0.65 (m, 14H), 0.55-0.50 (m, 2H), 0.28-0.25 (m, 2H). Mass: m/z=258 [M+H]+
- The following compounds were synthesized via a similar route:
-
Compound Name, ID Structure Data of 1H NMR (400 MHz), MS B169; N-benzyl-2- cyclohexyl-1- phenylethanamine hydrochloride 1H NMR (DMSO): δ 9.52 (brs, 1H), 9.33 (brs, 1H), 7.54-7.31 (m, 10H), 4.31 (brs, 1H), 4.06 (brs, 1H), 3.70 (brs, 1H), 1.99-0.86 (m, 13H); Mass: m/z = 294 [M − HCl + H]+ B168; 2- (benzylamino)-3- cyclohexylpropan-1-ol 1H NMR (DMSO): δ 8.88-8.60 (m, 2H), 7.53-7.44 (m, 2H), 7.42-7.31 (m, 3H), 4.28-4.10 (m, 2H), 3.72-3.71 (m, 1H), 3.57-3.56 (m, 1H), 3.11-3.01 (m, 1H), 1.78-0.72 (m, 13H); Mass: m/z = 248 [M + H]+ B202; N-benzyl-1- cyclohexyl-3- methoxypropan-2- amine hydrochloride 1H NMR (DMSO): δ 8.90-8.71 (m, 2H), 7.60-7.38 (m, 5H), 4.28-4.10 (m, 2H), 3.72-3.71 (m, 2H), 3.58-3.56 (m, 1H), 3.35 (s, 3H), 1.78-0.72 (m, 13H); Mass: m/z = 262 [M − HCl + H]+ B203; methyl 2- (benzylamino)-3- cyclohexylpropanoate hydrochloride 1H NMR (DMSO): δ 9.91 (brs, 1H), 9.64 (brs, 1H), 7.53-7.35 (m, 5H), 4.19-4.10 (m, 2H), 4.00 (brs, 1H), 3.75 (s, 3H), 1.84-0.83 (m, 13H); Mass: m/z = 276 [M − HCl + H]+ B204; 2- (benzylamino)-3- cyclohexylpropanoic acid 1H NMR (DMSO): δ 13.92 (brs, 1H), 9.59 (brs, 1H), 7.53-7.43 (m, 5H), 4.20-4.10 (m, 2H), 3.81 (s, 1H), 3.46-3.41 (m, 1H), 1.76-0.84 (m, 13H); Mass: m/z = 262 [M + H]+ B205; 2- (benzylamino)-3- cyclohexylpropanamide hydrochloride 1H NMR (DMSO): δ 9.30 (brs, 2H), 8.09 (s, 1H), 7.73 (s, 1H), 7.51-7.42 (m, 5H), 4.04 (s, 2H), 3.67 (s, 1H), 1.81-0.80 (m, 13H); Mass: m/z = 261 [M − HCl + H]+ B210; tert-butyl benzyl(1- cyclohexyl-3- oxopropan-2- yl)carbamate 1H NMR (DMSO): δ 9.40 (s, 1H), 7.40-7.15 (m, 5H), 4.15-4.10 (m, 2H), 3.95-3.80 (m, 1H), 1.70- 0.65 (m, 22H); Mass: m/z = 246 [M − Boc + H]+ -
- N-benzyl-2,3-dihydro-1H-inden-2-amine hydrochloride (B206) was synthesized according to
Synthetic Scheme 3. -
- To a solution of 7 (1 g, 5.915 mmol, 1 eq) in CH3CN (12 mL, c=0.5) was added BnBr (1.51 g, 8.87 mmol, 1.5 eq), K2CO3 (3.27 g, 23.66 mmol, 4 eq) and KI (295 mg, 1.775 mmol, 0.3 eq) and the reaction mixture was refluxed at room temperature for 4 h. After completion, the reaction mixture was washed with water (20 mL) and extracted with EA (2×20 mL). The combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated in vacuum. The residue was purified by column chromatography to give the desired product (421 mg, yield=32%) as a oil. After that, the product was dissolved in a solution of HCl/MeOH (4M, 2.0 mL) again and the resulting mixture was concentrated in vacuum to give the desired product B206 (480 mg, yield=95%) as a yellow oil. 1H NMR (400 MHz, DMSO): δ 9.80-9.55 (m, 1H), 7.70-7.60 (m, 2H), 7.50-7.35 (m, 3H), 7.25-7.10 (m, 4H), 4.25-4.15 (m, 2H), 4.05-3.90 (m, 1H), 3.35-3.25 (m, 2H), 3.25-3.15 (m, 2H). Mass: m/z=224 [M−HCl+H]+
- The following compounds were synthesized via a similar route:
-
Compound Name, ID Structure Data of 1H NMR (400 MHz), MS B207; (R)-N-benzyl- 2-cyclohexyl-1- phenylethanamine hydrochloride 1H NMR (DMSO): δ 9.60-9.35 (m, 2H), 7.70- 7.10 (m, 8H), 4.90-4.78 (m, 1H), 4.25-4.15 (m, 2H), 3.20-3.05 (m, 1H), 2.95-2.80 (m, 1H), 2.51-2.50 (m, 1H), 2.35-2.25 (m, 1H); Mass: m/z = 242 [M + H]+. B208; (S)-N-benzyl- 6-fluoro-2,3- dihydro-1H-inden-1- amine hydrochloride 1H NMR (DMSO): δ 9.60-9.35 (m, 2H), 7.70- 7.10 (m, 8H), 4.90-4.78 (m, 1H), 4.25-4.15 (m, 2H), 3.20-3.05 (m, 1H), 2.95-2.80 (m, 1H), 2.51-2.50 (m, 1H), 2.35-2.25 (m, 1H); Mass: m/z = 242 [M + H]+ B209; (S)-N-benzyl- 6-methoxy-2,3- dihydro-1H-inden-1- amine hydrochloride 1H NMR (DMSO): δ 9.60-9.56 (m, 2H), 7.65- 7.60 (m, 2H), 7.45-7.35 (m, 4H), 7.30-7.20 (m, 1H), 7.00-6.90 (m, 1H), 4.75 (s, 1H), 4.19 (s, 2H), 3.76 (s, 3H), 3.10-3.00 (m, 1H), 2.85-2.75 (m, 1H), 2.55-2.45 (m, 1H), 2.35-2.23 (m, 1H); Mass: m/z = 254 [M − HCl + H]+ B211; (1S,2R)-N- benzyl-2-(3,4- difluorophenyl) cyclopropanamine hydrochloride 1H NMR (DMSO): δ 9.88 (brs, 2H), 7.54 (s, 2H), 7.41-7.31 (m, 4H), 7.24-7.19 (m, 1H), 7.04-6.99 (m, 1H), 4.27 (s, 2H), 2.88 (s, 1H), 2.50 (s, 1H), 1.57-1.56 (m, 1H), 1.35-1.30 (m, 1H); Mass: m/z = 260 [M − HCl + H]+ B212; N-benzyl-2- (4,4- difluorocyclohexyl) ethanamine hydrochloride 1H NMR (DMSO): δ 9.25-8.90 (m, 2H), 7.55- 7.30 (m, 5H), 4.15-4.05 (m, 2H), 2.95-2.85 (m, 2H), 2.00-1.05 (m, 11H); Mass: m/z = 254 [M + H]+ B220; 3- ((benzylamino) methyl)-7- methoxybenzo[c][1, 2]oxaborol-1(3H)-ol hydrochloride 1H NMR (DMSO): δ 8.18-8.05 (m, 2H), 7.75- 7.65 (m, 1H), 7.40-7.25 (m, 5H), 7.05-6.85 (m, 2H), 4.70-4.65 (m, 1H), 4.40-4.30 (m, 2H), 4.15-4.05 (m, 1H), 3.77 (s, 3H), 3.15-3.00 (m, 2H); Mass: m/z = 284 [M + H]+ - Compound B255 was made according to Synthetic Scheme 4:
-
-
-
Compound Name Structure Data of 1H NMR (400 MHz), MS B255; (2-((2- cyclohexylethylamino) methyl)phenyl) methanol hydrochloride 1H NMR (DMSO): δ 8.95-8.75 (m, 2H), 7.58- 7.25 (m, 4H), 5.85-5.71 (s, 1H), 4.70-4.60 (m, 2H), 4.25-4.15 (m, 2H), 3.05-2.90 (m, 2H), 1.85-0.75 (m, 13H); Mass: m/z = 248 [M + H]+ -
- The synthetic scheme was similar to that of
synthetic scheme 3 and the corresponding data were summarized as follows: -
Compound Name, ID Structure Data of 1H NMR (400 MHz); MS B340; 2-((2- cyclohexylethylamino) methyl)phenylboronic acid 1H NMR (DMSO): δ 7.62-7.45 (m, 1H), 7.25- 7.00 (m, 3H), 4.05-3.85 (m, 2H), 2.80-2.65 (m, 2H), 1.90 (s, 2H), 1.70-0.68 (m, 13H); Mass: m/z = 262 [M + H]+ B376; 2-((2- cyclohexylethylamino) methyl)benzylboronic acid 1H NMR (DMSO): δ 7.25-6.90 (m, 4H), 3.90- 3.80 (m, 2H), 3.78-3.32 (m, 2H), 3.05-2.85 (m, 2H), 1.95-0.75 (m, 13H); Mass: m/z = 276 [M + H]+ B225; 2-cyclohexyl-N- (2-(trifluoromethyl) benzyl) ethanamine hydrochloride 1H NMR (DMSO): δ 9.68 (brs, 2H), 8.10-7.90 (m, 1H), 7.85-7.70 (m, 2H), 7.65-7.55 (m, 1H), 4.30-4.20 (m, 2H), 2.97-2.82 (m, 2H), 1.66- 0.85 (m, 13H); Mass: m/z = 286 [M − HCl + H]+ B228; 2-cyclohexyl-N- (2-ethylbenzyl) ethanamine hydrochloride 1H NMR (DMSO): δ 9.14 (brs, 2H), 7.61-7.53 (m, 1H), 7.40-7.10 (m, 3H), 4.16-4.08 (m, 2H), 3.10-2.90 (m, 2H), 2.80-2.65 (m, 2H), 1.80- 0.70 (m, 18H); Mass: m/z = 246 [M − HCl + H]+ B254; N-(2- (aminomethyl) benzyl)-2- cyclohexylethanamine hydrochloride 1H NMR (DMSO): δ 9.17 (brs, 2H), 8.44 (brs, 2H), 7.70-7.42 (m, 4H), 4.35-4.15 (m, 4H), 3.10-2.98 (m, 2H), 1.80-0.80 (m, 13H); Mass: m/z = 247 [M − 2HCl + H]+ -
-
-
Compound Name, ID Structure Data of 1H NMR (400 MHz); MS B339; 2-((2- cyclohexylethylamino) methyl)phenylboronic acid 1H NMR (DMSO): δ 7.58-7.35 (m, 3H), 5.08-5.00 (m, 2H), 4.22-4.10 (m, 2H), 2.85-2.78 (m, 2H), 1.70-0.70 (m, 13H); Mass: m/z = 274 [M + H]+ B341; 2-cyclohexyl- N-(2-(trimethylsilyl)- benzyl)ethanamine hydrochloride 1H NMR (DMSO): δ 9.50-8.80 (m, 2H), 7.80-7.30 (m, 4H), 4.25-4.10 (m, 2H), 3.10-2.90 (m, 2H), 1.70-0.75 (m, 13H), 0.34 (s, 9H); Mass: m/z = 290 [M + H]+ B226; 2-((2- cyclohexylethylamino) methyl)phenol 1H NMR (DMSO): δ 7.10-6.95 (m, 2H), 6.80-6.55 (m, 2H), 3.85-3.75 (m, 2H), 2.53-2.45 (m, 2H), 1.80-0.75 (m, 13H); Mass: m/z = 234 [M + H]+ B227; 2-cyclohexyl- N-(2- isopropylbenzyl) ethanamine hydrochloride 1H NMR (DMSO): δ 9.12 (brs, 2H), 7.60- 7.15 (m, 4H), 4.15-4.05 (m, 2H), 3.05- 2.95 (m, 3H), 1.75-0.80 (m, 19H); Mass: m/z = 260 [M + H]+ B229; N-(biphenyl-2- ylmethyl)-2- cyclohexylethanamine hydrochloride 1H NMR (DMSO): δ 9.34 (brs, 2H), 7.89- 7.86 (m, 1H), 7.51-7.31 (m, 8H), 4.10- 3.95 (m, 2H), 2.80-2.65 (m, 2H), 1.83- 0.65 (m, 13H); Mass: m/z = 294 [M + H]+ B230; 2-cyclohexyl- N-(2-(thiophen-2- yl)benzyl)ethanamine hydrochloride 1H NMR (DMSO): δ 9.31 (brs, 2H), 7.86- 7.84 (m, 1H), 7.71-7.69 (m, 1H), 7.50- 7.46 (m, 3H), 7.25-7.19 (m, 2H), 4.25- 4.15 (m, 2H), 2.90-2.78 (m, 2H), 1.70- 0.70 (m, 13H); Mass: m/z = 300 [M − HCl + H]+ B231; 2-cyclohexyl- N-(2-(pyridin-3- yl)benzyl)ethanamine hydrochloride 1H NMR (DMSO): δ 9.53 (brs, 2H), 9.04 (s, 1H), 8.96 (s, 1H), 8.58 (s, 1H), 8.09 (s, 1H), 8.08-7.99 (m, 1H), 7.63-7.55 (m, 2H), 7.45-7.43 (m, 1H), 4.20-3.90 (m, 2H), 2.85-2.75(m, 2H), 1.75-0.65 (m, 13H); Mass: m/z = 295 [M − HCl + H]+ B232; 2-cyclohexyl- N-(2- phenoxybenzyl) ethanamine hydrochloride 1H NMR (DMSO): δ 9.25-9.10 (m, 2H), 7.73-7.71 (m, 1H), 7.47-7.38 (m, 3H), 7.23-7.19 (m, 2H), 7.10-7.08 (m, 2H), 6.86-6.84 (m, 1H), 4.25-4.10 (m, 2H), 3.05-2.95 (m, 2H), 1.70-0.70 (m, 13H); Mass: m/z = 310 [M − HCl + H]+ B233; 2-cyclohexyl- N-(2- cyclopropylbenzyl) ethanamine hydrochloride 1H NMR (DMSO): δ 9.30-9.17 (m, 2H), 7.65-7.40 (m, 1H), 7.35-7.20 (m, 2H), 7.11-7.08 (m, 1H), 4.40-4.25 (m, 2H), 3.05-2.95 (m, 2H), 2.25-2.10 (m, 1H), 1.85-0.60 (m, 17H); Mass: m/z = 258 [M − HCl + H]+ B234; 2-cyclohexyl- N-(2-(naphthalen-2- yl)benzyl)ethanamine hydrochloride 1H NMR (DMSO): δ 9.09 (brs, 2H), 8.05- 7.35 (m, 11H), 4.16-4.08 (m, 2H), 2.75- 2.65 (m, 2H), 1.65-0.55 (m, 13H); Mass: m/z = 344 [M − HCl + H]+ B235; 2-((2- cyclohexylethylamino) methyl)aniline hydrochloride 1H NMR (DMSO): δ 10.30-8.30 (m, 2H), 7.68-7.20 (m, 4H), 4.43-4.11 (m, 2H), 3.05-2.85 (m, 2H), 1.85-0.80 (m, 13H); Mass: m/z = 233 [M − HCl + H]+ B236; 2-cyclohexyl- N-(2-(furan-2- yl)benzyl)ethanamine hydrochloride 1H NMR (DMSO): δ 9.31 (brs, 2H), 7.90- 7.70 (m, 3H), 7.55-7.35 (m, 2H), 6.95- 6.60 (m, 2H), 4.29-4.38 (m, 2H), 3.00- 2.85 (m, 2H), 1.80-0.75 (m, 13H); Mass: m/z = 284 [M − HCl + H]+ B237; 2-((2- cyclohexylethylamino) methyl)-N,N- dimethylaniline hydrochloride 1H NMR (DMSO): δ 9.08 (brs, 2H), 7.75- 7.20 (m, 4H), 4.36-4.24 (m, 2H), 3.05- 2.95 (m, 2H), 2.85 (s, 6H), 1.75-0.80 (m, 13H); Mass: m/z = 261 [M − HCl + H]+ B238; 2-cyclohexyl- N-(2-(naphthalen-1- yl)benzyl)ethanamine hydrochloride 1H NMR (DMSO): δ 8.06 (brs, 1H), 8.04 (brs, 1H), 8.15-8.05 (m, 2H), 7.90-7.82 (m, 1H), 7.70-7.20 (m, 8H), 3.95-3.85 (m, 1H), 3.75-3.60 (m, 1H), 2.60-2.50 (m, 2H), 1.65-0.50 (m, 13H); Mass: m/z = 344 [M − HCl + H]+ B253; 2-cyclohexyl- N-(2- methoxybenzyl) ethanamine hydrochloride 1H NMR (400 MHz, DMSO): δ 9.20-8.50 (m, 2H), 7.52-7.38 (m, 2H), 7.18-6.95 (m, 2H), 4.15-4.05 (m, 2H), 3.80 (s, 3H), 3.00- 2.75 (m, 2H), 1.75-0.70 (m, 13H); Mass: m/z = 248 [M − HCl + H]+ B256; 2-((2- cyclohexylethylamino) methyl)phenyl acetate 1H NMR (DMSO): δ 7.82-7.70 (m, 1H), 7.15-7.00 (m, 2H), 6.80-6.65 (m, 2H), 3.85-3.78 (m, 2H), 3.05-2.95 (m, 2H), 2.55-2.45 (s, 3H), 1.80-0.70 (m, 13H); Mass: m/z = 276 [M + H]+ B257; 2-((2- cyclohexylethylamino) methyl)benzoic acid hydrochloride 1H NMR (DMSO): δ 13.50 (brs, 1H), 8.95-8.80 (m, 2H), 8.10-8.00 (m, 1H), 7.75-7.55 (m, 3H), 4.50-4.32 (m, 2H), 3.10-2.90 (m, 2H), 1.80-0.70 (m, 13H); Mass: m/z = 262 [M − HCl + H]+ B258; methyl 2-((2- cyclohexylethylamino) methyl)benzoate hydrochloride 1H NMR (DMSO): δ 8.88 (brs, 2H), 8.10- 8.00 (m, 1H), 7.72-7.50 (m, 3H), 4.45- 4.30 (m, 2H), 3.85 (s, 3H), 3.05-2.90 (m, 2H), 1.78-0.75 (m, 13H); Mass: m/z = 276 [M − HCl + H]+ B259; 2-((2- cyclohexylethylamino) methyl)benzamide trifluoroacetate 1H NMR (DMSO): δ 8.77 (brs, 2H), 8.35 (s, 1H), 7.91 (s, 1H), 7.75-7.53 (m, 4H), 4.25-4.10 (m, 2H), 3.12-2.90 (m, 2H), 1.80-0.70 (m, 13H); Mass: m/z = 261 [M − TFA + H]+ B328; 2-cyclohexyl- N-(2-((tetrahydro-2H- pyran-2- yl)methoxy)benzyl) ethanamine hydrochloride 1H NMR (400 MHz, DMSO): δ 9.15-8.90 (m, 2H), 7.49-7.32 (m, 2H), 7.15-6.90 (m, 2H), 4.10-3.90 (m, 5H), 3.76-3.65 (m, 1H), 3.48-3.30 (m, 1H), 2.95-2.80 (m, 2H), 1.90-0.70 (m, 19H); Mass: m/z = 332 [M − HCl + H]+ B329; 2-cyclohexyl- N-(2- ((tetrahydrofuran-2- yl)methoxy)benzyl) ethanamine 1H NMR (DMSO): δ 7.41-7.30 (m, 2H), 7.06-6.80 (m, 2H), 4.21-4.20 (m, 1H), 4.06-3.86 (m, 2H), 3.95-3.85 (m, 2H), 3.85-3.60 (m, 2H), 2.80-2.72 (m, 2H), 2.05-0.70 (m, 17H); Mass: m/z = 318 [M + H]+ B330; 2-cyclohexyl- N-(2- ((tetrahydrofuran-3- yl)methoxy)benzyl) ethanamine 1H NMR (DMSO): δ 7.43-7.35 (m, 2H), 7.08-6.99 (m, 2H), 4.01-3.94 (m, 4H), 3.85-3.80 (m, 2H), 3.68-3.60 (m, 2H), 2.88-2.85 (m, 2H), 2.85-2.62 (m, 1H), 2.10-1.90 (m, 1H), 1.80-0.70 (m, 14H); Mass: m/z = 318 [M + H]+ B331; 2-cyclohexyl- N-(2-((tetrahydro-2H- pyran-4- yl)methoxy)benzyl) ethanamine 1H NMR (DMSO): δ 7.35-7.25 (m, 2H), 6.92-6.88 (m, 2H), 3.91-3.82 (m, 6H), 3.45-3.31 (m, 2H), 2.68-2.64 (m, 2H), 2.05-1.90 (m, 1H), 1.70-0.84 (m, 17H); Mass: m/z = 332 [M + H]+ B378; 3-(2-((1- cyclohexylpropan-2- ylamino)methyl) phenyl)propan-1-ol 1H NMR (DMSO): δ 7.56-7.35 (m, 1H), 7.30-7.08 (m, 3H), 3.95-3.78 (m, 2H), 3.45-3.32 (m, 2H), 3.10-2.85 (m, 1H), 2.85-2.65 (m, 2H), 1.85-0.75 (m, 18H); Mass: m/z = 290 [M + H]+ B399; 3-(2-((1- cyclohexylpropan-2- ylamino)methyl) phenyl)propanamide trifluoroacetate 1H NMR (DMSO): δ 8.76 (brs, 2H), 7.63 (s, 1H), 7.43-7.00 (m, 5H), 4.30-4.08 (m, 2H), 3.29-3.22 (m, 1H), 2.85-2.78 (m, 2H), 2.60-2.52 (m, 2H), 1.70-0.75 (m, 16H); Mass: m/z = 303 [M − TFA + H]+ B400; methyl 3-(2- ((1-cyclohexylpropan- 2- ylamino)methyl) phenyl)propanoate hydrochloride 1H NMR (DMSO): δ 8.73 (brs, 1H), 8.65 (brs, 1H), 7.60-7.05 (m, 4H), 4.45-4.16 (m, 2H), 3.75-3.50 (m, 3H), 2.95-2.85 (m, 1H), 2.60-2.55 (m, 2H), 1.85-0.65 (m, 18H); Mass: m/z = 318 [M + H]+ B401; 3-(2-((1- cyclohexylpropan-2- ylamino)methyl) phenyl)propanoic acid trifluoroacetate 1H NMR (DMSO): δ 8.60 (brs, 1H), 8.54 (brs, 1H), 7.47-7.45 (m, 1H), 7.37-7.29 (m, 3H), 4.32-4.20 (m, 2H), 3.50-3.28 (m, 1H), 2.95-2.88 (m, 2H), 2.60-2.55 (m, 2H), 1.85-0.75 (m, 16H); Mass: m/z = 304 [M + H]+ - The compounds listed below were synthesized according to the following general procedure:
- Amine 1 (0.5 mmol), aldehyde 2 (0.55 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours, then mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C., 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated and dissolved in 0.5 ml of DMSO. The residue was purified using HPLC. Yields: 31-67%.
- Synthesis of target compounds was carried out following the general scheme below:
- Amine 1 (0.5 mmol), aldehyde 2 (0.55 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours, then mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C., 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated and optionally dissolved in 0.5 ml of DMSO. The residue was purified using HPLC. Yield: 31-67%
- 1H NMR (400 MHz, DMSO-d6) δ 7.45 (d, J=7.3 Hz, 1H), 7.29 (dtd, J=27.0, 14.5, 12.6, 7.4 Hz, 7H), 7.17 (t, J=7.5 Hz, 1H), 6.26 (s, 1H), 3.75 (s, 2H), 2.80 (t, J=7.3 Hz, 2H), 2.69 (t, J=7.7 Hz, 2H), 2.54 (s, 1H);
- 1H NMR (400 MHz, Chloroform-d) δ 9.28 (s, 1H), 8.74 (s, 1H), 7.63 (d, J=7.0 Hz, 2H), 7.45 (dd, J=8.1, 6.2 Hz, 2H), 7.44-7.36 (m, 1H), 5.37 (d, J=3.7 Hz, 1H), 4.40 (d, J=7.1 Hz, 1H), 2.82 (p, J=11.9, 10.4 Hz, 2H), 2.58 (t, J=8.0 Hz, 2H), 1.98 (d, J=6.8 Hz, 3H), 1.94-1.88 (m, 2H), 1.74 (q, J=4.9 Hz, 2H), 1.50 (ddtd, J=16.3, 10.4, 5.5, 3.0 Hz, 4H);
- 1H NMR (400 MHz, DMSO-d6) δ 7.30-7.21 (m, 4H), 7.20 (s, 1H), 7.16 (ddd, J=8.6, 5.5, 2.5 Hz, 1H), 5.32 (s, 1H), 3.70 (s, 2H), 2.63 (t, J=7.0 Hz, 2H), 2.32-2.20 (m, 3H), 2.19 (d, J=8.8 Hz, 3H), 1.83 (p, J=7.5 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.25 (d, J=6.6 Hz, 4H), 7.17 (d, J=6.4 Hz, 1H), 5.08 (t, J=7.2 Hz, 1H), 3.70 (s, 2H), 2.52 (d, J=7.3 Hz, 2H), 2.12 (q, J=7.2 Hz, 2H), 1.68 (s, 3H), 1.61 (s, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.30-7.20 (m, 4H), 7.16 (t, J=7.0 Hz, 1H), 5.52 (s, 1H), 3.64 (s, 2H), 2.01-1.94 (m, 4H), 1.67-1.51 (m, 5H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.25 (d, J=6.5 Hz, 5H), 7.16 (dd, J=8.1, 4.9 Hz, 1H), 6.08 (dd, J=5.7, 3.0 Hz, 1H), 5.88 (dd, J=5.8, 2.8 Hz, 1H), 3.68 (s, 2H), 2.73 (s, 2H), 2.50 (d, J=14.5 Hz, 1H), 2.06 (qt, J=8.0, 3.7 Hz, 1H), 1.83 (ddd, J=12.2, 8.9, 3.8 Hz, 1H), 1.40-1.32 (m, 1H), 1.26 (dd, J=13.5, 6.7 Hz, 1H), 1.21 (dd, J=7.9, 4.3 Hz, 2H), 0.49 (dt, J=11.6, 3.3 Hz, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.35-7.21 (m, 4H), 7.17 (tq, J=5.7, 3.7, 3.0 Hz, 1H), 5.53 (t, J=6.4 Hz, 1H), 3.69 (s, 2H), 2.56 (t, J=7.0 Hz, 2H), 2.50 (s, 1H), 2.12 (d, J=7.0 Hz, 1H), 2.06 (dq, J=10.8, 6.1, 5.0 Hz, 5H), 1.88 (s, 6H), 1.72 (p, J=6.0 Hz, 2H), 1.44 (dt, J=10.4, 5.5 Hz, 4H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.24 (d, J=4.4 Hz, 4H), 7.16 (p, J=4.3 Hz, 1H), 5.46-5.40 (m, 1H), 3.69 (s, 2H), 2.36 (s, 2H), 2.03 (tt, J=6.2, 3.1 Hz, 2H), 1.87 (s, 1H), 1.88-1.78 (m, 1H), 1.62-1.47 (m, 5H), 1.00 (s, 6H), 0.95 (d, J=2.1 Hz, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 6.99-6.87 (m, 3H), 5.38 (s, 1H), 3.00 (s, 2H), 2.68 (t, J=6.9 Hz, 2H), 2.34 (s, 6H), 2.09 (t, J=7.0 Hz, 2H), 1.96 (d, J=6.2 Hz, 2H), 1.90 (d, J=14.3 Hz, 0H), 1.90 (s, 2H), 1.65-1.48 (m, 4H), 0.93 (s, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.25 (dd, J=12.9, 5.5 Hz, 4H), 7.15 (t, J=7.0 Hz, 1H), 3.00 (s, 2H), 2.71 (s, 1H), 2.49-2.41 (m, 1H), 2.27 (t, J=10.8 Hz, 1H), 2.21-2.08 (m, 2H), 1.84-1.76 (m, 1H), 1.60 (d, J=21.6 Hz, 8H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.22-7.03 (m, 2H), 7.03-6.96 (m, 1H), 5.45 (tt, J=3.7, 1.7 Hz, 1H), 3.73 (s, 2H), 2.65 (t, J=6.9 Hz, 2H), 2.14 (t, J=7.0 Hz, 2H), 1.98 (tdd, J=6.2, 3.8, 1.8 Hz, 2H), 1.92-1.84 (m, 2H), 1.66-1.49 (m, 3H), 1.35-1.29 (m, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.30-7.21 (m, 4H), 7.16 (td, J=6.5, 6.1, 2.5 Hz, 1H), 3.68 (s, 2H), 2.56-2.44 (m, 3H), 2.16 (d, J=4.7 Hz, 1H), 1.93 (d, J=3.5 Hz, 1H), 1.42 (dqt, J=21.5, 8.2, 3.5 Hz, 5H), 1.30 (d, J=9.8 Hz, 1H), 1.23 (s, 1H), 1.22-0.96 (m, 4H).
- 1H NMR (500 MHz, Chloroform-d) δ 7.29 (q, J=7.3, 6.8 Hz, 1H), 7.21 (d, J=7.2 Hz, 2H), 5.38 (d, J=3.9 Hz, 1H), 2.89 (t, J=6.7 Hz, 1H), 2.81 (t, J=7.0 Hz, 1H), 2.68 (t, J=7.0 Hz, 1H), 2.11 (t, J=7.0 Hz, 1H), 1.96-1.90 (m, 1H), 1.56 (ddt, J=8.6, 6.4, 4.0 Hz, 1H), 1.50 (dtt, J=9.3, 6.1, 2.8 Hz, 1H), 1.31 (s, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.19 (d, J=5.0 Hz, 1H), 6.92-6.83 (m, 2H), 5.38 (s, 1H), 3.89 (s, 2H), 2.62 (t, J=7.2 Hz, 2H), 2.50 (s, 0H), 2.07 (t, J=7.3 Hz, 2H), 1.97 (s, 3H), 1.88 (d, J=6.9 Hz, 2H), 1.57 (dq, J=19.1, 5.2 Hz, 5H).
- 1H NMR (400 MHz, Chloroform-d) δ 8.56-8.46 (m, 2H), 7.69-7.62 (m, 1H), 7.24 (dd, J=7.6, 4.8 Hz, 1H), 5.45 (s, 1H), 3.80 (s, 2H), 2.67 (t, J=6.9 Hz, 2H), 2.14 (t, J=6.9 Hz, 2H), 1.98 (s, 2H), 1.86 (d, J=7.4 Hz, 2H), 1.56 (dq, J=11.7, 6.3 Hz, 3H), 1.22 (s, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.26 (s, 3H), 7.23 (d, J=7.6 Hz, 1H), 7.16 (s, 1H), 3.84 (d, J=11.6 Hz, 1H), 3.68 (s, 1H), 3.29 (d, J=10.6 Hz, 2H), 3.20 (d, J=4.5 Hz, 1H), 2.56 (d, J=12.9 Hz, 2H), 1.79 (s, 1H), 1.58-1.49 (m, 2H), 1.46 (s, 2H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.32 (d, J=4.5 Hz, 3H), 7.28-7.20 (m, 1H), 3.80 (s, 2H), 2.70 (t, J=6.3 Hz, 2H), 2.44 (t, J=6.3 Hz, 2H), 2.33 (t, J=5.2 Hz, 4H), 1.90 (s, 1H), 1.55 (t, J=5.7 Hz, 3H), 1.41 (p, J=5.8 Hz, 2H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.36-7.28 (m, 3H), 7.28-7.21 (m, 1H), 3.77 (d, J=1.9 Hz, 2H), 3.00 (t, J=10.0 Hz, 2H), 2.64 (t, J=7.5 Hz, 2H), 2.52 (t, J=12.1 Hz, 1H), 2.24 (t, J=11.3 Hz, 1H), 2.05 (s, 5H), 1.79 (d, J=13.2 Hz, 1H), 1.63 (d, J=13.4 Hz, 1H), 1.41 (dtd, J=21.0, 15.1, 13.7, 5.1 Hz, 4H), 1.04 (tt, J=13.0, 6.5 Hz, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.34-7.25 (m, 2H), 3.66 (s, 1H), 2.59-2.43 (m, 3H), 1.90 (dd, J=13.0, 3.4 Hz, 1H), 1.33 (p, J=6.9 Hz, 1H), 1.27-1.13 (m, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.70 (s, 1H), 7.56 (d, J=7.9 Hz, 1H), 7.31 (d, J=7.6 Hz, 1H), 7.10 (t, J=7.7 Hz, 1H), 3.62 (s, 2H), 2.44 (d, J=13.6 Hz, 1H), 2.44 (s, 2H), 2.05 (s, 1H), 1.63 (d, J=11.4 Hz, 5H), 1.29 (d, J=7.4 Hz, 3H), 1.15 (h, J=12.3 Hz, 3H), 0.83 (d, J=11.1 Hz, 2H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.35-7.27 (m, 1H), 7.23 (t, J=9.0 Hz, 1H), 4.45 (s, 1H), 3.79 (s, 1H), 3.39 (s, 1H), 2.64 (t, J=7.5 Hz, 1H), 1.68 (d, J=12.4 Hz, 2H), 1.40 (q, J=7.2 Hz, 1H), 1.29 (s, 1H), 1.17 (p, J=12.4 Hz, 1H), 0.90 (q, J=11.2 Hz, 1H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.33 (s, 1H), 7.27-7.16 (m, 3H), 3.76 (s, 2H), 2.62 (t, J=7.4 Hz, 2H), 1.72-1.60 (m, 5H), 1.40 (q, J=7.1 Hz, 2H), 1.34 (s, 2H), 1.33-1.22 (m, 1H), 1.25 (s, 1H), 1.19 (d, J=9.1 Hz, 1H), 1.20-1.09 (m, 1H), 0.93 (d, J=11.6 Hz, 1H), 0.88 (s, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 10.63 (s, 1H), 7.37 (d, J=7.7 Hz, 1H), 7.18 (s, 1H), 6.93 (d, J=7.2 Hz, 1H), 6.88 (td, J=7.4, 2.1 Hz, 1H), 6.36 (d, J=2.7 Hz, 1H), 4.00 (s, 2H), 2.61-2.52 (m, 2H), 2.53 (s, 1H), 2.02 (s, 2H), 1.67 (d, J=12.4 Hz, 5H), 1.37 (q, J=6.9 Hz, 3H), 1.18 (h, J=11.9, 11.2 Hz, 3H), 0.88 (t, J=11.2 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.18 (t, J=7.8 Hz, 1H), 6.99 (s, 1H), 6.90 (d, J=7.5 Hz, 1H), 6.79-6.72 (m, 1H), 3.78 (d, J=3.0 Hz, 5H), 2.62 (t, J=7.5 Hz, 2H), 1.69 (d, J=12.6 Hz, 5H), 1.46-1.38 (m, 2H), 1.32 (s, 1H), 1.18 (dt, J=22.3, 12.6 Hz, 3H), 0.93 (d, J=11.5 Hz, 1H), 0.88 (s, 1H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.74 (d, J=7.6 Hz, 1H), 7.44 (d, J=5.4 Hz, 1H), 7.40-7.24 (m, 4H), 4.09 (s, 2H), 2.68 (t, J=7.4 Hz, 2H), 1.69 (s, 1H), 1.52 (s, 2H), 1.43 (q, J=7.3 Hz, 2H), 1.33 (s, 1H), 1.18 (h, J=12.1 Hz, 3H), 0.89 (q, J=11.8 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.24-7.15 (m, 2H), 7.12 (d, J=12.2 Hz, 2H), 3.74 (s, 2H), 3.66 (s, 2H), 2.53 (d, J=6.7 Hz, 2H), 1.68 (d, J=13.2 Hz, 5H), 1.33 (s, 3H), 1.24 (s, 1H), 1.19 (d, J=12.4 Hz, 2H), 0.88 (s, 2H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.12 (t, J=7.7 Hz, 1H), 6.75 (dd, J=18.8, 10.6 Hz, 3H), 6.02 (s, 3H), 3.71 (s, 2H), 2.70 (t, J=7.9 Hz, 2H), 1.61 (s, 1H), 1.47 (q, J=7.4 Hz, 2H), 1.31-1.06 (m, 4H), 0.94-0.80 (m, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 10.82 (s, 2H), 7.23 (d, J=7.9 Hz, 2H), 7.16 (t, J=2.9 Hz, 2H), 6.97 (dd, J=9.7, 5.6 Hz, 2H), 6.90 (d, J=7.2 Hz, 2H), 6.45 (s, 2H), 3.94 (d, J=3.6 Hz, 4H), 2.60 (t, J=7.0 Hz, 4H), 1.68 (d, J=13.5 Hz, 11H), 1.39-1.31 (m, 6H), 1.23 (s, 1H), 1.20 (s, 5H), 1.17 (s, 1H), 1.10 (d, J=10.7 Hz, 1H), 0.88 (d, J=12.1 Hz, 5H).
- 1H NMR (400 MHz, DMSO-d6) δ 9.62 (s, 2H), 9.35 (s, 1H), 9.19 (d, J=10.5 Hz, 1H), 7.64-7.57 (m, 2H), 7.42 (d, J=5.9 Hz, 3H), 4.11 (p, J=8.8, 7.0 Hz, 2H), 3.18 (d, J=12.0 Hz, 2H), 3.05 (s, 2H), 2.84-2.74 (m, 1H), 2.16 (dq, J=14.1, 6.5 Hz, 1H), 2.00 (dq, J=14.3, 7.2 Hz, 1H), 1.71 (td, J=30.9, 23.6, 10.6 Hz, 4H), 1.50-1.32 (m, 2H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.26 (s, 1H), 7.10 (t, J=7.7 Hz, 1H), 6.69 (d, J=11.1 Hz, 2H), 6.58 (d, J=8.0 Hz, 1H), 3.70 (s, 2H), 3.64 (s, 2H), 2.64 (t, J=7.6 Hz, 2H), 1.40 (q, J=7.2 Hz, 2H), 1.29 (s, 1H), 1.24 (d, J=13.0 Hz, 1H), 1.16 (dd, J=21.0, 11.6 Hz, 2H), 0.91 (t, J=11.6 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 6.78 (d, J=7.6 Hz, 1H), 6.73 (td, J=7.6, 3.2 Hz, 1H), 6.67 (d, J=7.5 Hz, 1H), 5.94 (d, J=3.3 Hz, 2H), 3.64 (d, J=3.3 Hz, 2H), 2.51 (dd, J=8.4, 4.8 Hz, 3H), 1.67 (d, J=12.8 Hz, 5H), 1.32 (d, J=6.1 Hz, 3H), 1.23 (s, 1H), 1.21-1.09 (m, 2H), 0.89 (t, J=11.2 Hz, 2H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.31 (d, J=10.3 Hz, 1H), 7.25 (d, J=9.0 Hz, 1H), 4.69 (s, 1H), 3.78 (s, 1H), 2.65 (t, J=7.5 Hz, 1H), 1.41 (q, J=7.3 Hz, 1H), 1.32-1.21 (m, 1H), 1.16 (dd, J=21.4, 11.5 Hz, 1H), 0.90 (q, J=11.6 Hz, 1H).
- Synthesis of target compounds was carried out following the scheme below:
- Amine 1 (0.5 mmol), benzaldehyde 2 (0.55 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours, then mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C., 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated and dissolved in 0.5 ml of DMSO. The residue was purified using HPLC. Yield: 31-59%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.26 (p, J=6.9, 6.3 Hz, 4H), 7.18 (s, 1H), 6.90-6.85 (m, 1H), 6.82-6.73 (m, 2H), 5.95 (s, 2H), 3.66 (s, 2H), 2.61 (s, 2H), 1.83 (s, 1H), 0.74-0.63 (m, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 8.08-8.01 (m, 1H), 7.94-7.87 (m, 1H), 7.79 (d, J=8.1 Hz, 1H), 7.65 (d, J=7.1 Hz, 1H), 7.48 (dq, J=7.2, 3.6, 2.9 Hz, 3H), 7.31 (dt, J=14.8, 7.5 Hz, 4H), 7.21 (t, J=7.1 Hz, 1H), 5.45 (s, 2H), 5.43 (d, J=3.8 Hz, 0H), 3.79 (s, 2H), 2.86-2.78 (m, 1H), 2.69 (dd, J=12.2, 7.8 Hz, 1H), 2.31 (s, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.29 (d, J=4.5 Hz, 4H), 7.20 (p, J=4.1 Hz, 1H), 6.90 (dd, J=9.6, 3.1 Hz, 1H), 6.77 (dd, J=8.7, 3.1 Hz, 1H), 5.22 (s, 2H), 4.84 (s, 2H), 3.69 s, 2H), 2.67 (s, 4H), 2.13 (s, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.34-7.22 (m, 4H), 7.17 (t, J=7.2 Hz, 1H), 7.16-7.03 (m, 3H), 7.00 (d, J=6.4 Hz, 1H), 3.59 (d, J=7.1 Hz, 1H), 3.26 (dd, J=14.1, 5.2 Hz, 1H), 2.99 (s, 1H), 2.90-2.77 (m, 3H), 1.73 (s, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.29 (d, J=4.5 Hz, 4H), 7.20 (dt, J=8.7, 4.3 Hz, 1H), 7.03 (s, 1H), 6.88 (d, J=8.2 Hz, 1H), 6.63 (d, J=8.1 Hz, 1H), 4.46 (t, J=8.6 Hz, 2H), 3.69 (s, 2H), 3.11 (t, J=8.7 Hz, 2H), 2.68-2.59 (m, 4H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.32-7.21 (m, 4H), 7.17 (t, J=6.9 Hz, 1H), 3.74 (d, J=13.5 Hz, 1H), 3.68 (d, J=13.5 Hz, 1H), 2.99 (s, 1H), 2.64 (d, J=6.2 Hz, 1H), 2.58 (dd, J=21.1, 9.9 Hz, 2H), 2.39-2.20 (m, 5H), 2.18 (d, J=4.8 Hz, 1H), 2.18-2.09 (m, 1H), 1.99 (d, J=9.6 Hz, 1H), 1.90 (s, 1H), 1.60 (d, J=10.2 Hz, 1H), 1.11 (d, J=10.2 Hz, 1H), 0.91 (dt, J=11.3, 3.7 Hz, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 8.91 (dd, J=4.1, 1.9 Hz, 1H), 8.39-8.26 (m, 2H), 8.20 (d, J=10.1 Hz, 1H), 7.81 (d, J=8.3 Hz, 2H), 7.62 (d, J=6.8 Hz, 1H), 7.52 (dq, J=8.1, 4.9, 3.5 Hz, 3H), 7.40 (s, 2H), 7.28 (q, J=7.8, 7.4 Hz, 7H), 7.23-7.15 (m, 2H), 3.74 (s, 3H), 3.38 (t, J=7.4 Hz, 3H), 2.87 (t, J=7.4 Hz, 3H), 2.54 (s, 1H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.35-7.21 (m, 4H), 7.20 (s, 1H), 7.11 (t, J=7.4 Hz, 1H), 7.05 (td, J=7.3, 1.5 Hz, 1H), 7.00 (d, J=7.3 Hz, 1H), 3.83 (s, 2H), 2.71 (dd, J=12.2, 6.7 Hz, 1H), 2.67-2.54 (m, 2H), 2.46 (td, J=15.6, 14.7, 6.2 Hz, 1H), 2.14 (ddt, J=13.3, 6.4, 2.1 Hz, 1H), 1.75-1.61 (m, 2H), 1.45 (dq, J=9.2, 3.5, 2.5 Hz, 1H), 1.42-1.35 (m 1H.
- 1H NMR (400 MHz, DMSO-d6) δ 7.36-7.26 (m, 4H), 7.21 (t, J=6.9 Hz, 11H), 6.87-6.76 (m, 2H), 6.81 (s, 2H), 4.33-4.25 (m, 1H), 4.25 (d, J=7.1 Hz, 11H), 3.87 (dd, J=11.2, 7.4 Hz, 11H), 3.70 (s, 2H), 2.67 (t, J=7.0 Hz, 2H), 2.54 (s, OH), 2.25 (s, 1H), 1.80-1.69 (m, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.29 (d, J=4.4 Hz, 4H), 7.20 (dt, J=8.7, 4.3 Hz, 1H), 6.82 (d, J=2.1 Hz, 1H), 6.69 (d, J=2.1 Hz, 11H), 4.26 (ddd, J=20.7, 6.1, 3.1 Hz, 4H), 3.68 (s, 2H), 2.69-2.62 (m, 2H), 2.58 (s, 1H), 2.62-2.52 (m, 2H), 2.01 (s, 1H).
- 1H NMR (400 MHz, Chloroform-d) δ 8.17 (s, 1H), 7.47 (s, 1H), 7.35-7.25 (m, 2H), 7.25 (s, 1H), 7.25-7.16 (m, 1H), 7.05 (d, J=8.3 Hz, 1H), 6.50 (s, 1H), 3.82 (s, 2H), 2.95 (s, 4H).
- 1H NMR (400 MHz, DMSO-d6) δ 12.89 (s, 1H), 7.97 (s, 1H), 7.63 (d, J=8.3 Hz, 1H), 7.30 (t, J=6.9 Hz, 5H), 7.21 (s, 1H), 6.96 (d, J=8.3 Hz, 1H), 3.72 (s, 2H), 2.85 (t, J=7.2 Hz, 2H), 2.77 (s, 2H), 2.54 (s, 1H), 2.02 (s, 1H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.29 (dt, J=20.2, 6.9 Hz, 4H), 3.78 (d, J=2.4 Hz, 2H), 2.96-2.86 (m, 2H), 2.16 (s, 1H), 2.08 (d, J=15.8 Hz, 2H), 1.77-1.52 (m, 3H), 1.40-1.13 (m, 5H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.36-7.28 (m, 8H), 7.25 (d, J=6.5 Hz, 3H), 3.91 (dd, J=16.5, 12.8 Hz, 2H), 3.66 (d, J=12.8 Hz, 2H), 2.52 (tt, J=11.5, 6.2 Hz, 2H), 1.77 (s, 1H), 1.71 (s, 2H), 1.42-1.31 (m, 4H), 1.18 (dd, J=12.8, 6.3 Hz, 1H), 1.09 (dd, J=10.6, 6.1 Hz, 7H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.31 (p, J=6.9, 6.1 Hz, 2H), 7.25 (d, J=3.2 Hz, 1H), 4.25 (s, 1H), 3.79 (s, 1H), 2.64 (t, J=5.8 Hz, 1H), 2.54-2.41 (m, 2H), 2.27 (dd, J=11.2, 2.1 Hz, 1H), 1.90-1.79 (m, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.31-7.14 (m, 4H), 7.18-7.09 (m, 1H), 7.05 (d, J=6.8 Hz, 2H), 4.96 (s, 4H), 3.72 (s, 2H), 2.76 (s, 4H), 1.58 (s, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.25 (d, J=6.7 Hz, 4H), 7.16 (t, J=6.8 Hz, 1H), 4.43-4.32 (m, 1H), 4.26 (t, J=5.0 Hz, 1H), 3.69 (s, 2H), 2.04-1.94 (m, 1H), 1.85 (tdd, J=11.4, 5.7, 2.8 Hz, 1H), 1.75 (ddd, J=12.7, 9.0, 3.9 Hz, 1H), 1.65-1.53 (m, 2H), 1.48 (p, J=6.7, 6.0 Hz, 2H), 1.43 (s, 1H), 1.35 (td, J=9.7, 4.2 Hz, 1H), 0.86 (dd, J=11.4, 5.1 Hz, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.31-7.20 (m, 4H), 7.16 (dq, J=7.0, 4.5, 3.2 Hz, 1H), 3.76 (d, J=13.4 Hz, 1H), 3.64 (d, J=13.3 Hz, 1H), 2.65 (h, J=6.4 Hz, 1H), 1.64 (q, J=10.5, 8.6 Hz, 5H), 1.35 (ddd, J=16.2, 8.2, 4.9 Hz, 1H), 1.32-1.14 (m, 2H), 1.17-1.04 (m, 1H), 1.00 (d, J=6.2 Hz, 3H), 0.91-0.76 (m, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.31-7.17 (m, 4H), 7.16 (dq, J=9.6, 4.4, 3.1 Hz, 1H), 3.76 (d, J=13.3 Hz, 1H), 3.64 (d, J=13.3 Hz, 1H), 2.65 (h, J=6.3 Hz, 1H), 1.65 (t, J=6.6 Hz, 5H), 1.35 (ddd, J=15.6, 8.2, 4.9 Hz, 1H), 1.32-1.22 (m, 1H), 1.15 (ddd, J=26.6, 14.4, 4.6 Hz, 2H), 1.10-0.97 (m, 3H), 0.83 (dd, J=16.0, 6.9 Hz, 2H.
- 1H NMR (400 MHz, DMSO-d6) δ 7.30-7.20 (m, 3H), 7.16 (td, J=6.2, 2.9 Hz, 1H), 2.98 (s, 1H), 2.53-2.47 (m, 4H), 1.93 (s, 2H), 1.65 (q, J=12.4 Hz, 5H), 1.49 (d, J=2.9 Hz, 4H), 1.24 (t, J=8.1 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 9.41 (s, 2H), 7.58 (d, J=6.9 Hz, 2H), 7.42 (d, J=6.9 Hz, 3H), 6.75 (t, J=7.4 Hz, 2H), 6.67 (s, 1H), 6.39 (t, J=7.4 Hz, 1H), 5.49 (s, 1H), 4.13 (s, 2H), 3.24 (t, J=5.5 Hz, 2H), 3.01-2.93 (m, 2H), 2.85 (t, J=8.0 Hz, 2H), 2.66 (d, J=6.4 Hz, 2H), 1.77 (p, J=6.0, 5.5 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.28 (d, J=7.5 Hz, 2H), 7.24 (t, J=7.4 Hz, 2H), 7.16 (t, J=7.0 Hz, 1H), 6.99 (td, J=7.7, 6.9, 2.6 Hz, 1H), 6.93 (d, J=6.0 Hz, 2H), 6.61 (d, J=7.8 Hz, 1H), 3.81-3.67 (m, 2H), 2.82 (t, J=6.1 Hz, 2H), 2.69 (d, J=6.9 Hz, 2H), 2.54 (s, 1H), 1.86 (s, 2H), 1.91-1.73 (m, 1H), 1.71-1.61 (m, 1H), 1.32 (dt, J=13.2, 6.5 Hz, 1H), 1.08 (dd, J=8.9, 4.6 Hz, 1H), 0.61-0.54 (m, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.34-7.23 (m, 4H), 7.20 (s, 1H), 6.98 (d, J=7.3 Hz, 1H), 6.90 (d, J=7.5 Hz, 1H), 6.69 (t, J=7.4 Hz, 1H), 3.69 (s, 2H), 2.96 (s 2H) 263 (dt, J=11.9, 6.1 Hz, 4H), 2.54 (s, 1H), 2.01 (s, 1H), 1.36 (s, 6H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.37-7.24 (m, 7H), 7.23-7.09 (m, 5H), 7.06 (d, J=6.1 Hz, 1H), 3.82 (d, J=15.7 Hz, 2H), 3.69 (d, J=13.4 Hz, 2H), 3.16 (ddd, J=20.1, 14.0, 5.6 Hz, 2H), 2.84 (d, J=14.2 Hz, 2H), 2.75 (d, J=7.5 Hz, 1H), 2.66 (s, 1H), 2.54 (s, 1H), 1.99 (s, 1H), 1.90 (s, 1H), 1.12 (d, J=6.3 Hz, 2H), 1.05 (d, J=6.3 Hz, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 8.19 (dd, J=8.4, 1.5 Hz, 1H), 7.96 (d, J=8.5 Hz, 1H), 7.52-7.37 (m, 2H), 7.32-7.25 (m, 2H), 7.23 (dd, J=15.5, 7.6 Hz, 3H), 7.21-7.12 (m, 1H), 6.75 (d, J=7.8 Hz, 1H), 3.97 (s, 3H), 3.75 (s, 2H), 3.14 (t, J=7.4 Hz, 2H), 2.87 (q, J=8.0, 7.3 Hz, 2H), 1.68 (s, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.31 (dt, J=11.4, 7.0 Hz, 4H), 7.25-7.17 (m, 1H), 7.04 (d, J=8.4 Hz, 1H), 6.65 (dd, J=8.5, 2.7 Hz, 1H), 6.58 (d, J=2.6 Hz, 1H), 3.79-3.65 (m, 5H), 2.79 (dd, J=9.4, 4.8 Hz, 1H), 2.63 (dd, J=7.8, 4.5 Hz, 3H), 2.55 (d, J=10.1 Hz, 1H), 2.07 (s, 1H), 1.88 (q, J=6.1, 5.5 Hz, 1H), 1.68 (s, 2H), 1.60 (s, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.29 (t, J=6.6 Hz, 2H), 7.25 (d, J=7.7 Hz, 1H), 7.26-7.18 (m, 2H), 7.21-7.09 (m, 4H), 7.01 (ddd, J=12.0, 8.7, 5.9 Hz, 6H), 3.69 (d, J=13.5 Hz, 1H), 3.53 (d, J=13.5 Hz, 1H), 3.27-3.16 (m, 1H), 3.12 (td, J=6.5, 3.9 Hz, 1H), 3.06 (s, 1H), 2.99 (s, 2H), 2.86-2.77 (m, 1H), 2.69 (q, J=5.9 Hz, 3H), 2.54 (s, 0H), 2.01-1.79 (m, 3H), 1.77-1.52 (m, 2H), 1.46 (s, 1H), 1.16 (s, 1H), 1.07 (d, J=6.4 Hz, 3H), 0.82 (d, J=6.4 Hz, 2H).
- 1H NMR (400 MHz, Chloroform-d) δ 8.25 (s, 1H), 7.57 (d, J=8.0 Hz, 1H), 7.31 (d, J=7.6 Hz, 1H), 7.31-7.20 (m, 6H), 7.16 (t, J=2.8 Hz, 1H), 6.99 (d, J=8.1 Hz, 1H), 6.52 (t, J=2.7 Hz, 1H), 3.81 (s, 2H), 2.95 (d, J=3.2 Hz, 4H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.32 (d, J=2.0 Hz, 3H), 7.28-7.20 (m, 4H), 3.78 (d, J=3.0 Hz, 5H), 3.03-2.92 (m, OH), 2.74 (dt, J=9.9, 2.8 Hz, 2H), 2.62-2.49 (m, 6H), 2.46-2.39 (m, 2H), 2.36 (s, 6H), 2.37-2.30 (m, 1H), 2.28 (s, 1H), 2.21 (s, 3H), 2.00 (dd, J=20.7, 10.3 Hz, 1H), 1.86-1.74 (m, 4H), 1.63 (s, 2H), 1.58 (dd, J=5.1, 2.1 Hz, 1H), 1.57-1.49 (m, 2H), 1.45-1.37 (m, 2H), 1.16 (s, 3H), 1.07-0.96 (m, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 8.71 (d, J=2.1 Hz, 1H), 8.02 (s, 1H), 7.87 (d, J=8.5 Hz, 1H), 7.65 (s, 1H), 7.52 (d, J=8.6 Hz, 1H), 7.34-7.16 (m, 6H), 3.73 (s, 2H), 2.91 (t, J=6.9 Hz, 2H), 2.82 (t, J=7.0 Hz, 2H), 2.54 (s, 0H), 2.48 (s, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.30 (d, J=7.1 Hz, 4H), 7.21 (t, J=6.8 Hz, 1H), 7.05 (d, J=7.7 Hz, 1H), 6.98 (t, J=7.7 Hz, 1H), 6.83 (t, J=7.3 Hz, 1H), 6.76 (d, J=8.1 Hz, 1H), 4.29 (d, J=7.2 Hz, 1H), 3.69 (s, 2H), 3.16 (dd, J=13.1, 2.1 Hz, 1H), 2.97 (dd, J=13.1, 8.1 Hz, 1H), 2.68 (t, J=6.8 Hz, 2H), 2.17 (s, 1H), 1.84 (dp, J=19.9, 7.1 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 8.77 (d, J=4.4 Hz, 2H), 8.73 (s, 1H), 8.15 (d, J=8.4 Hz, 2H), 8.00 (d, J=8.5 Hz, 3H), 7.71 (dt, J=16.7, 7.1 Hz, 2H), 7.60 (t, J=7.8 Hz, 2H), 7.45-7.34 (m, 3H), 7.29 (q, J=7.6 Hz, 8H), 7.20 (s, 3H), 3.74 (s, 3H), 3.24 (t, J=7.4 Hz, 3H), 2.86 (q, J=7.8 Hz, 4H), 2.54 (s, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.28 (t, J=5.4 Hz, 6H), 7.24-7.13 (m, 1H), 7.03 (d, J=8.3 Hz, 1H), 3.69 (s, 2H), 2.71 (dp, J=10.3, 5.1, 4.2 Hz, 4H), 2.08 (s, 1H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.32 (d, J=4.4 Hz, 2H), 7.26 (s, 1H), 7.24 (s, 1H), 3.80 (s, 1H), 2.71 (t, J=6.3 Hz, 1H), 2.49 (t, J=6.4 Hz, 1H), 2.34 (t, J=5.7 Hz, 2H), 1.87 (s, 1H), 1.44 (t, J=5.9 Hz, 3H), 1.31 (s, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.31 (d, J=14.6 Hz, 1H), 7.24 (tt, J=7.9, 3.6 Hz, 8H), 7.19-7.13 (m, 2H), 6.32 (t, J=7.4 Hz, 1H), 6.18 (t, J=7.3 Hz, 2H), 6.04 (t, J=7.5 Hz, 1H), 3.70 (t, J=5.0 Hz, 2H), 3.65 (d, J=2.6 Hz, 2H), 2.56 (d, J=15.3 Hz, 3H), 2.47 (s, 7H), 2.23 (dd, J=11.3, 8.3 Hz, 1H), 2.14 (dd, J=11.3, 6.5 Hz, 1H), 1.78 (s, 1H), 1.71-1.61 (m, 2H), 1.53-1.33 (m, 4H), 1.31-1.14 (m, 3H), 1.03 (d, J=12.8 Hz, 1H), 0.93-0.85 (m, 1H), 0.79-0.71 (m, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.31-7.20 (m, 4H), 7.16 (t, J=6.8 Hz, 1H), 3.70 (s, 2H), 2.47 (td, J=11.3, 5.1 Hz, 3H), 1.81-1.61 (m, 2H), 1.63-1.54 (m, 1H), 1.58-1.48 (m, 6H), 1.46-1.38 (m, 2H), 1.38-1.27 (m, 1H), 1.04-0.95 (m, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.30 (d, J=4.4 Hz, 4H), 7.21 (h, J=4.4 Hz, 1H), 3.67 (s, 2H), 2.82 (d, J=7.0 Hz, 1H), 2.82-2.74 (m, 1H), 2.23 (ddd, J=12.8, 7.5, 4.9 Hz, 1H), 2.10-2.01 (m, 1H), 2.04-1.98 (m, 1H), 1.74-1.60 (m, 2H), 1.60-1.54 (m, 1H), 1.54-1.49 (m, 1H), 1.52-1.37 (m, 3H), 1.27-1.15 (m, 1H), 1.18-1.05 (m, 1H), 1.07-0.94 (m, 1H), 0.94 (d, J=6.9 Hz, 1H), 0.90 (t, J=5.9 Hz, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.29-7.20 (m, 4H), 7.16 (dd, J=7.7, 4.6 Hz, 1H), 3.73 (s, 2H), 2.54 (s, 1H), 1.86 (dd, J=7.0, 3.9 Hz, 1H), 1.58-1.44 (m, 9H), 1.15 (s, 2H), 0.30 (dd, J=7.1, 4.3 Hz, 1H), 0.08 (t, J=4.1 Hz, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.32-7.15 (m, 3H), 3.68 (s, 1H), 2.68-2.54 (m, 1H), 2.57-2.51 (m, 1H), 2.25-2.02 (m, 1H), 1.85 (q, J=6.1 Hz, 1H), 1.75-1.60 (m, 1H), 1.49 (tdt, J=14.0, 10.5, 5.0 Hz, 2H), 1.36 (tt, J=7.0, 3.6 Hz, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.37-7.26 (m, 4H), 7.21 (t, J=7.1 Hz, 1H), 7.16-6.97 (m, 5H), 3.77 (d, J=13.7 Hz, 1H), 3.70 (d, J=13.7 Hz, 1H), 2.86 (dd, J=9.5, 4.8 Hz, 1H), 2.67 (dq, J=10.2, 5.9, 5.3 Hz, 3H), 2.62-2.52 (m, 1H), 2.18 (s, 1H), 1.98-1.88 (m, 1H), 1.76-1.61 (m, 4H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.35-7.25 (m, 5H), 7.23 (dd, J=16.0, 13.7 Hz, 0H), 7.21 (s, 2H), 7.09 (d, J=4.7 Hz, 3H), 7.02 (s, 1H), 3.71 (s, 2H), 3.52 (s, 2H), 2.77 (d, J=6.1 Hz, 2H), 2.71-2.52 (m, 6H), 2.03 (s, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.31-7.17 (m, 4H), 7.16 (ddd, J=8.8, 5.7, 3.3 Hz, 1H), 7.03 (q, J=4.4, 3.6 Hz, 3H), 6.97-6.91 (m, 1H), 3.71 (d, J=3.2 Hz, 2H), 3.58 (d, J=14.9 Hz, 1H), 3.03-2.88 (m, 3H), 2.84-2.73 (m, 3H), 2.59 (ddt, J=26.1, 12.6, 7.4 Hz, 2H), 2.43 (dd, J=11.6, 5.0 Hz, 1H), 1.88 (s, 1H), 0.99 (d, J=6.6 Hz, 3H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.28 (dd, J=8.0, 5.7 Hz, 4H), 7.15-7.08 (m, 3H), 6.99 (d, J=5.8 Hz, 1H), 3.88 (d, J=13.6 Hz, 1H), 3.81-3.71 (m, 2H), 3.64 (d, J=14.9 Hz, 1H), 2.83 (s, 3H), 2.75 (s, 5H), 2.73-2.65 (m, 1H), 2.59 (q, J=11.0, 9.7 Hz, 1H), 1.70 (s, 1H), 1.21 (dt, J=14.0, 8.2 Hz, 1H), 0.93 (t, J=7.4 Hz, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.25 (d, J=6.5 Hz, 4H), 7.20-7.11 (m, 1H), 3.68 (s, 2H), 2.53 (d, J=6.5 Hz, 1H), 1.68 (d, J=12.5 Hz, 5H), 1.33 (t, J=5.8 Hz, 3H), 1.29-1.09 (m, 3H), 0.89 (t, J=11.3 Hz, 2H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.83 (dd, J=7.6, 5.0 Hz, 4H), 7.46 (td, J=5.6, 2.5 Hz, 3H), 7.38-7.22 (m, 2H), 4.90 (dd, J=8.7, 3.6 Hz, 1H), 3.92-3.80 (m, 2H), 3.03 (dd, J=12.2, 3.7 Hz, 1H), 2.85 (dd, J=12.2, 8.7 Hz, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.37-7.26 (m, 4H), 7.27 (s, 1H), 7.21 (t, J=7.0 Hz, 1H), 7.01-6.89 (m, 2H), 6.57-6.46 (m, 2H), 3.76 (d, J=13.7 Hz, 1H), 3.69 (d, J=13.7 Hz, 1H), 3.17-3.05 (m, 2H), 2.82 (d, J=9.5 Hz, 1H), 2.79 (s, 3H), 2.62 (dd, J=11.9, 4.9 Hz, 1H), 2.55 (d, J=9.3 Hz, 1H), 2.16 (s, 1H), 2.08-1.99 (m, 1H), 1.83 (dt, J=12.4, 5.8 Hz, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.32-7.21 (m, 4H), 7.16 (t, J=6.9 Hz, 1H), 7.06 (d, J=5.1 Hz, 1H), 6.67 (d, J=5.2 Hz, 1H), 3.74 (s, 2H), 3.47 (s, 2H), 2.85-2.59 (m, 8H), 2.54 (s, 0H), 1.93 (s, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.26 (q, J=7.9 Hz, 4H), 7.18 (d, J=7.0 Hz, 1H), 6.54 (s, 1H), 6.47 (s, 1H), 3.73 (s, 3H), 3.44 (s, 2H), 3.01 (s, 7H), 2.76-2.52 (m, 7H), 1.82 (s, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 9.46 (s, 2H), 7.59 (d, J=7.1 Hz, 2H), 7.48-7.36 (m, 3H), 6.96 (t, J=7.7 Hz, 1H), 6.88 (d, J=7.4 Hz, 1H), 6.71 (d, J=8.2 Hz, 1H), 6.51 (t, J=7.3 Hz, 1H), 4.17 (s, 2H), 3.62 (t, J=7.5 Hz, 2H), 3.24 (t, J=5.6 Hz, 2H), 3.04 (t, J=7.5 Hz, 2H), 2.66 (t, J=6.4 Hz, 2H), 1.85 (p, J=6.3, 5.8 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.30 (d, J=4.4 Hz, 4H), 7.21 (q, J=4.5 Hz, 1H), 6.79 (d, J=8.2 Hz, 2H), 6.64 (dd, J=7.9, 1.8 Hz, 1H), 5.94 (s, 2H), 3.70 (s, 2H), 2.72-2.59 (m, J=4.2 Hz, 4H).
- 1H NMR (400 MHz, DMSO-d6) δ 8.25 (d, J=8.4 Hz, 2H), 7.90 (dd, J=12.6, 7.2 Hz, 5H), 7.71 (t, J=7.8 Hz, 3H), 7.53 (t, J=7.5 Hz, 2H), 7.44 (d, J=8.6 Hz, 1H), 7.34-7.24 (m, 8H), 7.21 (d, J=7.0 Hz, 2H), 7.13 (s, 1H), 5.16 (s, OH), 4.49 (d, J=5.4 Hz, 1H), 3.73 (d, J=4.3 Hz, 3H), 3.08 (t, J=7.1 Hz, 4H), 2.95 (q, J=9.1, 7.1 Hz, 4H), 2.54 (s, 1H), 2.33 (s, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.64-7.57 (m, 1H), 7.43-7.12 (m, 4H), 4.10 (s, 1H), 3.13-2.99 (m, 2H).
- Synthesis of compounds was carried out according to the scheme below:
- Amine 1 (0.5 mmol) and compound 2 (0.55 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours, then mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C., 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated and dissolved in 0.5 ml of DMSO. The residue was purified using HPLC. Yield: 42-74%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.32-7.19 (m, 4H), 7.15 (t, J=7.1 Hz, 1H), 3.94-3.77 (m, 1H), 3.80-3.70 (m, 2H), 3.65 (dd, J=13.2, 7.1 Hz, 1H), 3.63-3.55 (m, 1H), 2.73 (dh, J=10.0, 3.3 Hz, 1H), 1.93 (dtd, J=11.3, 6.7, 5.6, 3.4 Hz, 1H), 1.88-1.80 (m, 1H), 1.79 (ddd, J=12.5, 6.1, 3.0 Hz, 1H), 1.68-1.31 (m, 3H), 1.05 (dd, J=10.4, 6.2 Hz, 3H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.26 (s, 2H), 3.89 (d, J=15.7 Hz, 4H), 3.30 (t, J=11.7 Hz, 2H), 2.83 (t, J=7.7 Hz, 2H), 1.45 (s, 1H), 1.23 (d, J=12.8 Hz, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.29 (d, J=4.4 Hz, 4H), 7.28-7.17 (m, 1H), 3.77 (d, J=13.8 Hz, 1H), 3.70 (d, J=13.9 Hz, 1H), 2.64-2.57 (m, 1H), 2.50-2.42 (m, 1H), 2.26-2.11 (m, 4H), 2.06 (s, 3H), 1.97 (s, 1H), 0.92 (d, J=6.2 Hz, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.27 (dd, J=12.5, 5.6 Hz, 5H), 7.21 (d, J=7.2 Hz, 5H), 7.08 (t, J=6.8 Hz, 4H), 6.83 (d, J=8.1 Hz, 4H), 3.81-3.72 (m, 1H), 3.71 (s, 6H), 3.67 (s, 1H), 3.60 (d, J=14.4 Hz, 2H), 3.26 (s, 1H), 2.78-2.70 (m, 1H), 2.64 (s, 3H), 1.59 (s, 2H), 1.21 (d, J=6.8 Hz, 2H), 1.14 (d, J=7.0 Hz, 3H), 0.88 (d, J=6.2 Hz, 3H), 0.80 (d, J=6.1 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.31-7.20 (m, 4H), 7.20-7.12 (m, 1H), 3.84-3.73 (m, 2H), 3.64 (d, J=13.4 Hz, 1H), 3.25 (tdd, J=11.7, 5.5, 2.2 Hz, 2H), 2.66 (h, J=6.4 Hz, 1H), 1.64 (dqd, J=11.3, 7.3, 3.4 Hz, 1H), 1.54-1.42 (m, 2H), 1.36 (dt, J=13.7, 6.8 Hz, 1H), 1.26-1.00 (m, 6H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.30-7.21 (m, 4H), 7.16 (ddd, J=8.7, 5.3, 2.3 Hz, 1H), 3.67 (s, 2H), 2.43 (t, J=7.2 Hz, 2H), 2.32 (h, J=7.9 Hz, 1H), 2.02 (ddt, J=15.2, 11.4, 5.1 Hz, 2H), 1.92-1.79 (m, 1H), 1.83-1.73 (m, 1H), 1.67-1.49 (m, 4H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.26 (dt, J=14.8, 7.5 Hz, 4H), 7.16 (t, J=7.1 Hz, 1H), 3.82-3.54 (m, 5H), 3.15 (td, J=7.8, 5.8 Hz, 1H), 2.62-2.51 (m, 1H), 2.53 (s, 0H), 2.28 (hept, J=7.4 Hz, 1H), 1.95 (dqd, J=19.2, 7.5, 4.5 Hz, 1H), 1.57-1.18 (m, 2H), 1.05 (dd, J=6.2, 3.5 Hz, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.43-7.23 (m, 4H), 7.19 (t, J=7.0 Hz, 1H), 3.85 (s, 2H), 1.28 (tt, J=8.3, 5.2 Hz, 1H), 0.38 (ddd, J=14.4, 7.4, 3.0 Hz, 3H), 0.23 (d, J=3.8 Hz, 1H), 0.22 (d, J=4.3 Hz, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.34-7.17 (m, 4H), 7.20-7.11 (m, 1H), 2.53 (dd, J=7.6, 4.9 Hz, 1H), 2.40 (dq, J=15.7, 7.8 Hz, 1H), 2.06-1.94 (m, 2H), 1.93-1.70 (m, 2H), 1.66-1.50 (m, 3H), 1.34 (dt, J=13.7, 7.0 Hz, 1H), 0.98 (d, J=6.2 Hz, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.34-7.21 (m, 4H), 7.21-7.11 (m, 1H), 3.76 (d, J=13.4 Hz, 1H), 3.68 (d, J=13.4 Hz, 1H), 2.69 (p, J=6.3 Hz, 1H), 2.30 (s, 5H), 1.36-1.17 (m, 1H), 1.07 (d, J=6.3 Hz, 3H), 0.76-0.64 (m, 1H), 0.45-0.36 (m, 2H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.41-7.28 (m, 4H), 7.24 (dt, J=9.0, 2.7 Hz, 1H), 3.91 (d, J=13.2 Hz, 1H), 3.70 (d, J=13.2 Hz, 1H), 2.55-2.43 (m, 1H), 1.84 (dt, J=13.6, 7.7 Hz, 2H), 1.77-1.66 (m, 1H), 1.65-1.45 (m, 4H), 1.24-1.13 (m, 2H), 1.10 (d, J=6.3 Hz, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.34-7.24 (m, 2H), 7.24 (t, J=7.4 Hz, 2H), 7.16 (dq, J=9.4, 4.4, 3.1 Hz, 1H), 3.76 (d, J=13.3 Hz, 1H), 3.65 (d, J=13.3 Hz, 1H), 2.64-2.52 (m, 1H), 1.87 (dp, J=15.5, 7.7, 6.9 Hz, 1H), 1.71 (qd, J=10.1, 9.5, 3.7 Hz, 2H), 1.65-1.40 (m, 5H), 1.25 (dt, J=13.5, 6.9 Hz, 1H), 1.10-0.97 (m, 4H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.37-7.21 (m, 3H), 3.89 (t, J=7.7 Hz, 1H), 3.84 (td, J=8.2, 4.7 Hz, 1H), 3.79 (s, 2H), 3.73 (q, J=7.8 Hz, 1H), 3.33 (t, J=7.8 Hz, 1H), 2.65 (q, J=7.1 Hz, 2H), 2.24 (p, J=7.5 Hz, 1H), 2.09-1.96 (m, 1H), 1.65-1.44 (m, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.42 (s, 1H), 7.32-7.25 (m, 4H), 7.20 (d, J=7.7 Hz, 2H), 3.75 (s, 3H), 3.72 (q, J=13.5 Hz, 2H), 2.75-2.63 (m, 1H), 2.58-2.50 (m, 2H), 2.34 (dd, J=14.1, 7.0 Hz, 1H), 0.94 (d, J=6.2 Hz, 3H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.32 (dd, J=4.4, 2.2 Hz, 6H), 7.27-7.20 (m, 2H), 3.86-3.74 (m, 1H), 3.78 (s, 2H), 2.65-2.44 (m, 2H), 2.33 (dd, J=11.5, 6.9 Hz, 1H), 2.17 (d, J=12.2 Hz, 2H), 2.05 (s, 1H), 1.65-1.59 (m, 3H), 1.45-1.35 (m, 1H), 1.34-1.10 (m, 3H), 1.04 (dd, J=22.7, 11.6 Hz, 2H), 0.66-0.57 (m, 0H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.27 (d, J=5.8 Hz, 4H), 7.23-7.17 (m, 1H), 6.84 (d, J=8.2 Hz, 1H), 6.77 (d, J=2.0 Hz, 1H), 6.70 (dd, J=8.2, 2.0 Hz, 1H), 3.74-3.64 (m, 9H), 2.80 (q, J=7.0 Hz, 1H), 2.59 (qd, J=11.4, 7.1 Hz, 2H), 2.53 (s, 1H), 1.76 (s, 1H), 1.17 (d, J=6.9 Hz, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.59 (d, J=2.3 Hz, 1H), 7.27 (d, J=4.5 Hz, 4H), 7.20 (q, J=5.3, 4.7 Hz, 1H), 5.97 (d, J=2.3 Hz, 1H), 4.39 (p, J=6.7 Hz, 1H), 3.75 (d, J=13.5 Hz, 1H), 3.67 (d, J=13.5 Hz, 1H), 2.80 (q, J=6.3 Hz, 1H), 2.65 (dd, J=14.0, 6.1 Hz, 1H), 1.36 (d, J=6.7 Hz, 6H), 1.32 (s, 0H), 0.98 (d, J=6.2 Hz, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.34-7.17 (m, 10H), 7.21-7.16 (m, 1H), 3.77 (d, J=6.9 Hz, 2H), 2.79 (s, 2H), 1.81 (t, J=7.0 Hz, 1H), 0.52 (d, J=11.8 Hz, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.34 (d, J=7.5 Hz, 2H), 7.29 (t, J=7.5 Hz, 2H), 7.20 (t, J=7.2 Hz, 1H), 7.10 (d, J=8.1 Hz, 2H), 6.83 (d, J=8.1 Hz, 2H), 3.73 (d, J=9.7 Hz, 5H), 2.64 (s, 2H), 1.43 (s, 1H), 1.00 (s, 5H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.34-7.21 (m, 4H), 7.19 (s, 1H), 7.15 (tt, J=5.6, 2.9 Hz, 1H), 3.79-3.69 (m, 1H), 3.61 (d, J=13.5 Hz, 1H), 3.07 (s, 3H), 2.76 (h, J=6.2 Hz, 1H), 2.04 (p, J=10.6 Hz, 2H), 1.88-1.77 (m, 3H), 1.77-1.63 (m, 1H), 1.62-1.48 (m, 2H), 1.04 (d, J=6.2 Hz, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.28 (q, J=7.8, 7.3 Hz, 5H), 7.23 (d, J=13.1 Hz, 2H), 7.19 (s, 1H), 6.84 (d, J=8.3 Hz, 2H), 6.77 (s, 1H), 6.69 (d, J=8.9 Hz, 2H), 3.78 (d, J=14.0 Hz, 1H), 3.70 (d, J=6.9 Hz, 9H), 3.61 (d, J=15.6 Hz, 1H), 2.66 (s, 3H), 2.54 (s, 1H), 1.66 (s, 2H), 1.22 (d, J=5.9 Hz, 2H), 1.14 (d, J=6.9 Hz, 2H), 0.89 (t, J=7.4 Hz, 2H), 0.83 (d, J=5.3 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.33-7.12 (m, 8H), 7.10-6.98 (m, 4H), 3.75 (s, 2H), 2.64 (dd, J=12.2, 6.2 Hz, 1H), 2.57-2.47 (m, 2H), 1.70 (dt, J=9.2, 4.9 Hz, 1H), 1.30-1.19 (m, 1H), 0.83 (ddd, J=13.9, 9.5, 4.9 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.30-7.19 (m, 4H), 7.15 (t, J=7.1 Hz, 1H), 3.56 (t, J=4.6 Hz, 4H), 3.00 (s, 2H), 2.54 (dd, J=5.6, 3.4 Hz, 4H), 2.42 (s, 1H), 2.27 (s, 2H), 1.47 (s, 1H), 1.05 (s, 5H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.94 (d, J=2.4 Hz, 1H), 7.50 (dd, J=8.5, 2.4 Hz, 1H), 7.28 (d, J=4.5 Hz, 4H), 7.20 (q, J=4.4 Hz, 1H), 6.72 (d, J=8.4 Hz, 1H), 3.78 (d, J=23.2 Hz, 4H), 3.70 (d, J=13.6 Hz, 1H), 2.71 (ddt, J=18.8, 13.3, 6.0 Hz, 2H), 2.45 (dd, J=13.2, 6.7 Hz, 1H), 1.87 (s, 1H), 0.92 (d, J=6.1 Hz, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.29 (ddt, J=11.3, 8.2, 5.1 Hz, 4H), 7.20 (d, J=7.5 Hz, 1H), 3.83-3.65 (m, 2H), 3.20 (t, J=6.9 Hz, 1H), 3.12 (s, 1H), 2.54 (s, 1H), 2.17-2.01 (m, 1H), 2.01-1.81 (m, 1H), 1.13-0.95 (m, 4H), 0.96 (s, 1H), 0.35 (ddq, J=26.9, 8.7, 5.1 Hz, 1H), 0.13 (dddd, J=26.6, 18.0, 8.5, 4.4 Hz, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 8.46 (d, J=4.9 Hz, 1H), 7.67 (td, J=7.6, 2.0 Hz, 1H), 7.34-7.21 (m, 5H), 7.19 (dd, J=10.7, 4.7 Hz, 3H), 3.76 (d, J=13.6 Hz, 1H), 3.68 (d, J=13.8 Hz, 1H), 3.00-2.92 (m, 2H), 2.90 (d, J=7.0 Hz, 1H), 2.64 (dd, J=12.7, 6.7 Hz, 1H), 2.07 (s, 1H), 0.96 (d, J=6.0 Hz, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.38-7.24 (m, 4H), 7.21 (t, J=7.1 Hz, 1H), 7.08 (ddd, J=14.2, 7.1, 2.8 Hz, 3H), 7.02 (d, J=8.9 Hz, 1H), 3.76 (dd, J=17.5, 3.8 Hz, 2H), 2.54 (s, 1H), 2.13 (dt, J=14.5, 7.2 Hz, 1H), 2.02 (s, 1H), 1.69 (dt, J=8.6, 5.1 Hz, 1H), 1.11 (t, J=5.8 Hz, 3H), 1.00-0.84 (m, 2H), 0.77 (ddt, J=20.2, 9.0, 5.0 Hz, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 9.62 (s, 1H), 9.06 (s, 2H), 7.66-7.59 (m, 2H), 7.47-7.36 (m, 3H), 4.06 (d, J=13.1 Hz, 1H), 3.97 (d, J=13.0 Hz, 1H), 2.89 (dt, J=13.0, 6.4 Hz, 1H), 1.35 (d, J=6.4 Hz, 3H), 1.08 (d, J=17.4 Hz, 6H), 0.95 (s, 3H), 0.88 (s, 3H), 0.54 (d, J=10.6 Hz, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 9.27 (s, 3H), 8.88 (s, 3H), 7.63 (dd, J=6.5, 3.2 Hz, 5H), 7.42 (d, J=6.5 Hz, 8H), 4.24-4.15 (m, 3H), 4.09 (dq, J=13.8, 7.5, 6.8 Hz, 3H), 3.16 (s, 1H), 2.97 (s, 1H), 2.54 (s, 1H), 2.04 (s, 3H), 1.87 (dt, J=11.8, 6.0 Hz, 2H), 1.69 (d, J=12.7 Hz, 2H), 1.60 (d, J=12.5 Hz, 3H), 1.48 (s, 2H), 1.41 (s, 2H), 1.41 (d, J=12.6 Hz, 2H), 1.29-1.20 (m, 1H), 1.23-1.15 (m, 7H), 1.03 (td, J=12.7, 4.7 Hz, 1H), 0.97 (s, 2H), 0.95 (s, 2H), 0.93 (d, J=6.6 Hz, 0H), 0.86 (dq, J=13.5, 6.6 Hz, 10H), 0.64 (tq, J=12.2, 7.3, 6.8 Hz, 3H), 0.50 (q, J=12.0 Hz, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.57-7.46 (m, 5H), 7.26 (d, J=4.5 Hz, 4H), 7.19 (q, J=4.5 Hz, 1H), 3.77 (d, J=13.7 Hz, 1H), 3.70 (d, J=13.8 Hz, 1H), 2.82 (ddd, J=18.5, 12.6, 6.1 Hz, 2H), 2.62 (dd, J=12.2, 5.7 Hz, 1H), 2.22 (s, 1H), 0.95 (d, J=5.8 Hz, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 8.70 (d, J=4.9 Hz, 2H), 7.32 (t, J=4.9 Hz, 1H), 7.26 (d, J=5.5 Hz, 4H), 7.19 (d, J=5.5 Hz, 1H), 3.79-3.65 (m, 2H), 3.11 (ddd, J=22.8, 12.9, 6.2 Hz, 2H), 2.79 (dd, J=12.9, 6.7 Hz, 1H), 2.54 (s, 1H), 2.13 (s, 1H), 1.00 (d, J=6.1 Hz, 3H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.36-7.19 (m, 6H), 3.90-3.79 (m, 4H), 3.77 (s, 4H), 3.34 (ddd, J=11.0, 9.0, 4.3 Hz, 2H), 3.05 (t, J=10.6 Hz, 2H), 2.71-2.56 (m, 4H), 1.88-1.78 (m, 2H), 1.72-1.53 (m, 4H), 1.46-1.23 (m, 3H), 1.23-1.07 (m, 1H), 1.13 (s, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 8.66 (s, 1H), 7.27 (d, J=4.4 Hz, 4H), 7.19 (dt, J=8.9, 4.3 Hz, 1H), 6.78 (s, 1H), 3.89 (s, 3H), 3.75 (d, J=13.6 Hz, 1H), 3.69 (d, J=13.6 Hz, 1H), 3.00 (p, J=6.4 Hz, 1H), 2.83 (dd, J=13.2, 6.2 Hz, 1H), 2.62-2.52 (m, 1H), 2.09 (s, 1H), 0.97 (d, J=6.3 Hz, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 8.02 (d, J=5.2 Hz, 1H), 7.28 (d, J=4.4 Hz, 4H), 7.20 (q, J=4.4 Hz, 1H), 6.82-6.76 (m, 1H), 6.60 (s, 1H), 3.81 (s, 3H), 3.76 (d, J=14.1 Hz, 1H), 3.70 (d, J=13.8 Hz, 1H), 2.83 (q, J=6.3 Hz, 1H), 2.76 (dd, J=12.9, 5.8 Hz, 1H), 2.54 (s, 1H), 2.46 (dd, J=12.8, 7.0 Hz, 1H), 1.91 (s, 1H), 0.93 (d, J=6.1 Hz, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.38-7.15 (m, 7H), 7.09 (dt, J=22.5, 6.8 Hz, 3H), 3.79 (d, J=6.3 Hz, 1H), 3.74 (d, J=5.1 Hz, 1H), 2.13 (dq, J=13.9, 6.8 Hz, 1H), 2.04 (s, 1H), 1.71 (ddt, J=35.4, 9.4, 5.0 Hz, 1H), 1.11 (t, J=7.0 Hz, 3H), 1.03-0.88 (m, 1H), 0.92-0.69 (m, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.35-7.24 (m, 4H), 7.19 (t, J=7.2 Hz, 1H), 3.81 (d, J=13.7 Hz, 1H), 3.54 (d, J=13.7 Hz, 1H), 2.54 (s, 2H), 2.03 (s, 1H), 1.51-1.43 (m, 8H), 1.40 (s, 2H), 1.31 (s, 1H), 1.26 (s, 4H), 0.86 (d, J=6.5 Hz, 3H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.39-7.28 (m, 4H), 7.28-7.19 (m, 1H), 5.34 (d, J=3.1 Hz, 1H), 3.89-3.77 (m, 2H), 3.17 (dd, J=5.2, 2.8 Hz, 1H), 2.16 (p, J=6.8 Hz, 1H), 2.07-1.94 (m, 2H), 1.93-1.81 (m, 1H), 1.65-1.52 (m, 2H), 1.37 (s, 2H), 0.99 (d, J=6.8 Hz, 5H), 0.98-0.83 (m, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.31-7.20 (m, 8H), 7.15 (t, J=7.1 Hz, 2H), 3.81 (d, J=13.2 Hz, 1H), 3.72 (d, J=13.3 Hz, 1H), 3.61 (dd, J=27.8, 13.3 Hz, 2H), 3.00 (s, 1H), 2.72-2.58 (m, 2H), 1.73-1.62 (m, 10H), 1.54 (d, J=12.7 Hz, 1H), 1.39-1.26 (m, 2H), 1.21 (s, 3H), 1.14 (dddd, J=21.6, 16.3, 10.8, 7.7 Hz, 6H), 1.06-0.84 (m, 8H), 0.80 (dd, J=21.9, 6.6 Hz, 6H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.35-7.24 (m, 2H), 3.69-3.61 (m, 2H), 3.60-3.53 (m, 1H), 2.79 (q, J=5.4, 4.5 Hz, 2H), 2.46 (s, 1H), 1.74 (p, J=5.9 Hz, 1H), 1.65 (s, 1H), 1.01 (s, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.29 (ddt, J=11.3, 8.2, 5.1 Hz, 4H), 7.20 (d, J=7.5 Hz, 1H), 3.83-3.65 (m, 2H), 3.20 (t, J=6.9 Hz, 1H), 3.12 (s, 1H), 2.54 (s, 1H), 2.17-2.01 (m, 1H), 2.01-1.81 (m, 1H), 1.13-0.95 (m, 4H), 0.96 (s, 1H), 0.35 (ddq, J=26.9, 8.7, 5.1 Hz, 1H), 0.13 (dddd, J=26.6, 18.0, 8.5, 4.4 Hz, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.32-7.11 (m, 3H), 3.63 (s, 1H), 1.74 (ddd, J=13.2, 7.3, 3.2 Hz, 1H), 1.70-1.52 (m, 3H), 1.45 (q, J=11.5, 10.5 Hz, 2H), 1.37-1.22 (m, 2H), 1.08 (s, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.63 (d, J=7.8 Hz, 2H), 7.44 (d, J=7.9 Hz, 2H), 7.35 (d, J=7.4 Hz, 2H), 7.29 (t, J=7.5 Hz, 2H), 7.20 (t, J=7.2 Hz, 1H), 3.76 (d, J=7.5 Hz, 2H), 2.80 (s, 2H), 1.60 (t, J=7.6 Hz, 1H), 1.03 (s, 5H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.65 (d, J=7.9 Hz, 2H), 7.52 (d, J=7.8 Hz, 2H), 7.26 (d, J=4.4 Hz, 4H), 7.19 (td, J=6.7, 5.0, 3.0 Hz, 1H), 3.77 (d, J=4.9 Hz, 2H), 2.86 (s, 2H), 1.89 (s, 1H), 0.56 (dt, J=11.5, 2.1 Hz, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.35-7.22 (m, 6H), 7.26-7.15 (m, 1H), 7.11 (t, J=8.9 Hz, 2H), 3.75 (d, J=4.0 Hz, 2H), 2.76 (s, 2H), 2.54 (s, 0H), 1.83 (s, 1H, 0.52 (dt, J=14.7, 2.0 Hz, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.35-7.25 (m, 4H), 7.24-7.15 (m, 1H), 3.69 (s, 2H), 2.54 (s, 0H), 2.21 (s, 2H), 1.78 (s, 1H), 1.50-1.35 (m, 6H), 1.36 (s, 3H), 1.27-1.16 (m, 2H), 0.83 (s, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.31-7.23 (m, 4H), 7.23 (d, J=7.6 Hz, 2H), 7.20-7.11 (m, 1H), 3.77-3.61 (m, 3H), 2.53 (d, J=4.2 Hz, 1H), 1.73 (s, 1H), 1.70 (dddt, J=22.8, 9.6, 6.3, 3.0 Hz, 3H), 1.62-1.39 (m, 6H), 1.42-1.33 (m, 1H), 1.36-1.12 (m, 2H), 0.92 (d, J=6.4 Hz, 4H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.30 (d, J=6.6 Hz, 4H), 7.20 (s, 1H), 3.66 (s, 2H), 2.54 (s, 1H), 2.45 (dd, J=11.4, 5.7 Hz, 1H), 2.25 (dd, J=11.5, 7.6 Hz, 1H), 1.86 (s, 1H), 1.67 (d, J=12.4 Hz, 2H), 1.60 (d, J=11.8 Hz, 1H), 1.51 (d, J=11.9 Hz, 2H), 1.46-1.36 (m, 1H), 1.29 (dt, J=11.7, 3.8 Hz, 1H), 1.22-1.02 (m, 2H), 1.06-0.92 (m, 1H), 0.81 (d, J=6.9 Hz, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.30-7.20 (m, 8H), 7.16 (t, J=6.8 Hz, 2H), 2.53 (d, J=7.0 Hz, 3H), 1.88-1.74 (m, 2H), 1.78-1.67 (m, 4H), 1.65-1.51 (m, 3H), 1.55 s, 3H), 1.47 (dq, J=14.5, 7.3 Hz, 7H), 1.14-1.01 (m, 4H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.29 (s, 8H), 3.48 (s, 1H) 1.25 (s, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 9.61 (s, 2H), 8.82 (s, 2H), 7.64-7.57 (m, 3H), 7.48-7.36 (m, 5H), 4.14 (d, J=16.7 Hz, 4H), 2.54 (s, 2H), 2.38 (s, 2H), 1.33 (d, J=6.7 Hz, 4H), 1.08 (s, 4H), 0.55 (ddt, J=19.4, 10.4, 5.2 Hz, 3H), 0.34 (dq, J=9.7, 5.8, 5.4 Hz, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.32-7.21 (m, 4H), 7.17 (t, J=6.9 Hz, 1H), 4.10-4.05 (m, 1H), 3.76-3.64 (m, 2H), 3.25 (s, 1H), 2.54 (dd, J=11.4, 3.0 Hz, 1H), 2.41 (dd, J=11.6, 8.6 Hz, 1H), 1.79 (d, J=12.7 Hz, 1H), 1.70 (s, 3H), 1.67-1.54 (m, 2H), 1.24 (s, 1H), 1.20-1.14 (m, 2H), 1.13 (d, J=9.2 Hz, 1H), 1.06-0.89 (m, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.22 (dd, J=8.8, 5.7 Hz, 6H), 7.18-7.09 (m, 4H), 4.21 (d, J=5.5 Hz, 1H), 3.41-3.32 (m, 1H), 3.24 (dt, J=10.6, 5.0 Hz, 1H), 3.02 (s, 2H), 2.79-2.66 (m, 2H), 2.65 (dd, J=12.8, 7.1 Hz, 1H), 1.76 (s, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.26-7.11 (m, 10H), 4.22 (s, 1H), 3.75 (s, 2H), 3.36 (s, 1H), 2.79-2.62 (m, 3H), 1.76 (s, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.31 (d, J=4.4 Hz, 6H), 7.18 (s, 3H), 7.25-7.07 (m, 7H), 6.98 (d, J=7.2 Hz, 3H), 3.75 (d, J=7.3 Hz, 2H), 3.68-3.55 (m, 2H), 3.42-3.29 (m, 3H), 3.25 (s, 1H), 2.95 (s, 1H), 2.28 (s, 2H), 2.17 (ddd, J=21.2, 10.2, 4.2 Hz, 4H), 1.89 (t, J=9.2 Hz, 1H), 1.68 (s, 1H), 1.24 (s, 2H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.34 (s, 1H), 7.26 (s, 1H), 4.03 (d, J=13.3 Hz, 1H), 3.82 (d, J=13.3 Hz, 1H), 3.09 (s, 1H), 1.69 (d, J=13.0 Hz, 1H), 1.46 (d, J=11.4 Hz, 1H), 1.42 (s, 3H), 1.29 (s, 1H), 1.13 (d, J=10.6 Hz, 2H), 0.95 (d, J=11.6 Hz, 1H), 0.73 (s, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.25 (d, J=6.6 Hz, 4H), 7.17 (d, J=6.9 Hz, 1H), 3.69 (s, 2H), 1.73 (s, 1H), 1.54 (s, 1H), 1.42 (s, 2H), 1.34 (q, J=8.1 Hz, 2H), 1.30-1.22 (m, 1H), 0.89 (d, J=6.2 Hz, 1H), 0.83 (d, J=7.1 Hz, 2H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.31 (s, 3H), 7.30-7.18 (m, 2H), 3.77 (s, 3H), 2.62 (q, J=7.9 Hz, 3H), 1.75-1.59 (m, 1H), 1.66 (s, 2H), 1.57-1.12 (m, 7H), 1.09 (p, J=5.8, 5.2 Hz, 1H), 0.85 (dd, J=10.5, 6.7 Hz, 4H).
- 1H NMR (400 MHz,) δ 11.47 (d, J=4.0 Hz, 10H), 7.48 (d, J=7.6 Hz, 2H), 7.44 (t, J=7.6 Hz, 3H), 4.52 (dd, J=13.3, 4.1 Hz, 1H), 4.44-4.36 (m, 1H), 4.25-4.19 (m, 1H), 1.93 (t, J=6.9 Hz, 2H), 1.74 (d, J=12.7 Hz, 3H), 1.68 (s, 2H), 1.61 (d, J=4.6 Hz, 0H), 1.44 (s, 2H), 1.25 (s, 1H), 1.16 (s, 3H), 0.93 (s, 2H).
-
- Compound 1 (0.22 ml) was added to a suspension of 2-OH-benzaldehyde 2 (0.17 g) and potassium carbonate (0.20 g) in DMF (5 ml), and the mixture was stirred at 90° C. for 1 hour. The mixture was allowed to cool to room temperature, and neutralized with 1N hydrochloric acid. After extraction with ethyl acetate, the organic layer was washed with saturated salt water, dried over anhydrous sodium sulfate, and concentrated. The concentrate was purified by silica gel column chromatography (n-hexane/ethyl acetate=4/1). Yield: 23-39%.
- Amine 4 (0.5 mmol), aldehyde 3 (0.55 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours, then mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C., 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated and dissolved in 0.5 ml of DMSO. The
residue 5 was purified using HPLC. Yield: 23-38%. - 1H NMR (400 MHz, Chloroform-d) δ 7.24 (d, J=17.8 Hz, 1H), 6.97 (t, J=7.5 Hz, 1H), 6.84 (d, J=8.1 Hz, 1H), 5.97 (s, 1H), 5.42 (s, 1H), 4.97 (dq, J=9.4, 4.7 Hz, 1H), 4.17 (qd, J=10.2, 4.3 Hz, 2H), 3.79 (d, J=6.2 Hz, 3H), 3.62 (dd, J=8.7, 5.6 Hz, 1H), 3.56 (s, 1H), 2.65 (t, J=7.0 Hz, 2H), 2.13 (t, J=7.2 Hz, 2H), 1.95 (s, 2H), 1.80 (d, J=6.6 Hz, 2H), 1.54 (td, J=11.6, 5.9 Hz, 4H). Compound B377 was synthesized in accord with this procedure.
- 1H NMR (400 MHz, DMSO-d6) δ 7.29 (d, J=7.4 Hz, 1H), 7.19 (t, J=7.8 Hz, 1H), 6.98-6.87 (m, 2H), 4.84-4.78 (m, 1H), 4.16 (dd, J=8.8, 5.0 Hz, 1H), 4.08 (dd, J=11.1, 5.2 Hz, 1H), 3.75-3.64 (m, 2H), 3.58 (dd, J=14.2, 6.6 Hz, 1H), 3.43 (t, J=7.7 Hz, 1H), 2.55 (q, J=6.3 Hz, 4H), 1.57 (d, J=11.5 Hz, 5H), 1.48 (d, J=12.9 Hz, 1H), 1.27 (d, J=12.0 Hz, 2H), 1.18-1.09 (m, 1H), 1.04 (s, 2H), 0.95 (d, J=6.1 Hz, 3H), 0.76 (s, 3H), 0.72-0.62 (m, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.28 (d, J=7.4 Hz, 1H), 7.21 (t, J=7.8 Hz, 1H), 7.00-6.88 (m, 2H), 5.35 (s, 1H), 4.90-4.82 (m, 1H), 4.19 (dd, J=10.8, 3.0 Hz, 1H), 4.10 (dd, J=10.8, 4.4 Hz, 1H), 3.71 (t, J=9.0 Hz, 1H), 3.64 (s, 2H), 3.46 (dd, J=8.6, 6.1 Hz, 1H), 3.22 (q, J=7.2 Hz, 2H), 2.53 (d, J=6.2 Hz, 2H), 2.04 (t, J=7.2 Hz, 2H), 1.92 (s, 2H), 1.81 (d, J=6.6 Hz, 2H), 1.51 (ddt, J=19.8, 13.8, 6.5 Hz, 5H), 1.09 (t, J=7.2 Hz, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.30 (d, J=7.4 Hz, 1H), 7.20 (t, J=7.8 Hz, 1H), 6.96 (d, J=8.2 Hz, 1H), 6.91 (t, J=7.4 Hz, 1H), 4.87 (d, J=7.0 Hz, 1H), 4.19 (q, J=6.4, 3.5 Hz, 1H), 4.15-4.04 (m, 1H), 3.71 (dd, J=14.0, 8.9 Hz, 2H), 3.59 (dd, J=14.3, 8.8 Hz, 1H), 3.52-3.41 (m, 1H), 3.22 (q, J=7.4 Hz, 2H), 2.55 (d, J=7.6 Hz, 2H), 1.58 (d, J=11.3 Hz, 5H), 1.47 (t, J=15.1 Hz, 1H), 1.29 (dd, J=11.2, 5.4 Hz, 2H), 1.10 (t, J=7.2 Hz, 3H), 1.07-0.92 (m, 3H), 0.77 (t, J=13.9 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.28 (d, J=7.4 Hz, 1H), 7.20 (t, J=7.8 Hz, 1H), 6.93 (dd, J=17.2, 8.3 Hz, 2H), 5.35 (s, 1H), 4.80 (dt, J=9.2, 4.5 Hz, 1H), 4.16 (dd, J=11.0, 3.0 Hz, 1H), 4.07 (dd, J=11.0, 4.5 Hz, 1H), 3.68 (t, J=9.0 Hz, 1H), 3.62 (s, 2H), 3.42 (dd, J=8.6, 6.0 Hz, 1H), 2.60-2.47 (m, 4H), 2.04 (t, J=7.4 Hz, 2H), 1.92 (s, 2H), 1.81 (d, J=6.6 Hz, 2H), 1.67 (s, 0H), 1.50 (dt, J=19.6, 6.6 Hz, 4H), 0.77-0.65 (m, 4H).
- 1H NMR (400 MHz, Chloroform-d) δ 6.97 (t, J=7.3 Hz, 1H), 6.84 (d, J=8.2 Hz, 1H), 5.43 (s, 1H), 4.84 (s, 1H), 4.16 (s, 2H), 3.80-3.69 (m, 2H), 3.60-3.52 (m, 1H), 2.94 (s, 3H), 2.66 (t, J=7.0 Hz, 1H), 2.15 (s, 2H), 1.97 (s, 2H), 1.85 (s, 2H), 1.25 (s, 1H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.29 (s, 1H), 7.22 (d, J=8.0 Hz, 1H), 6.97 (t, J=7.3 Hz, 1H), 6.84 (d, J=8.1 Hz, 1H), 4.85 (s, 1H), 4.17 (dd, J=8.5, 5.0 Hz, 1H), 3.83 (d, J=13.3 Hz, 1H), 3.78-3.66 (m, 2H), 3.60-3.52 (m, 1H), 2.93 (s, 3H), 2.70 (d, J=6.7 Hz, 1H), 1.35 (s, 3H), 1.15 (d, J=10.5 Hz, 6H), 1.06 (d, J=6.3 Hz, 3H), 0.84 (s, 3H).
-
- Amine 1 (0.25 mmol) and aldehyde 2 (0.23 mmol) were dissolved in 0.3 ml MeOH, heated at 100° C. for 2 hours, then mixture was cooled, NaBH4 (0.25 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C., 3 ml of methanol and 0.1 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated and dissolved in 0.25 ml of DMSO. The residue was purified using HPLC. Yield: 32-47%.
- 1H NMR (400 MHz, DMSO-d6) δ 8.06 (d, J=8.0 Hz, 1H), 7.93-7.86 (m, 1H), 7.76 (d, J=8.0 Hz, 1H), 7.56-7.46 (m, 2H), 7.49-7.37 (m, 1H), 7.36 (d, J=6.9 Hz, 1H), 7.35-7.24 (m, 4H), 7.20 (t, J=7.0 Hz, 1H), 3.74 (s, 2H), 3.21 (t, J=7.6 Hz, 2H), 2.81 (t, J=7.6 Hz, 2H), 2.32 (s, 1H).
- 1H NMR (400 MHz, Chloroform-d) δ 8.30 (d, J=8.1 Hz, 1H), 7.98 (d, J=8.2 Hz, 1H), 7.50 (p, J=6.9 Hz, 2H), 7.25 (d, J=8.3 Hz, 2H), 7.17 (d, J=7.7 Hz, 2H), 7.10 (d, J=7.7 Hz, 2H), 6.73 (d, J=7.8 Hz, 1H), 3.98 (s, 3H), 3.78 (s, 2H), 3.22 (t, J=7.2 Hz, 2H), 3.00 (t, J=7.3 Hz, 2H), 2.32 (s, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 8.08-8.01 (m, 1H), 7.94-7.87 (m, 1H), 7.79 (d, J=8.1 Hz, 1H), 7.65 (d, J=7.1 Hz, 1H), 7.48 (dq, J=7.2, 3.6, 2.9 Hz, 3H), 7.31 (dt, J=14.8, 7.5 Hz, 4H), 7.21 (t, J=7.1 Hz, 1H), 5.45 (s, 2H), 5.43 (d, J=3.8 Hz, 0H), 3.79 (s, 2H), 2.86-2.78 (m, 1H), 2.69 (dd, J=12.2, 7.8 Hz, 1H), 2.31 (s, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.89-7.71 (m, 4H), 7.66 (s, 1H), 7.51-7.39 (m, 3H), 7.34 (d, J=9.0 Hz, 1H), 7.27 (d, J=6.6 Hz, 4H), 7.20 (d, J=6.5 Hz, 1H), 3.80 (d, J=13.6 Hz, 1H), 3.74 (d, J=13.8 Hz, 1H), 2.94 (ddd, J=26.2, 12.3, 5.7 Hz, 2H), 2.64 (dd, J=12.7, 7.0 Hz, 1H), 1.94 (s, 1H), 0.98 (d, J=6.1 Hz, 3H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.76 (dd, J=7.4, 1.9 Hz, 1H), 7.70 (d, J=8.3 Hz, 1H), 7.48-7.23 (m, 9H), 4.13 (s, 1H), 4.02 (d, J=13.3 Hz, 1H), 3.93 (d, J=13.3 Hz, 1H), 3.04 (d, J=16.3 Hz, 1H), 2.19 (dd, J=9.8, 4.8 Hz, 1H).
-
- A solution of 2-hydroxybenzaldehyde 1 (5.0 mmol, 1.0 equiv), K2CO3 (7.5 mmol, 1.5 equiv), compound 2 (5.0 mmol, 1.0 equiv) in CH3CN (50 mL) was refluxed and monitored by TLC. After completion of the reaction, the solution was cooled; solvent was evaporated under reduced pressure. The residue was poured into water (30 mL) and extracted with ethyl acetate (3×30 mL). The organic layer was washed with brine and dried over anhydrous MgSO4. Filtration of MgSO4 and evaporation of solvent under vacuum gave the crude product. The residue obtained was purified by using HPLC to obtain the
corresponding compound 3. Yield: 34-58%. - Aldehyde 3 (0.55 mmol), amine 4 (0.5 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours, then mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C., 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated and optionally dissolved in 0.5 mL of DMSO. The residue was purified using HPLC. Yield: 24-47%.
- 1H NMR (400 MHz, DMSO-d6) δ 8.56 (s, 1H), 7.19 (t, J=8.0 Hz, 2H), 6.93-6.84 (m, 2H), 4.51 (s, 2H), 3.78 (d, J=12.0 Hz, 1H), 3.65 (d, J=12.1 Hz, 1H), 2.71 (d, J=5.8 Hz, 2H), 2.66 (d, J=4.6 Hz, 3H), 2.54 (s, 1H), 1.67 (d, J=15.3 Hz, 5H), 1.35 (s, 1H), 1.20 (dd, J=22.0, 9.6 Hz, 2H), 1.05 (d, J=6.2 Hz, 3H), 0.86 (d, J=12.3 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 8.55 (d, J=6.8 Hz, 1H), 7.98 (s, 1H), 7.51 (d, J=9.0 Hz, 1H), 7.21 (ddd, J=28.6, 15.1, 7.8 Hz, 4H), 6.88 (t, J=6.9 Hz, 2H), 5.22 (d, J=2.6 Hz, 2H), 3.73 (d, J=13.6 Hz, 1H), 3.61 (d, J=13.8 Hz, 1H), 2.54 (s, 0H), 1.71 (s, 1H), 1.50 (d, J=11.8 Hz, 4H), 1.43 (s, 1H), 1.24 (s, 2H), 1.01 (d, J=16.2 Hz, 5H), 0.91 (d, J=6.0 Hz, 2H), 0.74-0.64 (m, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.24 (d, J=7.2 Hz, 1H), 7.17 (t, J=7.8 Hz, 11H), 6.94 (d, J=8.1 Hz, 1H), 6.86 (t, J=7.4 Hz, 1H), 4.00 (t, J=5.9 Hz, 2H), 3.71 (d, J=13.7 Hz, 1H), 3.58 (d, J=14.2 Hz, 1H), 2.79 (t, J=5.7 Hz, 2H), 2.60-2.52 (m, 4H), 1.61 (d, J=16.9 Hz, 3H), 1.56 (s, 2H), 1.49 (d, J=13.0 Hz, 1H), 1.28 (s, 2H), 1.17 (d, J=12.1 Hz, 1H), 1.12 (s, 2H), 1.07-0.92 (m, 8H), 0.81 (s, 1H), 0.80-0.71 (m, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.21-7.09 (m, 1H), 6.83 (s, 1H), 4.08 (t, J=5.6 Hz, 1H), 3.60 (t, J=4.7 Hz, 2H), 2.75 (t, J=5.8 Hz, 1H), 1.64 (s, 2H), 1.29 (s, 1H), 1.16 (s, 2H), 0.98 (d, J=6.1 Hz, 1H), 0.82 (s, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.21-7.11 (m, 2H), 6.87 (d, J=8.0 Hz, 1H), 6.81 (s, 1H), 4.06 (s, 2H), 3.73 (d, J=13.4 Hz, 1H), 3.61 (s, 4H), 2.54 (s, 1H), 1.92 (s, 2H), 1.63 (s, 6H), 1.29 (s, 4H), 1.16 (s, 4H), 1.07 (s, 1H), 0.99 (d, J=6.1 Hz, 3H), 0.83 (s, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.30 (dd, J=7.4, 4.9 Hz, 2H), 7.22 (t, J=7.8 Hz, 1H), 7.11 (d, J=8.2 Hz, 1H), 6.93 (t, J=7.4 Hz, 1H), 6.76 (d, J=3.5 Hz, 1H), 5.17 (d, J=3.5 Hz, 2H), 3.80 (s, 3H), 3.68 (d, J=13.8 Hz, 1H), 3.59 (d, J=13.8 Hz, 1H), 2.51 (s, 1H), 1.56 (s, 5H), 1.47 (d, J=12.7 Hz, 1H), 1.24 (s, 2H), 1.11 (q, J=10.6, 9.2 Hz, 2H), 0.91 (d, J=6.1 Hz, 3H), 0.75 (q, J=11.1 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 8.53 (d, J=5.0 Hz, 2H), 7.40 (d, J=5.4 Hz, 2H), 7.27 (d, J=7.4 Hz, 1H), 7.15 (t, J=8.2 Hz, 1H), 6.94-6.84 (m, 2H), 5.16 (s, 2H), 3.82 (d, J=13.5 Hz, 1H), 3.71 (d, J=13.5 Hz, 1H), 2.69-2.61 (m, 1H), 1.60 (q, J=14.9, 12.0 Hz, 6H), 1.28 (q, J=7.8 Hz, 3H), 1.12 (s, 5H), 1.00 (d, J=6.0 Hz, 3H), 0.86-0.75 (m, 2H).
- 1H NMR (400 MHz, Chloroform-d) δ 8.02 (s, 1H), 7.30-7.21 (m, 3H), 6.96 (t, J=7.4 Hz, 1H), 6.87 (d, J=8.2 Hz, 1H), 4.61 (s, 2H), 3.90 (d, J=12.0 Hz, 1H), 3.73 (d, J=12.0 Hz, 1H), 3.15 (q, J=5.8 Hz, 2H), 2.83-2.75 (m, 1H), 1.39 (dd, J=13.0, 6.5 Hz, 1H), 1.30 (s, 1H), 1.16 (s, 4H), 1.10 (d, J=6.1 Hz, 3H), 0.88 (s, 3H), 0.85 (d, J=2.3 Hz, 0H), 0.41 (d, J=7.7 Hz, 2H), 0.13 (d, J=5.2 Hz, 2H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.15 (t, J=7.7 Hz, 1H), 6.97 (t, J=8.5 Hz, 1H), 6.86-6.72 (m, 2H), 5.53 (s, 1H), 5.37 (s, 1H), 3.96-3.81 (m, 1H), 3.73 (d, J=14.4 Hz, 1H), 2.93 (s, 1H), 2.83 (p, J=7.0, 6.3 Hz, 2H), 2.40 (t, J=7.1 Hz, 2H), 1.67 (s, 2H), 1.61 (d, J=14.5 Hz, 4H), 1.43 (s, 2H), 1.28-1.19 (m, 2H), 1.22-1.12 (m, 4H), 1.12 (s, 1H), 1.10 (s, 1H), 1.05 (d, J=6.6 Hz, 2H), 0.87 (s, 3H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.29 (s, 1H), 7.26 (s, 1H), 7.23 (d, J=7.9 Hz, 2H), 6.99 (d, J=8.0 Hz, 4H), 5.27 (s, 4H), 3.86 (d, J=13.5 Hz, 2H), 3.74 (d, J=13.4 Hz, 2H), 2.69 (d, J=6.3 Hz, 2H), 2.57 (s, 6H), 1.35 (dd, J=12.9, 6.3 Hz, 1H), 1.28 (s, 3H), 1.15 (s, 8H), 1.12 (s, 1H), 1.05 (d, J=6.2 Hz, 6H), 0.83 (s, 6H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.17 (d, J=7.3 Hz, 1H), 7.11 (t, J=7.9 Hz, 1H), 6.84-6.75 (m, 2H), 3.83 (dd, J=6.8, 2.8 Hz, 2H), 3.73 (d, J=13.4 Hz, 1H), 3.60 (d, J=13.4 Hz, 1H), 1.63 (d, J=10.9 Hz, 5H), 1.56 (d, J=13.0 Hz, 1H), 1.29 (s, 6H), 1.15 (t, J=11.2 Hz, 2H), 1.08 (s, 2H), 0.99 (d, J=6.2 Hz, 3H), 0.87-0.77 (m, 2H), 0.61 (q, J=5.6 Hz, 2H), 0.37 (d, J=5.0 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.15 (d, J=7.5 Hz, 1H), 7.10 (t, J=7.5 Hz, 1H), 6.84-6.73 (m, 2H), 4.81 (s, 1H), 3.64 (s, 1H), 3.54 (s, 1H), 2.54 (s, 0H), 1.91 (s, 2H), 1.82 (d, J=15.6 Hz, 5H), 1.64 (s, 8H), 1.25 (s, 5H), 1.15 (s, 2H), 0.97 (d, J=6.1 Hz, 3H), 0.81 (s, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.20 (d, J=7.3 Hz, 1H), 7.13 (t, J=7.5 Hz, 1H), 6.84 (d, J=7.6 Hz, 2H), 6.06 (td, J=11.1, 5.2 Hz, 1H), 5.46-5.37 (m, 1H), 5.26 (d, J=10.4 Hz, 1H), 4.55 (d, J=4.8 Hz, 2H), 3.75 (d, J=13.6 Hz, 1H), 3.61 (d, J=13.6 Hz, 1H), 1.62 (d, J=10.9 Hz, 5H), 1.54 (s, 1H), 1.31-1.12 (m, 8H), 0.98 (d, J=6.1 Hz, 3H), 0.81 (dd, J=22.0, 11.4 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.20 (d, J=7.3 Hz, 1H), 7.13 (t, J=7.8 Hz, 1H), 6.84 (dd, J=11.9, 7.7 Hz, 2H), 4.65 (s, 2H), 3.75 (d, J=13.2 Hz, 1H), 3.63 (d, J=13.3 Hz, 1H), 3.51 (s, 2H), 3.40 (t, J=7.0 Hz, 2H), 2.61 (s, 1H), 2.54 (s, 1H), 2.02-1.94 (m, 2H), 1.86 (q, J=6.7 Hz, 2H), 1.63 (s, 6H), 1.32 (s, 2H), 1.16 (s, 5H), 1.06 (d, J=6.6 Hz, 0H), 0.98 (d, J=6.1 Hz, 3H), 0.83 (d, J=11.3 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.41 (d, J=7.4 Hz, 1H), 7.24 (t, J=7.6 Hz, 1H), 7.13 (dt, J=16.6, 7.7 Hz, 2H), 6.94 (s, 0H), 3.77 (d, J=13.5 Hz, 1H), 3.67 (d, J=13.5 Hz, 1H), 2.66 (q, J=6.4 Hz, 1H), 1.64 (s, 5H), 1.33 (s, 1H), 1.25-1.18 (m, 1H), 1.16 (s, 1H), 1.05 (dd, J=30.4, 6.4 Hz, 3H), 0.84 (t, J=11.6 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 8.95 (d, J=2.0 Hz, 1H), 7.54 (s, 1H), 7.23 (d, J=7.4 Hz, 1H), 7.16 (t, J=7.8 Hz, 1H), 6.99 (d, J=8.2 Hz, 1H), 6.86 (t, J=7.4 Hz, 1H), 5.24 (s, 2H), 3.78 (d, J=13.6 Hz, 1H), 3.65 (d, J=13.4 Hz, 1H), 2.62 (d, J=6.4 Hz, 1H), 1.60 (d, J=10.3 Hz, 6H), 1.53 (s, 1H), 1.27 (d, J=8.0 Hz, 2H), 1.12 (s, 4H), 1.04 (t, J=6.5 Hz, 1H), 0.97 (d, J=6.1 Hz, 3H), 0.79 (t, J=12.4 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.18 (d, J=7.2 Hz, 1H), 7.15-7.07 (m, 1H), 6.81 (d, J=7.7 Hz, 2H), 4.04 (q, J=7.0 Hz, 2H), 3.71 (d, J=13.5 Hz, 1H), 3.58 (d, J=13.5 Hz, 1H), 2.64-2.52 (m, 1H), 1.63 (d, J=10.8 Hz, 5H), 1.56 (d, J=13.5 Hz, 1H), 1.43 (t, J=6.9 Hz, 3H), 1.28 (d, J=6.5 Hz, 2H), 1.28-1.17 (m, 1H), 1.17-1.02 (m, 2H), 0.98 (d, J=6.1 Hz, 3H), 0.84 (d, J=12.2 Hz, 1H), 0.78 (d, J=11.9 Hz, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.20-7.09 (m, 2H), 6.88-6.78 (m, 2H), 4.09 (q, J=3.8 Hz, 2H), 3.77-3.67 (m, 1H), 3.71 (s, 2H), 3.58 (d, J=13.5 Hz, 1H), 3.00 (s, 12H), 2.61-2.52 (m, 1H), 1.62 (d, J=11.5 Hz, 4H), 1.54 (d, J=13.4 Hz, 1H), 1.29 (s, 2H), 1.30-1.22 (m, 0H), 0.97 (d, J=6.1 Hz, 3H), 0.79 (s, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 8.53 (d, J=4.8 Hz, 1H), 7.75 (t, J=7.6 Hz, 1H), 7.50 (d, J=7.8 Hz, 1H), 7.26 (t, J=7.1 Hz, 2H), 7.14 (t, J=7.8 Hz, 1H), 6.94-6.82 (m, 2H), 5.17 (s, 2H), 3.84 (d, J=13.5 Hz, 1H), 3.70 (d, J=13.5 Hz, 1H), 2.65 (q, J=6.3 Hz, 1H), 1.61 (s, 5H), 1.55 (s, 0H), 1.34-1.26 (m, 2H), 1.13-0.97 (m, 7H), 0.85-0.74 (m, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 8.64 (s, 1H), 8.50 (d, J=4.5 Hz, 1H), 7.82 (d, J=7.9 Hz, 1H), 7.38-7.30 (m, 1H), 7.26 (d, J=7.3 Hz, 1H), 7.16 (d, J=8.1 Hz, 1H), 6.98 (d, J=8.1 Hz, 1H), 6.88 (t, J=7.4 Hz, 1H), 5.14 (s, 2H), 3.77 (d, J=13.4 Hz, 1H), 3.65 (d, J=13.3 Hz, 1H), 2.63 (d, J=7.0 Hz, 1H), 1.61 (d, J=10.6 Hz, 5H), 1.26 (d, J=9.2 Hz, 2H), 1.12 (s, 4H), 1.05 (d, J=5.5 Hz, 1H), 0.97 (d, J=6.1 Hz, 3H), 0.79 (s, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.20-7.09 (m, 2H), 6.87-6.78 (m, 2H), 4.19 (q, J=6.0 Hz, 1H), 3.93 (t, J=5.7 Hz, 2H), 3.88-3.81 (m, 1H), 3.78-3.69 (m, 2H), 3.57 (d, J=13.5 Hz, 1H), 2.57 (dt, J=10.4, 5.3 Hz, 1H), 2.05 (d, J=8.4 Hz, 1H), 1.93 (dd, J=14.2, 7.1 Hz, 2H), 1.83 (ddt, J=26.4, 14.0, 6.6 Hz, 1H), 1.61 (d, J=12.3 Hz, 4H), 1.52 (d, J=13.3 Hz, 1H), 1.31-1.23 (m, 2H), 1.14 (s, 3H), 1.01 (dd, J=29.9, 6.3 Hz, 3H), 0.80 (dt, J=23.0, 11.0 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.21-7.10 (m, 2H), 6.87-6.80 (m, 2H), 4.79 (t, J=5.2 Hz, 1H), 3.93 (t, J=5.7 Hz, 2H), 3.78-3.66 (m, 3H), 3.60 (q, J=10.4, 9.1 Hz, 3H), 2.59 (s, 1H), 1.61 (d, J=12.4 Hz, 4H), 1.51 (d, J=13.1 Hz, 1H), 1.26 (d, J=24.1 Hz, 4H), 1.20 (d, J=7.2 Hz, 4H), 1.14 (s, 2H), 1.05 (s, 1H), 0.98 (d, J=6.1 Hz, 2H), 0.85-0.75 (m, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.23 (d, J=7.3 Hz, 1H), 7.12 (t, J=7.8 Hz, 1H), 7.02 (d, J=8.1 Hz, 1H), 6.88 (t, J=7.1 Hz, 1H), 5.21 (s, 2H), 3.71 (dd, J=9.4, 5.6 Hz, 3H), 3.61 (d, J=13.9 Hz, 1H), 2.64 (s, 1H), 2.54 (s, 1H), 1.63 (s, 5H), 1.33-1.25 (m, 1H), 1.21 (t, J=7.1 Hz, 2H), 0.99 (d, J=6.2 Hz, 3H), 0.81 (d, J=13.0 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.18 (d, J=7.4 Hz, 1H), 7.11 (d, J=7.8 Hz, 1H), 6.87-6.77 (m, 2H), 4.03 (d, J=8.0 Hz, 2H), 3.72 (d, J=13.4 Hz, 1H), 3.61-3.48 (m, 3H), 3.30 (s, 3H), 2.60 (s, 2H), 2.05-1.98 (m, 2H), 1.62 (d, J=11.3 Hz, 5H), 1.54 (d, J=12.2 Hz, 1H), 1.27 (s, 3H), 1.14 (s, 4H), 0.98 (d, J=6.0 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.14 (dd, J=17.4, 7.9 Hz, 2H), 6.83 (dd, J=12.1, 7.6 Hz, 2H), 4.08 (d, J=5.4 Hz, 2H), 3.77-3.70 (m, 3H), 3.61-3.50 (m, 3H), 2.52 (d, J=16.8 Hz, 2H), 1.61 (d, J=12.1 Hz, 4H), 1.52 (d, J=12.8 Hz, 1H), 1.29-1.16 (m, 3H), 1.15 (s, 1H), 0.97 (d, J=6.1 Hz, 2H), 0.82 (d, J=11.9 Hz, 1H), 0.77 (s, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.22-7.09 (m, 2H), 6.83 (t, J=7.7 Hz, 2H), 4.12 (s, 2H), 3.72 (d, J=13.6 Hz, 1H), 3.59 (d, J=13.6 Hz, 1H), 2.89 (t, J=6.5 Hz, 2H), 2.63 (q, J=7.5 Hz, 3H), 2.54 (s, 1H), 1.63 (d, J=10.6 Hz, 5H), 1.56 (d, J=13.2 Hz, 1H), 1.28 (t, J=7.4 Hz, 3H), 1.15 (s, 2H), 0.98 (d, J=6.1 Hz, 3H), 0.81 (s, 2H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.26 (s, 1H), 7.20 (t, J=7.7 Hz, 2H), 6.94-6.81 (m, 2H), 4.10 (t, J=5.9 Hz, 2H), 3.84 (d, J=13.1 Hz, 1H), 3.71 (d, J=13.1 Hz, 1H), 2.76 (t, J=5.9 Hz, 2H), 2.68 (q, J=6.4 Hz, 1H), 2.35 (s, 6H), 1.64 (s, 5H), 1.55 (d, J=12.7 Hz, 1H), 1.36 (dt, J=13.0, 6.7 Hz, 1H), 1.16 (s, 6H), 1.05 (d, J=6.2 Hz, 3H), 0.86 (s, 1H), 0.81 (d, J=11.3 Hz, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.26 (d, J=7.3 Hz, 1H), 7.15 (t, J=7.9 Hz, 1H), 6.88 (t, J=9.1 Hz, 2H), 4.89-4.76 (m, 2H), 3.74 (d, J=13.6 Hz, 1H), 3.63 (d, J=13.7 Hz, 1H), 3.00 (d, J=1.8 Hz, 3H), 2.84 (s, 3H), 2.80 (d, J=10.9 Hz, 0H), 2.55 (d, J=10.8 Hz, 2H), 1.92 (s, 1H), 1.57 (d, J=13.4 Hz, 6H), 1.31 (s, 1H), 1.11 (s, 4H), 0.95 (d, J=6.1 Hz, 2H), 0.83-0.73 (m, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.22 (d, J=7.4 Hz, 1H), 7.14 (t, J=7.8 Hz, 1H), 6.90-6.78 (m, 2H), 4.11 (dt, J=7.3, 3.5 Hz, 1H), 3.70 (dd, J=13.7, 7.0 Hz, 1H), 3.54 (t, J=13.3 Hz, 1H), 2.59 (s, 1H), 2.56 (d, J=12.6 Hz, 1H), 2.00-1.89 (m, 1H), 1.76 (d, J=3.9 Hz, 1H), 1.70 (s, 4H), 1.57 (d, J=12.4 Hz, 7H), 1.48 (d, J=15.0 Hz, 1H), 1.28-1.20 (m, 4H), 1.15 (d, J=11.3 Hz, 1H), 1.10 (s, 1H), 1.05 (d, J=2.2 Hz, 3H), 0.99-0.92 (m, 5H), 0.86 (s, 3H), 0.77 (t, J=13.6 Hz, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.28 (s, 1H), 7.15 (t, J=7.8 Hz, 1H), 6.90 (t, J=7.4 Hz, 1H), 6.81 (dd, J=8.2, 5.4 Hz, 1H), 5.02 (q, J=6.7 Hz, 1H), 3.73 (d, J=13.5 Hz, 1H), 3.67 (d, J=3.2 Hz, 5H), 2.65-2.52 (m, 2H), 1.68 (s, 1H), 1.59 (d, J=11.1 Hz, 6H), 1.52 (dd, J=6.8, 4.6 Hz, 3H), 1.31 (s, 2H), 1.12 (s, 5H), 1.09-1.01 (m, 0H), 0.97 (dd, J=6.2, 3.2 Hz, 3H), 0.82 (s, 1H), 0.78 (d, J=12.0 Hz, 1H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.18 (d, J=7.4 Hz, 1H), 6.94 (dd, J=12.7, 7.5 Hz, 2H), 3.89 (d, J=11.0 Hz, 1H), 3.74 (s, 2H), 3.63 (d, J=10.9 Hz, 1H), 2.81 (d, J=6.9 Hz, 1H), 1.41 (dd, J=12.7, 6.2 Hz, 1H), 1.25-1.17 (m, 1H), 1.18 (s, 4H), 1.12 (d J=6.1 Hz, 2H), 0.89 (t, J=13.5 Hz, 2H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.29-7.14 (m, 1H), 6.94-6.83 (m, 1H), 4.01-3.91 (m, 1H), 3.89 (s, 1H), 3.67 (d, J=11.5 Hz, 0H), 2.78 (d, J=8.7 Hz, 1H), 1.42-1.36 (m, 1H), 1.32 (d, J=13.6 Hz, 2H), 1.19 (s, 5H), 1.11 (d, J=6.1 Hz, 2H), 0.88 (d, J=12.5 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 11.22 (s, 1H), 9.18 (s, 1H), 9.07 (s, 1H), 7.56 (d, J=7.5 Hz, 1H), 7.38 (t, J=7.8 Hz, 1H), 7.06 (d, J=8.4 Hz, 1H), 6.98 (t, J=7.5 Hz, 1H), 4.10 (dq, J=12.7, 6.1 Hz, 12H), 4.02 (s, 2H), 3.58 (q, J=8.0 Hz, 1H), 3.20 (s, 2H), 2.72 (d, J=4.9 Hz, 3H), 2.25 (s, 3H), 1.99 (s, 2H), 1.84 (s, 2H), 1.72 (s, 2H), 1.62 (t, J=14.2 Hz, 8H), 1.55 (s, 4H), 1.52 (d, J=7.8 Hz, 1H), 1.31 (d, J=6.4 Hz, 3H), 1.14 (dd, J=23.8, 13.4 Hz, 3H), 0.94 (t, J=11.5 Hz, 1H), 0.80 (d, J=11.5 Hz, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.26-7.14 (m, 2H), 6.93 (d, J=8.1 Hz, 1H), 6.86 (t, J=7.3 Hz, 1H), 3.99-3.88 (m, 1H), 3.83 (q, J=5.1, 4.4 Hz, 2H), 3.73 (d, J=13.3 Hz, 1H), 3.59 (d, J=13.3 Hz, 1H), 3.33 (s, 1H), 2.57 (dd, J=13.4, 7.2 Hz, 1H), 1.58 (d, J=11.9 Hz, 5H), 1.50 (d, J=12.6 Hz, 1H), 1.27 (td, J=11.2, 10.3, 6.1 Hz, 2H), 1.16 (d, J=6.3 Hz, 3H), 1.11 (s, 4H), 0.99 (dd, J=24.3, 6.3 Hz, 3H), 0.76 (q, J=12.8, 12.2 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.28 (d, J=7.4 Hz, 1H), 7.16 (t, J=7.9 Hz, 1H), 6.94-6.84 (m, 2H), 4.80 (s, 2H), 3.74 (d, J=13.9 Hz, 1H), 3.69 (s, 3H), 3.64 (d, J=13.8 Hz, 1H), 2.62-2.51 (m, 1H), 1.77 (s, 1H), 1.61-1.49 (m, 5H), 1.29 (s, 2H), 1.27 (dd, J=13.7, 7.7 Hz, 0H), 1.10 (s, 3H), 0.95 (d, J=6.1 Hz, 3H), 0.79 (q, J=12.4, 11.8 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.26 (d, J=7.4 Hz, 1H), 7.18 (t, J=7.8 Hz, 1H), 6.94 (d, J=8.2 Hz, 1H), 6.87 (t, J=7.4 Hz, 1H), 4.04 (t, J=6.1 Hz, 2H), 3.71 (d, J=13.6 Hz, 1H), 3.59 (d, J=13.6 Hz, 1H), 2.69-2.52 (m, 3H), 2.07 (d, J=1.7 Hz, 2H), 2.00 (p, J=6.7 Hz, 2H), 1.58 (d, J=12.2 Hz, 5H), 1.50 (d, J=12.7 Hz, 1H), 1.26 (dd, J=13.5, 7.8 Hz, 2H), 1.21-1.11 (m, 2H), 1.05 (q, J=11.0, 6.1 Hz, 2H), 0.96 (dd, J=6.1, 1.7 Hz, 2H), 0.79 (dt, J=22.8, 11.4 Hz, 2H).
-
- General procedure for preparation of target compounds 5:
- The solution of 2-hydroxybenzaldehyde 1 (5.0 mmol, 1.0 equiv), K2CO3 (7.5 mmol, 1.5 equiv), compound 2 (5.0 mmol, 1.0 equiv) in CH3CN (50 mL) was refluxed and monitored by TLC. After completion of the reaction, the solution was cooled; solvent was evaporated under reduced pressure. The residue was poured into water (30 mL) and extracted with ethyl acetate (3×30 mL). The organic layer was washed with brine and dried over anhydrous MgSO4. Filtration of MgSO4 and evaporation of solvent under vacuum gave the crude product. The residue obtained was purified by using HPLC to obtain the
corresponding compound 3. Yield: 32-53%. - Aldehyde 3 (0.55 mmol), amine 4 (0.5 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours, then mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C., 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated and dissolved in 0.5 ml of DMSO, and purified using HPLC. Yield: 24-47%.
- 1H NMR (400 MHz, DMSO-d6) δ 8.49 (t, J=5.8 Hz, 1H), 7.26 (d, J=7.2 Hz, 1H), 7.20 (t, J=7.8 Hz, 1H), 6.96-6.87 (m, 2H), 4.52 (s, 2H), 3.77 (d, J=12.9 Hz, 1H), 3.64 (d, J=12.9 Hz, 1H), 3.12 (p, J=7.0 Hz, 2H), 2.63 (q, J=6.4 Hz, 1H), 1.82 (s, 1H), 1.61 (d, J=12.3 Hz, 5H), 1.54 (d, J=12.9 Hz, 1H), 1.33 (dd, J=11.6, 5.2 Hz, 2H), 1.14 (q, J=11.4, 9.5 Hz, 3H), 1.09-0.96 (m, 6H), 0.81 (d, J=11.0 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.85 (d, J=3.1 Hz, 1H), 7.79 (d, J=3.3 Hz, 1H), 7.33 (d, J=7.5 Hz, 1H), 7.22 (t, J=7.8 Hz, 1H), 7.10 (d, J=8.3 Hz, 1H), 6.95 (t, J=7.3 Hz, 1H), 5.44 (d, J=2.5 Hz, 2H), 3.80 (d, J=13.8 Hz, 1H), 3.68 (d, J=14.1 Hz, 1H), 2.61-2.52 (m, 2H), 1.67 (s, 1H), 1.55 (d, J=10.9 Hz, 5H), 1.47 (s, 0H), 1.26 (q, J=7.3 Hz, 2H), 1.07 (s, 5H), 0.96 (d, J=6.1 Hz, 2H), 0.76 (s, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.31 (d, J=7.4 Hz, 1H), 7.21 (t, J=7.9 Hz, 1H), 7.08 (d, J=8.2 Hz, 1H), 6.93 (t, J=7.5 Hz, 1H), 6.46 (s, 1H), 5.24 (d, J=2.9 Hz, 2H), 3.70 (d, J=14.0 Hz, 1H), 3.60 (d, J=13.9 Hz, 1H), 2.53 (s, 1H), 2.24 (s, 3H), 1.58 (s, 6H), 1.29-1.21 (m, 2H), 1.12 (d, J=12.5 Hz, 2H), 1.04 (s, 2H), 0.93 (d, J=6.1 Hz, 3H) 0.81-0.71 (m, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 8.45 (s, 2H), 7.27 (d, J=7.3 Hz, 2H), 7.20 (t, J=7.9 Hz, 2H), 6.96-6.87 (m, 4H), 4.54 (s, 4H), 3.77 (d, J=12.9 Hz, 2H), 3.64 (d, J=12.8 Hz, 2H), 3.05 (q, J=6.7 Hz, 4H), 2.63 (d, J=6.4 Hz, 1H), 1.80 (s, 1H), 1.59 (s, 8H), 1.53 (s, 1H), 1.40 (d, J=7.3 Hz, 1H), 1.40-1.29 (m, 7H), 1.14 (s, 4H), 1.12 (s, 1H), 0.99 (d, J=6.1 Hz, 6H), 0.75 (t, J=7.4 Hz, 14H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.19-7.08 (m, 2H), 6.82 (t, J=8.3 Hz, 2H), 4.05 (s, 2H), 3.96 (s, 1H), 3.77-3.66 (m, 3H), 3.57 (d, J=13.8 Hz, 1H), 1.68 (s, 7H), 1.61 (d, J=11.7 Hz, 3H), 1.52 (s, 3H), 1.29-1.16 (m, 2H), 1.14 (s, 2H), 0.96 (d, J=6.1 Hz, 3H), 0.85-0.71 (m, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.20-7.09 (m, 2H), 6.83 (dd, J=13.2, 7.4 Hz, 2H), 4.12-4.05 (m, 2H), 3.80-3.70 (m, 3H), 3.57 (d, J=13.6 Hz, 1H), 3.34 (d, J=6.7 Hz, 2H), 2.57 (dd, J=14.1, 7.7 Hz, 1H), 1.61 (d, J=11.8 Hz, 4H), 1.52 (d, J=13.2 Hz, 1H), 1.29 (s, 1H), 1.30-1.16 (m, 1H), 1.14 (s, 4H), 1.04 (d, J=6.6 Hz, 1H), 0.97 (d, J=6.1 Hz, 3H), 0.86-0.72 (m, 2H), 0.49 (t, J=6.4 Hz, 2H), 0.20 (d, J=5.1 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.21 (d, J=7.5 Hz, 2H), 7.13 (d, J=8.1 Hz, 1H), 6.86 (d, J=7.9 Hz, 4H), 4.12 (d, J=13.6 Hz, 4H), 3.99 (t, J=4.5 Hz, 3H), 3.73 (d, J=13.6 Hz, 2H), 3.60 (d, J=13.7 Hz, 2H), 2.60 (d, J=5.7 Hz, 1H), 2.54 (s, 1H), 1.62 (d, J=10.6 Hz, 9H), 1.53 (s, 1H), 1.29 (s, 5H), 1.15 (s, 9H), 1.06 (s, 1H), 0.97 (d, J=6.1 Hz, 5H), 0.86-0.75 (m, 4H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.25 (t, J=8.9 Hz, 1H), 7.15 (s, 2H), 6.90 (dd, J=16.3, 8.2 Hz, 3H), 4.86-4.71 (m, 2H), 4.19 (s, 1H), 3.73 (d, J=13.8 Hz, 1H), 3.62 (d, J=13.4 Hz, 2H), 3.18 (s, 1H), 2.84 (s, 2H), 1.93 (s, 1H), 1.75 (d, J=12.6 Hz, 2H), 1.57 (s, 9H), 1.47 (s, 3H), 1.44 (d, J=13.6 Hz, 1H), 1.30 (s, 5H), 1.10 (s, 6H), 1.03 (s, 1H), 0.95 (d, J=6.1 Hz, 3H), 0.77 (s, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.26 (d, J=7.3 Hz, 1H), 7.18 (t, J=7.7 Hz, 1H), 6.93 (d, J=8.1 Hz, 1H), 6.87 (t, J=7.4 Hz, 1H), 4.25 (t, J=8.0 Hz, 2H), 3.99 (t, J=6.2 Hz, 2H), 3.73 (d, J=13.7 Hz, 1H), 3.61 (d, J=13.8 Hz, 1H), 3.55 (t, J=7.9 Hz, 2H), 2.61-2.50 (m, 1H), 1.96 (q, J=6.7 Hz, 2H), 1.62-1.48 (m, 6H), 1.29 (s, 2H), 1.11 (td, J=22.0, 19.4, 8.9 Hz, 4H), 0.96 (d, J=6.1 Hz, 3H), 0.78 (s, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.96 (s, 1H), 7.30 (d, J=7.4 Hz, 1H), 7.20 (t, J=7.8 Hz, 1H), 7.00 (d, J=8.1 Hz, 1H), 6.91 (t, J=7.3 Hz, 1H), 6.79 (d, J=1.7 Hz, 1H), 5.29 (s, 2H), 3.84 (s, 3H), 3.76 (d, J=13.8 Hz, 1H), 3.63 (d, J=13.8 Hz, 1H), 2.59-2.47 (m, 1H), 1.56 (s, 5H), 1.23 (d, J=9.7 Hz, 2H), 1.07 (s, 4H), 1.05-0.97 (m, 0H), 0.93 (d, J=6.1 Hz, 2H), 0.76 (d, J=13.7 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.28-7.19 (m, 2H), 7.18 (d, J=8.0 Hz, 1H), 7.01 (d, J=8.2 Hz, 1H), 6.89 (t, J=7.4 Hz, 1H), 6.60-6.50 (m, 3H), 4.31 (d, J=2.4 Hz, 4H), 3.57 (d, J=13.9 Hz, 1H), 3.33 (s, 2H), 2.52 (d, J=17.3 Hz, 1H), 1.65 (s, 1H), 1.53 (s, 4H), 1.41 (d, J=13.1 Hz, 1H), 1.23 (s, 2H), 1.11-1.04 (m, 1H), 1.04 (s, 1H), 0.90 (d, J=6.1 Hz, 3H), 0.71 (dt, J=21.5, 11.1 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.83 (d, J=2.0 Hz, 1H), 7.28 (d, J=7.3 Hz, 1H), 7.21 (t, J=7.8 Hz, 1H), 7.09 (d, J=8.2 Hz, 1H), 6.92 (t, J=7.4 Hz, 1H), 6.81 (d, J=2.0 Hz, 1H), 5.42-5.30 (m, 2H), 3.78 (s, 3H), 3.65 (d, J=13.7 Hz, 1H), 3.55 (d, J=13.8 Hz, 1H), 2.74 (s, 1H), 2.53 (d, J=7.0 Hz, 1H), 1.56 (d, J=9.1 Hz, 6H), 1.48 (d, J=13.3 Hz, 1H), 1.24 (s, 2H), 1.23-1.11 (m, 1H), 1.09 (d, J=9.0 Hz, 1H), 0.89 (d, J=6.2 Hz, 3H), 0.77_(s, 1H), 0.73 (d, J=11.7 Hz, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.29 (d, J=7.3 Hz, 1H), 7.21 (t, J=7.9 Hz, 1H), 7.10 (d, J=8.2 Hz, 1H), 6.97-6.87 (m, 2H), 5.15 (d, J=2.7 Hz, 2H), 3.70 (d, J=13.8 Hz, 1H), 3.59 (d, J=14.0 Hz, 1H), 2.66 (q, J=7.6 Hz, 2H), 2.54 (s, 1H), 1.66 (s, 1H), 1.57 (s, 5H), 1.48 (d, J=12.4 Hz, 1H), 1.27 (s, 2H), 1.18 (t, J=7.5 Hz, 3H), 1.10 (s, 1H), 1.09-0.97 (m, 1H), 0.92 (d, J=6.1 Hz, 3H), 0.75 (t, J=15.1 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.24-7.12 (m, 2H), 6.93 (d, J=8.0 Hz, 1H), 6.85 (t, J=7.3 Hz, 1H), 4.81 (s, 1H), 4.46 (d, J=5.9 Hz, 2H), 4.40 (d, J=6.0 Hz, 2H), 4.13 (s, 2H), 3.73 (d, J=15.8 Hz, 4H), 3.60 (d, J=13.3 Hz, 1H), 2.62 (s, 2H), 2.54 (s, 1H), 1.63 (s, 6H), 1.56 (d, J=12.5 Hz, 1H), 1.29 (s, 3H), 1.16 (s, 5H), 1.06 (s, 1H), 0.98 (d, J=6.1 Hz, 3H), 0.82 (s, 3H).
- 1H NMR (400 MHz, Chloroform-d) δ 8.21 (d, J=10.2 Hz, 1H), 7.31-7.17 (m, 2H), 6.96 (t, J=7.4 Hz, 1H), 6.82 (d, J=8.2 Hz, 1H), 4.94 (d, J=5.8 Hz, 1H), 4.56 (s, 2H), 3.94 (dd, J=13.1, 3.1 Hz, 1H), 3.82 (dd, J=12.9, 4.1 Hz, 1H), 3.62 (s, 1H), 2.99 (d, J=2.3 Hz, 3H), 2.92 (d, J=2.1 Hz, 3H), 2.80 (d, J=7.2 Hz, 1H), 1.69-1.61 (m, 4H), 1.58 (s, 1H), 1.44-1.35 (m, 1H), 1.32 (d, J=6.8 Hz, 2H), 1.16 (s, 6H), 1.13 (dd, J=16.7, 8.8 Hz, 3H), 1.09 (s 1H, 0.83 (t, J=12.5 Hz, 2H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.29-7.17 (m, 2H), 6.94-6.79 (m, 6H), 4.16 (dt, J=22.9, 6.0 Hz, 4H), 3.85 (d, J=13.1 Hz, 1H), 3.76 (s, 3H), 3.70 (d, J=13.1 Hz, 1H), 2.66 (q, J=6.4 Hz, 1H), 2.28 (q, J=6.1 Hz, 2H), 1.50 (d, J=12.9 Hz, 1H), 1.38-1.20 (m, 2H), 1.13 (s, 5H), 1.03 (d, J=6.2 Hz, 3H), 0.81 (q, J=13.3, 12.8 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.21-7.10 (m, 2H), 6.90-6.79 (m, 2H), 4.10 (p, J=5.6 Hz, 2H), 3.80 (t, J=4.8 Hz, 2H), 3.75 (d, J=13.9 Hz, 1H), 3.02 (s, 8H), 2.56 (d, J=17.3 Hz, 1H), 1.62 (d, J=12.2 Hz, 5H), 1.51 (d, J=13.1 Hz, 1H), 1.27 (d, J=8.3 Hz, 3H), 1.23-0.95 (m, 6H), 0.80 (dd, J=21.9, 11.4 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.20-7.09 (m, 2H), 6.87 (d, J=8.2 Hz, 1H), 6.80 (t, J=7.4 Hz, 1H), 4.10 (q, J=10.4, 6.9 Hz, 3H), 3.70 (d, J=13.4 Hz, 1H), 3.56 (d, J=13.3 Hz, 1H), 2.64-2.52 (m, 1H), 1.89 (t, J=6.9 Hz, 2H), 1.63 (d, J=10.5 Hz, 5H), 1.55 (s, 1H), 1.30 (s, 3H), 1.27 (d, J=6.4 Hz, 0H), 1.20 (s, 6H), 1.15 (d, J=7.5 Hz, 1H), 0.97 (d, J=6.1 Hz, 3H), 0.81 (t, J=15.8 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.19 (d, J=7.5 Hz, 1H), 7.13 (t, J=7.7 Hz, 1H), 6.82 (t, J=8.4 Hz, 2H), 4.01 (t, J=6.2 Hz, 2H), 3.71 (d, J=13.5 Hz, 1H), 3.64 (s, 3H), 3.59 (d, J=13.4 Hz, 1H), 2.54 (s, 11H), 2.49 (s, 1H), 2.11-2.03 (m, 2H), 1.63 (d, J=10.3 Hz, 5H), 1.56 (d, J=13.0 Hz, 1H), 1.17 (d, J=13.8 Hz, 1H), 1.07 (d, J=6.8 Hz, 1H), 0.99 (d J=6.1 Hz, 3H), 0.81 (s, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.17 (s, 1H), 7.12 (s, 1H), 6.82 (d, J=8.2 Hz, 2H), 3.98 (s, 2H), 3.72 (d, J=13.7 Hz, 1H), 3.58 (d, J=13.0 Hz, 1H), 3.39 (s, 2H), 3.27 (s, 3H), 2.60 (s, 1H), 1.84 (s, 2H), 1.72 (s, 1H), 1.63 (s, 7H), 1.28 (s, 3H), 1.15 (s, 4H), 1.06 (s, 1H), 0.98 (d, J=5.9 Hz, 3H), 0.81 (s, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.33 (d, J=7.4 Hz, 1H), 7.21 (t, J=7.8 Hz, 1H), 7.05 (d, J=8.2 Hz, 1H), 6.96 (t, J=7.3 Hz, 1H), 5.49 (s, 2H), 3.81-3.70 (m, 1H), 3.64 (d, J=14.0 Hz, 1H), 2.36 (s, 3H), 1.69 (s, 1H), 1.58 (s, 5H), 1.52 (d, J=17.4 Hz, 1H), 1.29 (s, 2H), 1.26 (d, J=6.5 Hz, 0H), 1.08 (dd, J=19.4, 9.7 Hz, 4H), 1.02 (t, J=5.9 Hz, 1H), 0.95 (d, J=6.1 Hz, 3H), 0.81 (d, J=12.6 Hz, 1H), 0.75 (d, J=11.9 Hz, 1H).
- 1H NMR (400 MHz, Chloroform-d) δ 8.27 (s, 1H), 7.29-7.18 (m, 3H), 6.95 (t, J=7.5 Hz, 1H), 6.84 (d, J=8.1 Hz, 1H), 4.59 (s, 2H), 3.85 (d, J=11.9 Hz, 1H), 3.70 (d, J=11.8 Hz, 1H), 2.80 (d, J=6.6 Hz, 1H), 2.64 (s, 1H), 1.42 (dd, J=13.3, 6.7 Hz, 1H), 1.19 (s, 7H), 1.11 (d, J=6.2 Hz, 3H), 0.88 (d, J=12.2 Hz, 3H), 0.74 (d, J=6.6 Hz, 2H), 0.43 (s, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.19 (d, J=7.2 Hz, 1H), 7.12 (t, J=7.8 Hz, 1H), 6.83 (d, J=7.7 Hz, 2H), 3.95-3.87 (m, 2H), 3.82 (dd, J=6.4, 2.8 Hz, 2H), 3.72 (d, J=13.4 Hz, 1H), 3.58 (d, J=13.4 Hz, 1H), 3.36 (t, J=11.3 Hz, 2H), 2.61 (d, J=6.2 Hz, 1H), 2.05 (s, 1H), 1.73 (d, J=13.2 Hz, 2H), 1.63 (d, J=11.2 Hz, 5H), 1.54 (d, J=12.7 Hz, 1H), 1.44 (dt, J=12.5, 6.7 Hz, 1H), 1.27 (s, 3H), 1.15 (t, J=10.9 Hz, 2H), 0.98 (d, J=6.2 Hz, 3H), 0.81 (s, 2H).
- 1H NMR 400 MHz DMSO-d6) δ 7.26 (d, J=7.3 Hz, 2H), 7.16 (t, J=7.8 Hz, 2H), 6.90 (s, 3H), 6.87 (d, J=7.5 Hz, 1H), 4.89 (d, J=11.3 Hz, 2H), 4.78 (t, J=14.5 Hz, 2H), 4.19 (s, 0H), 4.10 (s, 1H), 3.79 (d, J=13.2 Hz, 3H), 3.73 (d, J=13.7 Hz, 3H), 3.62 (d, J=13.6 Hz, 2H), 3.45 (d, J=10.9 Hz, 1H), 3.14 (s, 8H), 2.81 (s, 1H), 2.69 (s, 1H), 2.55 (d, J=12.8 Hz, 1H), 2.40 (s, 7H), 1.89 (s, 2H), 1.59 (s, 7H), 1.09 (d, J=6.2 Hz, 7H), 0.95 (d, J=6.1 Hz, 5H), 0.77 (s, 5H).
- 1H NMR (400 MHz, DMSO-d6) δ 8.12 (s, 1H), 7.27 (d, J=7.4 Hz, 1H), 7.20 (t, J=8.0 Hz, 1H), 6.95-6.84 (m, 2H), 4.77 (d, J=3.5 Hz, 2H), 3.98 (q, J=6.8 Hz, 1H), 3.74 (d, J=13.2 Hz, 1H), 3.62 (d, J=13.3 Hz, 1H), 2.63 (s, 1H), 1.85 (dd, J=12.5, 6.2 Hz, 2H), 1.61-1.49 (m, 9H), 1.38 (s, 2H), 1.30 (s, 2H), 1.12 (d, J=12.3 Hz, 1H), 1.08 (s, 4H), 0.98 (d, J=6.2 Hz, 2H), 0.79 (d, J=16.2 Hz, 2H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.25 (d, J=8.1 Hz, 3H), 6.96 (t, J=7.4 Hz, 1H), 6.85 (d, J=8.2 Hz, 1H), 5.72 (s, 1H), 5.00 (s, 1H), 4.21 (s, 2H), 4.20-4.15 (m, 1H), 3.87 (dd, J=13.3, 6.7 Hz, 1H), 3.80 (s, 2H), 3.72 (dd, J=13.5, 8.4 Hz, 1H), 3.66 (s, 2H), 2.69 (q, J=6.4 Hz, 1H), 1.36 (s, 1H), 1.25 (s, 3H), 1.16 (d, J=12.3 Hz, 5H), 1.06 (d, J=6.1 Hz, 3H), 0.87-0.80 (m, 2H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.24 (dd, J=30.2, 8.7 Hz, 2H), 6.96 (t, J=7.5 Hz, 1H), 6.88 (d, J=8.2 Hz, 1H), 4.73 (d, J=3.5 Hz, 2H), 4.40 (d, J=13.2 Hz, 1H), 3.82 (d, J=11.8 Hz, 2H), 3.79-3.70 (m, 1H), 3.51 (s, 2H), 2.84 (t, J=11.8 Hz, 1H), 2.71 (d, J=6.4 Hz, 1H), 2.38 (t, J=11.9 Hz, 1H), 1.36 (dd, J=13.1, 6.6 Hz, 1H), 1.28 (s, 2H), 1.17 (dd, J=14.3, 6.2 Hz, 9H), 1.06 (d, J=6.2 Hz, 3H), 0.84 (d, J=11.8 Hz, 2H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.24 (dt, J=15.5, 5.9 Hz, 2H), 6.95 (dd, J=8.0, 5.4 Hz, 2H), 5.18 (d, J=2.1 Hz, 2H), 3.86 (d, J=13.2 Hz, 1H), 3.75 (d, J=13.2 Hz, 1H), 2.68 (q, J=6.4 Hz, 1H), 2.61 (s, 3H), 1.82 (s, 1H), 1.55 (d, J=13.3 Hz, 1H), 1.37 (dt, J=12.8, 6.5 Hz, 1H), 1.30 (s, 1H), 1.17-1.10 (m, 4H), 1.04 (d, J=6.2 Hz, 3H), 0.82 (s, 3H).
- 1H NMR (400 MHz, Chloroform-d) δ 8.12 (s, 1H), 7.30-7.23 (m, 1H), 7.21 (d, J=7.4 Hz, 1H), 6.97 (t, J=7.5 Hz, 1H), 6.87 (d, J=8.1 Hz, 1H), 5.11 (s, 1H), 4.74 (s, 2H), 3.84 (d, J=11.9 Hz, 1H), 3.76 (d, J=11.8 Hz, 1H), 2.86 (q, J=6.6 Hz, 1H), 1.49 (dt, J=13.5, 6.8 Hz, 1H), 1.26 (s, 1H), 1.12 (p, J=7.1 Hz, 7H), 0.84 (d, J=11.7 Hz, 3H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.27 (q, J=14.2, 11.0 Hz, 4H), 6.96 (t, J=7.4 Hz, 1H), 6.88 (d, J=8.3 Hz, 1H), 4.65 (s, 2H), 4.00 (d, J=14.6 Hz, 3H), 3.83 (d, J=12.0 Hz, 1H), 2.96 (s, 1H), 2.13 (s, 1H), 1.52 (s, 1H), 1.30 (s, 2H), 1.19 (d, J=6.1 Hz, 4H), 0.94-0.83 (m, 2H).
-
- A solution of 2-hydroxybenzaldehyde 1 (5.0 mmol, 1.0 equiv), K2CO3 (7.5 mmol, 1.5 equiv), compound 2 (5.0 mmol, 1.0 equiv) in CH3CN (50 mL) was refluxed and monitored by TLC. After completion of the reaction, the solution was cooled; solvent was evaporated under reduced pressure. The residue was poured into water (30 mL) and extracted with ethyl acetate (3×30 mL). The organic layer was washed with brine and dried over anhydrous MgSO4. Filtration of MgSO4 and evaporation of solvent under vacuum gave the crude product. The residue obtained was purified by using HPLC to obtain the
corresponding compound 3. Yield: 29-53%. - Aldehyde 3 (0.55 mmol), amine 4 (0.5 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours, then mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C., 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified using HPLC. Yield: 31-48%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.33 (d, J=7.4 Hz, 1H), 7.23 (t, J=7.8 Hz, 1H), 7.12 (d, J=8.1 Hz, 1H), 6.96 (t, J=7.3 Hz, 1H), 5.40 (s, 2H), 3.70 (d, J=13.8 Hz, 1H), 3.60 (d, J=14.0 Hz, 1H), 2.54 (s, 1H), 2.45 (d, J=1.9 Hz, 3H), 1.57 (s, 5H), 1.48 (s, 1H), 1.28-1.20 (m, 2H), 1.09 (s, 3H), 0.92 (d, J=6.1 Hz, 3H), 0.75 (t, J=11.8 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.29 (d, J=7.4 Hz, 1H), 7.20 (t, J=7.9 Hz, 1H), 7.09 (d, J=8.3 Hz, 1H), 6.92 (t, J=7.3 Hz, 1H), 5.09 (d, J=2.1 Hz, 2H), 3.69 (d, J=13.9 Hz, 1H), 3.58 (d, J=13.9 Hz, 1H), 2.58-2.47 (m, 2H), 2.23 (s, 3H), 2.02 (s, 3H), 1.57 (s, 5H), 1.49 (d, J=12.9 Hz, 1H), 1.30-1.21 (m, 2H), 1.10 (t, J=11.3 Hz, 2H), 1.02 (q, J=6.7, 6.2 Hz, 1H), 0.93 (d, J=6.1 Hz, 3H), 0.75 (s, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.27 (d, J=7.2 Hz, 1H), 7.16 (t, J=7.7 Hz, 1H), 7.12-7.06 (m, 1H), 6.96 (d, J=8.0 Hz, 3H), 6.87 (t, J=7.0 Hz, 2H), 3.99 (q, J=7.4, 7.0 Hz, 4H), 3.73 (d, J=13.7 Hz, 1H), 3.61 (d, J=13.6 Hz, 1H), 2.62-2.52 (m, 1H), 2.14-2.07 (m, 2H), 1.52 (q, J=16.7, 13.9 Hz, 6H), 1.27 (t, J=8.1 Hz, 2H), 1.06 (t, J=12.0 Hz, 4H), 0.96 (d, J=6.1 Hz, 3H), 0.75 (s, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.94 (s, 1H), 7.34-7.28 (m, 1H), 7.25-7.17 (m, 1H), 7.13 (d, J=8.2 Hz, 1H), 6.94 (t, J=7.3 Hz, 1H), 5.31 (s, 2H), 3.99 (s, 1H), 3.92 (s, 3H), 3.69 (d, J=13.7 Hz, 1H), 3.59 (d, J=14.1 Hz, 1H), 1.58 (s, 7H), 1.26 (s, 2H), 1.19-0.97 (m, 3H), 0.92 (d, J=6.1 Hz, 3H), 0.81-0.70 (m, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.22 (d, J=7.3 Hz, 1H), 7.15 (t, J=7.8 Hz, 1H), 6.90-6.80 (m, 2H), 4.11 (t, J=6.2 Hz, 2H), 3.75 (d, J=13.6 Hz, 1H), 3.61 (d, J=13.5 Hz, 1H), 3.26 (t, J=7.7 Hz, 2H), 2.63 (q, J=6.3 Hz, 1H), 2.50 (s, 2H), 2.24 (t, J=7.6 Hz, 2H), 1.65 (d, J=11.0 Hz, 4H), 1.59 (s, 1H), 1.34-1.20 (m, 3H), 1.16 (s, 4H), 1.15-1.03 (m, 1H), 1.00 (d, J=6.1 Hz, 3H), 0.88-0.77 (m, 2H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.59 (s, 1H), 7.28-7.19 (m, 3H), 7.02-6.90 (m, 2H), 5.26 (s, 2H), 4.11 (s, 3H), 3.86 (d, J=13.2 Hz, 1H), 3.72 (d, J=13.4 Hz, 11H), 2.66 (d, J=7.1 Hz, 11H), 1.50 (d, J=12.9 Hz, 11H), 1.32 (dd, J=13.0, 6.6 Hz, 1H), 1.17-1.07 (m, 3H), 1.03 (d, J=6.1 Hz, 3H), 0.85-0.75 (m, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.21-7.09 (m, 2H), 6.88-6.78 (m, 2H), 4.13-4.06 (m, 2H), 3.80 (t, J=4.8 Hz, 2H), 3.73 (d, J=13.5 Hz, 1H), 3.63 (t, J=4.8 Hz, 2H), 3.58 (d, J=13.3 Hz, 1H), 3.48 (t, J=4.8 Hz, 2H), 3.30 (s, 3H), 2.56 (d, J=17.9 Hz, 1H), 1.62 (d, J=11.6 Hz, 4H), 1.53 (d, J=12.9 Hz, 1H), 1.28 (s, 11H), 1.15 (s, 5H), 1.01 (dd, J=30.7, 6.3 Hz, 3H), 0.80 (q, J=10.3 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.32 (d, J=7.4 Hz, 1H), 7.22 (t, J=7.9 Hz, 1H), 7.08 (d, J=8.2 Hz, 11H), 6.96 (d, J=6.5 Hz, 2H), 5.33 (s, 2H), 3.70 (d, J=13.9 Hz, 1H), 3.61 (d, J=13.7 Hz, 1H), 2.55 (d, J=8.9 Hz, 1H), 2.49 (s, 1H), 1.57 (s, 6H), 1.49 (s, 0H), 1.26 (s, 2H), 1.10 (s, 3H), 1.09-0.98 (m, 1H), 0.93 (d, J=6.1 Hz, 3H), 0.81-0.71 (m, 2H).
- 1H NMR (400 MHz, Chloroform-d) δ 9.12 (s, 1H), 7.29 (d, J=7.8 Hz, 0H), 7.16 (d, J=6.9 Hz, 1H), 7.01-6.92 (m, 2H), 6.84 (d, J=8.2 Hz, 2H), 6.70 (d, J=8.1 Hz, 2H), 4.73 (d, J=4.3 Hz, 2H), 4.42 (dd, J=15.1, 5.8 Hz, 1H), 4.32 (dd, J=14.9, 5.3 Hz, 1H), 3.78 (d, J=15.2 Hz, 5H), 3.60 (d, J=11.6 Hz, 1H), 2.68-2.60 (m, 1H), 1.55 (t, J=14.7 Hz, 2H), 1.13 (d, J=11.1 Hz, 7H), 0.95 (d, J=6.3 Hz, 3H), 0.80 (d, J=13.1 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.20 (d, J=7.5 Hz, 1H), 7.12 (d, J=8.0 Hz, 1H), 6.88-6.78 (m, 2H), 4.06 (t, J=6.1 Hz, 2H), 3.92 (q, J=9.2 Hz, 2H), 3.80 (t, J=6.2 Hz, 2H), 3.72 (d, J=13.7 Hz, 1H), 3.59 (d, J=13.1 Hz, 1H), 2.61 (s, 1H), 2.08 (t, J=6.3 Hz, 2H), 1.63 (d, J=10.5 Hz, 5H), 1.54 (s, 1H), 1.28 (s, 3H), 1.20 (d, J=12.1 Hz, 0H), 1.15 (s, 3H), 1.06 (s, 1H), 0.98 (d, J=6.1 Hz, 2H), 0.82 (s, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 6.86 (d, J=9.7 Hz, 1H), 4.14 (s, 1H), 4.04 (d, J=8.8 Hz, 0H), 3.99 (s, 1H), 2.54 (s, 1H), 1.63 (s, 2H), 1.15 (s, 2H), 0.98 (d, J=5.7 Hz, 1H), 0.80 (s, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.30 (d, J=7.4 Hz, 1H), 7.22 (t, J=7.4 Hz, 1H), 7.09 (d, J=8.2 Hz, 1H), 6.92 (t, J=7.4 Hz, 1H), 4.92 (s, 2H), 3.65 (d, J=13.8 Hz, 1H), 3.56 (d, J=13.9 Hz, 1H), 2.55 (d, J=6.8 Hz, 1H), 2.40 (s, 3H), 2.30 (s, 3H), 2.23 (s, 3H), 1.57 (s, 4H), 1.50 (d, J=13.8 Hz, 3H), 1.22 (dd, J=14.2, 7.5 Hz, 2H), 1.11 (d, J=12.3 Hz, 3H), 1.04-0.96 (m, 1H), 0.91 (d, J=6.1 Hz, 3H), 0.80-0.70 (m, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.18-7.08 (m, 3H), 6.81 (dd, J=12.9, 7.4 Hz, 3H), 4.03 (hept, J=4.9 Hz, 3H), 3.74 (d, J=13.7 Hz, 1H), 3.67 (t, J=5.0 Hz, 3H), 3.56 (d, J=13.7 Hz, 2H), 2.55 (d, J=5.5 Hz, 1H), 1.60 (d, J=12.9 Hz, 7H), 1.47 (d, J=13.8 Hz, 3H), 1.28 (s, 2H), 1.25 (d, J=6.5 Hz, 1H), 1.21 (s, 12H), 1.12 (d, J=11.3 Hz, 1H), 1.06-0.93 (m, 4H), 0.77 (dd, J=28.9, 12.5 Hz, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 8.18 (s, 1H), 7.27 (d, J=7.4 Hz, 1H), 7.20 (t, J=7.7 Hz, 1H), 6.91 (dt, J=17.1, 8.1 Hz, 2H), 4.78 (d, J=3.5 Hz, 2H), 3.90 (d, J=8.7 Hz, 1H), 3.75 (d, J=13.2 Hz, 1H), 3.63 (d, J=13.3 Hz, 1H), 3.30 (s, 1H), 2.64 (s, 1H), 2.54 (s, 0H), 1.58 (s, 6H), 1.34 (d, J=7.2 Hz, 1H), 1.30 (s, 2H), 1.09 (p, J=14.1, 13.5 Hz, 8H), 0.98 (d, J=6.0 Hz, 3H), 0.81 (s, 1H), 0.76 (d, J=12.7 Hz, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.26 (d, J=7.3 Hz, 1H), 7.16 (t, J=7.7 Hz, 1H), 6.94-6.84 (m, 2H), 4.91-4.78 (m, 2H), 3.74 (d, J=13.8 Hz, 1H), 3.66-3.53 (m, 5H), 3.46 (s, 4H), 2.60-2.52 (m, 1H), 1.90 (s, 1H), 1.59 (s, 5H), 1.30 (s, 2H), 1.12 (s, 5H), 0.95 (d, J=6.0 Hz, 3H), 0.83-0.72 (m, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 10.55 (s, 1H), 8.82 (d, J=4.9 Hz, 2H), 7.43 (t, J=5.0 Hz, 1H), 7.09 (t, J=8.5 Hz, 2H), 6.71 (t, J=7.2 Hz, 2H), 3.96 (d, J=16.3 Hz, 1H), 3.82-3.69 (m, 2H), 3.64 (d, J=13.8 Hz, 1H), 2.78 (q, J=6.9 Hz, 1H), 1.50 (t, J=13.8 Hz, 3H), 1.38 (dd, J=13.5, 6.8 Hz, 1H), 1.26 (d, J=12.1 Hz, 3H), 1.02 (s, 4H), 0.98 (d, J=6.6 Hz, 3H), 0.68 (d, J=10.9 Hz, 1H), 0.57 (d, J=12.3 Hz, 1H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.25 (d, J=11.7 Hz, 3H), 7.02 (d, J=8.2 Hz, 1H), 6.95 (t, J=7.4 Hz, 1H), 5.36 (s, 2H), 4.37 (s, 3H), 3.87 (d, J=13.2 Hz, 1H), 3.75 (d, J=13.3 Hz, 1H), 2.68 (d, J=7.1 Hz, 1H), 1.54 (d, J=13.0 Hz, 1H), 1.36 (dd, J=12.9, 6.6 Hz, 1H), 1.28 (s, 1H), 1.13 (s, 5H), 1.04 (d, J=6.1 Hz, 3H), 0.82 (s, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.32 (d, J=7.4 Hz, 1H), 7.22 (t, J=7.7 Hz, 1H), 7.06 (d, J=8.3 Hz, 1H), 6.96 (t, J=7.4 Hz, 1H), 5.49 (d, J=2.5 Hz, 2H), 3.75 (d, J=13.8 Hz, 1H), 3.64 (d, J=13.8 Hz, 1H), 3.09 (p, J=7.0 Hz, 1H), 2.60-2.52 (m, 1H), 1.57 (s, 4H), 1.26 (d, J=7.0 Hz, 7H), 1.09 (s, 3H), 1.01 (s, 1H), 0.95 (d, J=6.1 Hz, 3H), 0.76 (t, J=12.8 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.33 (d, J=7.4 Hz, 1H), 7.22 (t, J=7.8 Hz, 1H), 7.06 (d, J=8.2 Hz, 1H), 6.96 (t, J=7.3 Hz, 1H), 5.49 (s, 2H), 3.75 (d, J=13.8 Hz, 1H), 3.64 (d, J=13.9 Hz, 1H), 2.74 (q, J=7.6 Hz, 2H), 2.59-2.52 (m, 1H), 1.70 (s, 1H), 1.57 (s, 5H), 1.51 (d, J=15.5 Hz, 1H), 1.28 (s, 2H), 1.23 (t, J=7.6 Hz, 3H), 1.07 (dt, J=17.1, 8.6 Hz, 2H), 0.94 (d, J=6.1 Hz, 3H), 0.78 (q, J=11.6 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 8.16 (s, 1H), 7.27 (d, J=7.3 Hz, 1H), 7.20 (t, J=7.9 Hz, 1H), 6.95-6.85 (m, 2H), 4.76 (d, J=3.3 Hz, 2H), 3.74 (d, J=13.1 Hz, 1H), 3.62 (d, J=13.2 Hz, 1H), 2.62 (d, J=6.8 Hz, 1H), 2.33 (s, 1H), 1.58 (s, 4H), 1.51 (s, 1H), 1.28 (s, 9H), 1.22-0.95 (m, 6H), 0.77 (s, 2H).
-
- Amine 1 (0.5 mmol) and compound 2 (0.55 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours, then mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C., 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified using HPLC. Yield: 23-58%.
- The following compounds were synthesized according to the Scheme shown in Example 10 above:
- 1H NMR (400 MHz, DMSO-d6) δ 7.28 (dd, J=14.3, 7.3 Hz, 4H), 7.17 (t, J=7.1 Hz, 1H), 3.78 (dd, J=13.4, 3.2 Hz, 1H), 3.65 (d, J=13.1 Hz, 1H), 2.43 (p, J=5.9 Hz, 1H), 1.71 (q, J=14.0, 13.6 Hz, 5H), 1.38-1.22 (m, 1H), 1.29 (s, 1H), 1.26-1.17 (m, 1H), 1.17 (s, 1H), 1.04 (d, J=14.0 Hz, 1H), 0.98 (d, J=6.6 Hz, 3H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.36-7.26 (m, 4H), 7.21 (td, J=6.5, 6.0, 2.5 Hz, 1H), 3.67 (s, 2H), 2.49 (s, 1H), 2.46-2.36 (m, 1H), 1.98 (pd, J=7.6, 4.1 Hz, 2H), 1.91-1.79 (m, 1H), 1.82-1.72 (m, 1H), 1.69-1.56 (m, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.37-7.26 (m, 4H), 7.22 (d, J=6.8 Hz, 1H), 3.68 (s, 2H), 2.29 (d, J=6.7 Hz, 2H), 1.93 (s, 1H), 1.68 (dp, J=13.3, 6.7 Hz, 1H), 0.87 (d, J=6.6 Hz, 5H).
- 1H NMR (400 MHz, DMSO-d6) δ 9.17 (s, 2H), 7.46 (d, J=7.8 Hz, 2H), 7.23 (d, J=7.6 Hz, 2H), 4.08 (s, 2H), 4.08 (d, J=12.1 Hz, 0H), 2.90 (s, 1H), 2.32 (s, 3H), 2.14-2.06 (m, 2H), 1.76 (d, J=12.8 Hz, 2H), 1.59 (d, J=12.0 Hz, 1H), 1.40 (s, 1H), 1.36 (d, J=10.8 Hz, 1H), 1.22 (d, J=12.5 Hz, 1H), 1.12 (dd, J=28.3, 13.2 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.29 (dt, J=15.0, 7.5 Hz, 6H), 7.19 (t, J=7.1 Hz, 2H), 3.16 (s, 4H), 2.70-2.64 (m, 2H), 2.55 (s, 1H), 1.60 (dd, J=13.2, 5.4 Hz, 3H), 1.49 (s, 4H), 1.47 (t, J=4.3 Hz, 1H), 1.45-1.32 (m, 5H), 0.91 (d, J=6.6 Hz, 4H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.31-7.20 (m, 3H), 7.16 (t, J=7.0 Hz, 1H), 3.70 (s, 1H), 1.44 (q, J=7.0 Hz, 1H), 1.28 (s, 9H), 0.90 (t, J=6.6 Hz 2H), 0.82 (s, 1H).
- 1H NMR (400 MHz, DMSO-d6) δ 8.95 (s, 2H), 7.69-7.62 (m, 1H), 7.47-7.41 (m, 1H), 7.42 (s, 2H), 6.99 (s, 2H), 4.55 (s, 2H), 4.24 (t, J=5.9 Hz, 2H), 3.00 (s, 2H), 1.65 (d, J=11.9 Hz, 5H), 1.55 (q, J=7.3 Hz, 3H), 1.30 (s, 1H), 1.16 (p, J=12.0 Hz, 3H), 0.89 (q, J=11.8 Hz, 2H). Yield: 39%.
- 1H NMR (400 MHz, Chloroform-d) δ 7.24-7.12 (m, 2H), 6.87 (t, J=7.4 Hz, 1H), 6.69 (d, J=8.1 Hz, 1H), 4.66 (p, J=7.2 Hz, 1H), 3.83 (d, J=13.0 Hz, 1H), 3.70 (d, J=13.0 Hz, 1H), 2.69 (h, J=6.4 Hz, 1H), 2.47 (dtt, J=12.3, 6.7, 2.7 Hz, 2H), 2.19 (d, J=10.1 Hz, 1H), 2.14 (d, J=10.2 Hz, 1H), 1.87 (q, J=10.0 Hz, 2H), 1.79-1.61 (m, 5H), 1.60 (s, 1H), 1.42-1.22 (m, 2H), 1.19 (s, 3H), 1.18-1.08 (m, 2H), 1.05 (d, J=6.2 Hz, 3H), 0.86 (s, 1H), 0.81 (dd, J=12.1, 4.0 Hz, 1H). Yield: 32%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.26-7.12 (m, 3H), 7.00-6.81 (m, 3H), 3.97 (q, J=7.8 Hz, 1H), 3.82 (q, J=8.6 Hz, 1H), 3.70 (dt, J=14.5, 6.4 Hz, 3H), 3.59 (d, J=11.8 Hz, 2H), 2.56 (p, J=6.0 Hz, 2H), 2.32 (s, 1H), 2.27 (s, 1H), 2.25-2.17 (m, 2H), 1.89 (p, J=7.4 Hz, 1H), 1.73 (t, J=12.1 Hz, 1H), 1.57 (d, J=11.6 Hz, 8H), 1.53-1.43 (m, 5H), 1.37 (d, J=9.9 Hz, 2H), 1.28 (dt, J=17.8, 7.4 Hz, 5H), 1.17 (s, 2H), 1.11 (t, J=11.6 Hz, 5H), 1.04 (d, J=7.9 Hz, 2H), 0.95 (d, J=5.7 Hz, 4H), 0.80 (d, J=10.1 Hz, 2H), 0.75 (s, 2H). Yield 29%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.24 (d, J=7.4 Hz, 1H), 7.15 (t, J=7.8 Hz, 1H), 6.96 (d, J=8.2 Hz, 1H), 6.83 (t, J=7.4 Hz, 1H), 4.43-4.34 (m, 1H), 3.69 (d, J=13.4 Hz, 1H), 3.58 (d, J=13.4 Hz, 1H), 2.58 (q, J=6.3 Hz, 1H), 1.87 (d, J=11.8 Hz, 2H), 1.69 (s, 2H), 1.58 (d, J=10.5 Hz, 6H), 1.50 (t, J=8.4 Hz, 4H), 1.35 (dt, J=20.6, 10.4 Hz, 4H), 1.30-1.21 (m, 1H), 1.11 (td, J=22.2, 19.3, 9.7 Hz, 4H), 0.96 (d, J=6.1 Hz, 3H), 0.83 (dd, J=18.2, 7.7 Hz, 1H), 0.75 (d, J=11.4 Hz, 1H). Yield 39%.
-
- Amine 1 (0.5 mmol), aldehyde 2 (0.55 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours, then mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C., 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified using HPLC. Yield: 31-54%.
- The following compounds were synthesized according to the Scheme shown in Example 10 above:
- 1H NMR (400 MHz, DMSO-d6) δ 7.69 (d, J=7.9 Hz, 1H), 7.61 (d, J=7.6 Hz, 1H), 7.44 (t, J=7.5 Hz, 1H), 7.32 (t, J=8.1 Hz, 2H), 7.22 (t, J=7.8 Hz, 1H), 7.05 (d, J=8.1 Hz, 1H), 6.92 (t, J=7.4 Hz, 1H), 5.13 (s, 2H), 3.75 (d, J=13.7 Hz, 1H), 3.64 (d, J=13.7 Hz, 1H), 2.56 (q, J=6.2 Hz, 1H), 1.58-1.44 (m, 6H), 1.28-1.17 (m, 2H), 1.04 (dt, J=28.1, 7.4 Hz, 5H), 0.91 (d, J=6.1 Hz, 3H), 0.73 (t, J=12.1 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.66-7.59 (m, 1H), 7.56-7.49 (m, 1H), 7.44-7.35 (m, 2H), 7.30 (d, J=7.3 Hz, 1H), 7.22 (t, J=7.6 Hz, 1H), 7.07 (d, J=8.1 Hz, 1H), 6.92 (t, J=7.4 Hz, 1H), 5.17 (s, 2H), 3.75 (d, J=13.6 Hz, 1H), 3.63 (d, J=13.8 Hz, 1H), 2.56 (s, 1H), 1.58 (d, J=12.3 Hz, 1H), 1.57-1.43 (m, 5H), 1.27-1.17 (m, 2H), 1.08 (d, J=8.1 Hz, 2H), 1.03 (s, 1H), 1.08-0.96 (m, 1H), 0.91 (d, J=6.1 Hz, 3H), 0.74 (t, J=12.1 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.44 (td, J=8.0, 5.9 Hz, 1H), 7.30 (d, J=6.8 Hz, 3H), 7.26-7.11 (m, 2H), 7.02 (d, J=8.2 Hz, 1H), 6.91 (t, J=7.4 Hz, 1H), 5.15 (s, 2H), 3.77 (d, J=13.6 Hz, 1H), 3.66 (d, J=13.6 Hz, 1H), 2.59 (q, J=6.3 Hz, 1H), 1.55 (d, J=12.9 Hz, 6H), 1.49 (s, 1H), 1.26 (dq, J=13.0, 6.8, 6.3 Hz, 2H), 1.05 (dt, J=21.5, 7.8 Hz, 5H), 0.95 (d, J=6.1 Hz, 3H), 0.75 (dd, J=17.6, 7.0 Hz, 2H).
- 1H NMR (400 MHz, DMSO-d6) δ 7.43 (d, J=7.2 Hz, 1H), 7.30 (d, J=7.4 Hz, 1H), 7.27-7.16 (m, 4H), 7.10 (d, J=8.2 Hz, 1H), 6.90 (t, J=7.3 Hz, 1H), 5.09 (s, 2H), 3.73 (d, J=13.7 Hz, 1H), 3.63 (d, J=13.8 Hz, 1H), 2.56 (q, J=6.3 Hz, 1H), 2.34 (s, 3H), 1.59-1.44 (m, 6H), 1.21 (dd, J=14.0, 7.5 Hz, 2H), 1.04 (dt, J=30.0, 7.8 Hz, 4H), 0.91 (d, J=6.1 Hz, 3H), 0.74 (t, J=12.1 Hz, 2H).
- 1H NMR (400 MHz, Chloroform-d) δ 7.88 (d, J=7.9 Hz, 1H), 7.52 (d, J=7.6 Hz, 1H), 7.38 (t, J=7.5 Hz, 1H), 7.32-7.19 (m, 3H), 7.04 (t, J=7.7 Hz, 1H), 6.99-6.89 (m, 2H), 5.07 (s, 2H), 3.95 (d, J=13.1 Hz, 1H), 3.82 (d, J=13.1 Hz, 1H), 2.72 (q, J=6.4 Hz, 1H), 1.60 (d, J=9.5 Hz, 5H), 1.52 (d, J=13.1 Hz, 1H), 1.35 (dt, J=13.3, 6.6 Hz, 1H), 1.18-1.02 (m, 7H), 0.80 (d, J=11.4 Hz, 2H).
-
- 2-(1H-indol-7-yl)ethan-1-amine (0.5 mmol) and benzaldehyde (0.55 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours, then mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C., 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated and dissolved in 0.5 ml of DMSO. The residue was purified using HPLC. Yield: 47%. Brown gum. 1H NMR (400 MHz, DMSO-d6) δ 11.21 (s, 1H), 7.37 (dd, J=6.7, 2.3 Hz, 1H), 7.29 (dd, J=9.1, 5.1 Hz, 5H), 7.25-7.16 (m, 1H), 7.11 (s, 1H), 6.94-6.85 (m, 2H), 6.44-6.38 (m, 1H), 3.74 (s, 2H), 3.01 (t, J=7.2 Hz, 2H), 2.83 (t, J=7.2 Hz, 2H).
- 2-(1H-indol-4-yl)ethan-1-amine (0.5 mmol) and benzaldehyde (0.55 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours, then mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C., 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated and dissolved in 0.5 ml of DMSO. The residue was purified using HPLC. Yield: 56%. Yellow gum. 1H NMR (400 MHz, Chloroform-d) δ 8.20 (s, 1H), 7.26 (s, 1H), 7.21 (s, 2H), 7.13 (t, J=7.7 Hz, 1H), 6.96 (d, J=7.1 Hz, H), 6.61 (s, 1H), 3.83 (s, 2H), 3.15 (t, J=7.2 Hz, 2H), 3.05 (t, J=7.2 Hz, 2H).
- 2-(cyclohex-1-en-1-yl)ethan-1-amine (0.5 mmol) and 3-methoxybenzaldehyde (0.55 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours, then mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C., 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated and dissolved in 0.5 ml of DMSO. The residue was purified using HPLC. Yield: 58%. Cream solid. 1H NMR (400 MHz, DMSO-d6) δ 9.70 (s, 2H), 7.29 (dd, J=15.7, 7.7 Hz, 2H), 7.11 (d, J=7.4 Hz, 1H), 6.90 (dd, J=8.4, 2.6 Hz, 1H), 5.47 (s, 1H), 3.82 (s, 3H), 3.09 (s, 1H), 2.88 (t, J=8.2 Hz, 2H), 2.37 (t, J=8.4 Hz, 3H), 1.98 (s, 2H), 1.91 (d, J=6.8 Hz, 2H), 1.67-1.57 (m, 2H), 1.60-1.50 (m, 2H).
- To borane tetrahydrofuran complex (1.6 ml, 1.6 mmol) was slowly added at 0° C. N-benzyl-2-(cyclohex-2-en-1-yl)acetamide (0.89 mmol) in tetrahydrofuran (3 ml). The reaction mixture was then stirred at 60° C. for 3 hours, cooled to room temperature and quenched with 6N aqueous hydrochloric acid. The solvent was removed by distillation and water (10 ml) 5 was added. The residue was purified using HPLC. Yield: 34%. 1H NMR (400 MHz, Chloroform-d) δ 7.37-7.19 (m, 3H), 5.66 (dq, J=9.8, 3.2 Hz, 1H), 5.59-5.51 (m, 1H), 3.79 (s, 2H), 2.69 (ddt, J=11.2, 6.4, 3.3 Hz, 2H), 2.14 (s, 1H), 1.96 (tp, J=5.1, 2.6 Hz, 2H), 1.82-1.66 (m, 2H), 1.62-1.41 (m, 2H), 1.29-1.16 (m, 1H).
- 2-(cyclohex-1-en-1-ylmethyl)pyrrolidine (0.5 mmol), benzaldehyde (0.55 mmol) were dissolved in 0.6 ml of CHCl3; NaBHAc3 (1.5 mmol) was added and stirred for 4 hours. The mixture was heated for 12 hours at 60° C., 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated and dissolved in 0.5 ml of DMSO. The residue was purified using HPLC. Yield: 32%. 1H NMR (400 MHz, DMSO-d6) δ 7.28 (q, J=5.5, 4.2 Hz, 4H), 7.21 (td, J=6.0, 3.0 Hz, 1H), 5.42 (s, 1H), 4.00 (d, J=13.1 Hz, 1H), 3.16 (d, J=13.1 Hz, 1H), 2.75 (dt, J=9.5, 4.8 Hz, 1H), 2.35-2.27 (m, 1H), 2.05 (q, J=8.6 Hz, 1H), 1.92 (d, J=6.0 Hz, 4H), 1.83 (t, J=6.9 Hz, 1H), 1.80 (s, 1H), 1.54 (dddd, J=22.2, 16.9, 10.3, 5.1 Hz, 6H), 1.49-1.33 (m, 1H).
- 2-(cyclohex-1-en-1-ylmethyl)piperidine (0.5 mmol), benzaldehyde (0.55 mmol) were dissolved in 0.6 ml of CHCl3; NaBHAc3 (1.5 mmol) was added and stirred for 4 hours. The mixture was heated for 12 hours at 60° C., 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated and dissolved in 0.5 ml of DMSO. The residue was purified using HPLC. Yield: 48%. 1H NMR (400 MHz, Chloroform-d) δ 7.34-7.21 (m, 4H), 7.21 (dd, J=7.6, 4.8 Hz, 1H), 5.16 (d, J=8.9 Hz, 1H), 4.10 (d, J=13.4 Hz, 1H), 3.02 (d, J=13.4 Hz, 1H), 2.88 (s, 1H), 2.82 (d, J=11.8 Hz, 1H), 2.27-2.14 (m, 2H), 2.11 (d, J=5.8 Hz, 2H), 1.86 (td, J=11.8, 3.0 Hz, 1H), 1.72-1.64 (m, 1H), 1.53 (s, 1H), 1.49-1.40 (m, 1H), 1.40-1.19 (m, 1H).
- (R)-1-(cyclohex-1-en-1-yl)propan-2-amine (0.5 mmol) and benzaldehyde (0.55 mmol) were dissolved in 0.6 ml CHCl3, NaBH(OAc)3 (1.5 mmol) was added and stirred for 4 hours. The mixture was heated for 12 hours at 60° C., 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated and dissolved in 0.5 ml of DMSO. The residue was purified using HPLC. Yield: 47%. 1H NMR (400 MHz, Chloroform-d) δ 7.37-7.24 (m, 3H), 7.22 (d, J=7.3 Hz, 2H), 5.47 (s, 1H), 4.69 (ddt, J=10.7, 7.2, 3.4 Hz, 1H), 4.16 (ddq, J=14.8, 11.9, 7.3 Hz, 3H), 4.00 (h, J=6.9 Hz, 1H), 3.44 (s, 1H), 3.28 (dd, J=13.3, 3.4 Hz, 1H), 2.67 (dd, J=13.3, 9.8 Hz, 1H), 2.57 (q, J=7.3 Hz, 1H), 2.47 (dd, J=13.7, 7.0 Hz, 1H), 2.07-1.97 (m, 2H), 1.66-1.56 (m, 2H), 1.59-1.48 (m, 3H), 1.32-1.05 (m, 5H).
- (S)-1-(cyclohex-1-en-1-yl)propan-2-amine (0.5 mmol) and benzaldehyde (0.55 mmol) were dissolved in 0.6 ml CHCl3, NaBH(OAc)3 (1.5 mmol) was added and stirred for 4 hours. The mixture was heated for 12 hours at 60° C., 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated and dissolved in 0.5 ml of DMSO. The residue was purified using HPLC. Yield: 36%. 1H NMR (400 MHz, Chloroform-d) δ 7.37-7.24 (m, 3H), 7.22 (d, J=7.3 Hz, 2H), 5.47 (s, 1H), 4.69 (ddt, J=10.7, 7.2, 3.4 Hz, 1H), 4.16 (ddq, J=14.8, 11.9, 7.3 Hz, 3H), 4.00 (h, J=6.9 Hz, 1H), 3.44 (s, 1H), 3.28 (dd, J=13.3, 3.4 Hz, 1H), 2.67 (dd, J=13.3, 9.8 Hz, 1H), 2.57 (q, J=7.3 Hz, 1H), 2.47 (dd, J=13.7, 7.0 Hz, 1H), 2.07-1.97 (m, 2H), 1.66-1.56 (m, 2H), 1.59-1.48 (m, 3H), 1.32-1.05 (m, 5H).
- To borane tetrahydrofuran complex (1.6 ml, 1.6 mmol) was slowly added at 0° C. N-(2-(bicyclo[4.1.0]heptan-1-yl)ethyl)benzamide (0.89 mmol) in tetrahydrofuran (3 ml). The reaction mixture was then stirred at 60° C. for 3 hours, cooled to room temperature and quenched with 6N aqueous hydrochloric acid. The solvent was removed by distillation and water (10 ml) was added. The residue was purified using HPLC. Yield: 37%. 1H NMR (400 MHz, DMSO-d6) δ 9.28 (s, 2H), 7.60-7.53 (m, 2H), 7.47-7.36 (m, 3H), 4.11 (s, 2H), 2.94 (t, J=8.5 Hz, 2H), 1.83 (dq, J=13.3, 6.4 Hz, 1H), 1.57 (dddd, J=34.1, 16.9, 13.1, 8.3 Hz, 5H), 1.20 (dd, J=14.8, 7.1 Hz, 1H), 1.17-1.06 (m, 3H), 0.71 (q, J=7.3 Hz, 1H), 0.38 (dd, J=9.2, 4.2 Hz, 1H), 0.20 (t, J=4.8 Hz, 1H).
- To borane tetrahydrofuran complex (1.6 ml, 1.6 mmol) was slowly added at 0° C. N-(2-(7,7-difluorobicyclo[4.1.0]heptan-1-yl)ethyl)benzamide (0.89 mmol) in tetrahydrofuran (3 ml). The reaction mixture was then stirred at 60° C. for 3 hours, cooled to room temperature and quenched with 6N aqueous hydrochloric acid. The solvent was removed by distillation and water (10 ml) was added. The residue was purified using HPLC. Yield: 34%. 1H NMR (400 MHz, DMSO-d6) δ 7.30 (dd, J=8.6, 5.1 Hz, 4H), 7.25-7.17 (m, 1H), 3.68 (s, 2H), 2.57 (dd, J=15.3, 7.7 Hz, 2H), 2.00 (s, 1H), 1.63-1.50 (m, 5H), 1.33 (dd, J=15.6, 8.4 Hz, 1H), 1.20 (dd, J=20.0, 9.1 Hz, 4H).
- 2-benzyloctahydroisoquinolin-1(2H)-one (0.1 mmol) was dissolved in methanol; an excess of hydrochloric acid (0.2 mmol) was added to the reaction mixture. The mixture was refluxed for 10 h, solvent was removed. The resulting compound was purified using HPLC. Yield: 44%. 1H NMR (400 MHz, DMSO-d6) δ 9.03 (s, 2H), 7.54-7.48 (m, 2H), 7.47-7.38 (m, 3H), 4.11 (t, J=8.7 Hz, 2H), 3.01-2.91 (m, 1H), 2.83 (s, 1H), 1.95 (dd, J=12.3, 8.9 Hz, 1H), 1.82 (d, J=12.6 Hz, 1H), 1.72 (d, J=12.8 Hz, 2H), 1.66 (s, 2H), 1.56-1.46 (m, 1H), 1.45 (s, 1H), 1.32 (d, J=11.8 Hz, 1H), 1.20 (d, J=10.4 Hz, 2H), 0.89 (d, J=12.2 Hz, 1H).
- To a flask was added 2-(2-(benzylamino)ethyl)cyclohexane-1-carboxylic acid (1 mmol),
anhydrous DMF 10 mL, potassium carbonate (2 mmol), catalytic amount of potassium iodide, stirring 10 min, then methyl iodide (1 mmol) was added, reacted at 70° C., monitored by TLC. After the reaction was allowed to cool to room temperature, the reaction solution was poured into ice water, stirred for 30 min, extracted with ethyl acetate. The organic layers were combined, washed with saturated brine. Dried over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure, dried in vacuo. The crude residue was purified by HPLC. Yield: 21%. 1H NMR (400 MHz, DMSO-d6) δ 9.04 (s, 1H), 8.97 (s, 1H), 7.50 (s, 1H), 7.42 (s, 2H), 4.10 (s, 2H), 3.59 (d, J=5.1 Hz, 2H), 2.94 (s, 1H), 2.80 (s, 1H), 2.07 (s, 1H), 1.76 (dd, J=26.2, 12.2 Hz, 1H), 1.65 (s, 3H), 1.43 (s, 1H), 1.20 (s, 2H), 0.92 (d, J=11.6 Hz, 1H). - To borane tetrahydrofuran complex (1.6 ml, 1.6 mmol) was slowly added at 0° C. N-benzyl-2-(1-hydroxycyclohexyl)acetamide (0.89 mmol) in tetrahydrofuran (3 ml). The reaction mixture was then stirred at 60° C. for 3 hours, cooled to room temperature and quenched with 6N aqueous hydrochloric acid. The solvent was removed by distillation and water (10 ml) 5 was added. The residue was purified using HPLC. Yield: 22%. 1H NMR (400 MHz, Chloroform-d) δ 7.36-7.22 (m, 2H), 3.77 (s, 2H), 2.94-2.87 (m, 2H), 1.69-1.58 (m, 3H), 1.35 (dt, J=22.6, 12.2 Hz, 3H), 1.26 (s, 1H).
- To a solution of tert-butyl benzyl(2-(2-chloro-1-hydroxycyclohexyl)ethyl)carbamate (0.1 mmol) in dichloromethane (25 mL) was slowly added trifluoroacetic acid (3.4 mmol) at 0° C. The reaction solution was stirred at room temperature for 5 h, and then 1N NaOH was added. The mixture was extracted with dichloromethane, and the organic layer was washed with brine, dried (Na2SO4), and filtered. The solvent was evaporated under reduced pressure to give the product. The crude residue was purified by HPLC. Yield: 46%. 1H NMR (400 MHz, DMSO-d6) δ 8.89 (s, 3H), 7.53-7.37 (m, 7H), 5.07 (s, 1H), 4.19 (d, J=11.6 Hz, 3H), 4.08 (s, 1H), 4.01 (dd, J=7.1, 3.6 Hz, 1H), 3.17 (s, 2H), 3.01 (d, J=9.0 Hz, 2H), 2.11 (t, J=9.8 Hz, 1H), 1.96 (dd, J=14.8, 7.1 Hz, 1H), 1.87 (td, J=13.7, 13.2, 5.8 Hz, 1H), 1.67 (q, J=14.9, 13.5 Hz, 2H), 1.59 (s, 4H), 1.36 (d, J=9.8 Hz, 3H).
- 2-(2-aminoethyl)cyclohexan-1-ol (0.5 mmol), benzaldehyde (0.55 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours, then mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C., 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated and dissolved in 0.5 ml of DMSO. The residue was purified using HPLC. Yield: 68%. 1H NMR (400 MHz, Chloroform-d) δ 7.34 (s, 1H), 7.27 (d, J=6.7 Hz, 1H), 4.53 (s, 2H), 3.80 (s, 2H), 3.79 (s, 0H), 3.13 (s, 1H), 3.01-2.89 (m, 1H), 2.63 (t, J=11.1 Hz, 1H), 2.00 (s, 1H), 1.42 (dd, J=15.6, 9.5 Hz, 1H), 1.21 (q, J=11.8, 11.0 Hz, 4H), 1.07-0.97 (m, 1H).
- To a solution of tert-butyl benzyl(2-(2-methoxycyclohexyl)ethyl)carbamate (0.1 mmol) in dichloromethane (25 mL) was slowly added trifluoroacetic acid (3.4 mmol) at 0° C. The reaction solution was stirred at room temperature for 5 h, and then 1N NaOH was added. The mixture was extracted with dichloromethane, and the organic layer was washed with brine, dried (Na2SO4), and filtered. The solvent was evaporated under reduced pressure to give the product. The crude residue was purified by HPLC. Yield: 57%. 1H NMR (400 MHz, DMSO-d6) δ 9.22 (s, 2H), 7.55 (d, J=7.9 Hz, 2H), 7.41 (d, J=6.6 Hz, 2H), 4.10 (s, 2H), 3.20 (s, 2H), 2.88 (s, 2H), 2.73 (td, J=9.9, 4.1 Hz, 1H), 2.05 (d, J=11.8 Hz, 1H), 1.97 (s, 1H), 1.67 (d, J=12.0 Hz, 2H), 1.55 (d, J=11.2 Hz, 1H), 1.50-1.44 (m, 1H), 1.27 (s, 1H), 1.13 (q, J=12.3 Hz, 2H), 1.01-0.89 (m, 2H).
- Benzylamine (0.25 mmol) and 1-(adamantan-2-yl)ethan-1-one (0.3 mmol) were dissolved in 0.3 ml MeOH, heated at 100° C. for 2 hours, then mixture was cooled, NaBH4 (0.25 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C., 3 ml of methanol and 0.1 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated and dissolved in 0.25 ml of DMSO. The residue was purified using HPLC. Yield: 34%. Cream solid. 1H NMR (400 MHz, DMSO-d6) δ 9.42 (s, 1H), 8.54 (s, 1H), 7.68-7.58 (m, 2H), 7.43 (q, J=5.8 Hz, 3H), 4.20 (q, J=8.6, 7.2 Hz, 1H), 4.13 (s, 1H), 3.22 (s, 1H), 2.49 (s, 1H), 2.06 (s, 1H), 1.86-1.75 (m, 5H), 1.66 (d, J=11.0 Hz, 4H), 1.43 (s, 2H), 1.36 (s, 2H), 1.28 (d, J=6.5 Hz, 2H).
- To borane tetrahydrofuran complex (1.6 ml, 1.6 mmol) was slowly added at 0° C. N-benzyl-2-(7-methoxynaphthalen-1-yl)acetamide (0.89 mmol) in tetrahydrofuran (3 ml). The reaction mixture was then stirred at 60° C. for 3 hours, cooled to room temperature and quenched with 6N aqueous hydrochloric acid. The solvent was removed by distillation and water (10 ml) 5 was added. The residue was purified using HPLC. Yield: 28%. 1H NMR (400 MHz, Chloroform-d) δ 7.76 (d, J=8.9 Hz, 1H), 7.66 (d, J=8.0 Hz, 1H), 7.36-7.22 (m, 6H), 7.16 (dd, J=9.0, 2.5 Hz, 1H), 3.90 (s, 3H), 3.87 (s, 1H), 3.85 (s, 2H), 3.27 (t, J=7.3 Hz, 2H), 3.07 (t, J=7.3 Hz, 2H).
- 2-(2-methoxynaphthalen-1-yl)ethan-1-amine (0.5 mmol) and benzaldehyde (0.55 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours, then mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C., 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated and dissolved in 0.5 ml of DMSO. The residue was purified using HPLC. Yield: 42%. 1H NMR (400 MHz, DMSO-d6) δ 9.58 (s, 1H), 8.14 (d, J=8.7 Hz, 0H), 7.94-7.86 (m, 1H), 7.61 (d, J=7.0 Hz, 1H), 7.45 (ddt, J=29.2, 22.6, 7.8 Hz, 3H), 4.22 (s, 1H), 3.51-3.43 (m, 1H), 3.34 (s, 1H), 3.00 (s, 1H).
- Benzylamine (0.5 mmol) and 1-(4-methoxynaphthalen-1-yl)propan-2-one (0.55 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours, then mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C., 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated and dissolved in 0.5 ml of DMSO. The residue was purified using HPLC. Yield: 36%. 1H NMR (400 MHz, DMSO-d6) δ 8.19-8.13 (m, 1H), 7.95-7.88 (m, 1H), 7.47 (q, J=5.0 Hz, 2H), 7.32-7.19 (m, 5H), 7.19 (s, 1H), 6.88 (d, J=7.8 Hz, 1H), 3.94 (s, 3H), 3.84 (d, J=13.9 Hz, 1H), 3.73 (d, J=13.9 Hz, 1H), 3.26 (dd, J=13.6, 5.0 Hz, 1H), 2.88 (s, 1H), 2.75 (dd, J=13.3, 8.1 Hz, 1H), 2.54 (s, 1H), 2.17 (s, 1H), 0.95 (d, J=6.0 Hz, 3H).
- To borane tetrahydrofuran complex (1.6 ml, 1.6 mmol) was slowly added at 0° C. N-benzyl-2-(4-methylcyclohexyl)acetamide (0.89 mmol) in tetrahydrofuran (3 ml). The reaction mixture was then stirred at 60° C. for 3 hours, cooled to room temperature and quenched with 6N aqueous hydrochloric acid. The solvent was removed by distillation and water (10 ml) 5 was added. The residue was purified using HPLC. Yield: 31%. 1H NMR (400 MHz, DMSO-d6) δ 9.27 (s, 1H), 7.60-7.54 (m, 1H), 7.42 (d, J=6.4 Hz, 2H), 4.10 (s, 1H), 2.87 (t, J=8.2 Hz, 1H), 1.64 (d, J=8.1 Hz, 2H), 1.55 (dt, J=11.6, 7.0 Hz, 1H), 0.86 (dd, J=15.6, 6.2 Hz, 3H).
- 2-(aminomethyl)benzenesulfonamide (0.5 mmol) and 2-cyclohexylacetaldehyde (0.55 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours, then mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C., 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified using HPLC. Yield: 34%. Light brown solid. 1H NMR (400 MHz, DMSO-d6) δ 7.86 (d, J=7.8 Hz, 1H), 7.54 (d, J=6.6 Hz, 2H), 7.45 (s, 1H), 4.03 (s, 2H), 1.63 (d, J=12.2 Hz, 5H), 1.29 (t, J=7.2 Hz, 2H), 1.21-1.11 (m, 1H), 0.84 (d, J=11.4 Hz, 2H).
- (2-((methylsulfonyl)methyl)phenyl)methanamine (0.5 mmol) and 2-cyclohexylacetaldehyde (0.55 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours, then mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C., 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified using HPLC. Yield: 49%. Yellow gum. m/z: 309.22
- To a solution of tert-butyl (2-cyclohexylethyl)(2-ureidobenzyl)carbamate (0.1 mmol) in dichloromethane (25 mL) was slowly added trifluoroacetic acid (3.4 mmol) at 0° C. The reaction solution was stirred at room temperature for 5 h, and then 1N NaOH was added. The mixture was extracted with dichloromethane, and the organic layer was washed with brine, dried (Na2SO4), and filtered. The solvent was evaporated under reduced pressure to give the product. The crude residue was purified by HPLC. Yield: 37%. 1H NMR (400 MHz, DMSO-d6) δ 8.96 (s, 2H), 8.88 (s, 1H), 7.61 (d, J=8.1 Hz, 1H), 7.51 (d, J=7.7 Hz, 1H), 7.34 (t, J=7.7 Hz, 1H), 7.12 (t, J=7.5 Hz, 1H), 6.12 (s, 5H), 4.12 (d, J=5.7 Hz, 2H), 2.99 (s, 2H), 1.66 (s, 2H), 1.61 (d, J=16.2 Hz, 3H), 1.54 (q, J=7.5 Hz, 3H), 1.30 (s, 1H), 1.17 (h, J=12.2 Hz, 3H), 0.88 (q, J=11.7 Hz, 2H).
- Methyl 2-(2-(aminomethyl)phenyl)acetate (0.5 mmol) and 2-cyclohexylacetaldehyde (0.55 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours, then mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C., 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified using HPLC. Yellow solid. Yield: 34%. 1H NMR (400 MHz, DMSO-d6) δ 7.27 (t, J=4.3 Hz, 1H), 7.27-7.16 (m, 3H), 4.46 (s, 2H), 3.42 (t, J=7.7 Hz, 2H), 3.33 (d, J=2.3 Hz, 1H), 1.65 (td, J=23.1, 18.8, 10.8 Hz, 5H), 1.39 (q, J=7.3 Hz, 2H), 1.20 (d, J=10.4 Hz, 1H), 1.17-1.07 (m, 3H), 0.92 (d, J=11.6 Hz, 1H), 0.86 (d, J=12.0 Hz, 1H).
- 1-cyclohexylpropan-2-amine (0.5 mmol) and 2-((5-oxopyrrolidin-3-yl)methoxy)benzaldehyde (0.55 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours, then mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C., 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated and dissolved in 0.5 ml of DMSO. The residue was purified using HPLC. Yield. 39%. 1H NMR (400 MHz, DMSO-d6) δ 7.60 (s, 1H), 7.27 (d, J=7.4 Hz, 1H), 7.19 (t, J=7.8 Hz, 1H), 6.95 (d, J=8.2 Hz, 1H), 6.88 (t, J=7.4 Hz, 1H), 4.03-3.90 (m, 2H), 3.71 (d, J=13.7 Hz, 1H), 3.59 (d, J=13.7 Hz, 1H), 3.42 (t, J=8.9 Hz, 1H), 3.13 (dd, J=9.9, 5.7 Hz, 1H), 2.90-2.80 (m, 1H), 2.62-2.52 (m, 1H), 2.33 (dd, J=16.6, 9.1 Hz, 1H), 2.07 (dd, J=16.6, 6.8 Hz, 1H), 1.58 (d, J=11.5 Hz, 4H), 1.49 (d, J=13.3 Hz, 1H), 1.27 (dt, J=13.5, 6.3 Hz, 2H), 1.20-1.00 (m, 4H), 0.96 (d, J=6.1 Hz, 3H), 0.77 (s, 2H).
-
-
- To a mixture of (methoxymethyl)triphenylphosphonium chloride (136.7 g, 399.4 mmol, 2.2 eq) in THF (450 mL) was added potassium tert-butylate (40.7 g, 363 mmol, 2.0 eq) at 0° C. for 20 min. Then, 1 (20 g, 181.6 eq, 1.0 eq) was added and the reaction mixture was stirred at room temperature. After completion, the mixture was poured into water, extracted with ethyl acetate and washed with brine. The combined organic phases were dried over Na2SO4, filtered and concentrated in vacuum. The residue was purified by column chromatography to give the product 2 (24.4 g) as an oil.
-
- To a mixture of 2 (12 g, 86.8 mmol, 1.0 eq) in THF (347 mL, c=0.25) was added aq. HCl (6N, 72 mL, 434 mmol, 5.0 eq). The reaction mixture was stirred at room temperature for 1.5 h. After completion, water (100 mL) was added and the resulting mixture was extracted with EA (80 mL×3). The organic phases were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to give the product 3 (2.6 g, yield=24.2%) as an oil.
-
- To a solution of 3 (200 mg, 1.6 mmol, 1.0 eq) in DCM (3.5 mL, c=0.46) was added benzylamine (173 mg, 1.6 mmol, 1.0 eq) and MgSO4 (290 mg, 2.4 mmol, 1.5 eq). After that, AcOH (0.4 mL) and NaBH3CN (182 mg, 4.8 mmol, 3.0 eq) were added and the reaction mixture was stirred at room temperature overnight. After completion, the mixture was poured into water, extracted with ethyl acetate and washed with brine. The combined organic phases were dried over Na2SO4, filtered and concentrated in vacuum. The residue was purified by column chromatography to give the product 4 (32 mg, yield=9.3%) as a solid.
-
- A mixture of 4 (26 mg, 0.12 mmol, 1.0 eq) in HCl/MeOH (1N, 2 mL, c=0.06) was stirred at room temperature for 1 h. After completion, the suspension was filtered and concentrated under reduced pressure to give the product B156 (31 mg, yield=100%) as a solid. 1H NMR (400 MHz, D2O): δ 7.43-7.41 (m, 5H), 5.68-5.63 (m, 2H), 4.16 (s, 2H), 3.06-3.02 (m, 2H), 2.03-1.89 (m, 3H), 1.66-1.57 (m, 5H), 1.21-1.12 (m, 1H); Mass: m/z=216 [M−HCl+H]+
-
-
- To a mixture of 1 (1.0 g, 8.07 mmol, 1.0 eq) in THF (16 mL, c=0.5) was added dropwise CH3MgBr (3N, 2.9 mL, 8.5 mmol, 1.05 eq) at −0° C. for 20 min and the mixture was stirred at room temperature for 1 h. After completion, the resulting mixture was poured into water, extracted with ethyl acetate and washed with brine. The combined organic phases were dried over Na2SO4, filtered and concentrated in vacuum. The residue was purified by column chromatography to give the product 2 (200 mg, yield=17.7%) as an oil.
-
- To a mixture of 2 (100 mg, 0.7 mmol, 1.0 eq) in DCM (3.5 mL, c=0.2) was added PCC (231 mg, 1.1 mmol, 1.5 eq) and the reaction mixture was stirred at room temperature overnight. After completion, the resulting mixture was filtered through celite and the filtrate was concentrated to dryness to obtain the product 3 (100 mg, yield=100%).
-
- To a solution of 3 (200 mg, 1.44 mmol, 1.0 eq) in DCM (5 mL, c=0.3) was added benzylamine (150.2 mg, 1.44 mmol, 1.0 eq) and MgSO4 (260 mg, 2.16 mmol, 1.5 eq). Then AcOH (0.36 mL) and NaBH3CN (164 mg, 4.32 mmol, 3.0 eq) was added and the reaction mixture was stirred at room temperature overnight. After completion, the mixture was poured into water, extracted with ethyl acetate and washed with brine. The combined organic phases were dried over Na2SO4, filtered and concentrated in vacuum. The residue was purified by column chromatography to give the product B157 (11 mg, yield=2.9%) as a solid. 1H NMR (400 MHz, DMSO-d6): δ 7.34-7.19 (m, 5H), 5.61 (s, 2H), 3.79-3.66 (m, 2H), 2.66-2.65 (m, 1H), 2.00-1.00 (m, 12H); Mass: m/z=230 [M+H]+
-
-
- To a mixture of 1 (2.0 g, 9.3 mmol, 1.0 eq) in DCM (46 mL, c=0.2) was added TEA (3.3 g, 32.5 mmol, 3.5 eq) at room temperature for 20 min. Then acetic anhydride (2.5 g, 24.2 mmol, 2.6 eq) was added dropwise at room temperature for 10 min and the reaction mixture was stirred for 1 h. After completion, the mixture was poured into water, extracted with ethyl acetate and washed with brine. The combined organic phases were dried over Na2SO4, filtered and concentrated in vacuum. The residue was purified by column chromatography to give the product 2 (1.92 g, yield=69%) as a solid.
-
- A solution of 2 (12 g, 40 mmol, 1.0 eq), bis(pinacolato)diboron (15.18 g, 60 mmol, 1.5 eq) and potassium acetate in dioxane (160 mL, c=0.25) was added trans-dichlorobis(triphenyl-phosphine)palladium(II) (3.3 g, 4 mmol, 0.1 eq) under nitrogen and the solution was heated at reflux overnight. After completion, the mixture was filtered and concentrated in vacuum. The crude was purified by column chromatography to give the product 3 (10.82 g, yield=77.7%) as a solid.
-
- To a solution of 3 (8 g, 23 mmol, 1.0 eq) in MeOH (24 mL) was added sodium hydroxide (3.7 g, 92 mmol, 4.0 eq) in MeOH (18.4 mL) and the solution was stirred at room temperature for 4 h. After that, the reaction mixture was concentrated in vacuum. The residue was dissolved in THF again and aq.HCl (2N) was added dropwise below 15° C. with stirring and the pH of the mixture was adjusted to 1. After that, the mixture was extracted with ethyl acetate and washed with brine. The combined organic phases were dried over Na2SO4, filtered and concentrated in vacuum. The resulting crude was washed by 30% EA/PE to get the pure product 4 (2.8 g, yield=74.3%) as a solid.
-
- To a mixture of 4 (1.5 g, 9.14 mmol, 1.0 eq) in DCM (183 mL, c=0.05) was added PCC (3.95 g, 13.7 mmol, 1.5 eq) and the reaction solution was stirred at room temperature for 1.5 h. After completion, the mixture was filtered and the filtrate was washed with aq.HCl (2N, 50 mL×2) and aq.NaOH (2N, 40 mL×2). After that, the pH of the aqueous phase was adjusted to 1-2 by hydrochloric acid and extracted with ethyl acetate. The combined organic phases were dried over Na2SO4, filtered and concentrated in vacuum. The resulting crude was washed by 5% EA/PE to get the pure product 5 (786 mg, yield=53%) as a solid.
-
- To a solution of 5 (50 mg, 0.309 mmol, 1.0 eq) and benzylamine (33.1 mg, 0.309 mmol, 1.0 eq) in DCM (1.2 mL, c=0.25) was added sodium sulfate (87.8 mg, 0.618 mmol, 2.0 eq) and the reaction mixture was stirred at room temperature under nitrogen overnight. After completion, the suspension was filtered and the filtrate was concentrated under reduced pressure to give the crude 6 (93 mg, y=122%) as a solid.
-
- To a solution of 6 (40 mg, 0.16 mmol, 1.0 eq) in MeOH (1.6 mL, c=0.1) was added platinum(IV) oxide (3.6 mg, 0.016 mmol, 0.1 eq) and the reaction mixture was stirred at room temperature for 45 min under H2. After completion, the suspension was filtered and the filtrate was concentrated under reduced pressure to give the product B158 (25 mg, y=62%) as a solid.
- 1H NMR (400 MHz, DMSO-d6): δ 9.11 (s, 1H), 7.70-7.19 (m, 8H), 4.96 (s, 2H), 4.10 (s, 1H), 3.71 (s, 2H), 3.17 (s, 2H); Mass: m/z=254[M+H]+
-
-
- To a mixture of (Methoxymethyl)triphenylphosphonium chloride (15.5 g, 45.1 mmol, 4.87 eq) in THF (60 mL) was added potassium tert-butylate (4.78 g, 42.6 mmol, 4.6 eq) at 0° C. for 20 min. Then, a mixture of 1 (20 g, 181.6 eq, 1.0 eq) in THF (32.6 mL) was added and the reaction mixture was stirred at 0° C. After completion, the mixture was poured into water, extracted with ethyl acetate and washed with brine. The combined organic phases were dried over Na2SO4, filtered and concentrated in vacuum. The residue was purified by column chromatography to give the product 2 (1.2 g, yield=68%) as a solid.
-
- To a mixture of 2 (1.2 g, 6.3 mmol, 1.0 eq) in THF (25 mL, c=0.25) was added aq.HCl (6N, 6.2 mL, 95 mmol, 15.0 eq) and the reaction mixture was stirred at room temperature for 1.5 h. After completion, water (20 mL) was added and the resulting solution was extracted with EA (15 mL×3). The organic phases were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to give the product 3 (420 mg, yield=38%) as a solid.
-
- To a solution of benzylamine acetate (142 mg, 0.85 mmol, 3.0 eq) in DMAc (1.9 mL, c=0.3) was added NaBH(OAc)3 (121 mg, 0.57 mmol, 2.0 eq) and MgSO4 (50.5 mg, 0.46 mmol, 1.5 eq) and the reaction mixture was stirred at room temperature for 0.5 h. Then, a mixture of 3 (50 mg, 0.28 mmol, 1.0 eq) in DMAc (0.5 mL) was added and the resulting solution was stirred at room temperature. After completion, the suspension was filtered and the filtrate was concentrated under reduced pressure. The residue was purified by C-18 reverse phase HPLC to afford the product B159 (44 mg, yield=58%) as a solid. 1H NMR (400 MHz, DMSO-d6): δ 9.05 (brs, 1H), 8.22 (s, 1H), 7.55 (s, 1H), 7.36-7.25 (m, 8H), 4.94 (s, 2H), 3.81 (s, 2H), 2.81 (s, 4H); Mass: m/z=268 [M+H]+
-
-
- To a solution of 1 (708 mg, 12.62 mmol, 1.28 eq) in cyclohexane (1.4 mL) 2 was added (810 mg, 9.86 mmol, 1.0 eq) and the reaction mixture was stirred at 60° C. overnight. After completion, the suspension was concentrated under reduced pressure to give the product 3 (540 mg, yield=39.7%) as an oil.
-
- To a solution of (methoxymethyl)triphenylphosphonium chloride (6.0 g, 17.6 m mol, 4.87 eq) in THF (28 mL) was added potassium tert-butylate (1.86 g, 16.55 mmol, 4.6 eq) at 0° C. and the mixture was stirred for 20 min. Then, 3 (500 mg, 3.6 eq, 1.0 eq) in THF (8 mL) was added and the resulting mixture was stirred at room temperature. After completion, the mixture was poured into water, extracted with ethyl acetate and washed with brine. The combined organic phases were dried over Na2SO4, filtered and concentrated in vacuum. The residue was purified by column chromatography to give the product 4 (504 mg, yield=84.8%) as an oil.
-
- To a solution of 4 (1.0 g, 6.0 mmol, 1.0 eq) in THF (30 mL, c=0.2) was added aq.HCl (6N, 15 mL, 90 mmol, 15.0 eq) and the reaction mixture was stirred at room temperature for 1.5 h. After completion, water (25 mL) was added and the mixture was extracted by EA (20 mL×3). The combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to give the product 5 (897 mg, yield=98%) as an oil.
-
- To a solution of 5 (600 mg, 3.95 mmol, 1.0 eq) in THF (8 mL, c=0.5) was added dropwise CH3MgBr (3N, 1.4 mL, 4.14 mmol, 1.05 eq) at 0° C. for 20 min and then the mixture was stirred at room temperature for 1 h. After completion, the mixture was poured into water, extracted with ethyl acetate and washed with brine. The combined organic phases were dried over Na2SO4, filtered and concentrated in vacuum to give the crude product 6 (575.6 mg, yield=87.8%) as an oil.
-
- To a solution of 6 (550 mg, 3.57 mmol, 1.0 eq) in DCM (18 mL, c=0.2) was added PCC (1.15 g, 15.36 mmol, 1.5 eq) and the reaction mixture was stirred at room temperature overnight. After completion, the resulting mixture was filtered through a pad of celite and the filtrate was concentrated to dryness. The residue was purified by column chromatography to give the product 7 (150 mg, yield=27.6%) as an oil.
-
- To a solution of 7 (60 mg, 0.361 mmol, 1.0 eq) in MeOH (1.8 mL, c=0.2) was added benzylamine (155 mg, 1.444 mmol, 4.0 eq) and MgSO4 (60 mg) and the reaction mixture was stirred at 25° C. for 1 h. Then, AcOH (0.1 mL) and NaBH3CN (68 mg, 1.083 mmol, 3.0 eq) was added and the reaction mixture was stirred at 80° C. overnight. After completion, the suspension was concentrated in vacuum and the residue was purified by column chromatography to give the desired product B162 (3.5 mg, yield=4%) as a yellow solid. 1H NMR (400 MHz, DMSO): δ7.59-7.32 (m, 5H), 4.13-4.05 (m, 2H), 2.82-2.73 (m, 1H), 1.75-1.20 (m, 18H). Mass: m/z=258 [M+H]+
-
- (2-cyclobutoxyphenyl)methanamine (0.5 mmol) and 1-cyclohexylpropan-2-one (0.55 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 39%.
- 1H NMR (400 MHz, Chloroform-d) δ 7.24-7.12 (m, 2H), 6.87 (t, J=7.4 Hz, 1H), 6.69 (d, J=8.1 Hz, 1H), 4.66 (p, J=7.2 Hz, 1H), 3.83 (d, J=13.0 Hz, 1H), 3.70 (d, J=13.0 Hz, 1H), 2.69 (h, J=6.4 Hz, 1H), 2.47 (dtt, J=12.3, 6.7, 2.7 Hz, 2H), 2.19 (d, J=10.1 Hz, 1H), 2.14 (d, J=10.2 Hz, 1H), 1.87 (q, J=10.0 Hz, 2H), 1.79-1.61 (m, 5H), 1.60 (s, 1H), 1.42-1.22 (m, 2H), 1.19 (s, 3H), 1.18-1.08 (m, 2H), 1.05 (d, J=6.2 Hz, 3H), 0.86 (s, 1H), 0.81 (dd, J=12.1, 4.0 Hz, 1H). m/z=302.3
-
- 1-cyclohexylpropan-2-amine (0.5 mmol) and 2-(bicyclo[2.2.1]heptan-2-ylmethoxy)benzaldehyde (0.55 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 42%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.26-7.12 (m, 3H), 7.00-6.81 (m, 3H), 3.97 (q, J=7.8 Hz, 1H), 3.82 (q, J=8.6 Hz, 1H), 3.70 (dt, J=14.5, 6.4 Hz, 3H), 3.59 (d, J=11.8 Hz, 2H), 2.56 (p, J=6.0 Hz, 2H), 2.32 (s, 1H), 2.27 (s, 1H), 2.25-2.17 (m, 2H), 1.89 (p, J=7.4 Hz, 1H), 1.73 (t, J=12.1 Hz, 1H), 1.57 (d, J=11.6 Hz, 8H), 1.53-1.43 (m, 5H), 1.37 (d, J=9.9 Hz, 2H), 1.28 (dt, J=17.8, 7.4 Hz, 5H), 1.17 (s, 2H), 1.11 (t, J=11.6 Hz, 5H), 1.04 (d, J=7.9 Hz, 2H), 0.95 (d, J=5.7 Hz, 4H), 0.80 (d, J=10.1 Hz, 2H), 0.75 (s, 2H). m/z=356.2
-
- (2-(cyclohexyloxy)phenyl)methanamine (0.5 mmol) and 1-cyclohexylpropan-2-one (0.55 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 51%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.24 (d, J=7.4 Hz, 1H), 7.15 (t, J=7.8 Hz, 1H), 6.96 (d, J=8.2 Hz, 1H), 6.83 (t, J=7.4 Hz, 1H), 4.43-4.34 (m, 1H), 3.69 (d, J=13.4 Hz, 1H), 3.58 (d, J=13.4 Hz, 1H), 2.58 (q, J=6.3 Hz, 1H), 1.87 (d, J=11.8 Hz, 2H), 1.69 (s, 2H), 1.58 (d, J=10.5 Hz, 6H), 1.50 (t, J=8.4 Hz, 4H), 1.35 (dt, J=20.6, 10.4 Hz, 4H), 1.30-1.21 (m, 1H), 1.11 (td, J=22.2, 19.3, 9.7 Hz, 4H), 0.96 (d, J=6.1 Hz, 3H), 0.83 (dd, J=18.2, 7.7 Hz, 1H), 0.75 (d, J=11.4 Hz, 1H). m/z=330.2
-
- 1-cyclohexylpropan-2-amine (0.5 mmol), 2-((2-iodobenzyl)oxy)benzaldehyde (0.5 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; then 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified using HPLC. Yield: 39%.
- 1H NMR (400 MHz, Chloroform-d) δ 7.88 (d, J=7.9 Hz, 1H), 7.52 (d, J=7.6 Hz, 1H), 7.38 (t, J=7.5 Hz, 1H), 7.32-7.19 (m, 3H), 7.04 (t, J=7.7 Hz, 1H), 6.99-6.89 (m, 2H), 5.07 (s, 2H), 3.95 (d, J=13.1 Hz, 1H), 3.82 (d, J=13.1 Hz, 1H), 2.72 (q, J=6.4 Hz, 1H), 1.60 (d, J=9.5 Hz, 5H), 1.52 (d, J=13.1 Hz, 1H), 1.35 (dt, J=13.3, 6.6 Hz, 1H), 1.18-1.02 (m, 7H), 0.80 (d, J=11.4 Hz, 2H). m/z=464.2
-
- (2-((2-methylcyclohexyl)oxy)phenyl)methanamine (0.5 mmol) and 1-cyclohexylpropan-2-one (0.55 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 38%.
- 1H NMR (400 MHz) δ 7.24 (d, J=7.4 Hz, 1H), 7.15 (t, J=7.8 Hz, 1H), 6.94 (t, J=7.2 Hz, 1H), 6.82 (t, J=7.6 Hz, 1H), 3.92 (td, J=9.6, 3.8 Hz, 1H), 3.71 (ddd, J=20.0, 13.4, 4.8 Hz, 1H), 3.67-3.55 (m, 1H), 3.33 (s, 2H), 2.59 (dt, J=20.5, 9.4 Hz, 1H), 2.50 (s, 1H), 2.05 (d, J=12.5 Hz, 1H), 1.78 (s, 1H), 1.70-1.46 (m, 8H), 1.40 (dt, J=16.3, 10.6 Hz, 1H), 1.30 (s, 6H), 1.27 (d, J=8.9 Hz, 1H), 1.28-1.02 (m, 4H), 0.97 (p, J=7.6 Hz, 5H), 0.78 (t, J=14.1 Hz, 2H). m/z=344.2
-
- (2-(bicyclo[2.2.1]heptan-2-yloxy)phenyl)methanamine (0.5 mmol) and 1-cyclohexylpropan-2-one (0.55 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 27%.
- 1H NMR (400 MHz, Chloroform-d) δ 7.23-7.13 (m, 2H), 6.86 (t, J=7.4 Hz, 1H), 6.76 (dd, J=8.2, 4.2 Hz, 1H), 4.61 (dt, J=8.8, 3.9 Hz, 1H), 3.85 (d, J=13.0 Hz, 1H), 3.70 (dd, J=13.0, 3.5 Hz, 1H), 2.68 (h, J=6.0 Hz, 1H), 2.60 (d, J=4.5 Hz, 1H), 2.29 (d, J=4.9 Hz, 1H), 2.06 (ddt, J=13.1, 7.5, 4.2 Hz, 1H), 2.02-1.91 (m, 1H), 1.80 (s, 1H), 1.63 (d, J=7.1 Hz, 4H), 1.56-1.42 (m, 1H), 1.39 (s, 1H), 1.36 (dd, J=6.4, 3.3 Hz, 1H), 1.29 (ddd, J=33.2, 8.7, 5.1 Hz, 1H), 1.14 (ddd, J=13.0, 7.2, 3.7 Hz, 3H), 1.05 (d, J=6.2 Hz, 3H), 0.91-0.72 (m, 2H). m/z=342.2
-
- (2-((3-methylcyclohexyl)oxy)phenyl)methanamine (0.5 mmol) and 1-cyclohexylpropan-2-one (0.55 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 41%.
- 1H NMR (400 MHz) δ 7.23 (d, J=7.2 Hz, 1H), 7.15 (t, J=7.9 Hz, 1H), 6.95 (dd, J=20.0, 8.3 Hz, 1H), 6.82 (q, J=5.6, 3.9 Hz, 1H), 4.26 (td, J=10.7, 10.0, 5.3 Hz, 1H), 3.75-3.51 (m, 2H), 3.33 (s, 1H), 2.58 (tt, J=10.9, 5.3 Hz, 1H), 2.50 (s, 1H), 2.05 (d, J=11.9 Hz, 1H), 1.87 (t, J=14.7 Hz, 1H), 1.74 (d, J=13.8 Hz, 1H), 1.58 (d, J=14.6 Hz, 7H), 1.51 (d, J=9.3 Hz, 1H), 1.44-1.25 (m, 1H), 1.28-1.03 (m, 3H), 0.91 (tdd, J=26.7, 21.1, 11.6 Hz, 6H), 0.75 (d, J=11.5 Hz, 1H). m/z=344.2
-
- 2-((2-ethylcyclohexyl)oxy)phenyl)methanamine (0.5 mmol) and 1-cyclohexylpropan-2-one (0.55 mmol) were dissolved in 0.6 ml MeOH, heated at 100 C for 2 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 35%.
- 1H NMR (400 MHz, Chloroform-d) δ 7.24-7.13 (m, 2H), 6.85 (d, J=7.8 Hz, 2H), 4.56 (s, 1H), 3.91-3.78 (m, 1H), 3.73 (t, J=13.2 Hz, 1H), 2.77-2.64 (m, 1H), 2.10 (dq, J=8.0, 4.0 Hz, 1H), 1.86-1.70 (m, 2H), 1.67 (s, 1H), 1.65-1.57 (m, 4H), 1.60-1.51 (m, 1H), 1.47 (dt, J=14.5, 6.5 Hz, 2H), 1.34 (dhept, J=22.3, 7.5 Hz, 2H), 1.22-1.10 (m, 2H), 1.06 (d, J=6.1 Hz, 3H), 0.95-0.77 (m, 5H). m/z=358.2
-
- (2-((octahydro-1H-4,7-methanoinden-5-yl)oxy)phenyl)methanamine (0.5 mmol) and 1-cyclohexylpropan-2-one (0.55 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 28%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.23 (d, J=7.4 Hz, 1H), 7.15 (t, J=7.8 Hz, 1H), 6.91-6.79 (m, 2H), 4.64 (dt, J=8.4, 3.7 Hz, 1H), 3.72-3.64 (m, 1H), 3.58 (dd, J=13.5, 5.7 Hz, 1H), 2.63-2.50 (m, 2H), 2.33 (d, J=4.1 Hz, 1H), 2.16-2.05 (m, 1H), 1.98 (d, J=4.6 Hz, 1H), 1.95-1.73 (m, 3H), 1.60 (t, J=12.1 Hz, 6H), 1.50 (d, J=10.6 Hz, 2H), 1.42 (d, J=10.8 Hz, 1H), 1.39-1.20 (m, 2H), 1.17 (s, 1H), 1.16-1.00 (m, 3H), 0.96 (d, J=6.2 Hz, 4H), 0.82 (dp, J=28.9, 8.7 Hz, 2H). m/z=382.2
- Synthesis of compounds B394, B395, B396, and B404 was performed according to the following general scheme.
- Amine 1 (0.5 mmol) and ketone 2 (0.55 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yields: 29-44%.
-
- 1H NMR (400 MHz) δ 7.24 (t, J=6.9 Hz, 1H), 7.15 (t, J=7.8 Hz, 1H), 6.95 (dd, J=13.9, 8.2 Hz, 1H), 6.83 (t, J=7.5 Hz, 1H), 4.23 (tt, J=10.2, 4.4 Hz, 1H), 3.76-3.52 (m, 2H), 3.33 (s, 1H), 2.59 (dq, J=18.5, 6.1 Hz, 1H), 2.50 (s, 1H), 2.08-2.00 (m, 2H), 1.90 (d, J=14.0 Hz, 1H), 1.75-1.67 (m, 2H), 1.59 (s, 3H), 1.58-1.53 (m, 4H), 1.53-1.44 (m, 1H), 1.38 (t, J=11.1 Hz, 1H), 1.29 (s, 2H), 1.29-1.19 (m, 1H), 1.19-0.83 (m, 11H), 0.83-0.71 (m, 2H). m/z=344.2
-
- 1H NMR (400 MHz, DMSO-d6) δ 17.91 (s, 1H), 7.24 (d, J=7.4 Hz, 1H), 7.15 (t, J=7.8 Hz, 1H), 6.88 (d, J=8.2 Hz, 1H), 6.82 (t, J=7.4 Hz, 1H), 4.52 (d, J=9.1 Hz, 1H), 3.76-3.66 (m, 1H), 3.59 (t, J=13.2 Hz, 1H), 2.59 (p, J=6.3 Hz, 1H), 2.08 (t, J=11.7 Hz, 1H), 1.95-1.80 (m, 2H), 1.67-1.36 (m, 14H), 1.25 (tt, J=8.3, 4.5 Hz, 2H), 1.19-0.93 (m, 6H), 0.77 (dq, J=22.3, 11.0 Hz, 2H); m/z=356.2
-
- 1H NMR (400 MHz, DMSO-d6) δ 7.29 (d, J=7.4 Hz, 1H), 7.19 (t, J=7.8 Hz, 1H), 7.02 (d, J=8.2 Hz, 1H), 6.88 (t, J=7.4 Hz, 1H), 4.69-4.62 (m, 1H), 3.69 (d, J=13.3 Hz, 1H), 3.60 (d, J=13.3 Hz, 1H), 2.60 (q, J=6.3 Hz, 1H), 2.01 (s, 6H), 1.89 (dt, J=8.6, 3.9 Hz, 4H), 1.59 (d, J=10.8 Hz, 5H), 1.50 (d, J=15.8 Hz, 1H), 1.28 (dq, J=13.1, 6.6, 5.9 Hz, 2H), 1.21-1.11 (m, 2H), 1.14-1.08 (m, 1H), 1.08-1.01 (m, 1H), 0.97 (d, J=6.1 Hz, 3H), 0.79 (p, J=12.5 Hz, 2H). m/z=366.2
-
- 1H NMR (400 MHz, DMSO-d6) δ 7.25 (dd, J=7.4, 1.8 Hz, 1H), 7.14 (td, J=7.8, 1.8 Hz, 1H), 6.92 (d, J=8.1 Hz, 1H), 6.82 (t, J=7.3 Hz, 1H), 4.53 (d, J=3.3 Hz, 1H), 3.75 (d, J=13.3 Hz, 1H), 3.64 (d, J=13.3 Hz, 1H), 2.61 (q, J=6.2 Hz, 1H), 2.06 (d, J=17.7 Hz, 4H), 1.82 (s, 6H), 1.71 (s, 2H), 1.57 (q, J=13.8 Hz, 8H), 1.25 (dt, J=13.1, 6.0 Hz, 2H), 1.10 (dt, J=17.7, 10.5 Hz, 3H), 1.06-0.92 (m, 3H), 0.78 (dt, J=21.3, 10.5 Hz, 2H). m/z=382.2
-
- tert-butyl (2-aminobenzyl)(1-cyclohexylpropan-2-yl)carbamate (1 mmol) and 2-fluorobenzaldehyde (1 mmol) were dissolved in 0.6 ml MeOH, heated at 100 C for 2 hours; then the mixture was cooled, NaBH4 (1 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C., then cooled and filtered.
- To a solution of tert-butyl (1-cyclohexylpropan-2-yl)(2-((2-fluorobenzyl)amino)benzyl)carbamate (0.5 mmol) in dichloromethane (5 mL) was slowly added trifluoroacetic acid (2.5 mmol) at 0° C. The reaction solution was stirred at room temperature for 5 h, and then 1N NaOH was added. The mixture was extracted with dichloromethane, and the organic layer was washed with brine, dried (Na2SO4), and filtered. The solvent was evaporated and the residue was purified by HPLC. Yield: 27%. 1H NMR (400 MHz, DMSO-d6) δ 9.16 (s, 1H), 8.97 (s, 1H), 7.46 (t, J=7.9 Hz, 1H), 7.32 (dd, J=19.2, 7.4 Hz, 2H), 7.19 (t, J=9.5 Hz, 1H), 7.13 (t, J=7.6 Hz, 2H), 6.64 (t, J=7.4 Hz, 1H), 6.54-6.45 (m, 2H), 4.39 (s, 2H), 4.14 (s, 2H), 1.73 (s, 1H), 1.62 (t, J=14.0 Hz, 5H), 1.45-1.37 (m, 2H), 1.32 (d, J=6.3 Hz, 3H), 1.22 (s, 2H), 1.18-1.11 (m, 3H), 0.92 (d, J=11.9 Hz, 1H), 0.84-0.77 (m, 2H). m/z=355.2
-
- tert-butyl (2-aminobenzyl)(1-cyclohexylpropan-2-yl)carbamate (0.5 mmol) and CDI (1 mmol) were dissolved in 0.6 ml CH3CN; the mixture was kept at a temperature of 70° C. for 1 hour, then the 2-fluorobenzoic acid (0.5 mmol) was added. The mixture was heated for 2 hours at 70° C., then filtered, evaporated. The residue was purified by HPLC.
- To a solution of tert-butyl (1-cyclohexylpropan-2-yl)(2-(2-fluorobenzamido)benzyl)carbamate (0.5 mmol) in dichloromethane (5 mL) was slowly added trifluoroacetic acid (2.5 mmol) at 0° C. The reaction solution was stirred at room temperature for 5 h; then 1N NaOH was added. The mixture was extracted with dichloromethane, and the organic layer was washed with brine, dried (Na2SO4), and filtered. The solvent was evaporated, and the residue was purified by HPLC. Yield: 24%.
- 1H NMR (400 MHz, DMSO-d6) δ 10.44 (s, 1H), 9.31 (s, 1H), 9.07 (d, J=14.5 Hz, 1H), 7.81 (t, J=7.5 Hz, 1H), 7.75 (d, J=7.7 Hz, 1H), 7.65-7.57 (m, 1H), 7.49 (s, 2H), 7.37 (t, J=9.0 Hz, 3H), 4.11 (s, 2H), 1.62 (d, J=13.4 Hz, 6H), 1.40 (s, 1H), 1.36 (d, J=11.8 Hz, 1H), 1.29 (d, J=6.3 Hz, 2H), 1.13 (dd, J=23.8, 12.8 Hz, 3H), 0.92-0.76 (m, 2H). m/z=369.2
-
- (2-(2-fluorophenoxy)phenyl)methanamine (0.5 mmol) and 1-cyclohexylpropan-2-one (0.5 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 3 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; then 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 28%. m/z=342.2
-
- tert-butyl (3-(aminomethyl)phenyl)(methyl)carbamate (1 mmol) and 2-cyclohexylacetaldehyde (1 mmol) were dissolved in 0.6 ml MeOH, heated at 80° C. for 2 hours; then the mixture was cooled, NaBH4 (1 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C., then cooled and filtered. Yield: 43%.
- To a solution of tert-butyl (3-(((2-cyclohexylethyl)amino) methyl)phenyl)(methyl)carbamate (0.5 mmol) in dichloromethane (5 mL) was slowly added trifluoroacetic acid (2.5 mmol) at 0° C. The reaction was stirred at room temperature for 5 h, and then 1N NaOH was added. The mixture was extracted with dichloromethane, and the organic layer was washed with brine, dried (Na2SO4), and filtered. The solvent was evaporated, and the residue was purified by HPLC. Yield: 23%. 1H NMR (400 MHz, DMSO-d6) δ 6.98 (t, J=7.7 Hz, 1H), 6.51-6.43 (m, 2H), 6.36 (dd, J=7.9, 2.4 Hz, 1H), 5.46 (d, J=6.3 Hz, 1H), 3.54 (s, 2H), 2.64 (d, J=5.0 Hz, 3H), 2.54-2.43 (m, 3H), 1.63 (d, J=12.4 Hz, 5H), 1.29 (t, J=5.7 Hz, 3H), 1.24-1.05 (m, 3H), 0.84 (q, J=11.1 Hz, 2H). m/z=247.2
-
- 1-cyclohexylpropan-2-amine (0.5 mmol) and 2-(((3-methyl-2-oxooxazolidin-5-yl)methyl)thio)benzaldehyde (0.5 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 4 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 31%.
- 1H NMR (400 MHz, Chloroform-d) δ 7.39 (dt, J=6.4, 1.8 Hz, 1H), 7.34 (d, J=5.7 Hz, 1H), 7.27-7.18 (m, 3H), 4.53 (ddd, J=9.2, 4.8, 2.6 Hz, 1H), 3.92 (d, J=13.0 Hz, 1H), 3.85-3.78 (m, 1H), 3.63 (t, J=8.7 Hz, 1H), 3.35 (ddd, J=9.4, 7.5, 3.9 Hz, 2H), 3.01 (ddd, J=13.5, 8.8, 4.5 Hz, 1H), 2.85 (d, J=1.7 Hz, 3H), 2.77-2.68 (m, 1H), 1.33 (s, 3H), 1.22 (d, J=11.8 Hz, 1H), 1.14 (d, J=11.0 Hz, 4H), 1.07 (dd, J=6.2, 1.7 Hz, 3H), 0.84 (s, 2H). m/z=377.2
-
- 1-cyclohexylpropan-2-amine (0.5 mmol) and 2-((4-fluorobenzyl)oxy)benzaldehyde (0.5 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; then 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 45%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.46 (t, J=6.7 Hz, 2H), 7.24 (d, J=7.5 Hz, 1H), 7.14 (d, J=8.3 Hz, 1H), 7.09 (t, J=8.7 Hz, 2H), 6.93 (d, J=8.2 Hz, 1H), 6.86 (t, J=7.5 Hz, 1H), 5.07 (s, 2H), 3.76 (d, J=13.4 Hz, 1H), 3.65 (d, J=13.3 Hz, 1H), 2.62 (s, 1H), 1.62 (s, 4H), 1.54 (s, 1H), 1.25 (d, J=9.4 Hz, 2H), 1.12 (s, 4H), 1.05 (d, J=6.9 Hz, 1H), 0.97 (d, J=6.1 Hz, 3H), 0.78 (s, 3H). m/z=356.2
-
- 1-cyclohexylpropan-2-amine (0.5 mmol) and 2-(benzyloxy)benzaldehyde (0.5 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; then 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 39%. 1H NMR (400 MHz, DMSO-d6) δ 7.43 (d, J=7.3 Hz, 2H), 7.36 (t, J=7.4 Hz, 2H), 7.32-7.26 (m, 1H), 7.24 (d, J=7.4 Hz, 1H), 7.15 (t, J=7.8 Hz, 1H), 6.94 (d, J=8.2 Hz, 1H), 6.86 (t, J=7.4 Hz, 1H), 5.10 (s, 2H), 3.78 (d, J=13.6 Hz, 1H), 3.66 (d, J=13.5 Hz, 1H), 2.63 (s, 1H), 1.60 (d, J=12.0 Hz, 5H), 1.26 (d, J=10.3 Hz, 2H), 1.12 (s, 5H), 0.97 (d, J=6.1 Hz, 2H), 0.80 (d, J=12.3 Hz, 2H). m/z=338.2
-
- 2-(tetrahydro-2H-thiopyran-4-yl)ethan-1-amine (0.5 mmol) and methyl 2-(2-(chloromethyl)phenyl)acetate (0.5 mmol) were mixed in 5 ml of DMF, and DIPEA (0.75 mmol) was added. The mixture was heated at 80° C. for 5 h, cooled; solvent was removed by evaporation and residue was purified by HPLC. Yield: 31%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.23 (qd, J=10.9, 9.9, 5.4 Hz, 2H), 4.46 (s, 1H), 3.50 (s, 1H), 3.43 (t, J=7.4 Hz, 1H), 2.58-2.51 (m, 2H), 1.99 (d, J=9.9 Hz, 1H), 1.42 (s, 1H), 1.26 (s, 2H). m/z=276.0
-
- 2-(cyclohex-1-en-1-yl)ethan-1-amine (0.5 mmol) and methyl 2-(2-(chloromethyl)phenyl)acetate (0.5 mmol) were mixed in 5 ml of DMF, and DIPEA (0.75 mmol) was added. The mixture was heated at 80° C. for 5 h, cooled; the solvent was removed by evaporation, and the residue was purified by HPLC. Yield: 37%. 1H NMR (400 MHz, DMSO-d6) δ 7.23 (p, J=8.0 Hz, 2H), 5.32 (s, 0H), 4.46 (s, 1H), 3.32 (s, 1H), 2.12 (t, J=7.3 Hz, 1H), 1.94 (s, 1H), 1.84 (s, 1H), 1.53 (q, J=6.3, 5.7 Hz, 1H), 1.46 (d, J=6.5 Hz, 1H). m/z=256.2
-
- 1-cyclohexylpropan-2-amine (0.5 mmol) and methyl 2-(2-(chloromethyl)phenyl)acetate (0.5 mmol) were mixed in 5 ml of DMF; DIPEA (0.75 mmol) was added. The mixture was heated at 80° C. for 5 h, cooled; solvent was removed by evaporation and residue was purified by HPLC. Yield: 47%. Yellow gum.
- 1H NMR (400 MHz, DMSO-d6) δ 7.36-7.30 (m, 1H), 7.23 (p, J=4.7 Hz, 3H), 4.72 (dt, J=9.8, 6.2 Hz, 1H), 4.32 (d, J=15.5 Hz, 1H), 4.25 (d, J=15.4 Hz, 1H), 3.51 (s, 2H), 1.74 (d, J=12.8 Hz, 1H), 1.61-1.42 (m, 5H), 1.24 (ddd, J=14.0, 8.5, 5.5 Hz, 1H), 1.05 (d, J=6.8 Hz, 4H), 1.01 (s, 3H), 0.79 (dt, J=23.0, 11.9 Hz, 2H). m/z=272.2
-
- 2-cyclohexylpropan-1-amine (0.5 mmol) and methyl 2-(2-(chloromethyl)phenyl)acetate (0.5 mmol) were mixed in 5 ml of DMF; DIPEA (0.75 mmol) was added. The mixture was heated at 80° C. for 5 h, cooled; solvent was removed by evaporation, and residue was purified by HPLC. Yield: 39%. 1H NMR (400 MHz, DMSO-d6) δ 7.26 (dd, J=13.9, 6.6 Hz, 1H), 7.22 (t, J=5.3 Hz, 1H), 4.43 (d, J=2.7 Hz, 1H), 3.52 (s, 1H), 3.42-3.23 (m, 1H), 1.63 (dq, J=49.9, 12.8, 11.0 Hz, 3H), 1.16 (d, J=11.8 Hz, 1H), 1.13-1.04 (m, 1H), 0.72 (d, J=6.8 Hz, 1H). m/z=272.2
-
- (2-(aminomethyl)phenyl)methanesulfonamide (0.5 mmol) and 1-cyclohexylpropan-2-one (0.5 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 51%.
- 1H NMR (400 MHz, Chloroform-d) δ 7.53-7.47 (m, 1H), 7.35 (q, J=6.3, 5.2 Hz, 3H), 4.55 (s, 2H), 3.95 (d, J=12.3 Hz, 1H), 3.82 (d, J=12.3 Hz, 1H), 2.92 (q, J=6.8 Hz, 1H), 1.69 (d, J=11.7 Hz, 4H), 1.64 (s, 1H), 1.43 (dt, J=13.0, 6.5 Hz, 1H), 1.30 (s, 1H), 1.24 (d, J=11.7 Hz, 1H), 1.22 (s, 2H), 1.18 (t, J=6.2 Hz, 4H), 0.99-0.89 (m, 1H), 0.87 (d, J=11.0 Hz, 1H). m/z=325.2
-
- 2-(2-methylcyclohexyl)ethan-1-amine (0.5 mmol) and methyl 2-(2-(chloromethyl)phenyl)acetate (0.5 mmol) were mixed in 5 ml of DMF, and DIPEA (0.75 mmol) was added. The mixture was heated at 80° C. for 5 h, cooled; solvent was removed by evaporation, and the residue was purified by HPLC. Yield: 45%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.23 (p, J=8.0 Hz, 2H), 5.32 (s, 0H), 4.46 (s, 1H), 3.32 (s, 1H), 2.12 (t, J=7.3 Hz, 1H), 1.94 (s, 1H), 1.84 (s, 1H), 1.53 (q, J=6.3, 5.7 Hz, 1H), 1.46 (d, J=6.5 Hz, 1H). m/z=272.2
-
- 2-cyclohexylethan-1-amine (0.5 mmol) and methyl 2-(2-(chloromethyl)phenyl)acetate (0.5 mmol) were mixed in 5 ml of DMF; DIPEA (0.75 mmol) was added. The mixture was heated at 80° C. for 5 h, cooled; solvent was removed by evaporation and residue was purified by HPLC. Yield: 31%.
- 1H NMR (400 MHz, Chloroform-d) δ 7.28-7.20 (m, 1H), 7.17 (t, J=6.5 Hz, 1H), 4.45 (s, 1H), 3.60 (s, 1H), 3.48 (t, J=7.6 Hz, 1H), 1.73-1.56 (m, 4H), 1.27-1.05 (m, 3H), 0.87 (t, J=11.3 Hz, 1H). m/z=272.2
-
- 1,2,3,4-tetrahydroisoquinoline (0.5 mmol) and 2-cyclohexylacetaldehyde (0.5 mmol) were dissolved in 0.6 ml CHCl3; NaBH(OAc)3 (1.5 mmol) was added and stirred for 4 hours. The mixture was heated for 12 hours at 60° C.; then 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated and dissolved in 0.5 ml of DMSO. The residue was purified by HPLC. Yield: 51%.
- 1H NMR (400 MHz, Chloroform-d) δ 7.10 (dq, J=9.7, 5.6, 4.9 Hz, 3H), 7.05-6.98 (m, 1H), 3.62 (s, 2H), 2.91 (t, J=6.0 Hz, 2H), 2.72 (t, J=5.9 Hz, 2H), 2.56-2.48 (m, 2H), 1.78-1.61 (m, 5H), 1.50 (q, J=7.0 Hz, 2H), 1.36-1.12 (m, 2H), 0.95 (q, J=11.0 Hz, 2H). m/z=244.2
-
- Cyclohexanamine (0.5 mmol) and methyl 2-(2-(chloromethyl)phenyl)acetate (0.5 mmol) were mixed in 5 ml of DMF; DIPEA (0.75 mmol) was added. The mixture was heated at 80° C. for 5 h, cooled; solvent was removed by evaporation, and residue was purified by HPLC. Yield: 47%.
- 1H NMR (400 MHz, Chloroform-d) δ 7.28-7.14 (m, 4H), 4.55 (ddq, J=11.8, 7.5, 3.8 Hz, 1H), 4.34 (s, 2H), 3.60 (s, 2H), 1.82 (d, J=10.5 Hz, 2H), 1.71 (d, J=4.1 Hz, 1H), 1.45 (hd, J=12.4, 3.2 Hz, 4H), 1.15 (tt, J=10.3, 4.6 Hz, 1H). m/z=230.2
-
- 2-cyclohexylethan-1-amine (0.5 mmol) and methyl 2-formylbenzoate (0.5 mmol) were dissolved in 0.6 ml isopropanol, heated at 80° C. for 2 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. Then 0.2 g of C-18 chromatographic phase was added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 41%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.66 (d, J=7.5 Hz, 1H), 7.57 (d, J=4.2 Hz, 2H), 7.46 (dp, J=8.5, 4.2 Hz, 1H), 4.44 (s, 2H), 3.53 (t, J=7.3 Hz, 2H), 1.78-1.69 (m, 2H), 1.60 (dt, J=17.9, 6.0 Hz, 3H), 1.48 (q, J=7.1 Hz, 2H), 1.27-1.12 (m, 3H), 1.10 (dd, J=15.1, 3.6 Hz, 1H), 0.90 (tt, J=12.0, 6.0 Hz, 2H). m/z=244.2
-
- tert-butyl (3-(aminomethyl)phenyl)(methyl)carbamate (1 mmol) and 2-cyclohexylacetaldehyde (1 mmol) were dissolved in 0.6 ml MeOH, heated at 80° C. for 2 hours; then the mixture was cooled, NaBH4 (1 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; then cooled and filtered. Yield: 510%.
- To a solution of tert-butyl (3-(((2-cyclohexylethyl)amino)methyl)phenyl)(methyl) carbamate (0.5 mmol) in dichloromethane (5 mL) was slowly added trifluoroacetic acid (2.5 mmol) at 0° C. The reaction solution was stirred at room temperature for 5 h, and then 1 N NaOH was added. The mixture was extracted with dichloromethane, and the organic layer was washed with brine, dried (Na2SO4), and filtered. The solvent was evaporated and the residue was purified by HPLC. Yield: 31%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.26-7.18 (m, 2H), 7.14 (d, J=7.4 Hz, 2H), 3.62 (d, J=16.2 Hz, 4H), 2.95 (s, 1H), 2.46 (d, J=7.0 Hz, 2H), 2.24 (s, 3H), 1.63 (d, J=12.3 Hz, 5H), 1.30 (t, J=6.1 Hz, 3H), 1.18 (d, J=11.9 Hz, 1H), 1.12 (d, J=9.7 Hz, 2H), 0.90-0.80 (m, 2H). m/z=261.2
-
- 2-phenylethan-1-amine (0.5 mmol) and methyl 2-(2-(chloromethyl)phenyl)acetate (0.5 mmol) were mixed in 5 ml of DMF; DIPEA (0.75 mmol) was added. The mixture was heated at 80° C. for 5 h, cooled; solvent was removed by evaporation and residue was purified by HPLC. Yield: 51%.
- 1H NMR (400 MHz, Chloroform-d) δ 7.31-7.16 (m, 6H), 7.16 (d, J=7.5 Hz, 1H), 7.04 (d, J=7.4 Hz, 1H), 4.29 (s, 2H), 3.75 (t, J=7.4 Hz, 2H), 3.60 (s, 2H), 2.92 (t, J=7.4 Hz, 2H). m/z=252.2
-
- Methyl 2-(2-(aminomethyl)phenyl)acetate (0.5 mmol) and 2-cycloheptylacetaldehyde (0.5 mmol) were dissolved in 0.6 ml isopropanol, heated at 80° C. for 2 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. Then 0.2 g of C-18 chromatographic phase was added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 34%.
- 1H NMR (400 MHz, Chloroform-d) δ 7.23 (dd, J=12.7, 6.9 Hz, 1H), 7.17 (t, J=6.7 Hz, 1H), 4.45 (s, 1H), 3.60 (s, 1H), 3.52 (t, J=7.5 Hz, 1H), 1.73 (ddt, J=13.4, 6.5, 3.1 Hz, 1H), 1.64 (ddd, J=17.1, 8.6, 5.3 Hz, 1H), 1.56-1.45 (m, 1H), 1.39 (dd, J=12.4, 9.6 Hz, 0H), 1.23 (ddt, J=13.4, 9.4, 4.8 Hz, 1H). m/z=272.2
-
- 1-cyclohexylpropan-2-amine (0.5 mmol) and 1-benzyl-1H-indole-7-carbaldehyde (0.55 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated and the residue was purified by HPLC. Yield: 34%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.50 (dd, J=6.4, 2.8 Hz, 1H), 7.37 (d, J=3.2 Hz, 1H), 7.27 (t, J=7.4 Hz, 2H), 7.20 (t, J=7.3 Hz, 1H), 6.95 (q, J=4.0, 3.4 Hz, 2H), 6.80 (d, J=7.5 Hz, 2H), 6.53 (d, J=3.1 Hz, 1H), 5.92 (d, J=17.1 Hz, 1H), 5.85 (d, J=17.1 Hz, 1H), 3.74 (d, J=11.8 Hz, 1H), 3.33 (s, 1H), 2.61 (s, 1H), 1.64-1.49 (m, 5H), 1.46 (s, 1H), 1.37 (s, 1H), 1.27 (dt, J=13.6, 6.9 Hz, 1H), 1.16 (d, J=12.3 Hz, 1H), 1.11 (s, 1H), 1.10-1.02 (m, 1H), 1.05-0.94 (m, 3H), 0.76 (p, J=11.6 Hz, 2H). m/z=361.4
-
- (2-((methylsulfonyl)methyl)phenyl)methanamine (0.5 mmol) and 1-cyclohexylpropan-2-one (0.55 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 49%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.42-7.36 (m, 1H), 7.34 (d, J=7.1 Hz, 1H), 7.26 (p, J=7.2 Hz, 2H), 4.72 (d, J=13.8 Hz, 1H), 4.63 (d, J=13.9 Hz, 1H), 3.92 (d, J=12.6 Hz, 1H), 3.76 (d, J=12.7 Hz, 1H), 3.03 (s, 1H), 2.89 (d, J=2.3 Hz, 3H), 2.68 (s, 1H), 2.50 (s, 1H), 1.66 (d, J=11.5 Hz, 5H), 1.38-1.22 (m, 2H), 1.20 (s, 1H), 1.17 (s, 1H), 1.11 (s, 1H), 1.05 (dd, J=6.2, 2.2 Hz, 3H), 0.90-0.79 (m, 2H). m/z=324.2
-
- Under argon, into a reaction vessel of 1,2,4,5-tetrahydro-3H-benzo[c]azepin-3-one (0.5 mmol), potassium iodide 0.70 g (0.4 mmol), potassium carbonate 0.70 g (0.5 mmol), DMF (1 mL) and (2-chloroethyl)cyclohexane (0.5 mmol) were added. The reaction vessel was heated to 80° C., and the mixture was stirred for 12 hours. The reaction vessel was cooled to room temperature, ethyl acetate 20 mL was added, the organic layer was washed with
water 50 mL, saturatedbrine 50 mL. Product was purified by HPLC. Yield: 80%. - 1H NMR (400 MHz, Chloroform-d) δ 7.27 (d, J=7.3 Hz, 1H), 7.17 (dd, J=10.5, 6.4 Hz, 3H), 3.97 (s, 2H), 3.74 (s, 0H), 2.69 (s, 2H), 2.24 (d, J=6.3 Hz, 2H), 2.14 (s, 2H), 1.65 (td, J=10.2, 4.6 Hz, 6H), 1.41 (q, J=7.6 Hz, 2H), 1.28-1.05 (m, 4H), 0.93-0.79 (m, 2H). m/z=272.2
-
- 1-cyclohexylpropan-2-amine (1.0 mmol) and 2-hydroxybenzaldehyde (1.0 mmol) were dissolved in 1 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH(OAc)3 (1.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; 5 ml of methanol and 0.3 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 58%.
- 2-(((1-cyclohexylpropan-2-yl)amino)methyl)phenol (0.5 mmol) and Boc2O (0.6 mmol) in THF (1 mL) were heated for 2 h at 50° C. Then Et3N (0.1 mL) was added, and the mixture was heated for 1 hour at 50° C. The solvent was evaporated, the residue was purified by LC. Yield: 41%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.34-7.25 (m, 2H), 7.14 (t, J=7.4 Hz, 1H), 7.02 (d, J=8.3 Hz, 1H), 4.50-4.35 (m, 2H), 4.31 (d, J=15.0 Hz, 1H), 1.78 (d, J=12.8 Hz, 1H), 1.65-1.51 (m, 5H), 1.28 (ddd, J=14.0, 8.5, 5.6 Hz, 1H), 1.13 (dd, J=16.8, 7.6 Hz, 7H), 0.87 (dt, J=23.3, 12.1 Hz, 2H). m/z=274.2
-
- 2-cyclopentylethan-1-amine (0.5 mmol) and methyl 2-(2-(chloromethyl)phenyl)acetate (0.5 mmol) were mixed in 5 ml of DMF; DIPEA (0.75 mmol) was added. The mixture was heated at 80° C. for 5 h, cooled; solvent was removed by evaporation and residue was purified by HPLC. Yield: 29%.
- 1H NMR (400 MHz, Chloroform-d) δ 7.28-7.21 (m, 1H), 7.18 (q, J=9.0, 6.8 Hz, 1H), 4.46 (s, 1H), 3.60 (s, 1H), 3.52 (dd, J=8.8, 6.6 Hz, 1H), 1.79 (td, J=13.1, 11.9, 7.1 Hz, 1H), 1.66-1.53 (m, 2H), 1.52 (t, J=6.6 Hz, 1H), 1.20-1.11 (m, 1H). m/z=243
-
- tert-butyl (1-cyclohexylpropan-2-yl)(2-(sulfamoylmethyl)benzyl)carbamate (2 mmol) and CDI (4 mmol) were dissolved in 1.2 ml CH3CN; the mixture was kept at a temperature of 70° C. for 1 hour, then (tert-butoxycarbonyl)-L-leucine (2 mmol) was added. The mixture was heated for 2 hours at 70° C., then filtered, evaporated. The residue was purified by HPLC.
- To a solution of tert-butyl (2-((N-((tert-butoxycarbonyl)-L-leucyl)sulfamoyl)methyl)benzyl)(1-cyclohexylpropan-2-yl)carbamate (1 mmol) in dichloromethane (5 mL) was slowly added trifluoroacetic acid (5 mmol) at 0° C. The reaction solution was stirred at room temperature for 5 h, and then 1N NaOH was added. The mixture was extracted with dichloromethane, and the organic layer was washed with brine, dried (Na2SO4), and filtered. The solvent was evaporated, and the residue was purified by HPLC. Yield: 31%.
- 1H NMR (400 MHz, Chloroform-d) δ 7.47 (d, J=7.3 Hz, 1H), 7.33 (dt, J=24.0, 7.5 Hz, 3H), 5.20 (s, 4H), 4.48 (s, 2H), 4.08 (s, 2H), 3.39 (s, 1H), 3.24 (s, 1H), 2.56 (s, 1H), 1.63 (d, J=15.6 Hz, 6H), 1.41 (t, J=11.1 Hz, 1H), 1.27 (d, J=5.6 Hz, 3H), 1.17 (dd, J=22.8, 11.2 Hz, 2H), 0.93 (dd, J=13.7, 5.1 Hz, 5H), 0.86 (s, 3H), 0.35 (s, 1H). m/z=438.2
-
- 1-cyclohexylpropan-2-amine (0.5 mmol) and 2-(2-fluorophenethoxy)benzaldehyde (0.5 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 31%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.42 (dt, J=8.9, 4.3 Hz, 1H), 7.34-7.24 (m, 1H), 7.28-7.10 (m, 4H), 6.95 (d, J=8.1 Hz, 1H), 6.85 (t, J=7.4 Hz, 1H), 4.26-4.12 (m, 2H), 3.63 (d, J=14.0 Hz, 1H), 3.48 (d, J=14.0 Hz, 1H), 3.09 (t, J=6.3 Hz, 2H), 2.54 (s, 1H), 2.49-2.42 (m, 1H), 1.56 (d, J=12.7 Hz, 4H), 1.49 (s, 1H), 1.40 (d, J=13.1 Hz, 1H), 1.16 (dd, J=9.4, 6.4 Hz, 1H), 1.14 (s, 2H), 1.08 (t, J=8.1 Hz, 3H), 0.95 (p, J=3.8 Hz, 1H), 0.88 (d, J=6.1 Hz, 3H), 0.73 (dt, J=23.4, 11.2 Hz, 2H). m/z=370.2
-
- 2-(tetrahydro-2H-pyran-4-yl)ethan-1-amine (0.5 mmol) and methyl 2-(2-(chloromethyl)phenyl)acetate (0.5 mmol) were mixed in 5 ml of DMF; DIPEA (0.75 mmol) was added. The mixture was heated at 80° C. for 5 h, cooled; solvent was removed by evaporation and residue was purified by HPLC. Yield: 410%.
- 1H NMR (400 MHz, Chloroform-d) δ 7.62 (ddt, J=16.3, 11.9, 5.3 Hz, 3H), 4.87 (s, 2H), 4.27-4.18 (m, 2H), 3.88 (d, J=8.7 Hz, 4H), 3.66 (td, J=11.7, 2.0 Hz, 2H), 3.56 (s, 2H), 2.91 (dd, J=3.8, 1.9 Hz, 1H), 2.05 (d, J=12.9 Hz, 2H), 1.88 (t, J=6.4 Hz, 3H), 1.68-1.57 (m, 2H). m/z=260.2
-
- 1-(2-(aminomethyl)phenyl)-N-(2,3-dihydroxypropyl)methanesulfonamide (0.5 mmol) and 1-cyclohexylpropan-2-one (0.5 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 3 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 5 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 38%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.34 (t, J=7.5 Hz, 2H), 7.27 (q, J=7.6, 7.1 Hz, 2H), 7.04 (s, 1H), 4.80 (d, J=4.9 Hz, 1H), 4.61 (dd, J=13.9, 10.8 Hz, 1H), 4.52 (dd, J=18.3, 9.2 Hz, 2H), 3.88 (d, J=13.0 Hz, 1H), 3.74 (d, J=12.8 Hz, 1H), 3.48 (s, 1H), 2.99 (s, 1H), 2.83 (d, J=5.8 Hz, 1H), 2.63 (s, 1H), 2.54 (s, 2H), 1.60 (s, 6H), 1.32 (d, J=16.0 Hz, 2H), 1.22-1.11 (m, 1H), 1.09-0.98 (m, 3H), 0.81 (t, J=12.2 Hz, 2H). m/z=399.1
-
- 1-(2-(aminomethyl)phenyl)-N-(1-methylpiperidin-4-yl)methanesulfonamide (0.5 mmol), 1-cyclohexylpropan-2-one (0.5 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 3 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 5 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified using HPLC. Yield: 42%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.37-7.23 (m, 3H), 7.23 (s, 1H), 7.27-7.17 (m, 1H), 4.60 (d, J=13.8 Hz, 1H), 4.46 (d, J=13.7 Hz, 1H), 3.88 (d, J=12.8 Hz, 1H), 3.76 (d, J=12.7 Hz, 1H), 2.95 (s, 1H), 2.65 (t, J=11.7 Hz, 3H), 2.54 (s, 1H), 2.09 (d, J=11.7 Hz, 3H), 1.81 (dd, J=24.7, 13.5 Hz, 3H), 1.73 (s, 1H), 1.62 (d, J=13.7 Hz, 5H), 1.50-1.27 (m, 3H), 1.25-1.09 (m, 2H), 1.09-0.98 (m, 3H), 0.87-0.77 (m, 2H). m/z=422.1
-
- 1-(2-(aminomethyl)phenyl)-N-((tetrahydrofuran-2-yl)methyl)methanesulfonamide (0.5 mmol) and 1-cyclohexylpropan-2-one (0.5 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 3 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 5 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 34%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.29 (dddd, J=28.1, 14.5, 7.5, 3.9 Hz, 5H), 4.61 (dd, J=13.9, 10.2 Hz, 1H), 4.50 (dd, J=13.8, 7.9 Hz, 1H), 3.88 (dd, J=12.9, 3.0 Hz, 1H), 3.81 (p, J=6.1 Hz, 1H), 3.79-3.69 (m, 2H), 3.61 (q, J=7.2 Hz, 1H), 2.89 (t, J=5.9 Hz, 2H), 2.63 (q, J=6.4 Hz, 1H), 2.54 (s, 1H), 1.86 (dq, J=11.7, 7.0 Hz, 1H), 1.84-1.73 (m, 2H), 1.65-1.57 (m, 4H), 1.54 (dt, J=10.5, 7.1 Hz, 2H), 1.33 (tt, J=13.5, 6.0 Hz, 2H), 1.14 (ddd, J=26.0, 19.5, 8.8 Hz, 4H), 1.01 (d, J=6.1 Hz, 3H), 0.83 (s, 1H), 0.79 (d, J=11.8 Hz, 1H). m/z=409.2
-
- 1-(2-(aminomethyl)phenyl)-N-(2-methoxyethyl)methanesulfonamide (0.5 mmol) and 1-cyclohexylpropan-2-one (0.5 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 3 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 5 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 39%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.38-7.20 (m, 4H), 7.30 (s, 2H), 4.61 (d, J=13.9 Hz, 1H), 4.50 (d, J=13.8 Hz, 1H), 3.88 (d, J=12.9 Hz, 1H), 3.75 (d, J=12.9 Hz, 1H), 3.33 (t, J=5.8 Hz, 2H), 3.25 (s, 3H), 3.02 (t, J=5.9 Hz, 2H), 2.63 (q, J=6.4 Hz, 1H), 2.54 (s, 1H), 1.61 (d, J=17.1 Hz, 1H), 1.61 (s, 4H), 1.38-1.26 (m, 2H), 1.18 (d, J=12.9 Hz, 1H), 1.15-1.05 (m, 1H), 1.01 (d, J=6.2 Hz, 3H), 0.86-0.75 (m, 2H). m/z=383.1
-
- tert-butyl ((1H-indol-7-yl)methyl)(1-cyclohexylpropan-2-yl)carbamate (1 mmol) was added to 10 mL of DMF. NaH (1.1 mmol) was added to the stirring solution at 0° C., and the mixture was allowed to reach r.t stirring for 20 min. Then, methyl 2-bromoacetate (1.1 mmol) was added. The reaction mixture was allowed to stir under argon for 5 h at 50° C. The reaction was quenched with water (10 mL) and extracted twice with EtOAc (20 mL). The combined organic layers were washed with brine, dried over Na2SO4 and concentrated under reduced pressure. The crude methyl 2-(7-(((tert-butoxycarbonyl)(1-cyclohexylpropan-2-yl)amino)methyl)-1H-indol-1-yl)acetate was purified by chromatography. Yield: 71%.
- To a solution of methyl 2-(7-(((tert-butoxycarbonyl)(1-cyclohexylpropan-2-yl)amino)methyl)-1H-indol-1-yl)acetate (0.5 mmol) in dichloromethane (5 mL) was slowly added trifluoroacetic acid (2.5 mmol) at 0° C. The reaction solution was stirred at room temperature for 5 h, and then 1N NaOH was added. The mixture was extracted with dichloromethane, and the organic layer was washed with brine, dried (Na2SO4), and filtered. The solvent was evaporated, and the residue was purified by HPLC. Yield: 58%.
- 1H NMR (400 MHz, DMSO-d6) δ 9.37 (s, 1H), 9.29 (s, 1H), 7.62 (d, J=7.8 Hz, 1H), 7.40-7.30 (m, 2H), 7.11 (t, J=7.6 Hz, 1H), 6.54 (d, J=3.2 Hz, 1H), 5.38 (s, 2H), 4.31 (s, 2H), 3.72 (s, 2H), 1.75 (t, J=9.0 Hz, 1H), 1.68 (d, J=13.2 Hz, 2H), 1.64 (s, 1H), 1.48 (td, J=12.8, 12.0, 7.1 Hz, 1H), 1.34 (d, J=6.4 Hz, 2H), 1.20 (s, 2H), 0.97 (q, J=11.3 Hz, 1H), 0.87 (s, 1H). m/z=343.2
-
- Methyl 2-(7-(((1-cyclohexylpropan-2-yl)amino)methyl)-1H-indol-1-yl)acetate (0.5 mmol) was dissolved in HCl (5 mmol). The reaction stirred at 50° C. overnight. The reaction was poured into water and extracted (2×) with dichloromethane. Reaction mixture was concentrated under reduced pressure. The crude residue was purified by HPLC. Yield: 26%.
- 1H NMR (400 MHz, DMSO-d6) δ 9.66 (s, 2H), 7.58 (d, J=7.8 Hz, 1H), 7.25 (d, J=3.2 Hz, 1H), 7.11 (d, J=7.1 Hz, 1H), 7.00 (t, J=7.5 Hz, 1H), 6.45 (d, J=3.2 Hz, 1H), 4.85 (d, J=2.4 Hz, 2H), 4.44 (d, J=13.2 Hz, 1H), 4.33 (d, J=13.2 Hz, 1H), 3.16 (s, 1H), 2.54 (s, 1H), 1.67 (d, J=12.3 Hz, 4H), 1.60 (d, J=12.0 Hz, 4H), 1.23 (t, J=8.1 Hz, 4H), 1.17 (s, 7H), 0.89 (dt, J=37.0, 11.3 Hz, 3H). m/z=329.2
-
- 1-(2-(aminomethyl)phenyl)-N,N-dimethylmethanesulfonamide (0.5 mmol) and 1-cyclohexylpropan-2-one (0.5 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 3 hours, then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 5 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered. The residue was purified by HPLC. Yield: 33%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.30 (dtd, J=27.2, 7.0, 6.5, 1.9 Hz, 4H), 4.64 (d, J=13.6 Hz, 1H), 4.56 (d, J=13.7 Hz, 1H), 3.88 (d, J=12.8 Hz, 1H), 3.75 (d, J=12.8 Hz, 1H), 2.79 (s, 6H), 2.64 (q, J=5.9, 5.4 Hz, 1H), 1.62 (d, J=12.5 Hz, 6H), 1.38-1.27 (m, 2H), 1.25-1.03 (m, 3H), 1.01 (d, J=6.1 Hz, 3H), 0.81 (s, 2H). m/z=353.2
-
- (S)-1-(2-(aminomethyl)phenyl)-N-(2,3-dihydroxypropyl)-N-methylmethanesulfonamide (0.5 mmol), 1-cyclohexylpropan-2-one (0.5 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 3 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 5 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered. The residue was purified by HPLC. Yield: 27%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.34 (s, 2H), 7.34-7.22 (m, 2H), 4.88 (d, J=5.3 Hz, 1H), 4.71-4.53 (m, 3H), 3.88 (d, J=13.0 Hz, 1H), 3.77 (s, 1H), 3.63 (s, 1H), 3.19 (d, J=13.5 Hz, 1H), 3.04-2.97 (m, 1H), 2.85 (s, 2H), 2.54 (s, 3H), 2.49 (s, 1H), 1.60 (s, 6H), 1.35 (s, 2H), 1.22-1.11 (m, 2H), 1.07 (s, 3H), 1.01 (d, J=6.1 Hz, 2H), 0.86-0.76 (m, 2H). m/z=413.3
-
- (2-(((4-methylpiperazin-1-yl)sulfonyl)methyl)phenyl)methanamine (0.5 mmol), 1-cyclohexylpropan-2-one (0.5 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 3 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 5 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered. The residue was purified by HPLC. Yield: 38%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.38-7.22 (m, 4H), 4.66 (d, J=13.7 Hz, 1H), 4.57 (d, J=13.7 Hz, 1H), 3.88 (d, J=12.7 Hz, 1H), 3.76 (d, J=12.7 Hz, 1H), 3.18 (d, J=5.1 Hz, 4H), 2.65 (t, J=6.4 Hz, 1H), 2.54 (s, 2H), 2.36 (t, J=5.0 Hz, 4H), 2.20 (s, 3H), 1.66-1.57 (m, 5H), 1.33 (dd, J=14.9, 7.9 Hz, 2H), 1.25-0.98 (m, 6H), 0.83 (d, J=10.5 Hz, 2H). m/z=408.1
-
- Methyl 2-(3-(aminomethyl)phenyl)acetate (0.5 mmol) and 2-cyclohexylacetaldehyde (0.55 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 41%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.26-7.15 (m, 1H), 3.62 (t, J=12.3 Hz, 2H), 1.66 (d, J=12.6 Hz, 1H), 1.32 (d, J=7.5 Hz, 1H), 1.16 (dt, J=22.6, 12.5 Hz, 1H), 0.86 (d, J=10.3 Hz, 1H). m/z=290.1
-
- tert-butyl ((1H-indol-7-yl)methyl)(1-cyclohexylpropan-2-yl)carbamate (1 mmol) was dissolved in 10 mL of DMF. NaH (1.1 mmol) was added to the stirring solution at 0° C., and the mixture was allowed to reach r.t. stirring for 20 min. Then CH3I (1.1 mmol) was added. The reaction mixture was allowed to stir under argon for 5 h at 50° C. The reaction was quenched with water (10 mL) and extracted twice with EtOAc (20 mL). The combined organic layers were washed with brine, dried over Na2SO4 and concentrated under reduced pressure. The crude product was purified by chromatography. Yield: 54%.
- To a solution of tert-butyl (1-cyclohexylpropan-2-yl)((1-methyl-1H-indol-7-yl)methyl)carbamate (0.5 mmol) in dichloromethane (5 mL) was slowly added trifluoroacetic acid (2.5 mmol) at 0° C. The reaction solution was stirred at room temperature for 5 h, and then 1N NaOH was added. The mixture was extracted with dichloromethane, and the organic layer was washed with brine, dried (Na2SO4), and filtered. The solvent was evaporated and the residue was purified by HPLC. Yield: 310%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.42 (d, J=7.8 Hz, 1H), 7.21 (d, J=3.1 Hz, 1H), 6.95 (d, J=6.9 Hz, 1H), 6.91 (s, 0H), 6.89 (t, J=7.4 Hz, 1H), 6.37 (d, J=3.2 Hz, 1H), 4.12 (d, J=21.9 Hz, 4H), 3.93 (d, J=12.0 Hz, 1H), 2.73 (q, J=6.4 Hz, 1H), 1.60 (d, J=14.0 Hz, 4H), 1.52 (d, J=13.7 Hz, 1H), 1.37 (s, 2H), 1.33 (q, J=6.7, 6.1 Hz, 1H), 1.08 (dd, J=13.3, 7.8 Hz, 7H), 0.79 (dd, J=25.2, 12.5 Hz, 2H). m/z=285.2
-
- tert-butyl ((1H-indol-7-yl)methyl)(1-cyclohexylpropan-2-yl)carbamate (1 mmol) was dissolved in 10 mL of DMF. NaH (1.1 mmol) was added to the stirring solution at 0° C., and the mixture was allowed to reach r.t. stirring for 20 min. Then 2-chloroethanol (1.1 mmol) was added. The reaction mixture was allowed to stir under argon for 5 h at 50° C. The reaction was quenched with water (10 mL) and extracted twice with EtOAc (20 mL). The combined organic layers were washed with brine, dried over Na2SO4 and concentrated under reduced pressure. The crude tert-butyl (1-cyclohexylpropan-2-yl)((1-(2-hydroxyethyl)-1H-indol-7-yl)methyl)carbamate was purified by chromatography. Yield: 51%.
- To a solution of tert-butyl (1-cyclohexylpropan-2-yl)((1-(2-hydroxyethyl)-1H-indol-7-yl)methyl)carbamate (0.5 mmol) in dichloromethane (5 mL) was slowly added trifluoroacetic acid (2.5 mmol) at 0° C. The reaction solution was stirred at room temperature for 5 h, and then 1 N NaOH was added. The mixture was extracted with dichloromethane, and the organic layer was washed with brine, dried (Na2SO4), and filtered. The solvent was evaporated and the residue was purified by HPLC. Yield: 27%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.44 (d, J=7.7 Hz, 1H), 7.29 (dd, J=6.7, 3.2 Hz, 1H), 6.96 (d, J=6.5 Hz, 1H), 6.90 (dd, J=8.8, 6.0 Hz, 1H), 6.42 (d, J=3.2 Hz, 1H), 4.68-4.52 (m, 2H), 4.06 (t, J=11.0 Hz, 1H), 3.90 (d, J=11.8 Hz, 1H), 3.71 (dt, J=11.4, 5.6 Hz, 2H), 3.49-3.42 (m, 0H), 2.72 (s, 1H), 2.54 (s, 1H), 1.59 (q, J=14.2, 13.0 Hz, 6H), 1.39-1.28 (m, 3H), 1.21-1.08 (m, 3H), 1.06 (d, J=6.0 Hz, 4H), 0.83 (d, J=11.0 Hz, 1H), 0.78 (d, J=10.8 Hz, 1H). m/z=315.2
-
- 1-(2-(aminomethyl)phenyl)-N-methylmethanesulfonamide (0.5 mmol) and 1-cyclohexylpropan-2-one (0.5 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 3 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 5 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 31%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.38-7.21 (m, 4H), 7.03 (d, J=6.0 Hz, 1H), 4.59 (d, J=13.9 Hz, 1H), 4.49 (d, J=13.9 Hz, 1H), 3.88 (d, J=12.9 Hz, 1H), 3.75 (d, J=12.8 Hz, 1H), 2.64 (dd, J=13.0, 6.6 Hz, 1H), 2.63-2.52 (m, 4H), 1.65-1.55 (m, 6H), 1.34 (tt, J=13.5, 8.1 Hz, 2H), 1.18 (dd, J=25.1, 12.9 Hz, 3H), 1.12-1.03 (m, 1H), 1.01 (d, J=6.2 Hz, 3H), 0.80 (td, J=13.1, 6.4 Hz, 2H). m/z=339.2
-
- 1-(2-(aminomethyl)phenyl)-N-ethylmethanesulfonamide (0.5 mmol) and 1-cyclohexylpropan-2-one (0.5 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 3 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 5 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 28%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.38-7.20 (m, 4H), 7.15 (t, J=5.6 Hz, 1H), 4.58 (d, J=13.8 Hz, 1H), 4.48 (d, J=13.8 Hz, 1H), 3.88 (d, J=12.8 Hz, 1H), 3.75 (d, J=12.9 Hz, 1H), 2.98-2.87 (m, 2H), 2.62 (q, J=6.4 Hz, 1H), 2.54 (s, 1H), 1.65-1.54 (m, 7H), 1.34 (ddt, J=19.8, 13.5, 7.2 Hz, 2H), 1.25-1.11 (m, 2H), 1.15-0.98 (m, 6H), 0.86-0.73 (m, 2H). m/z=353.2
-
- ((2-(aminomethyl)benzyl)sulfonyl)glycine (0.5 mmol), 1-cyclohexylpropan-2-one (0.5 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 3 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 5 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered. The residue was purified by HPLC. Yield: 29%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.47 (d, J=6.8 Hz, 1H), 7.45-7.33 (m, 3H), 4.67 (t, J=9.8 Hz, 2H), 4.15 (d, J=13.3 Hz, 1H), 4.07 (d, J=13.5 Hz, 1H), 3.06 (s, 1H), 1.64 (d, J=17.3 Hz, 4H), 1.56 (d, J=15.4 Hz, 2H), 1.38-1.31 (m, 1H), 1.25 (s, 1H), 1.18 (d, J=6.4 Hz, 3H), 1.15 (s, 3H), 0.86 (q, J=12.7, 12.0 Hz, 2H). m/z=383.2
-
- 1-(2-(aminomethyl)phenyl)-N-(cyclohexylcarbamoyl)methanesulfonamide (0.5 mmol) and 1-cyclohexylpropan-2-one (0.5 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 3 hours; then mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 5 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered. The residue was purified by HPLC. Yield: 37%.
- 1H NMR (400 MHz, DMSO-d6) δ 8.35 (s, 2H), 7.42 (d, J=7.2 Hz, 1H), 7.37-7.25 (m, 3H), 5.90 (s, 1H), 4.51 (d, J=13.5 Hz, 1H), 4.30 (d, J=13.3 Hz, 1H), 4.18-4.06 (m, 2H), 3.34 (d, J=9.5 Hz, 2H), 1.73 (d, J=10.8 Hz, 2H), 1.69-1.57 (m, 8H), 1.53 (d, J=12.3 Hz, 1H), 1.38-1.29 (m, 1H), 1.21 (dd, J=17.7, 5.4 Hz, 5H), 1.15 (s, 6H), 1.09 (t, J=11.1 Hz, 2H), 0.91 (d, J=11.9 Hz, 1H), 0.85 (d, J=11.3 Hz, 1H). m/z=450.2
-
- 1-(2-(aminomethyl)phenyl)-N-((4-methylcyclohexyl)carbamoyl)methanesulfonamide (0.5 mmol) and 1-cyclohexylpropan-2-one (0.5 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 3 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 5 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered. The residue was purified by HPLC. Yield: 28%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.43 (s, 0H), 7.36 (s, 1H), 7.32 (s, 1H), 4.17 (s, 1H), 2.54 (s, 9H), 1.75 (s, 2H), 1.64 (s, 5H), 1.36 (s, 1H), 1.27 (s, 3H), 1.13 (s, 3H), 0.91 (s, 2H), 0.85 (d, J=6.3 Hz, 2H). m/z=464.2
-
- 1-cyclohexylpropan-2-amine (1 mmol), N-(tert-butyl)-2-(2-formylphenyl)ethane-1-sulfonamide (1 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled; NaBH4 (1 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.4 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 54%.
- N-(tert-butyl)-2-(2-(((1-cyclohexylpropan-2-yl)amino)methyl)phenyl)ethane-1-sulfonamide (0.5 mmol) was dissolved in 2 ml MeOH; HCl (5 mmol) was added in the mixture. The reaction stirred at 60° C. for 2 hours. The reaction mixture was concentrated under reduced pressure. The crude residue was purified by HPLC. Yield: 29%.
- 1H NMR (400 MHz, DMSO-d6) δ 8.66 (s, 2H), 7.49 (d, J=7.0 Hz, 1H), 7.36 (s, 3H), 6.94 (s, 2H), 4.15 (s, 2H), 3.10 (d, J=7.9 Hz, 2H), 1.67 (d, J=16.6 Hz, 6H), 1.38 (s, 2H), 1.30 (d, J=6.3 Hz, 2H), 1.20 (s, 3H), 0.96 (d, J=12.3 Hz, 1H), 0.85 (d, J=12.1 Hz, 1H). m/z=339.2
-
- Methyl ((2-(aminomethyl)benzyl)sulfonyl)glycylglycinate (1.5 mmol) and 1-cyclohexylpropan-2-one (1.5 mmol) were dissolved in 0.8 ml MeOH, heated at 100° C. for 3 hours; then the mixture was cooled, NaBH4 (1.5 mmol) was added and stirred for 5 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.4 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered. The residue was purified by HPLC. Yield: 34%.
- Methyl ((2-(((1-cyclohexylpropan-2-yl)amino)methyl)benzyl)sulfonyl) glycylglycinate (0.5 mmol) was dissolved in HCl (5 mmol). The reaction was stirred at 50° C. overnight. The reaction was poured into water and extracted (2×) with dichloromethane. Reaction mixture was concentrated under reduced pressure. The crude residue was purified by HPLC. Yield: 26%.
- 1H NMR (500 MHz, DMSO-d6) δ 8.09 (s, 1H), 7.89 (s, 1H), 7.63 (d, J=6.9 Hz, 1H), 7.55 (s, 1H), 7.42 (d, J=6.8 Hz, 1H), 7.37-7.32 (m, 2H), 4.75-4.65 (m, 2H), 4.13 (d, J=13.5 Hz, 1H), 4.09 (d, J=13.6 Hz, 1H), 3.15 (s, 1H), 2.05 (s, 1H), 1.60 (dd, J=21.8, 11.2 Hz, 7H), 1.39-1.31 (m, 2H), 1.22 (d, J=6.5 Hz, 3H), 1.17 (s, 2H), 1.11 (dd, J=20.9, 10.8 Hz, 2H), 0.84 (dq, J=35.4, 11.0 Hz, 2H). m/z=440.2
-
- Methyl (1s,3s)-3-(((2-(aminomethyl)phenyl)methyl)sulfonamido)cyclobutane-1-carboxylate (1.5 mmol) and 1-cyclohexylpropan-2-one (1.5 mmol) were dissolved in 0.8 ml MeOH, heated at 100° C. for 3 hours; then the mixture was cooled, NaBH4 (1.5 mmol) was added and stirred for 5 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.4 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered. The residue was purified by HPLC. Yield: 41%.
- Methyl (1s,3s)-3-(((2-(((1-cyclohexylpropan-2-yl)amino)methyl)phenyl)methyl) sulfonamido)cyclobutane-1-carboxylate (0.5 mmol) was dissolved in HCl (5 mmol). The reaction was stirred at 50° C. overnight. The reaction was poured into water and extracted (2×) with dichloromethane. Reaction mixture was concentrated under reduced pressure. The crude residue was purified by HPLC. Yield: 34%.
- 1H NMR (500 MHz, DMSO-d6) δ 7.63 (s, 1H), 7.35 (s, 1H), 7.27 (s, 4H), 4.54 (s, 1H), 4.40 (d, J=14.2 Hz, 1H), 4.32 (s, 2H), 3.93-3.87 (m, 1H), 3.77 (s, 1H), 2.65 (s, 1H), 2.56 (s, 1H), 2.34 (s, 3H), 2.06 (s, 2H), 1.59 (s, 6H), 1.34 (s, 2H), 1.16 (s, 3H), 1.08 (s, 2H), 1.02 (s, 4H), 0.80 (s, 3H), 0.56 (s, 1H). m/z=423.2
-
- Methyl ((2-(aminomethyl)benzyl)sulfonyl)-L-alaninate (1.5 mmol) and 1-cyclohexylpropan-2-one (1.5 mmol) were dissolved in 0.8 ml MeOH, heated at 100° C. for 3 hours; then the mixture was cooled, NaBH4 (1.5 mmol) was added and stirred for 5 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.4 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered. The residue was purified by HPLC. Yield: 34%.
- Methyl ((2-(((1-cyclohexylpropan-2-yl)amino)methyl)benzyl)sulfonyl)-L-alaninate (0.5 mmol) was dissolved in HCl (5 mmol). The reaction was stirred at 50° C. overnight. The reaction was poured into water and extracted (2×) with dichloromethane. Reaction mixture was concentrated under reduced pressure. The crude residue was purified by HPLC. Yield: 27%.
- 1H NMR (400 MHz, Methanol-d4) δ 7.52 (d, J=7.1 Hz, 2H), 7.45 (d, J=4.7 Hz, 2H), 4.73 (d, J=14.2 Hz, 1H), 4.51 (dd, J=14.1, 8.9 Hz, 1H), 4.35 (dd, J=17.6, 10.1 Hz, 2H), 3.82 (s, 1H), 3.48 (s, 1H), 3.29 (s, 2H), 1.75 (s, 0H), 1.69 (s, 5H), 1.43 (s, 2H), 1.38 (d, J=6.9 Hz, 5H), 1.30 (d, J=14.6 Hz, 1H), 1.21 (dd, J=20.3, 11.3 Hz, 1H), 1.06-0.89 (m, 2H). m/z=397.2
-
- Methyl ((2-(aminomethyl)benzyl)sulfonyl)-D-alaninate (1.5 mmol) and 1-cyclohexylpropan-2-one (1.5 mmol) were dissolved in 0.8 ml MeOH, heated at 100° C. for 3 hours; then the mixture was cooled, NaBH4 (1.5 mmol) was added and stirred for 5 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.4 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered. The residue was purified by HPLC. Yield: 39%.
- Methyl ((2-(((1-cyclohexylpropan-2-yl)amino)methyl)benzyl)sulfonyl)-D-alaninate (0.5 mmol) was dissolved in HCl (5 mmol). The reaction stirred at 50° C. overnight. The reaction was poured into water and extracted (2×) with dichloromethane. Reaction mixture was concentrated under reduced pressure. The crude residue was purified by HPLC. Yield: 24%. m/z=397.2
-
- Methyl (1r,3r)-3-(((2-(aminomethyl)phenyl)methyl)sulfonamido)cyclobutane-1-carboxylate (1.5 mmol) and 1-cyclohexylpropan-2-one (1.5 mmol) were dissolved in 0.8 ml MeOH, heated at 100° C. for 3 hours; then the mixture was cooled, NaBH4 (1.5 mmol) was added and stirred for 5 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.4 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered. The residue was purified by HPLC. Yield: 44%.
- Methyl (1r,3r)-3-(((2-(((1-cyclohexylpropan-2-yl)amino)methyl)phenyl)methyl) sulfonamido) cyclobutane-1-carboxylate (0.5 mmol) was dissolved in HCl (5 mmol). The reaction was stirred at 50° C. overnight. The reaction was poured into water and extracted (2×) with dichloromethane. Reaction mixture was concentrated under reduced pressure. The crude residue was purified by HPLC. Yield: 31%.
- Methyl (1r,3r)-3-((2-((2-(aminomethyl)phenoxy)methyl)phenyl)sulfonamido) cyclobutane-1-carboxylate (1 mmol), and 1-cyclohexylpropan-2-one (1 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (1 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 54%.
- To a solution of methyl (1r,3r)-3-((2-((2-(((1-cyclohexylpropan-2-yl)amino)methyl)phenoxy)methyl)phenyl)sulfonamido)cyclobutane-1-carboxylate (0.5 mmol) in EtOH/H2O (5.0/2.5 ml) was added NaOH (1.5 mmol). The reaction stirred at room temperature overnight. To the reaction was added CH3COOH (1.5 mmol) and it was extracted (2×) with dichloromethane. The organic layers were dried over magnesium sulfate, filtered and concentrated. The crude residue was purified by HPLC. Yield: 38%.
- 1H NMR (500 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.33 (d, J=7.3 Hz, 1H), 7.25 (q, J=8.2, 7.5 Hz, 3H), 4.53 (d, J=13.8 Hz, 1H), 4.39 (d, J=13.8 Hz, 1H), 4.32 (s, 1H), 3.87 (d, J=12.3 Hz, 2H), 3.72 (d, J=12.9 Hz, 1H), 2.78 (t, J=9.8 Hz, 1H), 2.67-2.60 (m, 1H), 2.38-2.30 (m, 2H), 2.16 (q, J=10.2 Hz, 2H), 1.61 (s, 2H), 1.56 (d, J=14.8 Hz, 3H), 1.37-1.26 (m, 2H), 1.16 (d, J=12.2 Hz, 1H), 1.14-0.99 (m, 3H), 1.00 (s, 1H), 0.81 (q, J=12.1 Hz, 2H). m/z=423.2
-
- (4-(((2-(aminomethyl)phenyl)methyl)sulfonamido)phenyl)boronic acid (0.5 mmol) and 1-cyclohexylpropan-2-one (0.5 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 3 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 5 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered. The residue was purified by HPLC. Yield: 24%.
- 1H NMR (500 MHz, Methanol-d4) δ 7.47 (d, J=6.7 Hz, 1H), 7.47-7.34 (m, 5H), 7.24 (t, J=7.6 Hz, 1H), 7.15 (d, J=7.9 Hz, 1H), 4.61 (d, J=14.4 Hz, 1H), 4.57 (d, J=14.4 Hz, 1H), 4.11 (d, J=13.3 Hz, 1H), 4.04 (d, J=13.3 Hz, 1H), 3.15 (s, 1H), 2.66 (s, 1H), 1.71 (dd, J=27.8, 12.8 Hz, 6H), 1.56 (ddd, J=13.2, 8.5, 4.4 Hz, 1H), 1.39-1.15 (m, 6H), 1.00 (dd, J=13.4, 10.4 Hz, 1H), 0.92 (td, J=13.5, 12.3, 6.7 Hz, 1H). m/z=445.2
-
- (2-((2-isopropylbenzyl)oxy)phenyl)methanamine (0.5 mmol) and 1-cyclohexylpropan-2-one (0.55 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 39%.
- 1H NMR (400 MHz, Chloroform-d) δ 9.43 (s, 1H), 9.10 (s, 1H), 7.74 (d, J=7.6 Hz, 1H), 7.46 (d, J=7.6 Hz, 1H), 7.38 (s, 1H), 7.36-7.26 (m, 2H), 7.25 (d, J=8.4 Hz, 1H), 7.21-7.13 (m, 1H), 7.00-6.88 (m, 2H), 5.16 (s, 2H), 3.97 (d, J=13.2 Hz, 1H), 3.91 (d, J=13.9 Hz, 1H), 3.16 (hept, J=6.8 Hz, 1H), 2.93 (s, 1H), 1.58 (d, J=5.8 Hz, 2H), 1.40 (d, J=10.4 Hz, 1H), 1.37 (d, J=11.2 Hz, 2H), 1.23 (d, J=6.8 Hz, 6H), 1.17 (d, J=6.5 Hz, 4H), 1.04 (s, 1H), 1.00 (s, 1H), 0.76-0.63 (m, 1H), 0.60 (d, J=11.9 Hz, 1H). m/z=380.2
- 13C NMR (126 MHz, Chloroform-d) δ 157.23, 147.47, 132.71, 132.48, 130.65, 129.97, 128.94, 125.95, 125.48, 121.08, 119.45, 111.62, 68.21, 51.03, 41.87, 39.77, 33.94, 33.81, 31.54, 28.83, 26.29, 26.10, 25.88, 24.11, 24.03, 16.29.
-
- (2-((3-methoxybenzyl)oxy)phenyl)methanamine (1 mmol), 1-cyclohexylpropan-2-one (1 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then mixture was cooled, NaBH4 (1 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 44%.
- 1H NMR (500 MHz, Chloroform-d) δ 9.48 (s, 1H), 9.12 (s, 1H), 7.76-7.70 (m, 1H), 7.32-7.23 (m, 1H), 7.05 (t, J=5.8 Hz, 2H), 6.97-6.90 (m, 2H), 6.87 (dd, J=8.5, 2.6 Hz, 1H), 5.11 (d, J=2.2 Hz, 2H), 3.99 (p, J=7.4, 6.6 Hz, 2H), 3.82 (s, 3H), 3.00 (tt, J=10.2, 5.1 Hz, 1H), 1.68 (ddd, J=13.4, 9.5, 4.0 Hz, 1H), 1.63-1.56 (m, 3H), 1.50-1.39 (m, 3H), 1.26 (d, J=6.5 Hz, 3H), 1.21 (s, 2H), 1.17 (s, 1H), 1.09 (p, J=12.6, 12.0 Hz, 2H), 0.76 (qd, J=12.3, 3.2 Hz, 1H), 0.66 (tt, J=12.1, 6.0 Hz, 1H). m/z=368.2
-
- (2-((4-methylbenzyl)oxy)phenyl)methanamine (1 mmol) and 1-cyclohexylpropan-2-one (1 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (1 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 38%.
- 1H NMR (400 MHz, Chloroform-d) δ 9.42 (s, 1H), 9.04 (s, 1H), 7.69 (d, J=7.5 Hz, 1H), 7.35 (d, J=7.5 Hz, 2H), 7.24 (dd, J=9.9, 5.8 Hz, 1H), 7.15 (d, J=7.6 Hz, 2H), 6.92 (p, J=8.5, 7.4 Hz, 2H), 5.05 (s, 2H), 3.95 (q, J=4.9 Hz, 2H), 2.94 (dt, J=11.0, 5.7 Hz, 1H), 2.32 (s, 3H), 1.58 (dd, J=14.4, 8.8 Hz, 4H), 1.39 (tt, J=13.7, 5.2 Hz, 3H), 1.21 (d, J=6.5 Hz, 3H), 1.10 (dq, J=34.3, 9.4, 8.8 Hz, 4H), 0.71 (t, J=11.7 Hz, 1H), 0.62 (t, J=11.8 Hz, 1H). m/z=352.4
-
- (2-((3-methylbenzyl)oxy)phenyl)methanamine (1 mmol) and 1-cyclohexylpropan-2-one (1 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (1 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 32%.
- 1H NMR (500 MHz, Chloroform-d) δ 9.50 (s, 1H), 9.18 (s, 1H), 7.75 (dd, J=7.5, 1.7 Hz, 1H), 7.31-7.21 (m, 4H), 7.16-7.11 (m, 1H), 6.93 (t, J=8.1 Hz, 2H), 5.09 (s, 2H), 4.00 (q, J=4.5 Hz, 2H), 2.98 (dt, J=11.1, 5.5 Hz, 1H), 2.36 (s, 3H), 1.67 (ddd, J=13.5, 9.6, 4.0 Hz, 1H), 1.59 (dd, J=12.0, 6.5 Hz, 2H), 1.49-1.37 (m, 3H), 1.25 (d, J=6.5 Hz, 3H), 1.19 (s, 2H), 1.19-1.00 (m, 2H), 0.74 (qd, J=12.3, 3.3 Hz, 1H), 0.64 (qd, J=12.0, 3.0 Hz, 1H), −1.15 (s, 1H). m/z=352.4
-
- (2-((2-cyclopropylbenzyl)oxy)phenyl)methanamine (1 mmol) and 1-cyclohexylpropan-2-one (1 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (1 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 37%.
- 1H NMR (500 MHz, Chloroform-d) δ 17.10 (s, 1H), 9.50 (s, 1H), 9.17 (s, 1H), 7.78 (d, J=7.4 Hz, 1H), 7.45 (d, J=7.4 Hz, 1H), 7.27 (dt, J=15.5, 7.7 Hz, 2H), 7.18 (t, J=7.4 Hz, 1H), 7.01 (dd, J=16.7, 8.0 Hz, 2H), 6.95 (t, J=7.5 Hz, 1H), 5.32 (s, 2H), 4.04 (d, J=5.9 Hz, 1H), 4.01 (d, J=5.8 Hz, 1H), 2.98 (dt, J=11.6, 5.6 Hz, 1H), 1.98 (tt, J=8.5, 5.3 Hz, 1H), 1.65 (ddd, J=13.6, 9.6, 3.9 Hz, 1H), 1.57 (d, J=8.5 Hz, 3H), 1.47-1.37 (m, 3H), 1.24-1.13 (m, 4H), 1.07 (dt, J=25.2, 13.9 Hz, 2H), 0.94 (dq, J=6.2, 3.8 Hz, 2H), 0.78-0.67 (m, 3H), 0.70-0.57 (m, 1H). m/z=378.2
-
- (2-((2-phenoxybenzyl)oxy)phenyl)methanamine (1 mmol) and 1-cyclohexylpropan-2-one (1 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (1 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 39%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.63 (d, J=7.5 Hz, 1H), 7.39 (d, J=7.7 Hz, 2H), 7.34 (d, J=13.0 Hz, 2H), 7.30-7.17 (m, 2H), 7.13 (t, J=7.4 Hz, 1H), 7.08 (d, J=8.2 Hz, 1H), 6.95 (dd, J=22.4, 8.0 Hz, 4H), 5.15 (s, 2H), 3.81 (s, 2H), 2.79 (s, 1H), 1.56 (s, 3H), 1.49 (d, J=15.3 Hz, 2H), 1.34 (s, 1H), 1.24 (s, 1H), 1.09 (s, 5H), 1.01 (s, 2H), 0.74 (s, 2H). m/z=430.2
-
- 2-(3-methylcyclohexyl)ethan-1-amine (0.5 mmol) and methyl 2-(2-(chloromethyl)phenyl)acetate (0.5 mmol) were mixed in 5 ml of DMF; DIPEA (0.75 mmol) was added. The mixture was heated at 80° C. for 5 h, cooled; solvent was removed by evaporation and residue was purified by HPLC. Yield: 32%.
- 1H NMR (400 MHz, Chloroform-d) δ 7.26-7.10 (m, 4H), 4.42 (s, 2H), 3.57 (s, 2H), 3.50 (p, J=7.4, 6.4 Hz, 2H), 3.44 (s, 1H), 1.73 (dq, J=11.1, 4.0 Hz, 1H), 1.72-1.58 (m, 1H), 1.62-1.37 (m, 4H), 1.37-1.17 (m, 1H), 1.09 (td, J=10.2, 7.9, 4.7 Hz, 1H), 0.85 (t, J=6.5 Hz, 3H), 0.84-0.71 (m, 1H). m/z=272.2
-
- 1-(4-methylcyclohexyl)propan-2-amine (1 mmol) and 2-((2-fluorobenzyl)oxy)benzaldehyde (1 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (1 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, the solvent was evaporated. The residue was purified by HPLC. Yield: 57%.
- 1H NMR (400 MHz, DMSO-d6) δ 7.61-7.53 (m, 1H), 7.41 (tdd, J=7.6, 5.4, 1.8 Hz, 1H), 7.32-7.22 (m, 2H), 7.25-7.16 (m, 2H), 7.09 (d, J=8.1 Hz, 1H), 6.90 (t, J=7.3 Hz, 1H), 5.15 (s, 2H), 3.76-3.67 (m, 1H), 3.60 (d, J=13.7 Hz, 1H), 2.60-2.47 (m, 1H), 1.54 (dd, J=13.2, 8.3 Hz, 3H), 1.50-1.43 (m, 1H), 1.22-1.09 (m, 3H), 1.04-0.90 (m, 1H), 0.90 (d, J=6.1 Hz, 2H), 0.82 (dd, J=13.9, 6.7 Hz, 2H), 0.78-0.68 (m, 3H). m/z=370.2
-
- diethyl 2-acetamido-2-(2-(aminomethyl)benzyl)malonate (1 mmol) and 1-cyclohexylpropan-2-one (1 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (1 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C. Water (5 ml) were added, the organic layer was extracted with EtOAc (3*10 ml) and concentrated in vacuo. The residue was purified by HPLC. Yield: 57%.
- Diethyl 2-acetamido-2-(2-(((1-cyclohexylpropan-2-yl)amino)methyl)benzyl)malonate (0.05 mmol) was dissolved in 0.5 ml MeOH; 0.1 ml HCl was added. The mixture was refluxed for 1 hour. The precipitate was filtered and was purified by LC. Yield: 39%.
- 1H NMR (500 MHz, Chloroform-d) δ 7.38 (d, J=7.5 Hz, 1H), 7.24 (d, J=8.0 Hz, 2H), 7.15 (d, J=7.5 Hz, 1H), 6.71 (s, 4H), 4.00 (t, J=11.5 Hz, 1H), 3.79 (d, J=12.1 Hz, 1H), 3.55 (s, 1H), 3.20 (t, J=9.9 Hz, 1H), 3.00 (s, 2H), 1.66 (q, J=11.7, 10.9 Hz, 6H), 1.40-1.34 (m, 1H), 1.32-1.27 (m, 2H), 1.27-1.19 (m, 4H), 1.14 (dt, J=22.2, 11.8 Hz, 2H), 0.89 (dp, J=40.3, 11.5, 10.8 Hz, 2H). m/z=319.2
-
- diethyl 2-acetamido-2-(2-(aminomethyl)benzyl)malonate (5 mmol) and 2-cyclohexylpropanal (5 mmol) were dissolved in 1.5 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (5 mmol) was added and stirred for 1 hours at r.t. Thereafter, water (15 ml) was added, the organic layer was extracted with EtOAc (3×15 ml), and concentrated in vacuo. The residue was purified using HPLC. Yield: 54%.
- To a solution of diethyl 2-acetamido-2-(2-(((2-cyclohexylpropyl)amino)methyl)benzyl)malonate (2.5 mmol) in ethanol (10 ml) was added potassium hydroxide (2.5 mmol). The reaction was allowed to stir at reflux for 8 h and was then concentrated. The residue was dissolved in water and extracted with EtOAc. The aqueous layer was cooled to 0° C., carefully acidified to pH 2-3 using HCl, and extracted with EtOAc. The combined organics were dried over sodium sulfate, filtered, concentrated and purified by chiral chromatographic purification. Yield: 41%.
- (2S)-2-acetamido-3-(2-(((2-cyclohexylpropyl)amino)methyl)phenyl)propanoic acid (1 mmol) was dissolved in 0.5 ml AcOH; 0.2 ml HCl was added and was stirred for 2 hours. The precipitate was filtered and was purified using LC. Yield: 51%.
- 1H NMR (500 MHz, DMSO-d6) δ 7.04-6.89 (m, 3H), 6.90 (s, 1H), 4.28 (d, J=8.2 Hz, 8H), 3.83 (td, J=15.8, 15.4, 12.0 Hz, 2H), 3.65 (dd, J=9.0, 6.2 Hz, 1H), 2.96-2.88 (m, 1H), 2.78 (d, J=14.3 Hz, 1H), 2.66 (s, 1H), 2.46 (d, J=9.6 Hz, 1H), 1.28 (s, 1H), 1.21 (s, 2H), 1.19 (d, J=3.8 Hz, 1H), 1.12 (d, J=12.8 Hz, 1H), 1.05 (d, J=12.3 Hz, 2H), 0.74-0.65 (m, 1H), 0.63-0.49 (m, 1H), 0.47 (s, 2H), 0.45 (dd, J=7.1, 2.8 Hz, 2H). m/z=317.1
-
- 1-cyclohexylpropan-2-one (1 mmol) and (2-(2-fluorophenethyl)phenyl)methanamine (1 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (1 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C., 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, the solvent was evaporated. The residue was purified using HPLC. Yield: 31%. 1H NMR (400 MHz, Chloroform-d) δ 7.30 (d, J=4.4 Hz, 1H), 7.20-7.10 (m, 5H), 7.02 (q, J=8.4, 7.8 Hz, 2H), 3.80 (d, J=12.5 Hz, 1H), 3.67 (d, J=12.5 Hz, 1H), 2.99-2.90 (m, 4H), 2.77 (q, J=6.7 Hz, 1H), 1.62 (d, J=10.3 Hz, 5H), 1.39-1.30 (m, 1H), 1.10 (dd, J=23.7, 6.7 Hz, 5H), 0.84 (d, J=11.7 Hz, 2H). m/z=354.2
-
- 1-(4-(trifluoromethyl)cyclohexyl)propan-2-one (1 mmol) and (2-((2-fluorobenzyl)oxy)phenyl)methanamine (1 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (1 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C., 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, the solvent was evaporated. The residue was purified using HPLC. Yield: 28%.
- 1H NMR (400 MHz, Chloroform-d) δ 7.48 (s, 1H), 7.31 (d, J=7.1 Hz, 1H), 7.22 (t, J=9.4 Hz, 2H), 7.14 (t, J=7.5 Hz, 1H), 7.08 (t, J=9.2 Hz, 1H), 6.99-6.88 (m, 2H), 5.13 (s, 2H), 3.86 (dd, J=13.1, 8.6 Hz, 1H), 3.73 (dd, J=13.0, 8.8 Hz, 1H), 2.67-2.53 (m, 1H), 1.82 (t, J=13.7 Hz, 1H), 1.51 (s, 1H), 1.41 (s, 1H), 1.34 (ddd, J=25.5, 12.2, 6.1 Hz, 1H), 1.27-1.07 (m, 2H), 1.01 (td, J=6.6, 2.5 Hz, 3H), 0.84-0.73 (m, 1H). m/z=424.2
-
- 1-(4-ethylcyclohexyl)propan-2-amine (1 mmol) and 2-((2-fluorobenzyl)oxy)benzaldehyde (1 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (1 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C., 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, the solvent was evaporated. The residue was purified using HPLC. Yield: 38%.
- 1H NMR (400 MHz, Chloroform-d) δ 7.50 (t, J=7.5 Hz, 1H), 7.35-7.23 (m, 1H), 7.22 (d, J=7.6 Hz, 1H), 7.21-7.11 (m, 1H), 7.07 (dd, J=10.2, 8.1 Hz, 1H), 6.97-6.91 (m, 1H), 6.91 (d, J=7.3 Hz, 1H), 5.14 (s, 2H), 3.87 (dd, J=13.1, 6.2 Hz, 1H), 3.74 (dd, J=13.0, 4.3 Hz, 1H), 2.70-2.57 (m, 1H), 1.73 (s, 1H), 1.63 (s, 2H), 1.44-1.25 (m, 1H), 1.23 (d, J=6.5 Hz, 1H), 1.17 (dd, J=15.3, 8.6 Hz, 1H), 1.12-0.98 (m, 2H), 0.99 (s, 1H), 0.87-0.67 (m, 4H). m/z=384.2.
-
- 1-(4-isopropylcyclohexyl)propan-2-amine (1 mmol) and 2-((2-fluorobenzyl)oxy)benzaldehyde (1 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then mixture was cooled, NaBH4 (1 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C., 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, the solvent was evaporated. The residue was purified using HPLC. Yield: 41%.
- 1H NMR (400 MHz, Chloroform-d) δ 7.50 (t, J=7.7 Hz, 1H), 7.30 (d, J=7.0 Hz, 1H), 7.18 (dt, J=26.1, 6.7 Hz, 2H), 7.07 (t, J=9.2 Hz, 1H), 6.93 (dd, J=12.3, 7.6 Hz, 2H), 5.15 (s, 2H), 3.88 (d, J=13.1 Hz, 1H), 3.74 (d, J=13.1 Hz, 1H), 2.65 (d, J=6.4 Hz, 1H), 1.58 (dt, J=27.6, 12.6 Hz, 4H), 1.30 (dq, J=13.2, 6.6 Hz, 1H), 1.08 (dd, J=12.8, 6.3 Hz, 1H), 1.00 (d, J=6.2 Hz, 3H), 0.80 (d, J=6.9 Hz, 7H), 0.74 (d, J=11.6 Hz, 1H). m/z=398.2
-
- 1-(4-cyclopropylcyclohexyl)propan-2-amine (1 mmol) and 2-((2-fluorobenzyl)oxy)benzaldehyde (1 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then mixture was cooled, NaBH4 (1 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C., 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, the solvent was evaporated. The residue was purified using HPLC. Yield: 32%.
- 1H NMR (400 MHz, Chloroform-d) δ 7.50 (t, J=7.7 Hz, 2H), 7.30 (d, J=7.0 Hz, 1H), 7.26-7.03 (m, 6H), 6.97-6.88 (m, 3H), 5.14 (s, 3H), 3.88 (d, J=13.4 Hz, 2H), 3.75 (dd, J=13.2, 8.5 Hz, 2H), 2.65 (s, 2H), 1.70 (s, 4H), 1.61 (d, J=13.1 Hz, 1H), 1.40 (s, 7H), 1.31-1.16 (m, 1H), 1.20 (s, 6H), 1.13-0.98 (m, 5H), 0.94 (d, J=12.2 Hz, 1H), 0.90 (s, 1H), 0.76-0.66 (m, 2H), 0.53 (s, 1H), 0.33 (dd, J=15.5, 7.8 Hz, 5H). m/z=396.2
-
- 1-(4,4-difluorocyclohexyl)propan-2-amine (1 mmol) and 2-((2-fluorobenzyl)oxy)benzaldehyde (1 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (1 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C., 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, the solvent was evaporated. The residue was purified using HPLC. Yield: 39%.
- 1H NMR (400 MHz, Chloroform-d) δ 7.48 (dd, J=8.4, 6.6 Hz, 1H), 7.32 (d, J=7.2 Hz, 1H), 7.24 (d, J=1.7 Hz, 1H), 7.23 (s, 1H), 7.22-7.13 (m, 1H), 7.10 (dd, J=18.8, 9.4 Hz, 1H), 6.99-6.89 (m, 2H), 5.13 (s, 2H), 3.87 (d, J=13.1 Hz, 1H), 3.73 (d, J=13.1 Hz, 1H), 2.62 (dt, J=11.7, 5.7 Hz, 1H), 1.62 (d, J=12.5 Hz, 2H), 1.58-1.46 (m, 2H), 1.36 (q, J=6.2, 5.6 Hz, 1H), 1.32 (s, 2H), 1.18-1.07 (m, 3H), 1.02 (d, J=6.2 Hz, 3H). m/z=392.3
-
- 2-(cyclohex-1-en-1-yl)ethan-1-amine (0.5 mmol) and benzaldehyde (0.55 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated and dissolved in 0.5 ml of DMSO. The residue was purified by HPLC. Yield: 41%.
- 1H NMR (400 MHz, DMSO-d6) δ 9.73 (s, 2H), 7.61 (d, J=7.6 Hz, 2H), 7.39 (d, J=6.4 Hz, 3H), 5.46 (s, 1H), 4.07 (t, J=5.6 Hz, 2H), 3.11 (s, 2H), 2.88 (d, J=9.0 Hz, 2H), 2.36 (t, J=8.3 Hz, 2H), 1.98 (s, 2H), 1.90 (d, J=7.4 Hz, 2H), 1.60 (q, J=5.7 Hz, 2H), 1.55 (q, J=5.9 Hz, 2H). m/z=216.2
-
- 2-(cyclohex-1-en-1-yl)ethan-1-amine (0.5 mmol) and 4-methylbenzaldehyde (0.5 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 39%.
- 1H NMR (400 MHz, DMSO-d6) δ 9.34 (s, 1H), 7.45 (d, J=7.7 Hz, 1H), 7.22 (d, J=7.7 Hz, 1H), 5.43 (s, 0H), 4.06 (t, J=5.6 Hz, 1H), 2.88 (dq, J=11.3, 6.0 Hz, 1H), 2.31 (s, 3H), 1.94 (s, 1H), 1.85 (d, J=6.7 Hz, 1H), 1.59-1.53 (m, 1H), 1.53-1.43 (m, 1H). m/z=230.4
-
- 2-(cyclohex-1-en-1-yl)ethan-1-amine (0.5 mmol) and 3-methylbenzaldehyde (0.5 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated and the residue was purified by HPLC. Yield: 41%.
- 1H NMR (400 MHz, DMSO-d6) δ 8.95 (s, 2H), 7.36-7.26 (m, 3H), 7.21 (d, J=6.5 Hz, 1H), 5.44 (s, 1H), 4.05 (s, 2H), 2.94-2.86 (m, 2H), 2.30 (d, J=18.1 Hz, 6H), 1.94 (s, 2H), 1.87 (s, 2H), 1.61-1.53 (m, 2H), 1.49 (dd, J=6.7, 4.5 Hz, 1H). m/z=230.2
-
- 2-(cyclohex-1-en-1-yl)ethan-1-amine (0.5 mmol) and 2-methylbenzaldehyde (0.5 mmol) were dissolved in 0.6 ml MeOH, heated at 100° C. for 2 hours; then the mixture was cooled, NaBH4 (0.5 mmol) was added and stirred for 4 hours. The mixture was heated for 2 hours at 60° C.; 3 ml of methanol and 0.2 g of C-18 chromatographic phase were added, stirred for 2 hours, filtered, evaporated. The residue was purified by HPLC. Yield: 43%.
- 1H NMR (400 MHz, DMSO-d6) δ 9.24 (s, 2H), 7.57-7.51 (m, 1H), 7.34-7.21 (m, 3H), 5.47 (s, 1H), 4.11 (t, J=6.1 Hz, 2H), 3.03 (dq, J=11.3, 5.9 Hz, 2H), 2.56-2.47 (m, 2H), 2.37 (d, J=10.0 Hz, 5H), 1.96 (s, 2H), 1.91 (s, 1H), 1.58 (dd, J=10.7, 6.0 Hz, 2H), 1.52 (p, J=5.9 Hz, 2H). m/z=230.2
- Overnight bacterial cultures were grown in LB with no added antibiotics at 37° C. with shaking. A 1:1000 dilution of these cultures into LB was exposed to concentration gradients of compounds in 96-well plates (100 μL per well assay volume). Resulting plates were incubated at 37° C. for 24 h without shaking, and OD600 was measured at the end of the incubation. MICs were determined as the lowest concentrations at which OD600 remained at baseline.
- Antibacterial activity of the compounds of the invention is shown in Table 3.
- A luminescence assay was carried out via the following steps. The strain used in the luminescence assay was H37RvMA with the LuxCDABE operon integrated at the L5 site on a Kanamycin marked plasmid (pMV306hsp+LuxG13):
-
- 1. Inoculate −80 stock into 7H9 OADC+Kan (25 ug/mL)
- 2. When bacteria reach mid-log phase, passage cells in 7H9 OADC+Kan25
- 3. When cells reach mid log phase dilute to OD=0.05 in 7H9 OADC
- 4. Add 100 uL of cells to each well of the plate
- 5. Seal the plate with an optical film and read luminescence using the following protocol:
- a. Plate reader: Biotek Synergy H1
- b. Double orbital shaking (10 s); frequency: 282 cpm (3 mm)
- c. Luminescence endpoint parameters: is integration time, gain 200, read height 1 mm
- 6. Remove optical film, seal with a breathable film, and incubate shaking at 37 C
- 7. Read luminescence at
day
- An Alamar Blue/Resazurin assay was carried out via the following steps. The strain used in the Alamar Blue/Resazurin assay was H37RvMA:
-
- 1. Inoculate −80 stocks into 7H9 OADC
- 2. When cells reach mid-log phase passage in 7H9 OADC
- 3. When cells reach mid log phase, dilute to OD=0.006
- 4. Add 100 uL of cells (diluted to OD=0.006) to the plate (making final OD in plate 0.003)
- 5. Seal the plate with breathable film, place in a ziplock, and put the plate in a box
- a. Incubate shaking at 37° C. for 4 days
- 6. After incubation, add 20 uL of Resazurin/alamar blue (0.02%) to every well (not including water wells
- 7. Re-seal the plates and incubate at 37° C., check the plates after 24 and 48 hours
- a. Purple=no growth, pink=growth
- b. MIC recorded as the well with the lowest concentration of drug that there is killing (purple color).
-
-
TABLE 3 Antimicrobial Activity MIC MIC WT E. coli WT E. coli delta- MIC H37Rv LB TolC LB A. baumannii MTB Media Media LB Media Activity FRS-ID (μM) (μM) (μM) (μM) B1 60 46 150 >150 B2 >150 >150 >150 >150 B3 >150 >150 >150 >150 B4 >150 >150 >150 >150 B5 >150 >150 >150 >150 B6 >150 >150 >150 >150 B7 >150 >150 >150 >150 B8 >150 >150 >150 >150 B9 >150 >150 >150 >150 B10 >150 >150 >150 >150 B11 >150 >150 >150 >150 B12 >150 >150 >150 >150 B13 90 55 150 >150 B14 >150 >150 >150 >150 B15 >150 >150 >150 >150 B16 >150 >150 >150 >150 B17 >150 >150 >150 >150 B18 >150 >150 >150 >150 B19 >150 >150 >150 150 B20 >150 >150 >150 >150 B21 >150 >150 >150 >150 B22 >150 >150 >150 >150 B23 >150 >150 >150 >150 B24 >150 >150 >150 >150 B25 >150 >150 >150 >150 B26 >150 >150 >150 >150 B27 >150 >150 >150 91 B28 >150 >150 >150 >150 B29 >150 >150 >150 >150 B30 >150 >150 >150 >150 B31 >150 >150 >150 >150 B32 >150 >150 >150 >150 B33 >150 >150 >150 >150 B34 >150 >150 >150 >150 B35 >150 >150 >150 >150 B36 >150 >150 >150 >150 B37 >150 >150 >150 150 B38 91 90 150 >150 B39 >150 >150 >150 >150 B40 >150 >150 >150 >150 B41 >150 >150 >150 >150 B42 >150 >150 >150 >150 B43 >150 >150 >150 >150 B44 >150 >150 >150 >150 B45 >150 >150 >150 91 B46 >150 >150 >150 >150 B47 >150 >150 >150 >150 B48 >150 >150 150 150 B49 >150 >150 >150 >150 B50 >150 >150 >150 >150 B51 >150 >150 >150 >150 B52 >150 >150 >150 >150 B53 >150 >150 >150 >150 B54 >150 >150 >150 >150 B55 >150 >150 >150 150 B56 >150 >150 >150 >150 B57 >150 >150 >150 >150 B58 >150 >150 >150 >150 B59 >150 >150 >150 33 B60 >150 >150 >150 >150 B61 >150 >150 >150 >150 B62 >150 >150 >150 >150 B63 >150 >150 >150 >150 B64 >150 >150 >150 >150 B65 >150 >150 >150 >150 B66 >150 >150 >150 >150 B67 >150 >150 >150 >150 B68 >150 >150 >150 >150 B69 >150 >150 >150 >150 B70 >150 >150 >150 >150 B71 150 90 >150 91 B72 >150 >150 >150 >150 B73 >150 >150 >150 >150 B74 >150 >150 >150 >150 B75 >150 >150 >150 >150 B76 >150 >150 >150 >150 B77 >150 >150 >150 >150 B78 250 150 >150 55 B79 >150 >150 >150 91 B80 250 90 >150 >150 B81 >150 >150 >150 >150 B82 >150 >150 >150 >150 B83 >150 >150 >150 >150 B84 >150 >150 >150 >150 B85 >150 >150 >150 >150 B86 >150 >150 >150 >150 B87 300 >150 >150 >150 B88 >150 >150 >150 >150 B89 300 >150 >150 91 B90 >150 >150 >150 >150 B91 >150 90 >150 >150 B92 >150 >150 >150 >150 B93 >150 >150 >150 >150 B94 17 7 91 >150 B95 >150 >150 >150 55 B96 >150 90 >150 >150 B97 >150 >150 >150 >150 B98 >150 150 >150 >150 B99 >150 >150 >150 55 B100 >150 >150 >150 >150 B101 70 40 150 >150 B102 120 90 150 91 B103 150 150 >150 >150 B104 >150 91 >150 55 B105 >150 >150 >150 91 B106 >150 >150 >150 150 B107 >150 >150 >150 >150 B108 >150 >150 >150 >150 B109 >150 91 150 55 B110 >150 >150 >150 >150 B111 >150 150 150 33 B112 >150 >150 >150 >150 B113 >150 >150 >150 >150 B114 >150 >150 >150 >150 B115 >150 >150 >150 >150 B116 >150 >150 >150 >150 B117 >150 >150 >150 >150 B118 >150 >150 >150 >150 B119 >150 >150 >150 >150 B120 >150 >150 >150 >150 B121 >150 >150 >150 >150 B122 >150 >150 >150 150 B123 >150 >150 >150 150 B124 >150 >150 >150 >150 B125 >150 >150 >150 >150 B126 >150 >150 >150 >150 B127 >150 >150 >150 150 B128 >150 >150 >150 >150 B129 >150 >150 >150 >150 B130 >150 >150 >150 >150 B131 >150 >150 >150 >150 B132 124 85 150 >150 B133 >150 >150 >150 55 B134 120 >150 >150 >150 B135 >150 >150 >150 >150 B136 >150 >150 >150 >150 B137 >150 >150 >150 >150 B138 >150 >150 >150 >150 B139 >150 >150 >150 >150 B140 >150 >150 >150 >150 B141 >150 >150 >150 >150 B142 >150 >150 >150 >150 B143 >150 >150 >150 >150 B144 >150 >150 >150 >150 B145 >150, res >150 >150 91 B146 150 90 150 >150 B147 >150 >150 >150 >150 B148 >150 >150 >150 150 B149 >150 >150 >150 >150 B150 >150 >150 >150 >150 B151 >150 >150 >150 >150 B152 >150 >150 >150 >150 B153 >150 >150 >150 >150 B154 >150 >150 >150 >150 B155 >150 >150 >150 >150 B156 150 150 150 >150 B157 20 11 55 91 B158 >150 >150 >150 >150 B159 500 250 >150 >150 B160 >150 >150 >150 >150 B161 >300 >300 >150 >150 B162 >500 300 >150 >150 B163 >300 300 >150 >150 B164 >300 60 >150 >150 B165 >300 60 >150 >150 B166 >300 250 300 >150 B167 >300 >300 >300 >150 B168 170 182 410 >150 B169 >300 74 >300 >150 B170 >300 >300 >300 >150 B171 41 19 110 >150 B172 170 96 >300 >150 B173 >300 >300 >300 >150 B174 >300 >300 >300 >150 B176 >300 >300 >300 >150 B177 >300 >300 >300 >150 B178 >300 >300 >300 55 B179 >300 230 >300 150 B180 >300 >300 >300 >150 B181 >300 >300 >300 >150 B182 >300 >300 >300 91 B183 >300 >300 >300 >150 B184 >300 >300 >300 >150 B185 >300 >300 >300 >150 B187 >300 >300 >300 >150 B188 >300 >300 >300 >150 B189 >300 >300 >300 >150 B190 >300 >300 >300 >150 B191 >300 300 300 >150 B192 300 96 300 33 B193 >300 300 300 150 B194 >300 170 300 150 B195 >300 300 >300 >150 B196 >300 300 >300 55 B197 170 96 300 >150 B198 >300 170 170 91 B199 >300 170 170 150 B200 >300 170 300 91 B201 >300 96 170 91 B202 >300 >300 >300 >150 B203 >300 170 >300 >150 B204 >300 >300 >300 >150 B205 >300 >300 >300 >150 B206 >300 >300 >300 >150 B207 >300 >300 >300 >150 B208 >300 >300 >300 >150 B209 >300 >300 >300 >150 B210 >300 >300 >300 >150 B211 >300 300 300 >150 B212 >300 >300 >300 >150 B213 >300 >300 >300 >150 B214 >300 >300 >300 >150 B215 >300 >300 >300 >150 B216 >300 >300 >300 >150 B217 >300 >300 >300 >150 B218 >300 >300 >300 >150 B219 >300 >300 >300 >150 B220 >300 >300 >300 >150 B221 300 150 220 150 B222 >300 >150 >300 >150 B223 >300 >150 >300 >150 B224 >300 >150 >300 >150 B225 >300 >150 300 >150 B226 54 33 54 33 B227 170 12 170 150 B228 170 20 300 91 B229 170 7 96 33 B230 96 4 96 55 B231 300 54 >300 >150 B232 170 17 96 91 B233 300 10 170 91 B234 >300 10 31 55 B235 96 96 >300 >150 B236 54 17 300 150 B237 >300 170 >300 >150 B238 >300 10 54 55 B239 >150 20 >150 >150 B240 >150 7 >150 150 B241 150 4 >150 >150 B242 >150 12 >150 >150 B243 >150 12 >150 >150 B244 91 3 150 150 B245 150 4 150 150 B246 >150 12 >150 91 B247 150 2 91 >150 B248 >150 20 >150 >150 B249 >150 >150 >150 >150 B250 >150 12 >150 >150 B251 91 7 91 >150 B252 >150 4 150 150 B253 150 37 >150 >150 B254 >150 >150 >150 >150 B255 >150 84 >150 >150 B256 >150 150 >150 >150 B257 >150 67 >150 >150 B258 >150 100 >150 >150 B259 >150 125 >150 >150 B260 >150 7 >150 91 B261 >150 4 >150 150 B262 150 12 91 55 B263 >150 3 >150 91 B264 150 3 150 >150 B265 150 3 91 91 B266 150 2 33 55 B267 >150 7 >150 91 B268 >150 7 >150 91 B269 >150 7 55 >150 B270 >150 20 >150 >150 B271 150 3 55 55 B272 >150 12 >150 150 B273 >150 4 >150 150 B274 150 7 150 >150 B275 150 4 91 >150 B276 >150 4 >150 >150 B277 >150 4 >150 >150 B278 >150 12 >150 >150 B279 >150 12 >150 >150 B280 150 12 150 >150 B281 >150 4 91 91 B282 >150 3 >150 150 B283 91 7 91 150 B284 >150 7 >150 >150 B285 91 55 >150 >150 B286 91 3 91 33 B287 150 3 91 150 B288 >150 3 150 91 B289 91 3 150 150 B290 >150 33 >150 >150 B291 91 12 >150 >150 B292 >150 4 >150 150 B293 150 4 >150 >150 B294 >150 7 >150 >150 B295 >150 4 >150 150 B296 91 7 >150 >150 B297 >150 7 150 >150 B298 >150 12 >150 >150 B299 150 4 150 >150 B300 >150 12 >150 >150 B301 >150 12 >150 >150 B302 150 <1 150 55 B303 >150 7 >150 91 B304 >150 3 >150 91 B305 >150 3 91 150 B306 >150 12 >150 >150 B307 >150 20 >150 150 B308 >150 4 150 >150 B309 >150 33 >150 >150 B310 >150 55 >150 >150 B311 >150 7 >150 >150 B312 >150 7 >150 >150 B313 >150 7 >150 >150 B314 150 4 91 150 B315 91 150 150 >150 B316 >150 7 >150 >150 B317 91 3 91 55 B318 >150 7 >150 150 B319 33 12 >150 150 B320 >150 20 >150 >150 B321 >150 55 >150 >150 B322 150 4 150 >150 B323 >150 4 >150 150 B324 >150 7 >150 >150 B325 >150 4 150 91 B326 >150 12 >150 55 B327 >150 7 >150 >150 B328 >150 55 >150 150 B329 >150 33 >150 >150 B330 >150 33 >150 >150 B331 >150 33 >150 >150 B332 >150 >150 >150 ND B333 >150 7 >150 >150 B334 >150 7 >150 >150 B335 55 4 150 >150 B336 >150 33 >150 >150 B337 55 4 150 >150 B338 91 12 >150 >150 B339 >300 200 >300 >150 B340 >150 55 >150 >150 B341 >150 7 >150 150 B342 150 4 150 91 B343 150 4 150 >150 B344 150 91 91 150 B345 >150 20 33 >150 B346 >150 4 12 >150 B347 150 4 >150 >150 B348 >150 >150 >150 150 B349 >150 >150 >150 >150 B350 >150 >150 >150 >150 B351 >150 >150 >150 >150 B352 91 91 150 91 B353 >150 >150 >150 >150 B354 >150 150 >150 150 B355 >150 >150 >150 >150 B356 >150 >150 >150 >150 B357 150 20 91 91 B358 >150 20 >150 >150 B359 >150 12 150 >150 B360 >150 >150 >150 >150 B361 91 4 91 >150 B362 150 7 150 >150 B363 150 3 150 >150 B364 150 3 150 91 B365 >150 5 >150 >150 B366 150 150 >150 >150 B367 150 5 150 >150 B368 >150 20 >150 >150 B369 >150 3 >150 >150 B370 >150 12 >150 >150 B371 >150 33 >150 >150 B372 150 5 >150 >150 B373 >150 150 >150 >150 B374 >150 >150 >150 150 B375 >150 >150 >150 >150 B376 150 91 >150 >150 B377 75 2.3 150 >150 B378 91 7 150 150 B379 >150 150 >150 TBD B380 33 12 >150 >150 B381 55 4 55 20.2 B382 55 3 55 12.2 B383 55 2 91 12.2 B384 91 4 55 20.2 B385 91 2 150 90.9 B386 >150 5 55 20.2 B387 91 3 55 33.4 B388 150 7 33 33.4 B389 >150 3 91 33.4 B390 150 3 55 20.2 B391 150 3 91 20.2 B392 >150 7 150 33.4 B393 >150 7 150 20.2 B394 150 3 55 20.2 B395 >150 3 33 20.2 B396 150 3 150 55.1 B397 >150 5 >150 12.2 B398 >150 91 >150 150 B399 150 20 >150 >150 B400 >150 55 >150 >150 B401 >150 33 >150 >150 B402 150 33 >150 >150 B403 >150 7 >150 >150 B404 >150 7 150 20.2 B405 91 5 150 33.4 B406 >150 >150 >150 150 B407 150 7 >150 >150 B408 55 2 55 12.2 B409 55 3 55 12.2 B410 >150 >150 >150 >150 B411 >150 150 >150 7.4 B412 >150 55 >150 7.4 B413 >150 55 >150 7.4 B414 20 4 150 >150 B415 >150 55 >150 1.257 B416 >150 55 >150 2.5 B417 >150 >150 >150 >150 B418 >150 >150 >150 >150 B419 >150 150 >150 0.6 B420 >150 >150 >150 >150 B421 >150 >150 >150 55.1 B422 >150 150 >150 2.5 B423 >150 55 >150 150 B424 33 3 150 >150 B425 >150 33 >150 >150 B426 >150 55 >150 1.7 B427 >150 >150 >150 2.7 B428 >150 55 >150 >150 B429 55 2 33 20.2 B430 >150 >150 >150 55.1 B431 150 4 >150 >150 B432 150 33 >150 >150 B433 150 3 150 >150 B434 150 4 150 >150 B435 >150 150 >150 >150 B436 >150 91 >150 >150 B437 150 4 >150 >150 B438 150 7 >150 >150 B439 91 12 150 >150 B440 >150 >150 >150 150 B441 >150 91 >150 33.4 B442 >150 150 >150 150 B445 55 4 150 >150 B446 91 7 >150 >150 B448 >150 >150 >150 >150 B449 >150 12 >150 >150 B450 >150 150 >150 150 B451 55 4 150 >150 B452 >150 >150 >150 >150 B453 >150 20 >150 >150 B454 >150 91 >150 >150 B455 >150 91 >150 >150 B456 >150 33 >150 >150 B457 33 <1 33 >55 B458 >150 4 20 10 B459 55 2 91 17 B460 33 <1 33 10 B461 33 <1 33 10 B462 >150 4 33 10 B463 >150 4 >150 17 B464 >150 90 >150 2 B465 >150 7 90 20 B466 >150 >150 >150 >55 B467 ND ND ND ND B468 ND ND ND ND B469 ND ND ND ND B470 ND ND ND ND B471 ND ND ND ND B472 ND ND ND ND B473 ND ND ND ND B474 ND ND ND ND B475 ND ND ND ND ND = not determined - A serious problem for antibacterial use of tRNA synthetase inhibitors as antibiotics is high frequency of resistance. Recently, Anacor's Anti-LeuS AN3365 failed in clinical trials due to a high frequency of resistance. The problem of resistance may be overcome by employing a combination of molecules targeting different tRNA synthetases in order to decrease the frequency of resistance down to the product of two independent resistance frequencies. E. coli did not develop resistance to a combination of anti-LeuS Tavaborole with our dialkylamine B1 in multiple independent experiments, as shown in
FIG. 1 . Experimental details: Cultures of E. coli K-12 were started from single colonies on LB-agar plates and were grown in LB for 36 hours with shaking at 37° C. Following that, 108 cells were plated on LB-agar plates containing B1 or Tavaborole alone or in combination adjusted for dose equivalence and incubated at 37° C. for 24 hours. - The teachings of all patents, published applications and references cited herein are incorporated by reference in their entirety.
- While this invention has been particularly shown and described with references to example embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.
Claims (22)
1-74. (canceled)
75. A compound having the structure of formula (I-A):
or a pharmaceutically acceptable salt thereof;
wherein:
R1 is selected from the group consisting of (C3-C8)alkyl, (C2-C8)hydroxyalkyl, (C1-C8)aminoalkyl, (C4-C8)cycloalkyl, aryl, heteroaryl, (CH3SO2)(C1-C8)alkyl, and di((C1-C8)alkyl)amino;
each of R2, R3, R4, and R5 is independently selected from H, OH, —NH2, halide, sulfonamido, (C1-C6)alkylsulfonyl, —OC(O)((C1-C8)alkyl), —C(O)O((C1-C8)alkyl), —C(O)OH, optionally substituted —NHC(O)(aryl), —C(O)NH2, —B(OH)2, tri((C1-C8)alkyl)silyl, optionally substituted (C1-C8)alkyl, optionally substituted (C1-C8)alkoxy, optionally substituted (C1-C8)aminoalkyl, optionally substituted (C1-C8)hydroxyalkyl, optionally substituted (C1-C8)haloalkyl, optionally substituted (C1-C8)haloalkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryloxy, optionally substituted arylalkoxy, optionally substituted heteroaryloxy, optionally substituted heteroarylalkoxy, optionally substituted (C3-C10)cycloalkyl, optionally substituted (C3-C10)cycloalkoxy, optionally substituted (C2-C9)heterocycloalkyl, optionally substituted (C2-C9)heterocycloalkoxy, (H3CSO2)(C1-C8)alkylene, optionally substituted (Rb 2NSO2)(C1-C8)alkylene, optionally substituted di((C1-C8)alkyl)amino, —NH—CH2—R8, —O—CH2—R8, and —O—CH2CH2—O—R9;
or R2 and R3, R3 and R4, or R4 and R5, taken together with the intervening atoms, form an optionally substituted aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group;
R6 is H or (C1-C6)alkyl;
R7 is optionally substituted (C3-C10)cycloalkyl or (C3-C10)cycloalkenyl;
R8 is selected from —C(O)((C2-C9)heterocycloalkyl), —C(O)NH((C1-C8)alkyl), —C(O)NH(aryl(C1-C8)alkyl), —C(O)NH((C3-C8)cycloalkyl), —C(O)NH((C3-C8)cycloalkyl(C1-C8)alkyl), —C(O)N(CH3)((C3-C8)cycloalkyl), —C(O)N(CH3)(aryl(C1-C8)alkyl), —C(O)NHC(O)NH((C3-C8)cycloalkyl), —C(O)NHC(O)NH((C1-C8)alkyl), —C(O)NHC(O)NH2, optionally substituted heteroaryl wherein the heteroaryl is not 4-pyridinyl, benzimidazole or thiazole, optionally substituted aryloxy(C1-C8)alkyl, (C3-C8)cycloalkyl, (C2-C9)heterocycloalkyl, (C2-C9)heterocycloalkyl(C2-C8)alkyl, heteroaryl(C1-C8)alkyl, (C2-C8)alkoxy, (C3-C8)hydroxyalkyl, (C1-C8)alkoxy(C1-C8)alkyl, (C1-C8)haloalkoxy(C1-C8)alkyl, (C1-C8)thioalkoxy(C1-C8)alkyl, (CH3SO2)(C1-C8)alkyl, and ((C1-C8)alkylC(O))(C1-C8)alkyl;
R9 is selected from (C3-C10)cycloalkyl, (C3-C10)cycloalkyl(C1-C8)alkyl, (C1-C8)haloalkyl, (C1-C8)hydroxyalkyl, (C1-C8)alkyl, (C1-C8)alkoxy(C1-C8)alkyl, and optionally substituted aryl; and
Rb, independently for each occurrence, is selected from H, optionally substituted (C1-C8)alkyl, optionally substituted (C1-C8)haloalkyl, optionally substituted (C1-C8)hydroxyalkyl, optionally substituted (C3-C10)cycloalkyl, optionally substituted (C3-C10)cycloalkyl(C1-C8)alkyl, optionally substituted aryl, and optionally substituted aryl(C1-C8) alkyl.
76. The compound of claim 75 , wherein R6 is (C1-C6)alkyl.
77. The compound of claim 76 , wherein R6 is methyl.
78. The compound of claim 75 , wherein R6 is H.
79. The compound of claim 75 , wherein R7 is optionally substituted cyclohexyl or cyclohexenyl.
80. The compound of claim 75 , wherein R2, R3, R4, and R5 are each H.
81. The compound of claim 75 , wherein R1 is selected from the group consisting of aryl and heteroaryl.
82. A compound having the structure of formula (I-B):
or a pharmaceutically acceptable salt thereof;
wherein:
R1 represents optionally substituted (Rb 2NSO2)(C1-C8)alkylene;
each of R2, R3, R4, and R5 is independently selected from H, OH, —NH2, halide, sulfonamido, (C1-C6)alkylsulfonyl, —OC(O)((C1-C8)alkyl), —C(O)O((C1-C8)alkyl), —C(O)OH, optionally substituted —NHC(O)(aryl), —C(O)NH2, —B(OH)2, tri((C1-C8)alkyl)silyl, optionally substituted (C1-C8)alkyl, optionally substituted (C1-C8)alkoxy, optionally substituted (C1-C8)aminoalkyl, optionally substituted (C1-C8)hydroxyalkyl, optionally substituted (C1-C8)haloalkyl, optionally substituted (C1-C8)haloalkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryloxy, optionally substituted arylalkoxy, optionally substituted heteroaryloxy, optionally substituted heteroarylalkoxy, optionally substituted (C3-C10)cycloalkyl, optionally substituted (C3-C10)cycloalkoxy, optionally substituted (C2-C9)heterocycloalkyl, optionally substituted (C2-C9)heterocycloalkoxy, (H3CSO2)(C1-C8)alkylene, optionally substituted (Rb 2NSO2)(C1-C8)alkylene, optionally substituted di((C1-C8)alkyl)amino, —NH—CH2—R8, —O—CH2—R8, and —O—CH2CH2—O—R9;
or R2 and R3, R3 and R4, or R4 and R5, taken together with the intervening atoms, form an optionally substituted aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group;
R6 is H or (C1-C6)alkyl;
R7 is optionally substituted (C3-C10)cycloalkyl or (C3-C10)cycloalkenyl;
R8 is selected from —C(O)((C2-C9)heterocycloalkyl), —C(O)NH((C1-C8)alkyl), —C(O)NH(aryl(C1-C8)alkyl), —C(O)NH((C3-C8)cycloalkyl), —C(O)NH((C3-C8)cycloalkyl(C1-C8)alkyl), —C(O)N(CH3)((C3-C8)cycloalkyl), —C(O)N(CH3)(aryl(C1-C8)alkyl), —C(O)NHC(O)NH((C3-C8)cycloalkyl), —C(O)NHC(O)NH((C1-C8)alkyl), —C(O)NHC(O)NH2, optionally substituted heteroaryl wherein the heteroaryl is not 4-pyridinyl, benzimidazole or thiazole, optionally substituted aryloxy(C1-C8)alkyl, (C3-C8)cycloalkyl, (C2-C9)heterocycloalkyl, (C2-C9)heterocycloalkyl(C2-C8)alkyl, heteroaryl(C1-C8)alkyl, (C2-C8)alkoxy, (C3-C8)hydroxyalkyl, (C1-C8)alkoxy(C1-C8)alkyl, (C1-C8)haloalkoxy(C1-C8)alkyl, (C1-C8)thioalkoxy(C1-C8)alkyl, (CH3SO2)(C1-C8)alkyl, and ((C1-C8)alkylC(O))(C1-C8)alkyl;
R9 is selected from (C3-C10)cycloalkyl, (C3-C10)cycloalkyl(C1-C8)alkyl, (C1-C8)haloalkyl, (C1-C8)hydroxyalkyl, (C1-C8)alkyl, (C1-C8)alkoxy(C1-C8)alkyl, and optionally substituted aryl; and
Rb, independently for each occurrence, is selected from H, optionally substituted (C1-C8)alkyl, optionally substituted (C1-C8)haloalkyl, optionally substituted (C1-C8)hydroxyalkyl, optionally substituted (C3-C10)cycloalkyl, optionally substituted (C3-C10)cycloalkyl(C1-C8)alkyl, optionally substituted aryl, and optionally substituted aryl(C1-C8) alkyl.
83. The compound of claim 82 , wherein R6 is (C1-C6)alkyl.
84. The compound of claim 82 , wherein R6 is methyl.
85. The compound of claim 82 , wherein R6 is H.
86. The compound of claim 82 , wherein R7 is optionally substituted cyclohexyl or cyclohexenyl.
87. The compound of claim 82 , wherein R2, R3, R4, and R5 are each H.
88. A compound having the structure of formula (I-C):
or a pharmaceutically acceptable salt thereof;
wherein:
R1 is selected from the group consisting of —O—CH2—R8 and —O—CH2CH2—O—R9;
each of R2, R3, R4, and R5 is independently selected from H, OH, —NH2, halide, sulfonamido, (C1-C6)alkylsulfonyl, —OC(O)((C1-C8)alkyl), —C(O)O((C1-C8)alkyl), —C(O)OH, optionally substituted —NHC(O)(aryl), —C(O)NH2, —B(OH)2, tri((C1-C8)alkyl)silyl, optionally substituted (C1-C8)alkyl, optionally substituted (C1-C8)alkoxy, optionally substituted (C1-C8)aminoalkyl, optionally substituted (C1-C8)hydroxyalkyl, optionally substituted (C1-C8)haloalkyl, optionally substituted (C1-C8)haloalkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryloxy, optionally substituted arylalkoxy, optionally substituted heteroaryloxy, optionally substituted heteroarylalkoxy, optionally substituted (C3-C10)cycloalkyl, optionally substituted (C3-C10)cycloalkoxy, optionally substituted (C2-C9)heterocycloalkyl, optionally substituted (C2-C9)heterocycloalkoxy, (H3CSO2)(C1-C8)alkylene, optionally substituted (Rb 2NSO2)(C1-C8)alkylene, optionally substituted di((C1-C8)alkyl)amino, —NH—CH2—R8, —O—CH2—R8, and —O—CH2CH2—O—R9;
or R2 and R3, R3 and R4, or R4 and R5, taken together with the intervening atoms, form an optionally substituted aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group;
R6 is H or (C1-C6)alkyl;
R7 is optionally substituted (C3-C10)cycloalkyl or (C3-C10)cycloalkenyl;
R8 is selected from —C(O)((C2-C9)heterocycloalkyl), —C(O)NH((C1-C8)alkyl), —C(O)NH(aryl(C1-C8)alkyl), —C(O)NH((C3-C8)cycloalkyl), —C(O)NH((C3-C8)cycloalkyl(C1-C8)alkyl), —C(O)N(CH3)((C3-C8)cycloalkyl), —C(O)N(CH3)(aryl(C1-C8)alkyl), —C(O)NHC(O)NH((C3-C8)cycloalkyl), —C(O)NHC(O)NH((C1-C8)alkyl), —C(O)NHC(O)NH2, optionally substituted heteroaryl wherein the heteroaryl is not 4-pyridinyl, benzimidazole or thiazole, optionally substituted aryloxy(C1-C8)alkyl, (C3-C8)cycloalkyl, (C2-C9)heterocycloalkyl, (C2-C9)heterocycloalkyl(C2-C8)alkyl, heteroaryl(C1-C8)alkyl, (C2-C8)alkoxy, (C3-C8)hydroxyalkyl, (C1-C8)alkoxy(C1-C8)alkyl, (C1-C8)haloalkoxy(C1-C8)alkyl, (C1-C8)thioalkoxy(C1-C8)alkyl, (CH3SO2)(C1-C8)alkyl, and ((C1-C8)alkylC(O))(C1-C8)alkyl;
R9 is selected from (C3-C10)cycloalkyl, (C3-C10)cycloalkyl(C1-C8)alkyl, (C1-C8)haloalkyl, (C1-C8)hydroxyalkyl, (C1-C8)alkyl, (C1-C8)alkoxy(C1-C8)alkyl, and optionally substituted aryl; and
Rb, independently for each occurrence, is selected from H, optionally substituted (C1-C8)alkyl, optionally substituted (C1-C8)haloalkyl, optionally substituted (C1-C8)hydroxyalkyl, optionally substituted (C3-C10)cycloalkyl, optionally substituted (C3-C10)cycloalkyl(C1-C8)alkyl, optionally substituted aryl, and optionally substituted aryl(C1-C8) alkyl.
89. The compound of claim 88 , wherein R6 is (C1-C6)alkyl.
90. The compound of claim 89 , wherein R6 is methyl.
91. The compound of claim 88 , wherein R6 is H.
92. The compound of claim 88 , wherein R7 is optionally substituted cyclohexyl or cyclohexenyl.
93. The compound of claim 88 , wherein R2, R3, R4, and R5 are each H.
94. The compound of claim 88 , wherein R1 is —O—CH2—R8 and R8 is optionally substituted heteroaryl wherein the heteroaryl is not 4-pyridinyl, benzimidazole, or thiazole.
95. A method of treating a bacterial infection in a subject, comprising administering to the subject a therapeutically effective amount of a compound of claim 75 .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/573,405 US20230102879A1 (en) | 2018-01-12 | 2022-01-11 | Trna synthetase inhibitors |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862616979P | 2018-01-12 | 2018-01-12 | |
PCT/US2019/013305 WO2019140265A1 (en) | 2018-01-12 | 2019-01-11 | Trna synthetase inhibitors |
US202016961516A | 2020-07-10 | 2020-07-10 | |
US17/573,405 US20230102879A1 (en) | 2018-01-12 | 2022-01-11 | Trna synthetase inhibitors |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/961,516 Continuation US11261201B2 (en) | 2018-01-12 | 2019-01-11 | TRNA synthetase inhibitors |
PCT/US2019/013305 Continuation WO2019140265A1 (en) | 2018-01-12 | 2019-01-11 | Trna synthetase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230102879A1 true US20230102879A1 (en) | 2023-03-30 |
Family
ID=67219913
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/961,516 Active US11261201B2 (en) | 2018-01-12 | 2019-01-11 | TRNA synthetase inhibitors |
US17/573,405 Abandoned US20230102879A1 (en) | 2018-01-12 | 2022-01-11 | Trna synthetase inhibitors |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/961,516 Active US11261201B2 (en) | 2018-01-12 | 2019-01-11 | TRNA synthetase inhibitors |
Country Status (2)
Country | Link |
---|---|
US (2) | US11261201B2 (en) |
WO (1) | WO2019140265A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019140265A1 (en) | 2018-01-12 | 2019-07-18 | President And Fellows Of Harvard College | Trna synthetase inhibitors |
CN111333672B (en) * | 2020-04-07 | 2022-11-08 | 中国医学科学院放射医学研究所 | Sterol regulatory element binding protein and acidic nucleoplasm DNA binding protein-1 inhibitor, and preparation method and application thereof |
WO2023230649A1 (en) * | 2022-05-30 | 2023-12-07 | Psylo Pty Ltd | Compounds |
WO2024091450A1 (en) * | 2022-10-24 | 2024-05-02 | The Regents Of The University Of California | Compounds and methods for treating cancer |
WO2024086933A1 (en) * | 2022-10-25 | 2024-05-02 | Enveric Biosciences Canada Inc. | C1-substituted isoproylamine fused heterocyclic mescaline derivatives |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3310469A (en) | 1961-08-28 | 1967-03-21 | Du Pont | Pharmaceutical compositions and methods utilizing 1-aminoadamantane and its derivatives |
EP1619947A4 (en) * | 2003-05-01 | 2006-05-31 | Replidyne Inc | Antibacterial methods and compositions |
MX2007015863A (en) | 2005-06-17 | 2008-04-02 | Apogee Biotechnology Corp | Sphingosine kinase inhibitors. |
GB0516270D0 (en) * | 2005-08-08 | 2005-09-14 | Glaxo Group Ltd | Novel compounds |
WO2010096170A2 (en) * | 2009-02-19 | 2010-08-26 | President And Fellows Of Harvard College | Inhibition of trna synthetases and therapeutic applications thereof |
WO2013086131A1 (en) | 2011-12-06 | 2013-06-13 | The Trustees Of The University Of Pennsylvania | Inhibitors targeting drug-resistant influenza a |
JP6560436B2 (en) | 2015-07-27 | 2019-08-14 | チョン クン ダン ファーマシューティカル コーポレーション | 1,3,4-oxadiazolesulfonamide derivative compound as histone deacetylase 6 inhibitor and pharmaceutical composition containing the same |
WO2019140265A1 (en) | 2018-01-12 | 2019-07-18 | President And Fellows Of Harvard College | Trna synthetase inhibitors |
WO2019140254A1 (en) | 2018-01-12 | 2019-07-18 | President And Fellows Of Harvard College | Multicyclic compounds and use of same for treating tuberculosis |
-
2019
- 2019-01-11 WO PCT/US2019/013305 patent/WO2019140265A1/en active Application Filing
- 2019-01-11 US US16/961,516 patent/US11261201B2/en active Active
-
2022
- 2022-01-11 US US17/573,405 patent/US20230102879A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2019140265A1 (en) | 2019-07-18 |
US20210053997A1 (en) | 2021-02-25 |
US11261201B2 (en) | 2022-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230102879A1 (en) | Trna synthetase inhibitors | |
CA1049411A (en) | N-substituted pyridone and general method for preparing pyridones | |
AU675786B2 (en) | Azacyclic compounds | |
US4042699A (en) | Method for reducing serum glucose levels | |
US20150224125A1 (en) | Beta-lactamase inhibitors | |
TW200410939A (en) | Novel mycobacterial inhibitors | |
CS402991A3 (en) | Dichloroaniline derivatives, process of their preparation andpharmaceutical compositions comprising them | |
AU2009310807B2 (en) | Cyclohexane derivative and pharmaceutical use thereof | |
AU2003211692B2 (en) | Novel arylamidine derivative or salt thereof | |
AU2019227889B2 (en) | Pyrazole derivatives and their use as cannabinoid receptor mediators | |
US5646303A (en) | Method for controlling emesis caused by chemotherapeutic agents and antiemetic agents useful therein | |
US20220298155A1 (en) | Compounds and compositions as modulators of tlr signaling | |
CA3008776A1 (en) | Indane derivatives and the use thereof as soluble guanylate cyclase activators | |
US20120004227A1 (en) | Cyclohexane derivative having npy y5 receptor antagonism | |
CS226025B2 (en) | Method of preparing cephalosporine derivatives | |
ES2243313T3 (en) | DERIVATIVES OF ISOXAZOL AS INHIBITORS OF PHOSPHODIESTERASE VII. | |
US10457644B2 (en) | Pyrazol compounds as EAAT3 inhibitors | |
US7601843B2 (en) | 4-(2-furoyl)aminopiperidine compound useful as therapeutic agent for itching | |
US20150322024A1 (en) | Cinnamic Acid Amide Derivative | |
US3039930A (en) | Pyridyl carbamyl lower alkane derivatives: analgesic process | |
CA3092749A1 (en) | Deuterated compounds as rock inhibitors | |
US3714175A (en) | Certain-1-aryl-3-substituted benzamido-2-pyrrolidinones | |
US3836658A (en) | Tri-substituted imidazoles in the treatment of gout | |
WO2019140254A1 (en) | Multicyclic compounds and use of same for treating tuberculosis | |
WO2014069554A1 (en) | Quinuclidine amide derivative and medicinal use of same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: PRESIDENT AND FELLOWS OF HARVARD COLLEGE, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BAIDIN, VADIM;KAHNE, DANIEL E.;REEL/FRAME:060205/0556 Effective date: 20190503 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |